{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "schemaVersion": "4.0.0",
  "instanceType": "StudyDocument",
  "id": "USDM-M14-031-20251209212621",
  "name": "Protocol Extraction: M14-031",
  "sourceDocument": {
    "documentId": "DOC-CA112F8B9164AE1D",
    "filename": "abbvie_NCT02755597.pdf",
    "sha256Hash": "ca112f8b9164ae1d04c56a4842a7ab232fe608073a16b41f512b00d10ee54de7",
    "byteSize": 2930714,
    "uploadTimestamp": "2025-12-09T21:26:21.135995",
    "pageCount": 200
  },
  "extractionMetadata": {
    "extractionTimestamp": "2025-12-09T21:26:21.293444",
    "pipelineVersion": "3.1",
    "primaryModel": "gemini-2.5-pro",
    "agentCount": 16,
    "successfulAgents": [
      "study_metadata",
      "arms_design",
      "endpoints_estimands_sap",
      "adverse_events",
      "safety_decision_points",
      "concomitant_medications",
      "biospecimen_handling",
      "laboratory_specifications",
      "informed_consent",
      "pro_specifications",
      "data_management",
      "site_operations_logistics",
      "quality_management",
      "withdrawal_procedures",
      "imaging_central_reading",
      "pkpd_sampling"
    ],
    "failedAgents": [],
    "qualitySummary": {
      "study_metadata": {
        "overallScore": 0.9587562189054727,
        "fromCache": false
      },
      "arms_design": {
        "overallScore": 0.8834533123205944,
        "fromCache": false
      },
      "endpoints_estimands_sap": {
        "overallScore": 0.9986013986013985,
        "fromCache": false
      },
      "adverse_events": {
        "overallScore": 0.92,
        "fromCache": false
      },
      "safety_decision_points": {
        "overallScore": 0.9920466434176113,
        "fromCache": false
      },
      "concomitant_medications": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "biospecimen_handling": {
        "overallScore": 0.7992581602373888,
        "fromCache": false
      },
      "laboratory_specifications": {
        "overallScore": 0.959248496993988,
        "fromCache": false
      },
      "informed_consent": {
        "overallScore": 0.9972972972972972,
        "fromCache": false
      },
      "pro_specifications": {
        "overallScore": 0.843939393939394,
        "fromCache": false
      },
      "data_management": {
        "overallScore": 0.9800000000000001,
        "fromCache": false
      },
      "site_operations_logistics": {
        "overallScore": 0.8951550387596899,
        "fromCache": false
      },
      "quality_management": {
        "overallScore": 0.9331047706703482,
        "fromCache": false
      },
      "withdrawal_procedures": {
        "overallScore": 0.9800000000000001,
        "fromCache": false
      },
      "imaging_central_reading": {
        "overallScore": 0.9167948717948718,
        "fromCache": false
      },
      "pkpd_sampling": {
        "overallScore": 0.9751488288874431,
        "fromCache": false
      }
    },
    "averageQualityScore": 0.9395502769890937
  },
  "study": {
    "instanceType": "Study",
    "id": "M14-031",
    "name": "M14-031",
    "officialTitle": "A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors",
    "version": "8",
    "provenance": {
      "section_number": "1.0",
      "page_number": 1,
      "text_snippet": "Clinical Study Protocol M14-031\n\nA Phase 3, Multicenter, Randomized, Double Blind \nStudy of Bortezomib and Dexamethasone in \nCombination with Either Venetoclax or Placebo in \nSubjects with Relapsed or Refractory Multiple \nMyeloma Who are Sensitive or Naïve to Proteasome \nInhibitors"
    },
    "studyPhase": {
      "code": "C15602",
      "decode": "Phase 3",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "A Phase 3, Multicenter, Randomized, Double Blind \nStudy of Bortezomib and Dexamethasone in \nCombination with Either Venetoclax or Placebo in \nSubjects with Relapsed or Refractory Multiple \nMyeloma Who are Sensitive or Naïve to Proteasome \nInhibitors"
      }
    },
    "studyType": {
      "code": "C98388",
      "decode": "Interventional",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": "1.2",
        "page_number": 7,
        "text_snippet": "Methodology: \nThis is a Phase 3, multicenter, randomized, double blind, placebo-controlled, parallel group study. This \nstudy is designed to evaluate the efficacy and safety of venetoclax plus bortezomib and dexamethasone \n(Bd) in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to \nproteasome inhibitors and have received 1 to 3 prior lines of therapy for multiple myeloma."
      }
    },
    "studyIdentifiers": [
      {
        "id": "NCT02755597",
        "scopeId": "clinicaltrials.gov",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "NCT02755597"
        }
      },
      {
        "id": "2015-004411-20",
        "scopeId": "eudract",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "EudraCT 2015-004411-20"
        }
      }
    ],
    "studyProtocolVersions": [
      {
        "versionNumber": "Original",
        "versionDate": "2016-02-05",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Original 05 February 2016"
        }
      },
      {
        "versionNumber": "0.01",
        "versionDate": "2016-06-24",
        "amendmentNumber": "0.01",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Amendment 0.01 (France Only) 24 June 2016"
        }
      },
      {
        "versionNumber": "Japan Local Amendment 1",
        "versionDate": "2016-05-27",
        "amendmentNumber": "1",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Japan Local Amendment 1 27 May 2016"
        }
      },
      {
        "versionNumber": "1",
        "versionDate": "2017-06-16",
        "amendmentNumber": "1",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 1 16 June 2017"
        }
      },
      {
        "versionNumber": "2",
        "versionDate": "2017-12-15",
        "amendmentNumber": "2",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 2 15 December 2017"
        }
      },
      {
        "versionNumber": "3",
        "versionDate": "2018-03-09",
        "amendmentNumber": "3",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 3 09 March 2018"
        }
      },
      {
        "versionNumber": "4",
        "versionDate": "2019-01-09",
        "amendmentNumber": "4",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 4 09 January 2019"
        }
      },
      {
        "versionNumber": "Administrative Change 1",
        "versionDate": "2019-01-23",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Protocol Administrative Change 1 23 January 2019"
        }
      },
      {
        "versionNumber": "5",
        "versionDate": "2019-03-15",
        "amendmentNumber": "5",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 5 15 March 2019"
        }
      },
      {
        "versionNumber": "6",
        "versionDate": "2019-09-24",
        "amendmentNumber": "6",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 6 24 September 2019"
        }
      },
      {
        "versionNumber": "7",
        "versionDate": "2020-04-20",
        "amendmentNumber": "7",
        "provenance": {
          "section_number": "1.1",
          "page_number": 3,
          "text_snippet": "Global Amendment 7 20 April 2020"
        }
      },
      {
        "versionNumber": "8",
        "versionDate": "2020-12-16",
        "amendmentNumber": "8",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "M14-031 Protocol Amendment 8\n...\nDate: 16 December 2020"
        }
      }
    ],
    "studyPopulation": {
      "targetDisease": {
        "name": "Relapsed or Refractory Multiple Myeloma"
      },
      "ageRange": {
        "minAge": 18,
        "maxAgeNoLimit": true,
        "unit": "years"
      },
      "sex": {
        "allowed": [
          {
            "code": "C20197",
            "decode": "Male",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Study Population: Adult male and female subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors, have received 1 to 3 prior lines of therapy for multiple myeloma, and have measurable disease per International Myeloma Working Group (IMWG) criteria."
            }
          },
          {
            "code": "C16576",
            "decode": "Female",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Study Population: Adult male and female subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors, have received 1 to 3 prior lines of therapy for multiple myeloma, and have measurable disease per International Myeloma Working Group (IMWG) criteria."
            }
          }
        ]
      },
      "performanceStatus": {
        "scale": "ECOG",
        "allowedValues": [
          0,
          1,
          2
        ],
        "provenance": {
          "section_number": null,
          "page_number": 10,
          "text_snippet": "1. Eastern Collaborative Oncology Group (ECOG) performance score of ≤ 2."
        }
      },
      "keyInclusionSummary": {
        "values": [
          "Eastern Collaborative Oncology Group (ECOG) performance score of ≤ 2.",
          "Documented relapsed or progressive multiple myeloma on or after any regimen or is refractory to the most recent line of therapy.",
          "Received at least one, but no more than three, prior lines of therapy for multiple myeloma.",
          "Prior treatment with bortezomib or other proteasome inhibitor is allowed, provided disease is NOT refractory, best response was at least a Partial Response (PR), and subject did not discontinue due to intolerance or ≥ Grade 3 related toxicity.",
          "Measurable disease at Screening, defined as Serum M-protein ≥ 0.5 g/dL, OR Urine M-protein ≥ 200 mg in 24 hours, OR Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal."
        ],
        "provenance": {
          "section_number": null,
          "page_number": 10,
          "text_snippet": "Main Inclusion:\n1. Eastern Collaborative Oncology Group (ECOG) performance score of ≤ 2.\n2. Subjects has documented relapsed or progressive multiple myeloma on or after any regimen or is refractory to the most recent line of therapy.\n3. Subject must have received prior treatment with at least one, but no more than three, prior lines of therapy for multiple myeloma.\n4. Prior treatment with bortezomib or other proteasome inhibitor is allowed, provided: ALL of the following criteria are met:\n5."
        }
      },
      "keyExclusionSummary": {
        "values": [
          "Subject is refractory to any proteasome inhibitor.",
          "Subject has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug.",
          "Subject has non-secretory multiple myeloma, active plasma cell leukemia, Waldenström's macroglobulinemia, Amyloidosis, or POEMS syndrome.",
          "Significant cardiovascular disease, including uncontrolled angina, hypertension, arrhythmia, recent myocardial infarction within 6 months, or congestive heart failure NYHA Class ≥ 3.",
          "History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with specified exceptions.",
          "If subject had prior stem cell transplant (SCT), subject has evidence of ongoing graft-versus-host disease (GvHD)."
        ],
        "provenance": {
          "section_number": null,
          "page_number": 11,
          "text_snippet": "Main Exclusion:\n1. Subject is refractory to any proteasome inhibitor, defined as progression on or within 60 days of the last dose of a proteasome inhibitor-containing regimen.\n2. Subject has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug.\n3. Subject has any of the following conditions:\n4."
        }
      },
      "provenance": {
        "section_number": "1.2",
        "page_number": 7,
        "text_snippet": "Study Population: Adult male and female subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors, have received 1 to 3 prior lines of therapy for multiple myeloma, and have measurable disease per International Myeloma Working Group (IMWG) criteria."
      }
    },
    "studyMilestones": {
      "estimatedDurations": {
        "screeningPeriodDays": 21,
        "enrollmentPeriodMonths": 15,
        "treatmentPeriodDescription": "Subjects will receive venetoclax/placebo plus Bd until documented disease progression, unacceptable toxicity, withdrawal of consent, or the subject meets other criteria for discontinuation per study protocol.",
        "totalStudyDurationMonths": 26
      },
      "provenance": {
        "section_number": "1.2",
        "page_number": 7,
        "text_snippet": "Screening\nUnless otherwise specified, screening procedures must be performed within 21 days prior to \nrandomization, including disease assessments per the IMWG criteria."
      }
    },
    "studyDesignInfo": {
      "designType": "Parallel Assignment",
      "randomization": {
        "isRandomized": true,
        "allocationRatio": "2:1",
        "provenance": {
          "section_number": "5.1",
          "page_number": 39,
          "text_snippet": "Approximately 280 subjects at approximately 120 sites will be randomized in a 2:1 ratio to receive an oral daily dose of either venetoclax 800 mg or placebo plus Bd, respectively."
        }
      },
      "blinding": {
        "blindingType": "Double-blind",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "A Phase 3, Multicenter, Randomized, Double Blind \nStudy of Bortezomib and Dexamethasone in \nCombination with Either Venetoclax or Placebo in \nSubjects with Relapsed or Refractory Multiple \nMyeloma Who are Sensitive or Naïve to Proteasome \nInhibitors"
        }
      },
      "targetEnrollment": 280,
      "plannedSites": 120,
      "countries": {
        "values": [
          "France",
          "Japan"
        ],
        "provenance": {
          "section_number": null,
          "page_number": 67,
          "text_snippet": "Lung Disease Risk Assessment – JAPAN and FRANCE ONLY"
        }
      },
      "provenance": {
        "section_number": "1.2",
        "page_number": 7,
        "text_snippet": "Methodology: \nThis is a Phase 3, multicenter, randomized, double blind, placebo-controlled, parallel group study."
      }
    },
    "therapeuticArea": {
      "value": "Oncology",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "Subjects with Relapsed or Refractory Multiple \nMyeloma Who are Sensitive or Naïve to Proteasome \nInhibitors"
      }
    },
    "indication": {
      "value": "Relapsed or Refractory Multiple Myeloma",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "Subjects with Relapsed or Refractory Multiple \nMyeloma Who are Sensitive or Naïve to Proteasome \nInhibitors"
      }
    },
    "sponsorName": {
      "value": "AbbVie",
      "provenance": {
        "section_number": "1.0",
        "page_number": 1,
        "text_snippet": "Sponsor: AbbVie*"
      }
    },
    "isPivotal": true,
    "extensionAttributes": [
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "1.0",
          "title": "Title Page"
        }
      },
      {
        "name": "extractionMetadata",
        "value": {
          "extractedAt": "2024-07-16T12:00:00Z",
          "modelVersion": "gemini-1.5-flash"
        }
      }
    ]
  },
  "domainSections": {
    "studyDesign": {
      "moduleId": "arms_design",
      "instanceType": "StudyDesign",
      "data": {
        "id": "M14-031-arms-design",
        "instanceType": "StudyDesign",
        "name": "M14-031 Study Design",
        "provenance": {
          "section_number": "1.2",
          "page_number": 7,
          "text_snippet": "Methodology: \nThis is a Phase 3, multicenter, randomized, double blind, placebo-controlled, parallel group study. This \nstudy is designed to evaluate the efficacy and safety of venetoclax plus bortezomib and dexamethasone \n(Bd) in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to \nproteasome inhibitors and have received 1 to 3 prior lines of therapy for multiple myeloma. The study \nwill consist of three phases: Screening, Treatment, and Follow-Up."
        },
        "studyArms": [
          {
            "id": "ARM01",
            "instanceType": "StudyArm",
            "name": "Venetoclax + Bortezomib + Dexamethasone",
            "label": "Arm 1",
            "description": "Venetoclax 800 mg orally once daily in combination with Bortezomib 1.3 mg/m² subcutaneously or intravenously and Dexamethasone 20 mg orally on a cyclical schedule.",
            "armType": {
              "code": "C174266",
              "decode": "Experimental",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 2,
            "plannedSubjects": 187,
            "interventions": [
              {
                "id": "INT01",
                "instanceType": "StudyIntervention",
                "name": "Venetoclax",
                "type": "Drug",
                "role": {
                  "decode": "Investigational"
                },
                "drugClass": "BCL-2 inhibitor",
                "manufacturer": "AbbVie",
                "dosingRegimen": {
                  "dose": 800,
                  "doseUnit": "mg",
                  "frequency": "QD",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "formulation": "100 mg Tablet, film coated",
                "isBlinded": true,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 600,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -2,
                      "dose": 400,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -3,
                      "dose": 200,
                      "doseUnit": "mg"
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG01",
                      "condition": "Grade 3/4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except lymphopenia) - First episode",
                      "toxicityGrade": 4,
                      "action": "Hold",
                      "holdCriteria": "Until resolved to Grade 1 or baseline level, then resume at same dose.",
                      "provenance": {
                        "section_number": "6.2.1",
                        "page_number": 129,
                        "text_snippet": "First episode: Interrupt venetoclax/placebo and once the toxicity has resolved to Grade 1 or baseline level, venetoclax/placebo may be resumed at the same dose."
                      }
                    },
                    {
                      "id": "TRIG02",
                      "condition": "Grade 3/4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except lymphopenia) - Subsequent episodes",
                      "toxicityGrade": 4,
                      "action": "Hold then reduce",
                      "holdCriteria": "Until resolution, then resume at reduced dose.",
                      "provenance": {
                        "section_number": "6.2.1",
                        "page_number": 129,
                        "text_snippet": "For subsequent episodes: Interrupt venetoclax/placebo. Consider using G-CSF as clinically indicated. Follow dose reduction guidelines in Table 7 when resuming treatment with venetoclax/placebo after resolution."
                      }
                    },
                    {
                      "id": "TRIG03",
                      "condition": "Grade >= 3 or Serious Infections",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "holdCriteria": "Upon resolution, treatment can be resumed at a reduced dose or discontinued.",
                      "provenance": {
                        "section_number": "6.2.1",
                        "page_number": 129,
                        "text_snippet": "Grade ≥ 3 or Serious Infections\nInterrupt venetoclax/placebo and upon resolution, treatment can be resumed at a reduced dose or discontinued, depending on Investigator's clinical judgment."
                      }
                    },
                    {
                      "id": "TRIG04",
                      "condition": "Grade 3 or 4 non-hematologic events - Subsequent episodes",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "holdCriteria": "Until resolved to Grade <= 1 or baseline, then resume at reduced dose.",
                      "provenance": {
                        "section_number": "6.2.1",
                        "page_number": 129,
                        "text_snippet": "For subsequent episodes: Interrupt venetoclax/placebo. Follow dose reduction guidelines in Table 7 when resuming treatment with venetoclax/placebo after resolution."
                      }
                    },
                    {
                      "id": "TRIG05",
                      "condition": "Blood chemistry changes suggestive of TLS requiring more than 48 hours to resolve",
                      "action": "Reduce",
                      "provenance": {
                        "section_number": "6.2.1",
                        "page_number": 129,
                        "text_snippet": "For any blood chemistry changes requiring more than 48 hours to resolve, resume at a reduced dose (see Table 7)."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Dose level -3 is not tolerable"
                  ],
                  "provenance": {
                    "section_number": "6.2.1",
                    "page_number": 128,
                    "text_snippet": "If the dose of venetoclax/placebo at dose level –3 is not tolerable, then no further reductions will be allowed and venetoclax/placebo should be discontinued."
                  }
                },
                "provenance": {
                  "section_number": "1.0",
                  "page_number": 1,
                  "text_snippet": "AbbVie Investigational Product: Venetoclax (ABT-199)"
                }
              },
              {
                "id": "INT03",
                "instanceType": "StudyIntervention",
                "name": "Bortezomib",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 1.3,
                  "doseUnit": "mg/m²",
                  "frequency": "Cycles 1-8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15, 22",
                  "route": {
                    "code": "C38299",
                    "decode": "Subcutaneous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "BSA-based"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 1,
                      "doseUnit": "mg/m²"
                    },
                    {
                      "level": -2,
                      "dose": 0.7,
                      "doseUnit": "mg/m²"
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG06",
                      "condition": "Grade 3 non-hematological or Grade 4 hematological toxicity",
                      "action": "Hold then reduce",
                      "holdCriteria": "Until symptoms resolve, then reinitiate at a 25% reduced dose.",
                      "provenance": {
                        "section_number": "6.2.3",
                        "page_number": 132,
                        "text_snippet": "Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose. (1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                      }
                    },
                    {
                      "id": "TRIG07",
                      "condition": "Peripheral Neuropathy Grade 2 with pain or Grade 3",
                      "action": "Hold then reduce",
                      "targetLevel": -2,
                      "holdCriteria": "Until toxicity resolves to baseline or <= Grade 1, then reinitiate at 0.7 mg/m² once per week.",
                      "provenance": {
                        "section_number": "6.2.3",
                        "page_number": 132,
                        "text_snippet": "Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADLc)\nWithhold bortezomib therapy until toxicity resolves to baseline or ≥ Grade 1. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Grade 4 Peripheral Neuropathy"
                  ],
                  "provenance": {
                    "section_number": "6.2.3",
                    "page_number": 132,
                    "text_snippet": "Table 10. Dose Reductions and Treatment Guidelines for Toxicity Related to Bortezomib"
                  }
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 12,
                  "text_snippet": "Reference Therapy: Bortezomib powder for solution for injection"
                }
              },
              {
                "id": "INT04",
                "instanceType": "StudyIntervention",
                "name": "Dexamethasone",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 20,
                  "doseUnit": "mg",
                  "frequency": "Cycles 1-8: Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+: Days 1, 2, 8, 9, 15, 16, 22, 23",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 12,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -2,
                      "dose": 8,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -3,
                      "dose": 4,
                      "doseUnit": "mg"
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Acute pancreatitis"
                  ],
                  "provenance": {
                    "section_number": "6.2.3",
                    "page_number": 133,
                    "text_snippet": "Table 11. Dose Reductions for Dexamethasone\nTable 12. Treatment Guidelines for Toxicity Related to Dexamethasone"
                  }
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 12,
                  "text_snippet": "Reference Therapy: Dexamethasone tablet"
                }
              }
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 8,
              "text_snippet": " Arm 1: Venetoclax plus Bd"
            }
          },
          {
            "id": "ARM02",
            "instanceType": "StudyArm",
            "name": "Placebo + Bortezomib + Dexamethasone",
            "label": "Arm 2",
            "description": "Placebo matching venetoclax orally once daily in combination with Bortezomib 1.3 mg/m² subcutaneously or intravenously and Dexamethasone 20 mg orally on a cyclical schedule.",
            "armType": {
              "code": "C174268",
              "decode": "Placebo Comparator",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 93,
            "interventions": [
              {
                "id": "INT02",
                "instanceType": "StudyIntervention",
                "name": "Placebo for Venetoclax",
                "type": "Drug",
                "role": {
                  "decode": "Placebo"
                },
                "dosingRegimen": {
                  "dose": 0,
                  "doseUnit": "mg",
                  "frequency": "QD",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "formulation": "Tablet, film coated (matching venetoclax)",
                "isBlinded": true,
                "isPlacebo": true,
                "isComparator": true,
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 12,
                  "text_snippet": "Reference Therapy: Placebo (to match venetoclax 100 mg tablet)"
                }
              },
              {
                "id": "INT03",
                "instanceType": "StudyIntervention",
                "name": "Bortezomib",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 1.3,
                  "doseUnit": "mg/m²",
                  "frequency": "Cycles 1-8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15, 22",
                  "route": {
                    "code": "C38299",
                    "decode": "Subcutaneous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "BSA-based"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 1,
                      "doseUnit": "mg/m²"
                    },
                    {
                      "level": -2,
                      "dose": 0.7,
                      "doseUnit": "mg/m²"
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG06",
                      "condition": "Grade 3 non-hematological or Grade 4 hematological toxicity",
                      "action": "Hold then reduce",
                      "holdCriteria": "Until symptoms resolve, then reinitiate at a 25% reduced dose.",
                      "provenance": {
                        "section_number": "6.2.3",
                        "page_number": 132,
                        "text_snippet": "Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose. (1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                      }
                    },
                    {
                      "id": "TRIG07",
                      "condition": "Peripheral Neuropathy Grade 2 with pain or Grade 3",
                      "action": "Hold then reduce",
                      "targetLevel": -2,
                      "holdCriteria": "Until toxicity resolves to baseline or <= Grade 1, then reinitiate at 0.7 mg/m² once per week.",
                      "provenance": {
                        "section_number": "6.2.3",
                        "page_number": 132,
                        "text_snippet": "Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADLc)\nWithhold bortezomib therapy until toxicity resolves to baseline or ≥ Grade 1. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Grade 4 Peripheral Neuropathy"
                  ],
                  "provenance": {
                    "section_number": "6.2.3",
                    "page_number": 132,
                    "text_snippet": "Table 10. Dose Reductions and Treatment Guidelines for Toxicity Related to Bortezomib"
                  }
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 12,
                  "text_snippet": "Reference Therapy: Bortezomib powder for solution for injection"
                }
              },
              {
                "id": "INT04",
                "instanceType": "StudyIntervention",
                "name": "Dexamethasone",
                "type": "Drug",
                "role": {
                  "decode": "Concomitant"
                },
                "dosingRegimen": {
                  "dose": 20,
                  "doseUnit": "mg",
                  "frequency": "Cycles 1-8: Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+: Days 1, 2, 8, 9, 15, 16, 22, 23",
                  "route": {
                    "code": "C38288",
                    "decode": "Oral",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "doseCalculationBasis": "Fixed"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false,
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 12,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -2,
                      "dose": 8,
                      "doseUnit": "mg"
                    },
                    {
                      "level": -3,
                      "dose": 4,
                      "doseUnit": "mg"
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Acute pancreatitis"
                  ],
                  "provenance": {
                    "section_number": "6.2.3",
                    "page_number": 133,
                    "text_snippet": "Table 11. Dose Reductions for Dexamethasone\nTable 12. Treatment Guidelines for Toxicity Related to Dexamethasone"
                  }
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 12,
                  "text_snippet": "Reference Therapy: Dexamethasone tablet"
                }
              }
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 8,
              "text_snippet": " Arm 2: Placebo plus Bd"
            }
          }
        ],
        "studyEpochs": [
          {
            "id": "EPOCH01",
            "instanceType": "StudyEpoch",
            "name": "Screening",
            "description": "Screening procedures must be performed within 21 days prior to randomization.",
            "epochType": {
              "code": "C48262",
              "decode": "Screening",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 1,
            "durationDays": 21,
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Screening\nUnless otherwise specified, screening procedures must be performed within 21 days prior to randomization, including disease assessments per the IMWG criteria."
            }
          },
          {
            "id": "EPOCH02",
            "instanceType": "StudyEpoch",
            "name": "Treatment",
            "description": "Cycles 1-8 are 21-day cycles. Cycles 9 and beyond are 35-day cycles. Treatment continues until disease progression, unacceptable toxicity, or other discontinuation criteria are met.",
            "epochType": {
              "code": "C101526",
              "decode": "Treatment",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 2,
            "provenance": {
              "section_number": "1.2",
              "page_number": 8,
              "text_snippet": "Treatment\nDuring Treatment, all subjects will receive venetoclax/placebo orally (PO) once daily (QD) plus Bd as follows beginning on Cycle 1 Day 1."
            }
          },
          {
            "id": "EPOCH03",
            "instanceType": "StudyEpoch",
            "name": "Follow-up",
            "description": "Includes a Safety Follow-Up Visit approximately 30 days after the last dose of study treatment, followed by survival follow-up.",
            "epochType": {
              "code": "C99158",
              "decode": "Follow-up",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 3,
            "provenance": {
              "section_number": "1.2",
              "page_number": 9,
              "text_snippet": "Follow-Up\nAll subjects should have one Safety Follow-Up Visit approximately 30 days after the last dose of study treatment."
            }
          }
        ],
        "studyCells": [
          {
            "id": "CELL01",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT01",
              "INT03",
              "INT04"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 8,
              "text_snippet": " Arm 1: Venetoclax plus Bd"
            }
          },
          {
            "id": "CELL02",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT02",
              "INT03",
              "INT04"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 8,
              "text_snippet": " Arm 2: Placebo plus Bd"
            }
          }
        ],
        "designMetadata": {
          "id": "DESIGN01",
          "designType": {
            "code": "C82639",
            "decode": "Parallel",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          "isRandomized": true,
          "allocationRatio": "2:1",
          "randomizationDetails": {
            "randomization_type": "central",
            "randomization_method": "IRT",
            "provenance": {
              "section_number": "5.3.1.1.1",
              "page_number": 71,
              "text_snippet": "Interactive Response Technology (IRT) will be utilized to register (screen, re-screen and randomize) subjects on study."
            }
          },
          "blindingType": "Double-blind",
          "whoIsBlinded": [
            "Participant",
            "Investigator"
          ],
          "isPlaceboControlled": true,
          "isActiveControlled": true,
          "stratificationFactors": [
            {
              "id": "STRAT01",
              "name": "Prior exposure to bortezomib or other proteasome inhibitors",
              "levels": [
                {
                  "level_id": "STRAT01-L1",
                  "level_name": "proteasome inhibitor-naïve"
                },
                {
                  "level_id": "STRAT01-L2",
                  "level_name": "proteasome inhibitor-sensitive"
                }
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "1.2",
                "page_number": 8,
                "text_snippet": "Subjects will be stratified based on prior exposure to bortezomib or other proteasome inhibitors (proteasome inhibitor-naïve versus proteasome inhibitor-sensitive)"
              }
            },
            {
              "id": "STRAT02",
              "name": "Number of prior lines of therapy",
              "levels": [
                {
                  "level_id": "STRAT02-L1",
                  "level_name": "1"
                },
                {
                  "level_id": "STRAT02-L2",
                  "level_name": "2 or 3"
                }
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "1.2",
                "page_number": 8,
                "text_snippet": "and the number of prior lines of therapy (1 versus 2 or 3)."
              }
            }
          ],
          "provenance": {
            "section_number": "1.2",
            "page_number": 7,
            "text_snippet": "This is a Phase 3, multicenter, randomized, double blind, placebo-controlled, parallel group study."
          }
        }
      },
      "_agentDocumentation": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules → Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA → Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      }
    },
    "endpointsEstimandsSAP": {
      "moduleId": "endpoints_estimands_sap",
      "instanceType": "EndpointsEstimandsSAP",
      "data": {
        "id": "M14-031-endpoints-estimands-sap",
        "instanceType": "EndpointsEstimandsSAP",
        "name": "M14-031 Endpoints, Estimands & SAP",
        "documentType": "protocol",
        "protocol_endpoints": {
          "objectives": [
            {
              "id": "objective-001",
              "instanceType": "Objective",
              "name": "Primary Objective",
              "text": "To compare the progression-free survival (PFS) between treatment arms in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.",
              "level": {
                "code": "C85826",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-001"
              ],
              "provenance": {
                "section_number": "1.2",
                "page_number": 7,
                "text_snippet": "The primary objective of the study is to compare the progression-free survival (PFS) between treatment arms in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma."
              }
            },
            {
              "id": "objective-002",
              "instanceType": "Objective",
              "name": "Secondary Efficacy Objectives",
              "text": "To compare, between treatment arms, the following: Very Good Partial Response (VGPR) or better response rate; PFS in subjects with high BCL-2 expression; duration of response (DOR); Patient Reported Outcomes (PRO); overall survival (OS); time to disease progression (TTP); objective response rate (ORR); and minimal residual disease (MRD) negativity rate.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006",
                "endpoint-007",
                "endpoint-008",
                "endpoint-009"
              ],
              "provenance": {
                "section_number": "1.2",
                "page_number": 7,
                "text_snippet": "The secondary objectives are to compare, between treatment arms, the following: Very Good Partial Response (VGPR) or better response rate; PFS in subjects with high BCL-2 expression; duration of response (DOR); Patient Reported Outcomes (PRO) including Worst Pain (Brief Pain Inventory – Short Form [BPI-SF]), Physical Functioning and Global Health Status/Quality of Life (GHS/QoL) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core [EORTC QLQ-C30]), and"
              }
            },
            {
              "id": "objective-003",
              "instanceType": "Objective",
              "name": "Secondary Safety Objective",
              "text": "To compare safety between treatment arms.",
              "level": {
                "code": "C49657",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-013"
              ],
              "provenance": {
                "section_number": "1.2",
                "page_number": 7,
                "text_snippet": "The secondary objectives are to compare, between treatment arms, the following: ... and safety."
              }
            },
            {
              "id": "objective-004",
              "instanceType": "Objective",
              "name": "Exploratory Objectives",
              "text": "To assess clinical benefit rate (CBR), disease control rate (DCR), time to response (TTR), time to next treatment (TNT), other PRO endpoints, and a preliminary assessment of potential biomarkers for association with PK, safety and efficacy.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-010",
                "endpoint-011",
                "endpoint-012"
              ],
              "provenance": {
                "section_number": "4.0",
                "page_number": 38,
                "text_snippet": "The tertiary objectives of the study are to assess clinical benefit rate (CBR), disease control rate (DCR), time to response (TTR), time to next treatment (TNT), other PRO endpoints (remaining subscales/items from BPI-SF, EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Multiple Myeloma Module [EORTC QLQ-MY20], and Euroqol EQ-5D-5L), and a preliminary assessment of potential biomarkers for association with PK, safety and efficacy."
              }
            }
          ],
          "endpoints": [
            {
              "id": "endpoint-001",
              "instanceType": "Endpoint",
              "name": "Progression-Free Survival (PFS)",
              "label": "Primary Efficacy Endpoint",
              "text": "Time from randomization to the first documented disease progression (PD) per IMWG criteria or death due to any cause, whichever occurs first.",
              "purpose": "To assess the effect of treatment on disease progression or death.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Independent Review Committee (IRC)",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "Primary Efficacy Endpoint:\nThe primary efficacy endpoint is PFS. PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first. The primary analysis of PFS will be based on data from the IRC's assessment of disease progression."
              }
            },
            {
              "id": "endpoint-002",
              "instanceType": "Endpoint",
              "name": "Very Good Partial Response (VGPR) or Better Response Rate",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of subjects with documented Complete Response (CR), stringent Complete Response (sCR), or VGPR.",
              "purpose": "To assess deep tumor response to treatment.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "VGPR or better response rate is defined as the proportion of subjects with documented Complete Response (CR), stringent Complete Response (sCR), or VGPR."
              }
            },
            {
              "id": "endpoint-003",
              "instanceType": "Endpoint",
              "name": "Overall Survival (OS)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to death due to any cause.",
              "purpose": "To assess the effect of treatment on survival.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Survival follow-up",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "OS is defined as time from randomization to death due to any cause."
              }
            },
            {
              "id": "endpoint-004",
              "instanceType": "Endpoint",
              "name": "PFS in Subjects with High BCL-2 Expression",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to PD or death in the subgroup of subjects with high BCL-2 expression.",
              "purpose": "To assess treatment effect in a biomarker-defined subgroup.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria and IHC analysis",
              "assessor": "IRC",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "Secondary efficacy endpoints are as follows: ... PFS in subjects with high BCL-2 expression"
              }
            },
            {
              "id": "endpoint-005",
              "instanceType": "Endpoint",
              "name": "Duration of Response (DOR)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from first documented response (PR or better) to the date of first documented PD or death due to multiple myeloma, whichever occurs first.",
              "purpose": "To assess the durability of response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "DOR is defined as the time from first documented response (PR or better) to the date of first documented PD or death due to multiple myeloma, whichever occurs first."
              }
            },
            {
              "id": "endpoint-006",
              "instanceType": "Endpoint",
              "name": "Time to Progression (TTP)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time from randomization to the date of first documented PD or death due to multiple myeloma, whichever occurs first.",
              "purpose": "To assess time to disease progression.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "TTP is defined as the time from randomization to the date of first documented PD or death due to multiple myeloma, whichever occurs first."
              }
            },
            {
              "id": "endpoint-007",
              "instanceType": "Endpoint",
              "name": "Objective Response Rate (ORR)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of subjects with documented PR or better.",
              "purpose": "To assess overall tumor response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "ORR is defined as the proportion of subjects with documented PR or better."
              }
            },
            {
              "id": "endpoint-008",
              "instanceType": "Endpoint",
              "name": "Minimal Residual Disease (MRD) Negativity Rate",
              "label": "Secondary Efficacy Endpoint",
              "text": "Proportion of subjects with MRD negativity, defined at 10^-5 threshold as assessed by NGS.",
              "purpose": "To assess very deep levels of response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Next Generation Sequencing (NGS)",
              "assessor": "Central Laboratory",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "8.1.3.3",
                "page_number": 141,
                "text_snippet": "MRD negativity will be defined at 10–5 threshold as described in Section 5.3.6."
              }
            },
            {
              "id": "endpoint-009",
              "instanceType": "Endpoint",
              "name": "Patient Reported Outcomes (PROs)",
              "label": "Secondary Efficacy Endpoint",
              "text": "Change from baseline in Worst Pain (BPI-SF), Physical Functioning (EORTC QLQ-C30), Global Health Status/Quality of Life (EORTC QLQ-C30), and Fatigue (PROMIS Cancer Fatigue SF).",
              "purpose": "To assess the impact of treatment on patient-reported symptoms and quality of life.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "BPI-SF, EORTC QLQ-C30, PROMIS",
              "assessor": "Patient",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "Secondary efficacy endpoints are as follows: ... PROs: Worst Pain (BPI-SF), Physical Functioning (EORTC QLQ-C30); ... PROs GHS/QoL (EORTC QLQ-C30), and Fatigue (PROMIS Cancer Fatigue SF)."
              }
            },
            {
              "id": "endpoint-010",
              "instanceType": "Endpoint",
              "name": "Clinical Benefit Rate (CBR)",
              "label": "Exploratory Endpoint",
              "text": "Proportion of subjects with documented Minimal Response (MR) or better.",
              "purpose": "To assess the proportion of subjects deriving clinical benefit.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "8.1.3.3",
                "page_number": 141,
                "text_snippet": "CBR is defined as the proportion of subjects with documented MR or better."
              }
            },
            {
              "id": "endpoint-011",
              "instanceType": "Endpoint",
              "name": "Disease Control Rate (DCR)",
              "label": "Exploratory Endpoint",
              "text": "Proportion of subjects with documented MR or better or Stable Disease (SD) lasting at least 8 weeks.",
              "purpose": "To assess the proportion of subjects with controlled disease.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "8.1.3.3",
                "page_number": 141,
                "text_snippet": "DCR is defined as the proportion of subjects with documented MR or better or SD lasting at least 8 weeks."
              }
            },
            {
              "id": "endpoint-012",
              "instanceType": "Endpoint",
              "name": "Time to Response (TTR)",
              "label": "Exploratory Endpoint",
              "text": "Time from randomization to the date of first documented response (PR or better).",
              "purpose": "To assess the speed of response.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "IMWG Criteria",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "8.1.3.3",
                "page_number": 142,
                "text_snippet": "For a given subject, TTR is defined as the number of days from the date the subject was randomized to the date of first documented response (PR or better)."
              }
            },
            {
              "id": "endpoint-013",
              "instanceType": "Endpoint",
              "name": "Safety and Tolerability",
              "label": "Safety Endpoint",
              "text": "Incidence, severity, and causality of adverse events (AEs), serious adverse events (SAEs), and changes in laboratory values, vital signs, and ECGs.",
              "purpose": "To evaluate the safety profile of the treatment.",
              "level": {
                "code": "C49656",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25463",
                "decode": "Count Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "NCI CTCAE v4.03",
              "assessor": "Investigator",
              "primary_timepoint_weeks": null,
              "assessment_timepoints_weeks": [],
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "1.2",
                "page_number": 13,
                "text_snippet": "Safety:\nAbbVie will assess adverse events, laboratory data, electrocardiograms (ECG) and vital signs throughout the study. Adverse events intensity and laboratory evaluation changes will be assessed by utilizing National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03."
              }
            }
          ],
          "estimands": [
            {
              "id": "estimand-001",
              "instanceType": "Estimand",
              "name": "Primary Estimand for PFS",
              "text": "Treatment effect on Progression-Free Survival comparing Venetoclax plus Bortezomib and Dexamethasone vs Placebo plus Bortezomib and Dexamethasone in the ITT population.",
              "endpoint_id": "endpoint-001",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Venetoclax plus Bortezomib and Dexamethasone (Bd)"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Placebo plus Bortezomib and Dexamethasone (Bd)"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 8,
                  "text_snippet": "Once screening procedures are complete and eligibility is confirmed, subjects will be randomized 2:1 to one of the following two arms:\nArm 1: Venetoclax plus Bd\nArm 2: Placebo plus Bd"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Intent-to-Treat population, including all randomized subjects.",
                "provenance": {
                  "section_number": "8.1.1",
                  "page_number": 137,
                  "text_snippet": "Intent-To-Treat (ITT) analysis set consists of all randomized subjects. The data from the ITT population will be analyzed by the treatment group assignment given at the time of randomization, even if the subject does not receive the correct treatment or is not compliant to the protocol procedures."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-001",
                "description": "Progression-Free Survival (PFS) per IRC assessment, defined as time from randomization to disease progression or death from any cause.",
                "provenance": {
                  "section_number": "8.1.3.1",
                  "page_number": 138,
                  "text_snippet": "The primary endpoint is PFS based on IMWG criteria for multiple myeloma (Appendix J)13,14 per IRC assessment.\n\nFor a given subject, PFS is defined as the number of days from the date the subject was randomized to the date of the first documented PD or death due to any cause, whichever occurs first."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-001",
                  "name": "Discontinuation of study treatment",
                  "description": "Subject discontinues study treatment for reasons other than disease progression (e.g., toxicity, withdrawal of consent).",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "All events of PD or death are included, regardless of whether the subject was still taking study drug or had previously discontinued.",
                  "provenance": {
                    "section_number": "8.1.3.1",
                    "page_number": 138,
                    "text_snippet": "All events of PD will be included, regardless of whether the event occurred while the subject was still taking study drug or had previously discontinued study drug."
                  }
                },
                {
                  "id": "ice-002",
                  "name": "Initiation of new anti-cancer therapy",
                  "description": "Subject starts a new anti-cancer therapy prior to documented disease progression.",
                  "strategy": {
                    "code": "C178901",
                    "decode": "Hypothetical Strategy"
                  },
                  "strategy_rationale": "Subjects are censored at the date of the last adequate assessment prior to the start of new anti-cancer therapy.",
                  "provenance": {
                    "section_number": "Table 13",
                    "page_number": 139,
                    "text_snippet": "Start of new anti-cancer therapy prior to PD/death | If no adequate assessment is available prior to start of new anti-cancer therapy then date of randomization. Otherwise, date of the last adequate assessment prior to start of new anti-cancer therapy | Censor"
                  }
                },
                {
                  "id": "ice-003",
                  "name": "Death",
                  "description": "Death without prior documented disease progression.",
                  "strategy": {
                    "code": "C178900",
                    "decode": "Composite Strategy"
                  },
                  "strategy_rationale": "Death is a component of the composite endpoint of Progression-Free Survival.",
                  "provenance": {
                    "section_number": "8.1.3.1",
                    "page_number": 138,
                    "text_snippet": "For a given subject, PFS is defined as the number of days from the date the subject was randomized to the date of the first documented PD or death due to any cause, whichever occurs first."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-001",
                "sens-002",
                "sens-003",
                "sens-004"
              ],
              "provenance": {
                "section_number": "8.1.5.1",
                "page_number": 143,
                "text_snippet": "The study is designed to test the following primary statistical hypothesis:\nH0: S(t)Venetoclax + Bd = S(t)Placebo + Bd vs. H1: S(t)Venetoclax +Bd ≠ S(t)Placebo + Bd ,\nwhere S(t) is the survivorship function of PFS at time t."
              }
            },
            {
              "id": "estimand-002",
              "instanceType": "Estimand",
              "name": "Estimand for VGPR or better rate",
              "text": "Treatment effect on VGPR or better rate comparing Venetoclax+Bd vs Placebo+Bd in the ITT population.",
              "endpoint_id": "endpoint-002",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Venetoclax plus Bortezomib and Dexamethasone (Bd)"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Placebo plus Bortezomib and Dexamethasone (Bd)"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 8,
                  "text_snippet": "Once screening procedures are complete and eligibility is confirmed, subjects will be randomized 2:1 to one of the following two arms:\nArm 1: Venetoclax plus Bd\nArm 2: Placebo plus Bd"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Intent-to-Treat population, including all randomized subjects.",
                "provenance": {
                  "section_number": "8.1.1",
                  "page_number": 137,
                  "text_snippet": "Intent-To-Treat (ITT) analysis set consists of all randomized subjects."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-002",
                "description": "VGPR or better response rate (CR, sCR, or VGPR).",
                "provenance": {
                  "section_number": "8.1.3.2",
                  "page_number": 139,
                  "text_snippet": "VGPR or better response rate is defined as the proportion of subjects with documented CR, sCR, or VGPR."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-004",
                  "name": "Discontinuation of study treatment or death",
                  "description": "Subject discontinues treatment or dies before a response can be assessed or confirmed.",
                  "strategy": {
                    "code": "C178900",
                    "decode": "Composite Strategy"
                  },
                  "strategy_rationale": "Subjects who discontinue or die before achieving a response are considered non-responders.",
                  "provenance": {
                    "section_number": "8.1.5.2",
                    "page_number": 143,
                    "text_snippet": "VGPR or better response rate and ORR will be analyzed by using Cochran-Mantel-Haenszel test. Estimated rates along with corresponding 95% confidence intervals will be presented."
                  }
                }
              ],
              "summary_measure": {
                "code": "C68680",
                "decode": "Risk Difference"
              },
              "sensitivity_analysis_ids": [],
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 143,
                "text_snippet": "VGPR or better response rate and ORR will be analyzed by using Cochran-Mantel-Haenszel test."
              }
            },
            {
              "id": "estimand-003",
              "instanceType": "Estimand",
              "name": "Estimand for Overall Survival",
              "text": "Treatment effect on Overall Survival comparing Venetoclax+Bd vs Placebo+Bd in the ITT population.",
              "endpoint_id": "endpoint-003",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "Venetoclax plus Bortezomib and Dexamethasone (Bd)"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98390",
                    "decode": "Placebo Comparator Arm"
                  },
                  "description": "Placebo plus Bortezomib and Dexamethasone (Bd)"
                },
                "provenance": {
                  "section_number": "1.2",
                  "page_number": 8,
                  "text_snippet": "Once screening procedures are complete and eligibility is confirmed, subjects will be randomized 2:1 to one of the following two arms:\nArm 1: Venetoclax plus Bd\nArm 2: Placebo plus Bd"
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Intent-to-Treat population, including all randomized subjects.",
                "provenance": {
                  "section_number": "8.1.1",
                  "page_number": 137,
                  "text_snippet": "Intent-To-Treat (ITT) analysis set consists of all randomized subjects."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-003",
                "description": "Overall Survival, defined as time from randomization to death from any cause.",
                "provenance": {
                  "section_number": "8.1.3.2",
                  "page_number": 140,
                  "text_snippet": "For a given subject, time to death (OS) is defined as the number of days from the date the subject was randomized to the date of the subject's death due to any cause."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-005",
                  "name": "Discontinuation of study treatment or initiation of new anti-cancer therapy",
                  "description": "Subject discontinues assigned treatment and/or initiates subsequent anti-cancer therapy.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "All deaths are included regardless of whether the subject discontinued study drug or received other therapies.",
                  "provenance": {
                    "section_number": "8.1.3.2",
                    "page_number": 140,
                    "text_snippet": "All events of death will be included, regardless of whether the event occurred while the subject was still taking study drug or after the subject discontinued study drug."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [],
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 144,
                "text_snippet": "The OS will be analyzed by using a stratified two-sided 3-look group sequential log-rank test with a cumulative two-sided type-I error rate of α = 0.05 (one-sided type I error rate of α = 0.025)."
              }
            }
          ],
          "analysis_populations": [
            {
              "id": "population-001",
              "instanceType": "AnalysisPopulation",
              "name": "Intent-to-Treat Population",
              "label": "ITT",
              "text": "All randomized subjects. The data from the ITT population will be analyzed by the treatment group assignment given at the time of randomization.",
              "population_type": {
                "code": "C71104",
                "decode": "Intent-to-Treat Population"
              },
              "inclusion_criteria": [
                "All randomized subjects"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006",
                "endpoint-007",
                "endpoint-008",
                "endpoint-009",
                "endpoint-010",
                "endpoint-011",
                "endpoint-012"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.1.1",
                "page_number": 137,
                "text_snippet": "Intent-To-Treat (ITT) analysis set consists of all randomized subjects. The data from the ITT population will be analyzed by the treatment group assignment given at the time of randomization, even if the subject does not receive the correct treatment or is not compliant to the protocol procedures."
              }
            },
            {
              "id": "population-002",
              "instanceType": "AnalysisPopulation",
              "name": "Safety Population",
              "label": "Safety",
              "text": "All randomized subjects who take at least one dose of study drug.",
              "population_type": {
                "code": "C115932",
                "decode": "Safety Population"
              },
              "inclusion_criteria": [
                "All randomized subjects who received at least one dose of study drug"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-013"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "8.1.1",
                "page_number": 137,
                "text_snippet": "Safety analysis set consists of all randomized subjects who take at least one dose of study drug."
              }
            }
          ],
          "provenance": {
            "section_number": "4.0",
            "page_number": 38,
            "text_snippet": "4.0 Study Objectives"
          }
        },
        "sap_analyses": {
          "sensitivity_analyses": [
            {
              "id": "sens-001",
              "instanceType": "SensitivityAnalysis",
              "name": "PFS by Investigator Assessment",
              "description": "The primary PFS analysis will be repeated based on the Investigator's assessment of disease progression.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the robustness of the primary PFS result to the choice of assessor (IRC vs Investigator).",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Censoring rules as per primary analysis.",
              "statistical_model": "Stratified log-rank test and Cox proportional hazards model.",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "1. PFS based on assessment by Investigator."
              }
            },
            {
              "id": "sens-002",
              "instanceType": "SensitivityAnalysis",
              "name": "PFS using actual event date",
              "description": "The primary PFS analysis will be repeated using the actual event date of PD or death as the event date, regardless of the number of preceding missing assessments.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the impact of censoring rules related to missing assessments on the primary PFS result.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "No censoring for missing assessments prior to an event.",
              "statistical_model": "Stratified log-rank test and Cox proportional hazards model.",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "2. Using the actual event date of PD or death as event date, regardless of the number of preceding missing assessments."
              }
            },
            {
              "id": "sens-003",
              "instanceType": "SensitivityAnalysis",
              "name": "PFS without censoring for new therapy",
              "description": "The primary PFS analysis will be repeated without considering the start of new anticancer therapy as a reason for censoring.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To evaluate a treatment policy strategy for the intercurrent event of starting new anti-cancer therapy.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Subjects are not censored at the start of new anti-cancer therapy.",
              "statistical_model": "Stratified log-rank test and Cox proportional hazards model.",
              "covariates": [],
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "3. Not considering taking new anticancer therapy as a reason for censoring."
              }
            },
            {
              "id": "sens-004",
              "instanceType": "SensitivityAnalysis",
              "name": "PFS Robustness Analysis with Covariates",
              "description": "A robustness analysis for PFS will be performed using a stratified, adjusted Cox model.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the robustness of the treatment effect after adjusting for important baseline prognostic factors.",
              "analysis_population_id": "population-001",
              "missing_data_handling": "Handled by the Cox model for subjects censored for other reasons.",
              "statistical_model": "Stratified Cox proportional hazards model.",
              "covariates": [
                "age group (< 65 years/≥ 65 years)",
                "renal function",
                "cytogenetic (high risk/standard risk)",
                "prior stem cell transplant (yes/no)",
                "BCL-2 expression (high/low)",
                "MM stage"
              ],
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "4. A robustness analysis will be performed using a stratified, adjusted Cox model, i.e., the MODEL statement will include the treatment group variable; and, e.g., age group (< 65 years/≥ 65 years), renal function, cytogenetic (high risk/standard risk), prior stem cell transplant (yes/no), BCL-2 expression (high/low) and MM stage as covariates."
              }
            }
          ],
          "statistical_methods": [
            {
              "id": "method-001",
              "instanceType": "StatisticalMethod",
              "name": "Primary Analysis of PFS",
              "description": "A stratified two-sided log-rank test will be used to test PFS. The hazards ratio (HR) for treatment effect will be estimated from a Cox's proportional hazards model with treatment and stratification factors included. Survivorship functions will be estimated using the Kaplan-Meier method.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "model_type": "Cox Proportional Hazards Model",
              "stratification_factors": [
                "prior exposure to bortezomib or other proteasome inhibitors (proteasome inhibitor-naïve versus proteasome inhibitor-sensitive)",
                "number of prior lines of therapy (1 versus 2 or 3)"
              ],
              "covariates": [
                "treatment"
              ],
              "alpha": 0.05,
              "multiplicity": {},
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.1",
                "page_number": 143,
                "text_snippet": "For PFS, a stratified two-sided log-rank test with two-sided type-I error rate of α = 0.05 (one-sided type I error rate of α = 0.025) will be used to test the primary null hypothesis. The hazards ratio (HR) for treatment effect will be estimated and its two-sided 95% confidence interval will be provided. The estimation will be based on a Cox's proportional hazards model with treatment and stratification factors included."
              }
            },
            {
              "id": "method-002",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of Binary Endpoints",
              "description": "VGPR or better response rate, ORR, MRD negativity rate, CBR, and DCR will be analyzed by using Cochran-Mantel-Haenszel test. Estimated rates along with corresponding 95% confidence intervals will be presented.",
              "for_endpoint_ids": [
                "endpoint-002",
                "endpoint-007",
                "endpoint-008",
                "endpoint-010",
                "endpoint-011"
              ],
              "model_type": "Cochran-Mantel-Haenszel",
              "stratification_factors": [],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {},
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 143,
                "text_snippet": "VGPR or better response rate and ORR will be analyzed by using Cochran-Mantel-Haenszel test. Estimated rates along with corresponding 95% confidence intervals will be presented."
              }
            },
            {
              "id": "method-003",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of Overall Survival",
              "description": "OS will be analyzed by using a stratified two-sided 3-look group sequential log-rank test with a cumulative two-sided type-I error rate of α = 0.05. The HR will be estimated from a Cox's proportional hazards model.",
              "for_endpoint_ids": [
                "endpoint-003"
              ],
              "model_type": "Group Sequential Log-Rank Test",
              "stratification_factors": [
                "prior exposure to bortezomib or other proteasome inhibitors (proteasome inhibitor-naïve versus proteasome inhibitor-sensitive)",
                "number of prior lines of therapy (1 versus 2 or 3)"
              ],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {
                "method": "Group Sequential (O'Brien-Fleming)",
                "description": "3-look group sequential design with alpha-spending."
              },
              "software_package": "EAST version 6.4",
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 144,
                "text_snippet": "The OS will be analyzed by using a stratified two-sided 3-look group sequential log-rank test with a cumulative two-sided type-I error rate of α = 0.05 (one-sided type I error rate of α = 0.025). The hazards ratio for treatment effect will be estimated and its two-sided 95% confidence interval will be provided. The estimation will be based on a Cox's proportional hazards model with treatment and stratification factors in it."
              }
            },
            {
              "id": "method-004",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of Other Time-to-Event Endpoints",
              "description": "PFS in subjects with high BCL-2 expression, DOR, TTP, TTR, and TNT will be analyzed by using stratified log-rank test. The HRs will be estimated from a Cox's proportional hazards model.",
              "for_endpoint_ids": [
                "endpoint-004",
                "endpoint-005",
                "endpoint-006",
                "endpoint-012"
              ],
              "model_type": "Stratified Log-Rank Test",
              "stratification_factors": [
                "prior exposure to bortezomib or other proteasome inhibitors (proteasome inhibitor-naïve versus proteasome inhibitor-sensitive)",
                "number of prior lines of therapy (1 versus 2 or 3)"
              ],
              "covariates": [],
              "alpha": 0.05,
              "multiplicity": {},
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 144,
                "text_snippet": "DOR and TTP will be analyzed by using stratified log-rank test.\n\nThe hazards ratios for treatment effect will be estimated and two-sided 95% confidence intervals will be provided. The estimation will be based on a Cox's proportional hazards model with treatment and stratification factors in it."
              }
            },
            {
              "id": "method-005",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of Patient-Reported Outcomes",
              "description": "For PROs, change in score from baseline will be compared between treatment arms. Descriptive statistics will be used to summarize outcomes.",
              "for_endpoint_ids": [
                "endpoint-009"
              ],
              "model_type": "Descriptive Statistics",
              "stratification_factors": [],
              "covariates": [],
              "alpha": null,
              "multiplicity": {},
              "software_package": null,
              "procedure": null,
              "provenance": {
                "section_number": "8.1.5.3",
                "page_number": 145,
                "text_snippet": "For PROs, change in score from baseline will be compared between treatment arms for the following domains: Worst Pain (BPI-SF), Physical Functioning (EORTC QLQ-C30), Fatigue (PROMIS-Fatigue), and Global Health Status/QoL (EORTC QLQ-C30)."
              }
            }
          ],
          "subgroup_analyses": [
            {
              "id": "subgroup-001",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by BCL-2 Expression",
              "description": "A subgroup analysis will be performed for the primary endpoint PFS by BCL-2 expression levels (high/low).",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "BCL-2 expression",
              "categories": [
                {
                  "name": "High BCL-2 expression",
                  "definition": "BCL-2 expression above a pre-defined threshold"
                },
                {
                  "name": "Low BCL-2 expression",
                  "definition": "BCL-2 expression at or below a pre-defined threshold"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.5.2",
                "page_number": 144,
                "text_snippet": "To assess PFS in subjects with high BCL-2 expression, a subgroup analysis will be performed for the primary endpoint PFS by BCL-2 expression levels (high/low)."
              }
            },
            {
              "id": "subgroup-002",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by Age Group",
              "description": "Subgroup analysis of PFS by age group.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Age",
              "categories": [
                {
                  "name": "< 65 years",
                  "definition": "Age less than 65 years"
                },
                {
                  "name": ">= 65 years",
                  "definition": "Age 65 years or greater"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "A robustness analysis will be performed using a stratified, adjusted Cox model, i.e., the MODEL statement will include the treatment group variable; and, e.g., age group (< 65 years/≥ 65 years)... as covariates."
              }
            },
            {
              "id": "subgroup-003",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by Prior Lines of Therapy",
              "description": "Subgroup analysis of PFS by number of prior lines of therapy.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Number of prior lines of therapy",
              "categories": [
                {
                  "name": "1 prior line",
                  "definition": "1 prior line of therapy"
                },
                {
                  "name": "2 or 3 prior lines",
                  "definition": "2 or 3 prior lines of therapy"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.2",
                "page_number": 137,
                "text_snippet": "Frequencies and percentages will be computed for categorical data (e.g., sex, race, number of prior therapies [1 versus 2 versus 3]..."
              }
            },
            {
              "id": "subgroup-004",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by Prior Proteasome Inhibitor Exposure",
              "description": "Subgroup analysis of PFS by prior exposure to bortezomib or other proteasome inhibitors.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Prior PI exposure",
              "categories": [
                {
                  "name": "Proteasome inhibitor-naïve",
                  "definition": "No prior exposure to proteasome inhibitors"
                },
                {
                  "name": "Proteasome inhibitor-sensitive",
                  "definition": "Prior exposure and sensitive to proteasome inhibitors"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.2",
                "page_number": 137,
                "text_snippet": "Frequencies and percentages will be computed for categorical data (e.g., ... prior exposure to bortezomib or other proteasome inhibitors [proteasome inhibitor-sensitive versus proteasome inhibitor-naïve]..."
              }
            },
            {
              "id": "subgroup-005",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by Cytogenetic Risk",
              "description": "Subgroup analysis of PFS by cytogenetic risk status.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Cytogenetic risk",
              "categories": [
                {
                  "name": "High risk",
                  "definition": "High risk cytogenetics"
                },
                {
                  "name": "Standard risk",
                  "definition": "Standard risk cytogenetics"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "A robustness analysis will be performed using a stratified, adjusted Cox model, i.e., the MODEL statement will include ... cytogenetic (high risk/standard risk)... as covariates."
              }
            },
            {
              "id": "subgroup-006",
              "instanceType": "SubgroupAnalysis",
              "name": "PFS by Prior Stem Cell Transplant",
              "description": "Subgroup analysis of PFS by prior stem cell transplant status.",
              "for_endpoint_ids": [
                "endpoint-001"
              ],
              "subgroup_variable": "Prior SCT",
              "categories": [
                {
                  "name": "Yes",
                  "definition": "Subject had a prior stem cell transplant"
                },
                {
                  "name": "No",
                  "definition": "Subject did not have a prior stem cell transplant"
                }
              ],
              "analysis_method": "Subgroup-specific HR and 95% CI from Cox model.",
              "interaction_test": false,
              "forest_plot": false,
              "provenance": {
                "section_number": "8.1.5.4",
                "page_number": 146,
                "text_snippet": "A robustness analysis will be performed using a stratified, adjusted Cox model, i.e., the MODEL statement will include ... prior stem cell transplant (yes/no)... as covariates."
              }
            }
          ],
          "multiplicity_adjustment": {
            "method": "Hierarchical Testing / Gatekeeping",
            "description": "Statistical testing of the secondary endpoints will be performed only if the primary efficacy analysis of PFS is significant. The testing order and details of testing procedures will be provided in the SAP.",
            "alpha_allocation": "Overall family-wise two-sided type I error rate of 0.05.",
            "gatekeeping_strategy": "The primary endpoint of PFS serves as the gatekeeper for testing secondary endpoints.",
            "provenance": {
              "section_number": "8.1.5.6",
              "page_number": 147,
              "text_snippet": "Statistical tests for the secondary endpoints will be implemented in the testing strategy to maintain family-wise two-sided type I error rate at 0.05. Each of these tests will be performed at an overall two-sided significance level of 0.05. Statistical testing of the secondary endpoints will be performed only if the primary efficacy analysis of PFS is significant."
            }
          },
          "missing_data_handling": {
            "primary_method": "Censoring",
            "method_description": "For time-to-event endpoints (PFS, OS, DOR, TTP), data for subjects who do not experience the event of interest by the end of the study or are lost to follow-up will be censored at the last date they were known to be event-free. Specific censoring rules are defined for different scenarios, such as missing assessments or starting new anti-cancer therapy.",
            "assumptions": [],
            "provenance": {
              "section_number": "Table 13",
              "page_number": 139,
              "text_snippet": "Table 13. Event and Censoring Date Used in PFS"
            }
          },
          "provenance": {
            "section_number": "8.0",
            "page_number": 136,
            "text_snippet": "8.0 Statistical Methods and Determination of Sample Size"
          }
        },
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-031"
        }
      },
      "_agentDocumentation": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA → Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal → Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      }
    },
    "adverseEvents": {
      "moduleId": "adverse_events",
      "instanceType": "AdverseEvents",
      "data": {
        "id": "M14-031-adverse-events",
        "instanceType": "AdverseEvents",
        "name": "M14-031 Adverse Events",
        "ae_definitions": {
          "ae_definition": "Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.",
          "teae_definition": "Any adverse event with onset or worsening reported by a subject from the time that the first dose of venetoclax/placebo, bortezomib, or dexamethasone is administered until 30 days have elapsed following discontinuation of venetoclax/placebo, bortezomib, and dexamethasone administration.",
          "collection_start": "signing of the study specific informed consent",
          "collection_end": "30 days following discontinuation of study treatment administration",
          "collection_end_days": 30,
          "pre_existing_condition_handling": "Any worsening of a pre-existing condition or illness is considered an adverse event.",
          "provenance": {
            "section_number": "6.1.1.1",
            "page_number": 114,
            "text_snippet": "An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment... Any worsening of a pre-existing condition or illness is considered an adverse event."
          }
        },
        "sae_criteria": {
          "sae_definition": "An adverse event that meets any of the following criteria: Death of Subject, Life-Threatening, Hospitalization or Prolongation of Hospitalization, Congenital Anomaly, Persistent or Significant Disability/Incapacity, Important Medical Event.",
          "criteria": [
            {
              "id": "sae-001",
              "criterion_type": {
                "code": "C48275",
                "decode": "Death",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in the death of a subject.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 115,
                "text_snippet": "Death of Subject An event that results in the death of a subject."
              }
            },
            {
              "id": "sae-002",
              "criterion_type": {
                "code": "C82569",
                "decode": "Life Threatening",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that, in the opinion of the Investigator, would have resulted in immediate fatality if medical intervention had not been taken. This does not include an event that would have been fatal if it had occurred in a more severe form.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 115,
                "text_snippet": "Life-Threatening An event that, in the opinion of the Investigator, would have resulted in immediate fatality if medical intervention had not been taken. This does not include an event that would have been fatal if it had occurred in a more severe form."
              }
            },
            {
              "id": "sae-003",
              "criterion_type": {
                "code": "C83052",
                "decode": "Hospitalization Required",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in an admission to the hospital for any length of time.",
              "exclusions": [
                "Emergency room visit or admission to an outpatient facility."
              ],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 115,
                "text_snippet": "Hospitalization or Prolongation of Hospitalization: An event that results in an admission to the hospital for any length of time or prolongs the subject's hospital stay. This does not include an emergency room visit or admission to an outpatient facility."
              }
            },
            {
              "id": "sae-004",
              "criterion_type": {
                "code": "C83053",
                "decode": "Prolonged Hospitalization",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that prolongs the subject's hospital stay.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 115,
                "text_snippet": "Hospitalization or Prolongation of Hospitalization: An event that results in an admission to the hospital for any length of time or prolongs the subject's hospital stay."
              }
            },
            {
              "id": "sae-005",
              "criterion_type": {
                "code": "C82577",
                "decode": "Disability",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An event that results in a condition that substantially interferes with the activities of daily living of a study subject.",
              "exclusions": [
                "Experiences of relatively minor medical significance such as headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle)."
              ],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 116,
                "text_snippet": "Persistent or Significant Disability/Incapacity: An event that results in a condition that substantially interferes with the activities of daily living of a study subject. Disability is not intended to include experiences of relatively minor medical significance such as headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle)."
              }
            },
            {
              "id": "sae-006",
              "criterion_type": {
                "code": "C82579",
                "decode": "Congenital Anomaly",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An anomaly detected at or after birth, or any anomaly that results in fetal loss.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 115,
                "text_snippet": "Congenital Anomaly: An anomaly detected at or after birth, or any anomaly that results in fetal loss."
              }
            },
            {
              "id": "sae-007",
              "criterion_type": {
                "code": "C84265",
                "decode": "Medically Important",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above (i.e., death of subject, life-threatening, hospitalization, prolongation of hospitalization, congenital anomaly, or persistent or significant disability/incapacity). Additionally, any elective or spontaneous abortion or stillbirth is considered an important medical event. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.",
              "exclusions": [],
              "provenance": {
                "section_number": "6.1.1.2",
                "page_number": 116,
                "text_snippet": "Important Medical Event Requiring Medical or Surgical Intervention to Prevent Serious Outcome: An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may jeopardize the subject and may require medical or surgical intervention to prevent any of the outcomes listed above..."
              }
            }
          ],
          "provenance": {
            "section_number": "6.1.1.2",
            "page_number": 115,
            "text_snippet": "If an adverse event meets any of the following criteria, it is to be reported to AbbVie as a serious adverse event (SAE) within 24 hours of the site being made aware of the serious adverse event:"
          }
        },
        "grading_system": {
          "system_name": "NCI CTCAE",
          "system_version": "4.03",
          "grade_definitions": [
            {
              "grade": 1,
              "label": "Mild",
              "definition": "The adverse event is transient and easily tolerated by the subject (mild)."
            },
            {
              "grade": 2,
              "label": "Moderate",
              "definition": "The adverse event causes the subject discomfort and interrupts the subject's usual activities (moderate)."
            },
            {
              "grade": 3,
              "label": "Severe",
              "definition": "The adverse event causes considerable interference with the subject's usual activities and may be incapacitating (moderate to severe)."
            },
            {
              "grade": 4,
              "label": "Life-threatening",
              "definition": "The adverse event is life threatening requiring urgent intervention (severe)."
            },
            {
              "grade": 5,
              "label": "Death",
              "definition": "The adverse event resulted in death of the subject (severe)."
            }
          ],
          "provenance": {
            "section_number": "6.1.2",
            "page_number": 117,
            "text_snippet": "The Investigator will rate the severity of each adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.03). For adverse events not captured by the Common Terminology Criteria, the following should be used: Grade 1 The adverse event is transient and easily tolerated by the subject (mild). Grade 2 The adverse event causes the subject discomfort and interrupts the subject's usual activities (moderate)."
          }
        },
        "causality_assessment": {
          "method_description": "The Investigator will assess the relationship of each adverse event to venetoclax, to bortezomib, and to dexamethasone.",
          "categories": [
            {
              "category_name": "Reasonable Possibility",
              "definition": "An adverse event where there is evidence to suggest a causal relationship between the study treatment and the adverse event.",
              "cdisc_mapping": {
                "code": "C53258",
                "decode": "Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              }
            },
            {
              "category_name": "No Reasonable Possibility",
              "definition": "An adverse event where there is no evidence to suggest a causal relationship between the study treatment and the adverse event.",
              "cdisc_mapping": {
                "code": "C53257",
                "decode": "Not Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              }
            }
          ],
          "provenance": {
            "section_number": "6.1.3",
            "page_number": 118,
            "text_snippet": "The Investigator will use the following definitions to assess the relationship of the adverse event to the use of the study treatment:\nReasonable Possibility: An adverse event where there is evidence to suggest a causal relationship between the study treatment and the adverse event.\nNo Reasonable Possibility: An adverse event where there is no evidence to suggest a causal relationship between the study treatment and the adverse event."
          }
        },
        "coding_dictionary": {
          "dictionary_name": "MedDRA",
          "dictionary_version": null,
          "provenance": {
            "section_number": "8.1.7.2",
            "page_number": 148,
            "text_snippet": "Treatment-emergent adverse events will be coded and summarized by system organ class and preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event coding dictionary."
          }
        },
        "reporting_procedures": {
          "routine_ae_reporting": null,
          "sae_reporting": {
            "initial_report_hours": 24,
            "followup_report_days": null,
            "recipients": [
              "sponsor",
              "irb_ec",
              "regulatory_agencies"
            ],
            "method": "SAE data entry into EDC RAVE® system. If RAVE is not operable, documented on the SAE Non-CRF forms and emailed or faxed to Clinical Pharmacovigilance.",
            "provenance": {
              "section_number": "6.1.5",
              "page_number": 119,
              "text_snippet": "In the event of a serious adverse event, whether associated with the study treatment or not, the Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse event by entering the serious adverse event data into EDC RAVE® system. Serious adverse events that occur prior to the site having access to the RAVE® system, or if RAVE® is not operable, should be documented on the SAE Non-CRF forms and emailed (preferred route) or faxed to"
            }
          },
          "susar_reporting": null,
          "pregnancy_reporting": {
            "timeline_hours": 24,
            "outcome_tracking": true,
            "partner_pregnancy": true,
            "provenance": {
              "section_number": "6.1.6",
              "page_number": 122,
              "text_snippet": "Pregnancy in a study subject must be reported to an AbbVie representative (Section 6.1.5) within 1 working day of the site becoming aware of the pregnancy... In the event of a pregnancy occurring in the partner of an enrolled subject, written informed consent for release of medical information from the partner must be obtained prior to the collection of any pregnancy-specific information, and the pregnancy will be followed to outcome."
            }
          },
          "expedited_reporting_criteria": [],
          "unblinding_procedures": "The IRT system can provide access to blinded subject treatment information during the study if identification of the study drug is required for medical emergency, i.e., situation in which the knowledge of the specific blinded treatment will affect the immediate management of the subject/subject's conditions (e.g., antidote is available). AbbVie must then be notified within 24 hours of the blind being broken.",
          "provenance": {
            "section_number": "5.5.5.1",
            "page_number": 110,
            "text_snippet": "The IRT system can provide access to blinded subject treatment information during the study if identification of the study drug is required for medical emergency, i.e., situation in which the knowledge of the specific blinded treatment will affect the immediate management of the subject/subject's conditions (e.g., antidote is available). AbbVie must then be notified within 24 hours of the blind being broken."
          }
        },
        "aesi_list": [],
        "dlt_criteria": {
          "has_dlt_criteria": false
        },
        "safety_committees": [
          {
            "committee_name": "Independent Data Monitoring Committee",
            "committee_type": {
              "code": "C93494",
              "decode": "Data Monitoring Committee",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "charter_availability": "Details of the IDMC review will be outlined in the IDMC Charter.",
            "responsibilities": "Periodically review the safety and efficacy data for this study in an un-blinded fashion. Aggregate blinded clinical safety and efficacy data will be reviewed on a real-time basis throughout the course of the study. Once the final Overall Survival (OS) analysis is complete, a final review of safety and efficacy data will be conducted by the IDMC.",
            "provenance": {
              "section_number": "5.5.5.2",
              "page_number": 110,
              "text_snippet": "An IDMC will periodically review the safety and efficacy data for this study in an un-blinded fashion. Aggregate blinded clinical safety and efficacy data will be reviewed on a real-time basis throughout the course of the study. Once the final Overall Survival (OS) analysis is complete (refer to Section 8.1.5.5.2), a final review of safety and efficacy data will be conducted by the IDMC. AbbVie will continue to monitor subjects' safety data after the final IDMC meeting."
            }
          }
        ],
        "extraction_statistics": {
          "aesi_count": 0,
          "dlt_criteria_count": 0,
          "sae_criteria_count": 7,
          "has_grading_system": true,
          "has_causality_assessment": true,
          "has_dlt_criteria": false
        },
        "provenance": {
          "section_number": "6.1",
          "page_number": 114,
          "text_snippet": "6.1 Medical Complaints\nThe Investigator will monitor each subject for clinical and laboratory evidence of adverse events on a routine basis throughout the study."
        }
      },
      "_agentDocumentation": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death → 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death → 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds → Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds → Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      }
    },
    "safetyDecisionPoints": {
      "moduleId": "safety_decision_points",
      "instanceType": "SafetyDecisionPoints",
      "data": {
        "id": "M14-031-safety-decision-points",
        "instanceType": "SafetyDecisionPoints",
        "name": "M14-031 Safety Decision Points",
        "discovered_categories": [
          {
            "category_id": "cat-001",
            "category_name": "Hematologic Toxicity",
            "category_description": "Adverse events related to blood cell counts and bone marrow function.",
            "parameters_count": 2,
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Table 8. Hematological and Non-Hematological Toxicities Related to Venetoclax/Placebo*"
            }
          },
          {
            "category_id": "cat-002",
            "category_name": "Infection",
            "category_description": "Adverse events related to infections.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Grade ≥ 3 or Serious Infections"
            }
          },
          {
            "category_id": "cat-003",
            "category_name": "Non-Hematologic Toxicity",
            "category_description": "General adverse events not classified as hematologic.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Table 8. Hematological and Non-Hematological Toxicities Related to Venetoclax/Placebo*"
            }
          },
          {
            "category_id": "cat-004",
            "category_name": "Tumor Lysis Syndrome (TLS)",
            "category_description": "Adverse events and laboratory changes related to Tumor Lysis Syndrome.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Blood chemistry changes or symptoms suggestive of TLS"
            }
          },
          {
            "category_id": "cat-005",
            "category_name": "Drug-Drug Interaction",
            "category_description": "Dose adjustments due to concomitant medications.",
            "parameters_count": 2,
            "provenance": {
              "section_number": "6.2.2",
              "page_number": 130,
              "text_snippet": "Dose Modifications for Moderate or Strong CYP3A Inhibitors Used with Venetoclax/Placebo"
            }
          },
          {
            "category_id": "cat-006",
            "category_name": "Neurologic Toxicity",
            "category_description": "Adverse events related to the nervous system, including peripheral neuropathy.",
            "parameters_count": 2,
            "provenance": {
              "section_number": null,
              "page_number": 132,
              "text_snippet": "Peripheral Neuropathy:a"
            }
          },
          {
            "category_id": "cat-007",
            "category_name": "Gastrointestinal Toxicity",
            "category_description": "Adverse events related to the gastrointestinal system.",
            "parameters_count": 2,
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Gastrointestinal"
            }
          },
          {
            "category_id": "cat-008",
            "category_name": "Cardiovascular Toxicity",
            "category_description": "Adverse events related to the cardiovascular system.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Cardiovascular"
            }
          },
          {
            "category_id": "cat-009",
            "category_name": "Musculoskeletal Toxicity",
            "category_description": "Adverse events related to muscle function.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Musculoskeletal"
            }
          },
          {
            "category_id": "cat-010",
            "category_name": "Metabolic Toxicity",
            "category_description": "Adverse events related to metabolic function, such as hyperglycemia.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Metabolic"
            }
          },
          {
            "category_id": "cat-011",
            "category_name": "General Safety",
            "category_description": "General safety events like pregnancy or COVID-19 infection.",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.2",
              "page_number": 126,
              "text_snippet": "Interruption/Discontinuation of Study Drug Due to Confirmed or Suspected COVID-19 Infection:"
            }
          }
        ],
        "decision_points": [
          {
            "id": "dp-001",
            "parameter_name": "Neutropenia (Venetoclax/Placebo)",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-001-r1",
                "rule_type": "supportive_care",
                "rule_description": "Administer G-CSF for neutropenia if clinically indicated.",
                "conditions": {
                  "grade": "3 or 4",
                  "description": "Grade 3 or 4 neutropenia with infection or fever."
                },
                "actions": [
                  {
                    "action_type": "administer_supportive_care",
                    "action_description": "G-CSF or growth factors for neutropenia may be administered."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "G-CSF or growth factors for neutropenia may be administered with venetoclax/placebo if clinically indicated."
                }
              },
              {
                "rule_id": "dp-001-r2",
                "rule_type": "supportive_care",
                "rule_description": "Administer antibiotic prophylaxis for Grade 4 neutropenia without infection.",
                "conditions": {
                  "grade": "4",
                  "description": "Grade 4 neutropenia without infection."
                },
                "actions": [
                  {
                    "action_type": "administer_supportive_care",
                    "action_description": "Administer Levofloxacin (500 mg once daily) or equivalent until neutropenia improves to Grade 3 or better (ANC > 500 cells/µL)."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "For Grade 4 neutropenia without infection, anti-infective prophylaxis with Levofloxacin (500 mg once daily, adjusted for renal function) or equivalent antibiotic therapy, per institutional guidelines must be administered until the neutropenia improves to Grade 3 or better (ANC > 500 cells/µL) (See Section 6.1.7.1)."
                }
              },
              {
                "rule_id": "dp-001-r3",
                "rule_type": "dose_hold",
                "rule_description": "First episode of Grade 3/4 neutropenia with infection/fever or Grade 4 hematologic toxicity.",
                "conditions": {
                  "grade": ">=3",
                  "description": "First episode of Grade 3 or 4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except lymphopenia)."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt venetoclax/placebo."
                  }
                ],
                "recovery_criteria": {
                  "description": "Resume at the same dose once the toxicity has resolved to Grade 1 or baseline level."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "First episode: Interrupt venetoclax/placebo and once the toxicity has resolved to Grade 1 or baseline level, venetoclax/placebo may be resumed at the same dose."
                }
              },
              {
                "rule_id": "dp-001-r4",
                "rule_type": "dose_reduce",
                "rule_description": "Subsequent episodes of Grade 3/4 neutropenia with infection/fever or Grade 4 hematologic toxicity.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Subsequent episode of Grade 3 or 4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except lymphopenia)."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt venetoclax/placebo."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Resume treatment at a reduced dose level per Table 7 after resolution."
                  }
                ],
                "recovery_criteria": {
                  "description": "Toxicity has resolved."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "For subsequent episodes: Interrupt venetoclax/placebo. Consider using G-CSF as clinically indicated. Follow dose reduction guidelines in Table 7 when resuming treatment with venetoclax/placebo after resolution."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Grade 3 or Grade 4 neutropenia with infection or fever; or Grade 4 hematologic toxicities (except for lymphopenia)"
            }
          },
          {
            "id": "dp-002",
            "parameter_name": "Infections (Venetoclax/Placebo)",
            "parameter_category": "Infection",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-002-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt treatment for Grade 3 or serious infections.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Grade ≥ 3 or Serious Infections."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt venetoclax/placebo."
                  }
                ],
                "recovery_criteria": {
                  "description": "Upon resolution, treatment can be resumed at a reduced dose or discontinued, depending on Investigator's clinical judgment."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "Interrupt venetoclax/placebo and upon resolution, treatment can be resumed at a reduced dose or discontinued, depending on Investigator's clinical judgment."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Grade ≥ 3 or Serious Infections"
            }
          },
          {
            "id": "dp-003",
            "parameter_name": "Non-hematologic events (Venetoclax/Placebo)",
            "parameter_category": "Non-Hematologic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-003-r1",
                "rule_type": "dose_hold",
                "rule_description": "First episode of Grade 3 or 4 non-hematologic events.",
                "conditions": {
                  "grade": "3 or 4",
                  "description": "First episode of Grade 3 or 4 non-hematologic events."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt venetoclax/placebo."
                  }
                ],
                "recovery_criteria": {
                  "description": "Resume at the same dose once toxicity has resolved to Grade ≤ 1 or baseline."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "First episode: Interrupt venetoclax/placebo. Once toxicity has resolved to Grade ≤ 1 or baseline, venetoclax/placebo may be resumed at the same dose. No dose modification is required."
                }
              },
              {
                "rule_id": "dp-003-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Subsequent episodes of Grade 3 or 4 non-hematologic events.",
                "conditions": {
                  "grade": "3 or 4",
                  "description": "Subsequent episodes of Grade 3 or 4 non-hematologic events."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt venetoclax/placebo."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Follow dose reduction guidelines in Table 7 when resuming treatment after resolution."
                  }
                ],
                "recovery_criteria": {
                  "description": "Toxicity has resolved."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "For subsequent episodes: Interrupt venetoclax/placebo. Follow dose reduction guidelines in Table 7 when resuming treatment with venetoclax/placebo after resolution."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Grade 3 or 4 non-hematologic events"
            }
          },
          {
            "id": "dp-004",
            "parameter_name": "Tumor Lysis Syndrome (TLS) (Venetoclax/Placebo)",
            "parameter_category": "Tumor Lysis Syndrome (TLS)",
            "measurement_type": "Clinical signs or laboratory changes",
            "decision_rules": [
              {
                "rule_id": "dp-004-r1",
                "rule_type": "dose_hold",
                "rule_description": "Hold dose for blood chemistry changes suggestive of TLS resolving within 48 hours.",
                "conditions": {
                  "description": "Blood chemistry changes or symptoms suggestive of TLS."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Withhold the next day's dose."
                  }
                ],
                "recovery_criteria": {
                  "description": "If resolved within 24 – 48 hours of last dose, resume at the same dose."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "Withhold the next day's dose. If resolved within 24 – 48 hours of last dose, resume at the same dose."
                }
              },
              {
                "rule_id": "dp-004-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce dose for blood chemistry changes suggestive of TLS requiring more than 48 hours to resolve.",
                "conditions": {
                  "description": "Any blood chemistry changes requiring more than 48 hours to resolve."
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Resume at a reduced dose (see Table 7)."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "For any blood chemistry changes requiring more than 48 hours to resolve, resume at a reduced dose (see Table 7)."
                }
              },
              {
                "rule_id": "dp-004-r3",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce dose for any event of clinical TLS.",
                "conditions": {
                  "description": "Any events of clinical TLS."
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Resume at a reduced dose following resolution."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 129,
                  "text_snippet": "For any events of clinical TLS, resume at a reduced dose following resolution."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 129,
              "text_snippet": "Blood chemistry changes or symptoms suggestive of TLS"
            }
          },
          {
            "id": "dp-005",
            "parameter_name": "Concomitant Moderate CYP3A Inhibitor Use",
            "parameter_category": "Drug-Drug Interaction",
            "measurement_type": "Medication review",
            "decision_rules": [
              {
                "rule_id": "dp-005-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce venetoclax/placebo dose by 50% when co-administered with a moderate CYP3A inhibitor.",
                "conditions": {
                  "description": "Co-administration with a moderate CYP3A inhibitor."
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce the current venetoclax/placebo dose by 50% (e.g., 800mg to 400mg, 600mg to 300mg, etc.)."
                  }
                ],
                "recovery_criteria": {
                  "description": "After discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax/placebo dose is increased back to previous dose level."
                },
                "provenance": {
                  "section_number": "6.2.2",
                  "page_number": 130,
                  "text_snippet": "If the administration of a moderate or strong CYP3A4 is absolutely necessary based on the investigator's clinical judgment, then the venetoclax/placebo dose should be reduced during the period it is co-administered with a moderate or strong CYP3A4... After discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax/placebo dose is increased back to previous dose level."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 130,
              "text_snippet": "With Moderate CYP3A Inhibitor"
            }
          },
          {
            "id": "dp-006",
            "parameter_name": "Concomitant Strong CYP3A Inhibitor Use",
            "parameter_category": "Drug-Drug Interaction",
            "measurement_type": "Medication review",
            "decision_rules": [
              {
                "rule_id": "dp-006-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Reduce venetoclax/placebo dose by 75% when co-administered with a strong CYP3A inhibitor.",
                "conditions": {
                  "description": "Co-administration with a strong CYP3A inhibitor."
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reduce the current venetoclax/placebo dose by 75% (e.g., 800mg to 200mg, 600mg to 100mg, etc.)."
                  },
                  {
                    "action_type": "hold_dose",
                    "action_description": "For subjects on 200 mg QD, interrupt venetoclax/placebo temporarily."
                  }
                ],
                "recovery_criteria": {
                  "description": "After discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax/placebo dose is increased back to previous dose level."
                },
                "provenance": {
                  "section_number": "6.2.2",
                  "page_number": 130,
                  "text_snippet": "If the administration of a moderate or strong CYP3A4 is absolutely necessary based on the investigator's clinical judgment, then the venetoclax/placebo dose should be reduced during the period it is co-administered with a moderate or strong CYP3A4... After discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax/placebo dose is increased back to previous dose level."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 130,
              "text_snippet": "With Strong CYP3A Inhibitor"
            }
          },
          {
            "id": "dp-007",
            "parameter_name": "General Toxicity (Bortezomib)",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-007-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose reduction for Grade 3 non-hematological or Grade 4 hematological toxicity related to Bortezomib.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Grade 3 non-hematological or Grade 4 hematological (other than neuropathy)."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Withhold bortezomib therapy until symptoms resolve."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Reinitiate at a 25% reduced dose (1.3 mg/m2 to 1 mg/m2; 1 mg/m2 to 0.7 mg/m2)."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose. (1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 132,
              "text_snippet": "Grade 3 non-hematological or Grade 4 hematological (other than neuropathy)"
            }
          },
          {
            "id": "dp-008",
            "parameter_name": "Peripheral Neuropathy (Bortezomib)",
            "parameter_category": "Neurologic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-008-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose modification for Grade 1 with pain or Grade 2 peripheral neuropathy.",
                "conditions": {
                  "grade": "1 with pain or 2",
                  "description": "Grade 1 with pain or Grade 2 (moderate symptoms; limiting instrumental ADL)."
                },
                "actions": [
                  {
                    "action_type": "modify_schedule",
                    "action_description": "For subjects on twice-weekly bortezomib, change schedule to 1.3 mg/m2 once per week."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Alternatively, reduce bortezomib current dose by one level."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "For subjects receiving twice-weekly bortezomib, only, change treatment schedule to 1.3 mg/m2 once per week (Day 1, 8 and 15 in a 21-day cycle) OR Reduce bortezomib current dose by one level (1.3 mg/m2 to 1 mg/m2 to 0.7 mg/m2)"
                }
              },
              {
                "rule_id": "dp-008-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Dose modification for Grade 2 with pain or Grade 3 peripheral neuropathy.",
                "conditions": {
                  "grade": "2 with pain or 3",
                  "description": "Grade 2 with pain or Grade 3 (severe symptoms; limiting self care ADL)."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Withhold bortezomib therapy."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week."
                  }
                ],
                "recovery_criteria": {
                  "description": "Toxicity resolves to baseline or ≤ Grade 1."
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "Withhold bortezomib therapy until toxicity resolves to baseline or ≥ Grade 1. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 132,
              "text_snippet": "Peripheral Neuropathy:a"
            }
          },
          {
            "id": "dp-009",
            "parameter_name": "Gastrointestinal Toxicity (Dexamethasone)",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-009-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose reduction for persistent Grade 1-2 GI toxicity.",
                "conditions": {
                  "grade": "1-2",
                  "description": "Dyspepsia, gastric or duodenal ulcer, gastritis Grades 1–2 that persists despite supportive measures."
                },
                "actions": [
                  {
                    "action_type": "administer_supportive_care",
                    "action_description": "Treat with H2 blockers, sucralfate, or proton pump inhibitor."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "If symptoms persist, decrease dexamethasone dose by 1 dose level."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Treat with H2 blockers, sucralfate, or proton pump inhibitor. If symptoms persist despite above measures, decrease dexamethasone dose by 1 dose level."
                }
              },
              {
                "rule_id": "dp-009-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Dose modification for Grade 3 or higher GI toxicity.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Grade 3 or higher GI toxicity requiring hospitalization or surgery."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Hold dexamethasone until symptoms adequately controlled."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Restart at 1 dose decrement. If symptoms persist, reduce to dose level –3 or discontinue permanently."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Hold dexamethasone until symptoms adequately controlled. Restart at 1 dose decrement along with concurrent therapy with H2 blockers, sucralfate, or proton pump inhibitor. If symptoms persist despite above measures, reduce to dose level –3 or discontinue dexamethasone permanently."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Gastrointestinal"
            }
          },
          {
            "id": "dp-010",
            "parameter_name": "Edema (Dexamethasone)",
            "parameter_category": "Cardiovascular Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-010-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose modification for Grade 3 or higher edema.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Edema ≥ Grade 3 (limiting function and unresponsive to therapy or anasarca)."
                },
                "actions": [
                  {
                    "action_type": "administer_supportive_care",
                    "action_description": "Diuretics as needed."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Restart dexamethasone at 1 dose decrement. If edema persists, decrease dose by another level. If it persists again, discontinue permanently."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Diuretics as needed, and restart dexamethasone at 1 dose decrement; if edema persists despite above measures, decrease dose by another level. Discontinue dexamethasone permanently if symptoms persist despite second reduction."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Cardiovascular Edema ≥ Grade 3 (limiting function and unresponsive to therapy or anasarca)"
            }
          },
          {
            "id": "dp-011",
            "parameter_name": "Neurologic Toxicity (Dexamethasone)",
            "parameter_category": "Neurologic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-011-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose modification for neurologic toxicity greater than Grade 2.",
                "conditions": {
                  "grade": ">2",
                  "description": "Confusion or mood alteration > Grade 2."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Hold dexamethasone until symptoms resolve."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Restart at 1 dose decrement. If symptoms persist, decrease by another level or discontinue permanently."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Hold dexamethasone until symptoms resolve. Restart at 1 dose decrement. If symptoms persist despite above measures, decrease by another level or discontinue dexamethasone permanently."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Neurology Confusion or mood alteration > Grade 2 (interfering with function ± interfering with activities of daily living)"
            }
          },
          {
            "id": "dp-012",
            "parameter_name": "Muscle Weakness (Dexamethasone)",
            "parameter_category": "Musculoskeletal Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-012-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose reduction for muscle weakness greater than Grade 2.",
                "conditions": {
                  "grade": ">2",
                  "description": "Muscle weakness > Grade 2."
                },
                "actions": [
                  {
                    "action_type": "reduce_dose",
                    "action_description": "Decrease dexamethasone by 1 dose level. If weakness persists, decrease by 1 more dose level. Discontinue permanently if symptoms persist."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Decrease dexamethasone by 1 dose level. If weakness persists, decrease dose by 1 more dose level. Discontinue dexamethasone permanently if symptoms persist."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Musculoskeletal Muscle weakness > Grade 2 (symptomatic and interfering with function ± interfering with activities of daily living)"
            }
          },
          {
            "id": "dp-013",
            "parameter_name": "Hyperglycemia (Dexamethasone)",
            "parameter_category": "Metabolic Toxicity",
            "measurement_type": "NCI CTCAE Grade",
            "decision_rules": [
              {
                "rule_id": "dp-013-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Dose reduction for uncontrolled Grade 3 or higher hyperglycemia.",
                "conditions": {
                  "grade": ">=3",
                  "description": "Hyperglycemia ≥ Grade 3 that is uncontrolled despite supportive measures."
                },
                "actions": [
                  {
                    "action_type": "administer_supportive_care",
                    "action_description": "Treatment with insulin or oral hypoglycemic agents as needed."
                  },
                  {
                    "action_type": "reduce_dose",
                    "action_description": "If uncontrolled, decrease dose by 1 dose level until levels are satisfactory."
                  }
                ],
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Treatment with insulin or oral hypoglycemic agents as needed. If uncontrolled despite above measures, decrease dose by 1 dose level until levels are satisfactory."
                }
              }
            ],
            "provenance": {
              "section_number": null,
              "page_number": 133,
              "text_snippet": "Metabolic Hyperglycemia ≥ Grade 3"
            }
          },
          {
            "id": "dp-014",
            "parameter_name": "COVID-19 Infection",
            "parameter_category": "General Safety",
            "measurement_type": "Viral test or clinical suspicion",
            "decision_rules": [
              {
                "rule_id": "dp-014-r1",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt all study drugs for confirmed or suspected COVID-19 infection.",
                "conditions": {
                  "description": "Confirmed (viral test positive) or suspected COVID-19 infection."
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Interrupt all study drugs."
                  }
                ],
                "recovery_criteria": {
                  "description": "Symptomatic subjects: At least 2 negative viral tests in a row, ≥ 24 hours apart after at least 14 days have passed since recovery. Asymptomatic subjects: At least 2 negative viral tests in a row, ≥ 24 hours apart after at least 14 days have passed since prior positive result."
                },
                "provenance": {
                  "section_number": "6.2",
                  "page_number": 126,
                  "text_snippet": "Subjects with a confirmed (viral test positive) or suspected COVID-19 infection must interrupt all study drugs until the following COVID-19 viral clearance criteria are met... Symptomatic subjects: At least 2 negative viral tests in a row, ≥ 24 hours apart after at least 14 days have passed since recovery... Asymptomatic subjects: At least 2 negative viral tests in a row, ≥ 24 hours apart after at least 14 days have passed since prior positive result..."
                }
              }
            ],
            "provenance": {
              "section_number": "6.2",
              "page_number": 126,
              "text_snippet": "Interruption/Discontinuation of Study Drug Due to Confirmed or Suspected COVID-19 Infection:"
            }
          }
        ],
        "stopping_rules_summary": {
          "total_permanent_stopping_conditions": 10,
          "stopping_conditions": [
            {
              "condition_id": "stop-001",
              "condition_type": "individual_subject",
              "description": "Toxicity related to study treatment requires more than a 3-week dose interruption.",
              "trigger_threshold": "> 3-week (21 day) dose interruption of all study drugs due to an AE",
              "action": "Discontinue from study treatment.",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 99,
                "text_snippet": "The subject experiences toxicities related to study treatment that requires more than a 3-week dose interruption of the study treatment;"
              }
            },
            {
              "condition_id": "stop-002",
              "condition_type": "individual_subject",
              "description": "Subject becomes pregnant or begins breastfeeding.",
              "trigger_threshold": "Confirmed pregnancy or start of breastfeeding",
              "action": "Discontinue from study treatment.",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 99,
                "text_snippet": "The subject becomes pregnant or begins breastfeeding;"
              }
            },
            {
              "condition_id": "stop-003",
              "condition_type": "individual_subject",
              "description": "Unacceptable toxicity as determined by the Investigator.",
              "trigger_threshold": "Investigator decision",
              "action": "Discontinue from study treatment.",
              "provenance": {
                "section_number": "5.4.1",
                "page_number": 99,
                "text_snippet": "Unacceptable toxicity;"
              }
            },
            {
              "condition_id": "stop-004",
              "condition_type": "individual_subject",
              "description": "Inability to tolerate the lowest dose level of Venetoclax/Placebo.",
              "trigger_threshold": "Toxicity at Dose Level –3 (200 mg QD)",
              "action": "Discontinue venetoclax/placebo.",
              "provenance": {
                "section_number": "6.2.1",
                "page_number": 128,
                "text_snippet": "If the dose of venetoclax/placebo at dose level –3 is not tolerable, then no further reductions will be allowed and venetoclax/placebo should be discontinued."
              }
            },
            {
              "condition_id": "stop-005",
              "condition_type": "individual_subject",
              "description": "Grade 4 peripheral neuropathy related to Bortezomib.",
              "trigger_threshold": "Grade 4 (life-threatening consequences) peripheral neuropathy",
              "action": "Discontinue bortezomib.",
              "provenance": {
                "section_number": null,
                "page_number": 132,
                "text_snippet": "Grade 4 (life-threatening consequences; urgent intervention indicated) Discontinue bortezomib"
              }
            },
            {
              "condition_id": "stop-006",
              "condition_type": "individual_subject",
              "description": "Acute pancreatitis related to Dexamethasone.",
              "trigger_threshold": "Diagnosis of acute pancreatitis",
              "action": "Discontinue dexamethasone permanently.",
              "provenance": {
                "section_number": null,
                "page_number": 133,
                "text_snippet": "Acute pancreatitis Discontinue dexamethasone permanently."
              }
            },
            {
              "condition_id": "stop-007",
              "condition_type": "individual_subject",
              "description": "Persistent Grade 3+ GI toxicity related to Dexamethasone despite dose reduction.",
              "trigger_threshold": "Persistent symptoms after reduction to dose level -3",
              "action": "Discontinue dexamethasone permanently.",
              "provenance": {
                "section_number": null,
                "page_number": 133,
                "text_snippet": "If symptoms persist despite above measures, reduce to dose level –3 or discontinue dexamethasone permanently."
              }
            },
            {
              "condition_id": "stop-008",
              "condition_type": "individual_subject",
              "description": "Persistent Grade 3+ edema related to Dexamethasone despite dose reductions.",
              "trigger_threshold": "Persistent symptoms after second dose reduction",
              "action": "Discontinue dexamethasone permanently.",
              "provenance": {
                "section_number": null,
                "page_number": 133,
                "text_snippet": "Discontinue dexamethasone permanently if symptoms persist despite second reduction."
              }
            },
            {
              "condition_id": "stop-009",
              "condition_type": "individual_subject",
              "description": "Persistent neurologic or musculoskeletal toxicity related to Dexamethasone despite dose reductions.",
              "trigger_threshold": "Persistent symptoms after dose reductions",
              "action": "Discontinue dexamethasone permanently.",
              "provenance": {
                "section_number": null,
                "page_number": 133,
                "text_snippet": "Discontinue dexamethasone permanently if symptoms persist."
              }
            },
            {
              "condition_id": "stop-010",
              "condition_type": "study_level",
              "description": "Continued exposure to the study treatment represents a significant risk to subjects.",
              "trigger_threshold": "Judgment of the Investigators and AbbVie",
              "action": "The study will be stopped.",
              "provenance": {
                "section_number": "5.4.4",
                "page_number": 102,
                "text_snippet": "If, in the judgment of the Investigators and AbbVie, the continued exposure to the study treatment represents a significant risk to subjects, the study will be stopped."
              }
            }
          ],
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 99,
            "text_snippet": "Discontinuation of Individual Subjects from Treatment"
          }
        },
        "dose_modification_levels": {
          "Venetoclax/Placebo": {
            "has_defined_levels": true,
            "levels": [
              {
                "level_id": "dose-1",
                "level_name": "Starting Dose",
                "dose_percentage": 100,
                "absolute_dose": "800 mg QD",
                "provenance": {
                  "section_number": null,
                  "page_number": 128,
                  "text_snippet": "Dose Level 1 800 mg QD"
                }
              },
              {
                "level_id": "dose--1",
                "level_name": "First Reduction",
                "dose_percentage": 75,
                "absolute_dose": "600 mg QD",
                "provenance": {
                  "section_number": null,
                  "page_number": 128,
                  "text_snippet": "Dose Level –1 600 mg QD"
                }
              },
              {
                "level_id": "dose--2",
                "level_name": "Second Reduction",
                "dose_percentage": 50,
                "absolute_dose": "400 mg QD",
                "provenance": {
                  "section_number": null,
                  "page_number": 128,
                  "text_snippet": "Dose Level –2 400 mg QD"
                }
              },
              {
                "level_id": "dose--3",
                "level_name": "Third Reduction",
                "dose_percentage": 25,
                "absolute_dose": "200 mg QD",
                "provenance": {
                  "section_number": null,
                  "page_number": 128,
                  "text_snippet": "Dose Level –3 200 mg QD"
                }
              }
            ],
            "minimum_dose": "200 mg QD",
            "re_escalation_allowed": true,
            "re_escalation_criteria": "Upon resolution of the AE leading to dose reduction, the dose can be increased once, based on the Investigator's clinical judgment.",
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 128,
              "text_snippet": "Upon resolution of the AE leading to dose reduction, the dose of venetoclax/placebo can be increased once following Table 7 guidelines, based on the Investigator's clinical judgment."
            }
          },
          "Bortezomib": {
            "has_defined_levels": true,
            "levels": [
              {
                "level_id": "dose-1",
                "level_name": "Starting Dose",
                "absolute_dose": "1.3 mg/m2",
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "(1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                }
              },
              {
                "level_id": "dose--1",
                "level_name": "First Reduction",
                "absolute_dose": "1.0 mg/m2",
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "(1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                }
              },
              {
                "level_id": "dose--2",
                "level_name": "Second Reduction",
                "absolute_dose": "0.7 mg/m2",
                "provenance": {
                  "section_number": null,
                  "page_number": 132,
                  "text_snippet": "(1.3 mg/m2 reduces to 1 mg/m2/dose; 1 mg/m2/dose reduces to 0.7 mg/m2/dose)."
                }
              }
            ],
            "minimum_dose": "0.7 mg/m2",
            "re_escalation_allowed": false,
            "re_escalation_criteria": "Not specified.",
            "provenance": {
              "section_number": "6.2.3",
              "page_number": 132,
              "text_snippet": "Table 10. Dose Reductions and Treatment Guidelines for Toxicity Related to Bortezomib"
            }
          },
          "Dexamethasone": {
            "has_defined_levels": true,
            "levels": [
              {
                "level_id": "dose-1",
                "level_name": "Starting Dose",
                "absolute_dose": "20 mg",
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Dexamethasone 20 mg"
                }
              },
              {
                "level_id": "dose--1",
                "level_name": "First Reduction",
                "absolute_dose": "12 mg",
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Dose –1 12 mg"
                }
              },
              {
                "level_id": "dose--2",
                "level_name": "Second Reduction",
                "absolute_dose": "8 mg",
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Dose –2 8 mg"
                }
              },
              {
                "level_id": "dose--3",
                "level_name": "Third Reduction",
                "absolute_dose": "4 mg",
                "provenance": {
                  "section_number": null,
                  "page_number": 133,
                  "text_snippet": "Dose –3 4 mg"
                }
              }
            ],
            "minimum_dose": "4 mg",
            "re_escalation_allowed": false,
            "re_escalation_criteria": "Not specified.",
            "provenance": {
              "section_number": "6.2.3",
              "page_number": 133,
              "text_snippet": "Table 11. Dose Reductions for Dexamethasone"
            }
          },
          "provenance": {
            "section_number": "6.2",
            "page_number": 125,
            "text_snippet": "6.2 Guidelines for Dose Modifications and Treatment"
          }
        },
        "organ_specific_adjustments": [
          {
            "id": "organ-001",
            "organ_system": "Renal",
            "organ_system_detail": "Mild or moderate renal impairment",
            "adjustment_trigger": "Creatinine clearance (CrCl) ≥ 30 mL/min",
            "adjustment_action": "No dose adjustment is recommended.",
            "monitoring_requirements": "Standard study monitoring.",
            "provenance": {
              "section_number": "3.3",
              "page_number": 32,
              "text_snippet": "No dose adjustment is recommended in patients with mild or moderate hepatic or renal (creatinine clearance [CrCl] ≥ 30 mL/min) impairment based on results of the population pharmacokinetic analysis."
            }
          },
          {
            "id": "organ-002",
            "organ_system": "Hepatic",
            "organ_system_detail": "Mild or moderate hepatic impairment",
            "adjustment_trigger": "Mild or moderate hepatic impairment",
            "adjustment_action": "No dose adjustment is recommended.",
            "monitoring_requirements": "Standard study monitoring.",
            "provenance": {
              "section_number": "3.3",
              "page_number": 32,
              "text_snippet": "No dose adjustment is recommended in patients with mild or moderate hepatic or renal (creatinine clearance [CrCl] ≥ 30 mL/min) impairment based on results of the population pharmacokinetic analysis."
            }
          }
        ],
        "extraction_statistics": {
          "decision_points_count": 14,
          "stopping_rules_count": 10,
          "organ_adjustments_count": 2,
          "dose_levels_count": 3,
          "categories_count": 11
        },
        "provenance": {
          "section_number": "6.2",
          "page_number": 125,
          "text_snippet": "6.2 Guidelines for Dose Modifications and Treatment"
        }
      },
      "_agentDocumentation": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs → Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms → Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      }
    },
    "concomitantMedications": {
      "moduleId": "concomitant_medications",
      "instanceType": "ConcomitantMedications",
      "data": {
        "id": "M14-031-concomitant-medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "name": "M14-031 Concomitant Medication Restrictions",
        "description": "Medication restrictions and requirements for M14-031",
        "prohibited_medications": [
          {
            "id": "proh-001",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Systemic anti-myeloma therapies",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "efficacy_interference"
            },
            "prohibition_reason_detail": "Prohibited to avoid confounding efficacy assessment. Only bortezomib, dexamethasone, and venetoclax/placebo are permitted.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "While on study treatment.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Any systemic anti-myeloma therapies other than bortezomib, dexamethasone and venetoclax while on study treatment."
            }
          },
          {
            "id": "proh-002",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Biologic agents for anti-neoplastic intent",
            "specific_drugs": [
              "monoclonal antibodies"
            ],
            "prohibition_reason": {
              "decode": "efficacy_interference"
            },
            "prohibition_reason_detail": "Prohibited to avoid confounding efficacy assessment.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "While on study treatment.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Biologic agents (e.g., monoclonal antibodies) for anti-neoplastic intent."
            }
          },
          {
            "id": "proh-003",
            "instanceType": "ProhibitedMedication",
            "medication_class": "BCL-2 family inhibitors",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "study_design"
            },
            "prohibition_reason_detail": "Prior treatment with a BCL-2 family inhibitor is an exclusion criterion.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Subjects with any prior exposure are excluded from the study.",
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "7. Subject has received prior treatment with a BCL-2 family inhibitor."
            }
          }
        ],
        "restricted_medications": [
          {
            "id": "rest-001",
            "instanceType": "RestrictedMedication",
            "medication_class": "Systemic Corticosteroids",
            "specific_drugs": [
              "prednisone"
            ],
            "restriction_type": {
              "decode": "dose_limit"
            },
            "conditions": {
              "max_dose": "10 mg/day prednisone equivalent",
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": "Systemic corticosteroids > 10 mg/day prednisone equivalent should not be given on the same day as dexamethasone.",
              "clinical_scenario": "Allowed for reasons other than multiple myeloma (e.g., asthma). Doses >10mg/day are allowed only if dexamethasone is not interrupted, duration is <7 days, and cumulative dose is <120mg."
            },
            "rationale": "To minimize confounding effects on efficacy and safety assessments.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Only low dose corticosteroids (e.g., prednisone ≤ 10 mg PO QD or its equivalent), inhaled steroids and topical preparations for reasons other than multiple myeloma (e.g., asthma) are allowed during study treatment. Systemic corticosteroids > 10 mg PO QD of prednisone (or its equivalent) should not be given on the same day as dexamethasone is administered."
            }
          },
          {
            "id": "rest-002",
            "instanceType": "RestrictedMedication",
            "medication_class": "Warfarin and coumadin derivatives",
            "specific_drugs": [
              "warfarin"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": "Closely monitor the international normalized ratio (INR).",
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Potential for drug-drug interaction.",
            "provenance": {
              "section_number": null,
              "page_number": 193,
              "text_snippet": "2 Closely monitor the international normalized ratio (INR)."
            }
          },
          {
            "id": "rest-003",
            "instanceType": "RestrictedMedication",
            "medication_class": "P-gp substrates",
            "specific_drugs": [
              "aliskiren",
              "ambrisentan",
              "colchicine",
              "dabigatran etexilate",
              "digoxin",
              "everolimus",
              "fexofenadine",
              "lapatinib",
              "loperamide",
              "maraviroc",
              "nilotinib",
              "ranolazine",
              "saxagliptin",
              "sirolimus",
              "sitagliptin",
              "talinolol",
              "tolvaptan",
              "topotecan"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Venetoclax is a P-gp inhibitor and may increase exposure of P-gp substrates.",
            "provenance": {
              "section_number": "Appendix I",
              "page_number": 192,
              "text_snippet": "P-gp substrates\nAliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus,* fexofenadine, lapatinib,* loperamide, maraviroc, nilotinib,* ranolazine, saxagliptin, sirolimus,* sitagliptin, talinolol, tolvaptan, topotecan*"
            }
          },
          {
            "id": "rest-004",
            "instanceType": "RestrictedMedication",
            "medication_class": "BCRP substrates",
            "specific_drugs": [
              "methotrexate",
              "mitoxantrone",
              "irinotecan",
              "lapatinib",
              "rosuvastatin",
              "sulfasalazine",
              "topotecan"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Venetoclax is a BCRP inhibitor and may increase exposure of BCRP substrates.",
            "provenance": {
              "section_number": "Appendix I",
              "page_number": 192,
              "text_snippet": "BCRP substrates\nMethotrexate,* mitoxantrone,* irinotecan,* lapatinib,* rosuvastatin, sulfasalazine, topotecan*"
            }
          },
          {
            "id": "rest-005",
            "instanceType": "RestrictedMedication",
            "medication_class": "OATP1B1/1B3 substrates",
            "specific_drugs": [
              "atorvastatin",
              "bosentan",
              "ezetimibe",
              "fluvastatin",
              "glyburide",
              "rosuvastatin",
              "simvastatin",
              "pitavastatin",
              "pravastatin",
              "repaglinide",
              "telmisartan",
              "valsartan",
              "olmesartan"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Venetoclax is an OATP1B1 inhibitor and may increase exposure of OATP1B1/1B3 substrates.",
            "provenance": {
              "section_number": "Appendix I",
              "page_number": 192,
              "text_snippet": "OATP1B1/1B3 substrates\nAtorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, rosuvastatin, simvastatin acid, pitavastatin, pravastatin, repaglinide, telmisartan, valsartan, olmesartan"
            }
          },
          {
            "id": "rest-006",
            "instanceType": "RestrictedMedication",
            "medication_class": "P-gp inhibitors",
            "specific_drugs": [
              "amiodarone",
              "carvedilol",
              "dronedarone",
              "felodipine",
              "quercetin",
              "ranolazine",
              "ticagrelor"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Venetoclax is a P-gp substrate; co-administration with P-gp inhibitors may increase venetoclax concentrations.",
            "provenance": {
              "section_number": "Appendix I",
              "page_number": 192,
              "text_snippet": "P-gp inhibitors\nAmiodarone, captopril, carvedilol, dronedarone, felodipine, quercetin, ronalzine, ticagrelor"
            }
          },
          {
            "id": "rest-007",
            "instanceType": "RestrictedMedication",
            "medication_class": "BCRP inhibitors",
            "specific_drugs": [
              "gefitinib"
            ],
            "restriction_type": {
              "decode": "use_with_caution"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": null
            },
            "rationale": "Venetoclax is a BCRP substrate; co-administration with BCRP inhibitors may increase venetoclax concentrations.",
            "provenance": {
              "section_number": "Appendix I",
              "page_number": 192,
              "text_snippet": "BCRP inhibitors\nGefitinib,†"
            }
          }
        ],
        "required_medications": [
          {
            "id": "req-001",
            "instanceType": "RequiredMedication",
            "medication_name": "acyclovir",
            "medication_class": "Antiviral",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": "400mg",
              "route": {
                "decode": "PO"
              },
              "frequency": "Twice a day"
            },
            "timing": {
              "relative_to": "bortezomib dosing",
              "time_before_minutes": null,
              "timing_description": "Must start at least 24 hours prior to dosing with bortezomib."
            },
            "purpose": "Herpes zoster prophylaxis during treatment with bortezomib.",
            "alternatives": [
              "valacyclovir 500 mg PO once a day",
              "other equivalent antiviral"
            ],
            "provenance": {
              "section_number": "5.2.4.1",
              "page_number": 52,
              "text_snippet": "All subjects must start the following treatment at least 24 hours prior to dosing with bortezomib:\n● Acyclovir (400 mg orally [PO] twice a day or local standard dosing) or valacyclovir (500 mg PO once a day or local standard dosing) or other equivalent antiviral during treatment with bortezomib (additional prophylaxis is at the Investigator's discretion)."
            }
          },
          {
            "id": "req-002",
            "instanceType": "RequiredMedication",
            "medication_name": "trimethoprim/sulfamethoxazole",
            "medication_class": "Antibiotic",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": "1 tablet (forte)",
              "route": {
                "decode": "PO"
              },
              "frequency": "3 times a week"
            },
            "timing": {
              "relative_to": "study treatment",
              "time_before_minutes": null,
              "timing_description": "Required while on treatment."
            },
            "purpose": "Antibiotic prophylaxis for subjects receiving venetoclax/placebo with a proteasome inhibitor.",
            "alternatives": [
              "equivalent therapy"
            ],
            "provenance": {
              "section_number": "6.1.7.1",
              "page_number": 123,
              "text_snippet": "All subjects receiving treatment with venetoclax/placebo in combination with a proteasome inhibitor must receive antibiotic prophylaxis with Bactrim forte® (1 tablet 3 times a week) or equivalent therapy while on treatment."
            }
          },
          {
            "id": "req-003",
            "instanceType": "RequiredMedication",
            "medication_name": "levofloxacin",
            "medication_class": "Antibiotic",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": "500 mg (adjusted for renal function as necessary)",
              "route": {
                "decode": "PO"
              },
              "frequency": "Daily"
            },
            "timing": {
              "relative_to": "study treatment",
              "time_before_minutes": null,
              "timing_description": "Must be administered for the first 90 days on study and when Grade 4 neutropenia develops, continuing until ANC > 500 cells/µL."
            },
            "purpose": "Antibiotic prophylaxis.",
            "alternatives": [
              "equivalent antibiotic therapy"
            ],
            "provenance": {
              "section_number": "6.1.7.1",
              "page_number": 123,
              "text_snippet": "Additionally, Levofloxacin (500 mg daily, adjusted for renal function as necessary) or equivalent antibiotic therapy per institutional guidelines must be administered for the first 90 days on study and when Grade 4 neutropenia develops (ANC < 500 cells/µL) and continued until the neutropenia improves to Grade 3 or better (ANC > 500 cells/µL)."
            }
          },
          {
            "id": "req-004",
            "instanceType": "RequiredMedication",
            "medication_name": "Oral hydration",
            "medication_class": "Supportive Care",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": "1-2 liters",
              "route": {
                "decode": "PO"
              },
              "frequency": "Each day"
            },
            "timing": {
              "relative_to": "first dose of venetoclax/placebo",
              "time_before_minutes": null,
              "timing_description": "Consider in all subjects at least 72 hours prior to the first day of dosing."
            },
            "purpose": "Tumor Lysis Syndrome (TLS) prophylaxis.",
            "alternatives": [],
            "provenance": {
              "section_number": "6.2",
              "page_number": 125,
              "text_snippet": "Consider TLS prophylaxis with oral hydration (at least 1 – 2 liters, as tolerable, each day) in all subjects at least 72 hours prior to the first day of dosing with venetoclax/placebo."
            }
          },
          {
            "id": "req-005",
            "instanceType": "RequiredMedication",
            "medication_name": "Uric acid reducing agents",
            "medication_class": "TLS Prophylaxis",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": null
            },
            "timing": {
              "relative_to": "study treatment",
              "time_before_minutes": null,
              "timing_description": "May be required during treatment."
            },
            "purpose": "Tumor Lysis Syndrome (TLS) prophylaxis for subjects with high uric acid levels.",
            "alternatives": [],
            "provenance": {
              "section_number": "6.2",
              "page_number": 125,
              "text_snippet": "Prophylaxis with uric acid reducing agents may be required for subjects with high uric acid levels."
            }
          }
        ],
        "rescue_medications": [
          {
            "id": "resc-001",
            "instanceType": "RescueMedication",
            "medication_name": null,
            "medication_class": "Best supportive care",
            "indication": "Management of symptoms and side effects, including but not limited to pain, nausea, infections, and thromboembolic events.",
            "dosing_instructions": "As needed per institutional guidelines and investigator's discretion.",
            "documentation_required": true,
            "impact_on_endpoints": "Use of supportive care medications will be documented as concomitant medications.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Best supportive care and treatment (e.g., antiemetics, antibiotics, transfusions, nutritional support, pain control, etc.)."
            }
          }
        ],
        "washout_requirements": [
          {
            "id": "wash-001",
            "instanceType": "WashoutRequirement",
            "medication_class": "Proteasome inhibitors",
            "specific_drugs": [],
            "washout_duration_days": 60,
            "washout_description": "60 days prior to first dose of study drug.",
            "rationale": "To distinguish study drug effects from prior therapy.",
            "applies_to": {
              "decode": "first_dose"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 49,
              "text_snippet": "2. Subject has had prior treatment with proteasome inhibitor within 60 days prior to first dose of study drug."
            }
          },
          {
            "id": "wash-002",
            "instanceType": "WashoutRequirement",
            "medication_class": "Allogeneic or syngeneic stem cell transplant (SCT)",
            "specific_drugs": [],
            "washout_duration_days": 112,
            "washout_description": "16 weeks prior to randomization.",
            "rationale": "Allow for recovery from transplant procedure.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Allogeneic or syngeneic SCT within 16 weeks prior to randomization."
            }
          },
          {
            "id": "wash-003",
            "instanceType": "WashoutRequirement",
            "medication_class": "Autologous stem cell transplant (SCT)",
            "specific_drugs": [],
            "washout_duration_days": 84,
            "washout_description": "12 weeks prior to randomization.",
            "rationale": "Allow for recovery from transplant procedure.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Autologous SCT within 12 weeks prior to randomization."
            }
          },
          {
            "id": "wash-004",
            "instanceType": "WashoutRequirement",
            "medication_class": "Live vaccines",
            "specific_drugs": [],
            "washout_duration_days": 56,
            "washout_description": "8 weeks prior to randomization.",
            "rationale": "Safety concern for immunosuppressed patients.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Immunization with live vaccine within 8 weeks prior to randomization."
            }
          },
          {
            "id": "wash-005",
            "instanceType": "WashoutRequirement",
            "medication_class": "Anti-myeloma monoclonal antibodies",
            "specific_drugs": [],
            "washout_duration_days": 42,
            "washout_description": "6 weeks prior to randomization.",
            "rationale": "To allow for clearance of prior therapy and avoid overlapping toxicity.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Anti-myeloma monoclonal antibodies within 6 weeks prior to randomization."
            }
          },
          {
            "id": "wash-006",
            "instanceType": "WashoutRequirement",
            "medication_class": "Anti-myeloma therapy",
            "specific_drugs": [
              "chemotherapy",
              "biological therapy",
              "immunotherapy",
              "investigational therapy",
              "targeted small molecule agents"
            ],
            "washout_duration_days": 14,
            "washout_description": "2 weeks prior to randomization.",
            "rationale": "To allow for clearance of prior therapy and avoid overlapping toxicity.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Any anti-myeloma therapy (other than monoclonal antibodies), including chemotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents within 2 weeks prior to randomization."
            }
          },
          {
            "id": "wash-007",
            "instanceType": "WashoutRequirement",
            "medication_class": "Anti-myeloma radiotherapy",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "14 days prior to randomization.",
            "rationale": "To allow for recovery from prior therapy.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Anti-myeloma radiotherapy within 14 days prior to randomization."
            }
          },
          {
            "id": "wash-008",
            "instanceType": "WashoutRequirement",
            "medication_class": "Corticosteroids",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "Corticosteroid therapy at a dose equivalent to > 4 mg/day of dexamethasone must be stopped within 2 weeks prior to randomization.",
            "rationale": "To avoid confounding effects of prior high-dose steroid therapy.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 50,
              "text_snippet": "Corticosteroid therapy at a dose equivalent to > 4 mg/day of dexamethasone or a single dose of corticosteroid greater than or equal to the equivalence of 40 mg/day dexamethasone within 2 weeks prior to randomization."
            }
          },
          {
            "id": "wash-009",
            "instanceType": "WashoutRequirement",
            "medication_class": "Strong or moderate CYP3A inhibitors or inducers",
            "specific_drugs": [],
            "washout_duration_days": 7,
            "washout_description": "1 week prior to randomization.",
            "rationale": "To avoid pharmacokinetic interactions at study start.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.2.2",
              "page_number": 51,
              "text_snippet": "A strong or moderate CYP3A inhibitor or inducer within 1 week prior to randomization (refer to Section 5.3.1.2)."
            }
          }
        ],
        "drug_interactions": [
          {
            "id": "int-001",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inhibitor"
            },
            "severity": {
              "decode": "strong"
            },
            "affected_drugs": [
              "boceprevir",
              "clarithromycin",
              "cobicistat",
              "conivaptan",
              "danoprevir",
              "elvitegravir",
              "idelalisib",
              "indinavir",
              "itraconazole",
              "ketoconazole",
              "luliconazole",
              "lopinavir",
              "nefazodone",
              "nelfinavir",
              "ombitasvir",
              "paritaprevir",
              "posaconazole",
              "ritonavir",
              "saquinavir",
              "telaprevir",
              "telithromycin",
              "tipranavir",
              "voriconazole"
            ],
            "clinical_effect": "Increases venetoclax concentration, potentially increasing toxicity.",
            "management": {
              "decode": "dose_adjustment"
            },
            "management_detail": "Reduce the venetoclax dose by 4-fold during co-administration. Monitor closely for toxicities. After discontinuation of inhibitor, wait 3 days before increasing venetoclax dose.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Strong and Moderate CYP3A inhibitors\nConsider alternative medications. If subject requires use of these medications, use with caution and reduce the venetoclax dose by 2-fold for moderate inhibitors and 4-fold for strong inhibitors during co-administration. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted.\nAfter discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax dose is increased back to the previous dose level."
            }
          },
          {
            "id": "int-002",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inhibitor"
            },
            "severity": {
              "decode": "moderate"
            },
            "affected_drugs": [
              "amprenavir",
              "aprepitant",
              "atazanavir",
              "cimetidine",
              "ciprofloxacin",
              "crizotinib",
              "cyclosporine",
              "darunavir",
              "diltiazem",
              "erythromycin",
              "fluconazole",
              "fosamprenavir",
              "imatinib",
              "isavuconazole",
              "lixivaptan",
              "verapamil"
            ],
            "clinical_effect": "Increases venetoclax concentration, potentially increasing toxicity.",
            "management": {
              "decode": "dose_adjustment"
            },
            "management_detail": "Reduce the venetoclax dose by 2-fold during co-administration. Monitor closely for toxicities. After discontinuation of inhibitor, wait 3 days before increasing venetoclax dose.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Strong and Moderate CYP3A inhibitors\nConsider alternative medications. If subject requires use of these medications, use with caution and reduce the venetoclax dose by 2-fold for moderate inhibitors and 4-fold for strong inhibitors during co-administration. Patients should be monitored more closely for signs of toxicities and the dose may need to be further adjusted.\nAfter discontinuation of CYP3A inhibitor, wait for 3 days before venetoclax dose is increased back to the previous dose level."
            }
          },
          {
            "id": "int-003",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inducer"
            },
            "severity": {
              "decode": "strong"
            },
            "affected_drugs": [
              "avasimibe",
              "carbamazepine",
              "enzalutamide",
              "mitotane",
              "phenytoin",
              "rifampin",
              "St. John's Wort"
            ],
            "clinical_effect": "Decreases venetoclax concentration, potentially reducing efficacy.",
            "management": {
              "decode": "avoid_if_possible"
            },
            "management_detail": "Consider alternative medications. If use is required, use with caution and contact the AbbVie TA MD or designee for guidance.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Strong and Moderate CYP3A inducers\nConsider alternative medications. If subject requires use of these medications, use with caution and contact AbbVie TA MD or designee (refer to Section 6.1.5) for guidance."
            }
          },
          {
            "id": "int-004",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inducer"
            },
            "severity": {
              "decode": "moderate"
            },
            "affected_drugs": [
              "bosentan",
              "efavirenz",
              "etravirine",
              "modafinil",
              "nafcillin"
            ],
            "clinical_effect": "Decreases venetoclax concentration, potentially reducing efficacy.",
            "management": {
              "decode": "avoid_if_possible"
            },
            "management_detail": "Consider alternative medications. If use is required, use with caution and contact the AbbVie TA MD or designee for guidance.",
            "provenance": {
              "section_number": null,
              "page_number": 56,
              "text_snippet": "Strong and Moderate CYP3A inducers\nConsider alternative medications. If subject requires use of these medications, use with caution and contact AbbVie TA MD or designee (refer to Section 6.1.5) for guidance."
            }
          }
        ],
        "allowed_medications": [
          {
            "id": "allow-001",
            "instanceType": "AllowedMedication",
            "medication_class": "Hormonal contraceptives",
            "specific_drugs": [],
            "notes": "Allowed if associated with inhibition of ovulation for at least 3 months prior to taking study treatment.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Hormonal contraceptives (examples include birth control pills, vaginal rings, or patches), associated with inhibition of ovulation for at least 3 months prior to taking study treatment."
            }
          },
          {
            "id": "allow-002",
            "instanceType": "AllowedMedication",
            "medication_class": "Colony stimulating factors",
            "specific_drugs": [
              "G-CSF",
              "GM-CSF"
            ],
            "notes": "Allowed per American Society of Clinical Oncology (ASCO) guidelines.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Colony stimulating factors (granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]) will be allowed per American Society of Clinical Oncology (ASCO) guidelines."
            }
          },
          {
            "id": "allow-003",
            "instanceType": "AllowedMedication",
            "medication_class": "Bisphosphonates",
            "specific_drugs": [],
            "notes": "Allowed IV or PO as indicated per Institutional guidelines.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Bisphosphonates intravenous (IV) or PO as indicated per Institutional guidelines."
            }
          },
          {
            "id": "allow-004",
            "instanceType": "AllowedMedication",
            "medication_class": "Oral proton-pump inhibitors",
            "specific_drugs": [
              "lansoprazole",
              "omeprazole",
              "esomeprazole"
            ],
            "notes": "Allowed as prophylactic therapy for peptic ulcer disease during treatment with dexamethasone.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Oral proton-pump inhibitor (lansoprazole, omeprazole, esomeprazole, etc.) as prophylactic therapy for peptic ulcer disease during treatment with dexamethasone."
            }
          },
          {
            "id": "allow-005",
            "instanceType": "AllowedMedication",
            "medication_class": "Antimicrobial prophylaxis",
            "specific_drugs": [],
            "notes": "Includes anti-fungal prophylaxis.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Antimicrobial (including anti-fungal) prophylaxis."
            }
          },
          {
            "id": "allow-006",
            "instanceType": "AllowedMedication",
            "medication_class": "Anticoagulants",
            "specific_drugs": [],
            "notes": "Allowed to prevent or treat thromboembolic events.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Anticoagulants to prevent or treat thromboembolic events."
            }
          },
          {
            "id": "allow-007",
            "instanceType": "AllowedMedication",
            "medication_class": "Best supportive care",
            "specific_drugs": [
              "antiemetics",
              "antibiotics",
              "transfusions",
              "nutritional support",
              "pain control"
            ],
            "notes": "Allowed as needed.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 54,
              "text_snippet": "Best supportive care and treatment (e.g., antiemetics, antibiotics, transfusions, nutritional support, pain control, etc.)."
            }
          },
          {
            "id": "allow-008",
            "instanceType": "AllowedMedication",
            "medication_class": "Surgery and radiation",
            "specific_drugs": [],
            "notes": "Localized radiation therapy, kyphoplasty, vertebroplasty, or emergency orthopedic surgery is permitted under specific conditions, may require sponsor approval.",
            "provenance": {
              "section_number": "5.2.4.2",
              "page_number": 55,
              "text_snippet": "Surgery and radiation:\n○ Localized radiation therapy to a site of pre-existing disease may be permitted while on study...\n○ Kyphoplasty, vertebroplasty, or emergency orthopedic surgery is permitted."
            }
          }
        ],
        "vaccine_policy": {
          "instanceType": "VaccinePolicy",
          "live_vaccines_prohibited": true,
          "live_vaccine_washout_days": 56,
          "inactivated_vaccines_allowed": true,
          "covid_vaccine_policy": "A delay in pneumococcal and/or influenza vaccination may take place per PI discretion if the subject tests positive for COVID-19.",
          "specific_restrictions": [
            "Live attenuated vaccines are not allowed while on study treatment.",
            "All subjects must be vaccinated against pneumococcus and receive a yearly influenza vaccination (inactivated only) while on study treatment."
          ],
          "provenance": {
            "section_number": "5.2.4.1",
            "page_number": 53,
            "text_snippet": "All subjects must be vaccinated against pneumococcus and receive a yearly influenza vaccination (live attenuated vaccines are not allowed), while on study treatment... COVID-19 Pandemic-Related Acceptable Protocol Modification: A delay in pneumococcal and/or influenza vaccination may take place per PI discretion if the subject tests positive for COVID-19 until such time that the subject has clinically recovered or per institutional guidelines."
          }
        },
        "herbal_supplements_policy": {
          "instanceType": "HerbalSupplementsPolicy",
          "prohibited_supplements": [
            "St. John's Wort",
            "grapefruit",
            "grapefruit products",
            "Seville oranges",
            "starfruit"
          ],
          "rationale": "St. John's Wort is a strong CYP3A inducer. Grapefruit, Seville oranges, and starfruit are CYP3A inhibitors.",
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 74,
            "text_snippet": "Subjects may not consume the following: grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit within the 3-day period prior to the first study treatment administration and until the last day of treatment is completed due to possible CYP3A mediated metabolic interaction."
          }
        },
        "provenance": {
          "section_number": "5.2.4",
          "page_number": 52,
          "text_snippet": "5.2.4 Prior and Concomitant Therapy\nAny medication or vaccine (including over-the-counter or prescription medications, vitamins and/or herbal supplements) that the subject is receiving at the time of enrollment, or receives during the study, must be documented in source documents and electronic case report forms (eCRFs) along with the reason for use, date(s) of administration including start and end dates, and dosage information including dose, route, and frequency."
        }
      },
      "_agentDocumentation": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility → Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      }
    },
    "biospecimenHandling": {
      "moduleId": "biospecimen_handling",
      "instanceType": "BiospecimenHandling",
      "data": {
        "discovered_specimen_types": [
          {
            "specimen_id": "SPEC-001",
            "specimen_name": "Serum",
            "specimen_category": "blood",
            "specimen_subtype": "serum",
            "purpose": "biomarker",
            "purpose_description": "For biomarker analysis and exploratory research",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected for biomarker analysis and exploratory research at designated time points throughout the study."
            }
          },
          {
            "specimen_id": "SPEC-002",
            "specimen_name": "Plasma",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "biomarker",
            "purpose_description": "For biomarker analysis and exploratory research",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected for biomarker analysis and exploratory research at designated time points throughout the study."
            }
          },
          {
            "specimen_id": "SPEC-003",
            "specimen_name": "Plasma for Uric Acid",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "safety",
            "purpose_description": "To avoid ex vivo uric acid degradation from rasburicase",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "a. For samples analyzed locally, at room temperature, rasburicase causes enzymatic degradation of the uric acid in blood/plasma/serum samples potentially resulting in spuriously low plasma uric acid readings. The following special sample handling procedure must be followed to avoid ex vivo uric acid degradation.\n1. Uric acid must be analyzed in plasma."
            }
          },
          {
            "specimen_id": "SPEC-004",
            "specimen_name": "Bone Marrow Aspirate",
            "specimen_category": "bone_marrow",
            "specimen_subtype": "aspirate",
            "purpose": "biomarker",
            "purpose_description": "For biomarker analysis, exploratory research, disease response assessment, qPCR, MRD, and FISH",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected for biomarker analysis and exploratory research at designated time points throughout the study."
            }
          },
          {
            "specimen_id": "SPEC-005",
            "specimen_name": "Bone Marrow Core Biopsy",
            "specimen_category": "bone_marrow",
            "specimen_subtype": "biopsy",
            "purpose": "biomarker",
            "purpose_description": "For biomarker analysis, exploratory research, and Immunohistochemistry (IHC)",
            "provenance": {
              "section_number": "1.2",
              "page_number": 7,
              "text_snippet": "Serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected for biomarker analysis and exploratory research at designated time points throughout the study."
            }
          },
          {
            "specimen_id": "SPEC-006",
            "specimen_name": "Whole Blood for DNA",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "pharmacogenetic",
            "purpose_description": "Optional sample for deoxyribonucleic acid (DNA) isolation for exploratory research.",
            "provenance": {
              "section_number": null,
              "page_number": 78,
              "text_snippet": "Pharmacogenetic Sample (Optional JPMA Category B)\nAn optional 4 mL whole blood sample for deoxyribonucleic acid (DNA) isolation will be collected on Cycle 1 Day 1 (prior to the first dose of study treatment), Cycle 5 Day 1 and TCV from each subject who consents to provide samples for exploratory research."
            }
          },
          {
            "specimen_id": "SPEC-007",
            "specimen_name": "Blood for Venetoclax Assay",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "purpose": "pk",
            "purpose_description": "For pharmacokinetic analysis of venetoclax.",
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected at the following times:"
            }
          },
          {
            "specimen_id": "SPEC-008",
            "specimen_name": "Blood for Bortezomib Assay",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "purpose": "pk",
            "purpose_description": "For pharmacokinetic analysis of bortezomib.",
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected at the following times:"
            }
          },
          {
            "specimen_id": "SPEC-009",
            "specimen_name": "Blood for Dexamethasone Assay",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "purpose": "pk",
            "purpose_description": "For pharmacokinetic analysis of dexamethasone in Japanese subjects.",
            "provenance": {
              "section_number": null,
              "page_number": 80,
              "text_snippet": "Blood Samples for Dexamethasone Assay (Japan Subjects Only)\nJapanese subjects enrolled in the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected at the following times:"
            }
          }
        ],
        "collection_containers": [
          {
            "container_id": "CONT-001",
            "container_type": "pre-chilled tube",
            "anticoagulant": "heparin",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "1. Uric acid must be analyzed in plasma. Blood must be collected into pre-chilled tubes containing heparin anticoagulant."
            }
          }
        ],
        "collection_schedule": [
          {
            "schedule_id": "SCHED-001",
            "specimen_ref": "SPEC-007",
            "timepoint_name": "Cycle 1 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "6 hours post-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected at the following times:\n● Cycle 1 Day 1: 6 hour post dose (optional)"
            }
          },
          {
            "schedule_id": "SCHED-002",
            "specimen_ref": "SPEC-007",
            "timepoint_name": "Cycles 2, 4, 6, 8 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "0 hour (pre-dose)",
            "collection_window": null,
            "number_of_samples": 4,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected at the following times:\n● Cycles 2, 4, 6 and 8 (Day 1): 0 hour (pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-003",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Cycle 1 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "0.5 hour post-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected at the following times:\n● Cycle 1 Day 1: 0.5 hour post dose"
            }
          },
          {
            "schedule_id": "SCHED-004",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Cycles 2, 4, 6, 8 Day 11",
            "timepoint_type": "treatment",
            "relative_time": "0 hour (pre-dose)",
            "collection_window": null,
            "number_of_samples": 4,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected at the following times:\n● Cycles 2, 4, 6 and 8 (Day 11): 0 hour (pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-005",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "Cycle 1 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "0.5 and 6 hour post-dose",
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 80,
              "text_snippet": "Blood Samples for Dexamethasone Assay (Japan Subjects Only)\nJapanese subjects enrolled in the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected at the following times:\n● Cycle 1 Day 1: 0.5 and 6 hour post dose"
            }
          },
          {
            "schedule_id": "SCHED-006",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "Cycle 1 Day 11",
            "timepoint_type": "treatment",
            "relative_time": "0 (pre-dose), 0.5, 1, 2, 4, 8 and 24 (Day 12 pre-dose) hours post dose",
            "collection_window": null,
            "number_of_samples": 7,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 80,
              "text_snippet": "● Cycle 1 Day 11: 0 (pre-dose), 0.5, 1, 2, 4, 8 and 24 (Day 12 pre-dose) hours post dose"
            }
          },
          {
            "schedule_id": "SCHED-007",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Cycle 1 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "Pre-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL of blood will be collected at the following time points:\n● Cycle 1 Day 1 (Pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-008",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Cycle 1 Day 5",
            "timepoint_type": "treatment",
            "relative_time": "Pre-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL of blood will be collected at the following time points:\n● Cycle 5 Day 1 (Pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-009",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "Disease Progression or TCV",
            "timepoint_type": "discontinuation",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL of blood will be collected at the following time points:\n● Disease Progression or TCV"
            }
          },
          {
            "schedule_id": "SCHED-010",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Cycle 1 Day 1",
            "timepoint_type": "treatment",
            "relative_time": "Pre-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Serum Markers\nApproximately 3.5 mL of blood will be collected at the following time points:\n● Cycle 1 Day 1 (Pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-011",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Cycle 1 Day 5",
            "timepoint_type": "treatment",
            "relative_time": "Pre-dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Serum Markers\nApproximately 3.5 mL of blood will be collected at the following time points:\n● Cycle 5 Day 1 (Pre-dose)"
            }
          },
          {
            "schedule_id": "SCHED-012",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Disease Progression or TCV",
            "timepoint_type": "discontinuation",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Serum Markers\nApproximately 3.5 mL of blood will be collected at the following time points:\n● Disease Progression or TCV"
            }
          },
          {
            "schedule_id": "SCHED-013",
            "specimen_ref": "SPEC-005",
            "timepoint_name": "Screening",
            "timepoint_type": "screening",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 76,
              "text_snippet": "Pre-Treatment Bone Marrow Core (BMC) Biopsy Tissue Collection for Immunohistochemistry (IHC)\nOne of the following forms of pre-therapy tumor tissue (newly collected tissue or archived tissue) should be collected at Screening:"
            }
          },
          {
            "schedule_id": "SCHED-014",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "Screening or Cycle 1 Day 1",
            "timepoint_type": "screening",
            "relative_time": "Screening (preferred) or prior to first dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "qPCR and MRD Sample Collection\nA 6 mL aspirate sample will be collected at the following time point for qPCR and baseline assessment of disease using MRD assay:\n● Screening (preferred) or prior to first dose of study treatment (Cycle 1 Day 1)"
            }
          },
          {
            "schedule_id": "SCHED-015",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "At time of suspected CR/sCR",
            "timepoint_type": "treatment",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "MRD Assessment\nA 3 mL aspirate sample will be collected at the following time points for MRD assessment:\n● At the time of suspected CR/stringent complete response (sCR) for confirmation of clinical response"
            }
          },
          {
            "schedule_id": "SCHED-016",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "6 and 12 months post-CR/sCR confirmation",
            "timepoint_type": "follow_up",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "MRD Assessment\nA 3 mL aspirate sample will be collected at the following time points for MRD assessment:\n● At approximately 6 months and 12 months after confirmation of CR/sCR for subjects who maintain this response"
            }
          },
          {
            "schedule_id": "SCHED-017",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "Screening or Cycle 1 Day 1",
            "timepoint_type": "screening",
            "relative_time": "Screening (preferred) or prior to first dose",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "Fluorescent In Situ Hybridization (FISH)\nA 4 mL aspirate sample will be collected at the following time point for baseline assessment of chromosomal abnormalities...:\n● Screening (preferred) or prior to first dose of study treatment (Cycle 1 Day 1)."
            }
          },
          {
            "schedule_id": "SCHED-018",
            "specimen_ref": "SPEC-006",
            "timepoint_name": "Cycle 1 Day 1, Cycle 5 Day 1, TCV",
            "timepoint_type": "treatment",
            "relative_time": "C1D1 (prior to first dose), C5D1, TCV",
            "collection_window": null,
            "number_of_samples": 3,
            "fasting_required": false,
            "provenance": {
              "section_number": null,
              "page_number": 78,
              "text_snippet": "Pharmacogenetic Sample (Optional JPMA Category B)\nAn optional 4 mL whole blood sample for deoxyribonucleic acid (DNA) isolation will be collected on Cycle 1 Day 1 (prior to the first dose of study treatment), Cycle 5 Day 1 and TCV from each subject who consents to provide samples for exploratory research."
            }
          }
        ],
        "processing_requirements": [
          {
            "processing_id": "PROC-001",
            "specimen_ref": "SPEC-003",
            "processing_step": "centrifugation",
            "processing_description": "Samples should be prepared by centrifugation in a pre-cooled centrifuge (4°C).",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Plasma samples must be prepared by centrifugation in a pre-cooled centrifuge (4°C)."
            }
          },
          {
            "processing_id": "PROC-002",
            "specimen_ref": "SPEC-003",
            "processing_step": "maintain_on_ice",
            "processing_description": "The plasma must be maintained in an ice water bath and analyzed for uric acid within 4 hours of collection.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Immediately immerse plasma samples for uric acid measurement in an ice water bath. ... Finally, the plasma must be maintained in an ice water bath and analyzed for uric acid within 4 hours of collection."
            }
          },
          {
            "processing_id": "PROC-003",
            "specimen_ref": "SPEC-005",
            "processing_step": "fixation",
            "processing_description": "Tissue should be fixed in formalin, decalcified, and embedded in paraffin according to institutional procedures.",
            "provenance": {
              "section_number": null,
              "page_number": 76,
              "text_snippet": "Tissue should be fixed in formalin, decalcified, and embedded in paraffin according to institutional procedures."
            }
          }
        ],
        "storage_requirements": [
          {
            "storage_id": "STOR-001",
            "specimen_ref": "SPEC-005",
            "storage_condition": "ffpe",
            "storage_duration": null,
            "provenance": {
              "section_number": null,
              "page_number": 76,
              "text_snippet": "While sending Formalin-Fixed, Paraffin-Embedded (FFPE) blocks is preferred, slides prepared and stored by the local pathology laboratory are acceptable and should be prepared as described in the study-specific laboratory manual."
            }
          },
          {
            "storage_id": "STOR-002",
            "specimen_ref": null,
            "storage_condition": "secure_storage",
            "storage_duration": {
              "value": 20,
              "unit": "years",
              "description": "No longer than 20 years after study completion"
            },
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 74,
              "text_snippet": "AbbVie (or people or companies working with AbbVie) will store the biomarker and exploratory research samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on venetoclax (or drugs of this class) or this disease and related conditions continues, but for no longer than 20 years after study completion, or per local requirements."
            }
          }
        ],
        "shipping_requirements": [
          {
            "shipping_id": "SHIP-001",
            "specimen_ref": null,
            "shipping_conditions": "As outlined in the study-specific laboratory manual",
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 74,
              "text_snippet": "All samples should be prepared, labeled, and shipped as outlined in the study-specific laboratory manual."
            }
          }
        ],
        "central_laboratory": [
          {
            "lab_id": "LAB-001",
            "lab_name": "Certified central laboratory",
            "lab_type": "central",
            "analyses_performed": [
              "coagulation",
              "viral serologies",
              "urinalysis",
              "special chemistry"
            ],
            "provenance": {
              "section_number": null,
              "page_number": 68,
              "text_snippet": "A certified central laboratory will be utilized to process and provide results for coagulation, viral serologies, urinalysis, and special chemistry labs listed in Table 3. These data will be used for all data analysis. The central laboratory will provide instructions regarding the collection, processing, handling, and shipping of samples."
            }
          }
        ],
        "kit_specifications": null,
        "quality_requirements": null,
        "regulatory_requirements": null,
        "volume_summary": [
          {
            "specimen_ref": "SPEC-007",
            "volume": 3,
            "unit": "mL",
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood samples (3 mL) for venetoclax assay will be collected at the following times:"
            }
          },
          {
            "specimen_ref": "SPEC-008",
            "volume": 4,
            "unit": "mL",
            "provenance": {
              "section_number": null,
              "page_number": 79,
              "text_snippet": "Blood samples (4 mL) for bortezomib assay will be collected at the following times:"
            }
          },
          {
            "specimen_ref": "SPEC-009",
            "volume": 3,
            "unit": "mL",
            "provenance": {
              "section_number": null,
              "page_number": 80,
              "text_snippet": "Japanese subjects enrolled in the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected at the following times:"
            }
          },
          {
            "specimen_ref": "SPEC-002",
            "volume": 12,
            "unit": "mL",
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL of blood will be collected at the following time points:"
            }
          },
          {
            "specimen_ref": "SPEC-001",
            "volume": 3.5,
            "unit": "mL",
            "provenance": {
              "section_number": "5.3.1.3.1",
              "page_number": 75,
              "text_snippet": "Blood Collection for Serum Markers\nApproximately 3.5 mL of blood will be collected at the following time points:"
            }
          },
          {
            "specimen_ref": "SPEC-004",
            "volume": 6,
            "unit": "mL",
            "purpose": "qPCR and MRD",
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "qPCR and MRD Sample Collection\nA 6 mL aspirate sample will be collected at the following time point for qPCR and baseline assessment of disease using MRD assay:"
            }
          },
          {
            "specimen_ref": "SPEC-004",
            "volume": 3,
            "unit": "mL",
            "purpose": "MRD Assessment",
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "MRD Assessment\nA 3 mL aspirate sample will be collected at the following time points for MRD assessment:"
            }
          },
          {
            "specimen_ref": "SPEC-004",
            "volume": 4,
            "unit": "mL",
            "purpose": "FISH",
            "provenance": {
              "section_number": null,
              "page_number": 77,
              "text_snippet": "Fluorescent In Situ Hybridization (FISH)\nA 4 mL aspirate sample will be collected at the following time point for baseline assessment of chromosomal abnormalities"
            }
          },
          {
            "specimen_ref": "SPEC-006",
            "volume": 4,
            "unit": "mL",
            "provenance": {
              "section_number": null,
              "page_number": 78,
              "text_snippet": "Pharmacogenetic Sample (Optional JPMA Category B)\nAn optional 4 mL whole blood sample for deoxyribonucleic acid (DNA) isolation will be collected"
            }
          }
        ],
        "id": "biospecimen-handling-001",
        "instanceType": "BiospecimenHandling",
        "name": "M14-031 Protocol Biospecimen Handling"
      },
      "_agentDocumentation": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA → Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "laboratorySpecifications": {
      "moduleId": "laboratory_specifications",
      "instanceType": "LaboratorySpecifications",
      "data": {
        "id": "LS-001",
        "instanceType": "LaboratorySpecifications",
        "name": "Laboratory Specifications",
        "description": "Protocol-discovered laboratory testing requirements for AbbVie M14-031 Protocol Amendment 8.",
        "central_laboratory": {
          "vendor_name": "A certified central laboratory will be utilized",
          "accreditations": null,
          "data_transfer_method": null,
          "provenance": {
            "section_number": "5.3.1.1.1",
            "page_number": 68,
            "text_snippet": "A certified central laboratory will be utilized to process and provide results for coagulation, viral serologies, urinalysis, and special chemistry labs listed in Table 3."
          }
        },
        "discovered_panels": [
          {
            "panel_id": "PNL-001",
            "panel_name": "Hematology",
            "panel_code": null,
            "panel_description": "Hematology panel performed at local lab.",
            "panel_category": "hematology",
            "test_count": 11,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nHematology – Local Lab"
            }
          },
          {
            "panel_id": "PNL-002",
            "panel_name": "Serum Chemistry",
            "panel_code": null,
            "panel_description": "Serum Chemistry panel performed at local lab.",
            "panel_category": "chemistry",
            "test_count": 14,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nSerum Chemistry – Local Lab"
            }
          },
          {
            "panel_id": "PNL-003",
            "panel_name": "Urinalysis",
            "panel_code": null,
            "panel_description": "Urinalysis panel performed at central lab.",
            "panel_category": "urinalysis",
            "test_count": 7,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nUrinalysis – Central Lab"
            }
          },
          {
            "panel_id": "PNL-004",
            "panel_name": "Coagulation",
            "panel_code": null,
            "panel_description": "Coagulation panel performed at central lab.",
            "panel_category": "coagulation",
            "test_count": 3,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nCoagulation – Central Lab"
            }
          },
          {
            "panel_id": "PNL-005",
            "panel_name": "Viral Serologies",
            "panel_code": null,
            "panel_description": "Viral Serologies panel performed at central lab.",
            "panel_category": "immunology",
            "test_count": 2,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nViral Serologies – Central Lab"
            }
          },
          {
            "panel_id": "PNL-006",
            "panel_name": "Special Chemistry Labs",
            "panel_code": null,
            "panel_description": "Special Chemistry panel performed at central lab.",
            "panel_category": "chemistry",
            "test_count": 4,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nSpecial Chemistry Labs – Central Lab"
            }
          },
          {
            "panel_id": "PNL-007",
            "panel_name": "Viral Serology - Local Lab",
            "panel_code": null,
            "panel_description": "SARS-CoV-2 testing performed at local lab.",
            "panel_category": "microbiology",
            "test_count": 1,
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Table 3. Clinical Laboratory Tests\nViral Serology – Local Lab\nSARS-CoV-2b testing"
            }
          },
          {
            "panel_id": "PNL-008",
            "panel_name": "Myeloma Disease Assessment Panel",
            "panel_code": null,
            "panel_description": "Panel of tests for multiple myeloma disease assessment and response.",
            "panel_category": "other",
            "test_count": 7,
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 84,
              "text_snippet": "Laboratory Tests for Multiple Myeloma:\nAll serum and urine laboratory tests for multiple myeloma must be sent to a certified central laboratory."
            }
          }
        ],
        "laboratory_tests": [
          {
            "test_id": "LAB-001",
            "test_name": "Hematocrit",
            "test_code": "4544-3",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of CBC for assessing anemia.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nHematocrit"
            }
          },
          {
            "test_id": "LAB-002",
            "test_name": "Hemoglobin",
            "test_code": "718-7",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "g/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for eligibility criteria and monitoring for anemia.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Hemoglobin ≥ 8.0 g/dL, within 2 weeks prior to randomization."
            }
          },
          {
            "test_id": "LAB-003",
            "test_name": "RBC count",
            "test_code": "789-8",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of CBC for assessing anemia.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nRBC count"
            }
          },
          {
            "test_id": "LAB-004",
            "test_name": "White blood cell (WBC) count",
            "test_code": "6690-2",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of CBC for monitoring immune status.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nWhite blood cell (WBC) count"
            }
          },
          {
            "test_id": "LAB-005",
            "test_name": "Neutrophils",
            "test_code": "751-8",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of WBC differential.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nNeutrophils"
            }
          },
          {
            "test_id": "LAB-006",
            "test_name": "Lymphocytes",
            "test_code": "736-9",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of WBC differential.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nLymphocytes"
            }
          },
          {
            "test_id": "LAB-007",
            "test_name": "Monocytes",
            "test_code": "742-7",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of WBC differential.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nMonocytes"
            }
          },
          {
            "test_id": "LAB-008",
            "test_name": "Basophils",
            "test_code": "706-2",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of WBC differential.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nBasophils"
            }
          },
          {
            "test_id": "LAB-009",
            "test_name": "Eosinophils",
            "test_code": "713-8",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of WBC differential.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Hematology – Local Lab\nEosinophils"
            }
          },
          {
            "test_id": "LAB-010",
            "test_name": "Platelet count",
            "test_code": "777-3",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "/mm3",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for eligibility criteria and monitoring for thrombocytopenia.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Platelet count ≥ 50,000/millimeter (mm)3, within 2 weeks prior to randomization."
            }
          },
          {
            "test_id": "LAB-011",
            "test_name": "Reticulocyte Count",
            "test_code": "17848-2",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses bone marrow function.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Reticulocyte Count (Screening, Day 1 of each cycle, and TCV only)"
            }
          },
          {
            "test_id": "LAB-012",
            "test_name": "Blood urea nitrogen (BUN) or urea",
            "test_code": "3094-0",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nBlood urea nitrogen (BUN) or urea"
            }
          },
          {
            "test_id": "LAB-013",
            "test_name": "Creatinine",
            "test_code": "2160-0",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "mg/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses renal function, used to calculate CrCl for eligibility.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nCreatinine"
            }
          },
          {
            "test_id": "LAB-014",
            "test_name": "Total bilirubin",
            "test_code": "1975-2",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses liver function, used for eligibility.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Total bilirubin ≤ 1.5 × ULN."
            }
          },
          {
            "test_id": "LAB-015",
            "test_name": "Alanine aminotransferase (ALT/SGPT)",
            "test_code": "1742-6",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses liver function, used for eligibility.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "AST and ALT ≤ 3 × upper limit of normal (ULN)."
            }
          },
          {
            "test_id": "LAB-016",
            "test_name": "Aspartate aminotransferase (AST/SGOT)",
            "test_code": "1920-8",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "x ULN",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses liver function, used for eligibility.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "AST and ALT ≤ 3 × upper limit of normal (ULN)."
            }
          },
          {
            "test_id": "LAB-017",
            "test_name": "Alkaline phosphatase",
            "test_code": "6768-6",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nAlkaline phosphatase"
            }
          },
          {
            "test_id": "LAB-018",
            "test_name": "Sodium",
            "test_code": "2951-2",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nSodium"
            }
          },
          {
            "test_id": "LAB-019",
            "test_name": "Potassium",
            "test_code": "2823-3",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors electrolyte balance, particularly for TLS.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nPotassium"
            }
          },
          {
            "test_id": "LAB-020",
            "test_name": "Calcium",
            "test_code": "17861-6",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for hypercalcemia, a sign of progressive disease.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nCalcium"
            }
          },
          {
            "test_id": "LAB-021",
            "test_name": "Inorganic phosphorus",
            "test_code": "2777-1",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for TLS.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nInorganic phosphorus"
            }
          },
          {
            "test_id": "LAB-022",
            "test_name": "Uric acid",
            "test_code": "3084-1",
            "panel_ref": "PNL-002",
            "specimen_type": "plasma",
            "collection_container": "pre-chilled heparin tubes",
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Immediately immerse in ice water bath, centrifuge in pre-cooled centrifuge (4°C), analyze within 4 hours.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Monitors for TLS.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Uric acida\na. ...The following special sample handling procedure must be followed to avoid ex vivo uric acid degradation."
            }
          },
          {
            "test_id": "LAB-023",
            "test_name": "Total protein",
            "test_code": "2885-2",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nTotal protein"
            }
          },
          {
            "test_id": "LAB-024",
            "test_name": "Glucose",
            "test_code": "2345-7",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nGlucose"
            }
          },
          {
            "test_id": "LAB-025",
            "test_name": "Albumin",
            "test_code": "1751-7",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "g/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for correcting serum calcium levels.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nAlbumin"
            }
          },
          {
            "test_id": "LAB-026",
            "test_name": "Lactate dehydrogenase (LDH)",
            "test_code": "2532-0",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nLactate dehydrogenase (LDH)"
            }
          },
          {
            "test_id": "LAB-027",
            "test_name": "Magnesium",
            "test_code": "2601-3",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nMagnesium"
            }
          },
          {
            "test_id": "LAB-028",
            "test_name": "Chloride",
            "test_code": "2075-0",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Component of chemistry panel.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Serum Chemistry – Local Lab\nChloride"
            }
          },
          {
            "test_id": "LAB-029",
            "test_name": "Prothrombin time (PT)",
            "test_code": "5902-2",
            "panel_ref": "PNL-004",
            "specimen_type": "plasma",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses coagulation pathway.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Coagulation – Central Lab\nPT"
            }
          },
          {
            "test_id": "LAB-030",
            "test_name": "Activated Partial Thromboplastin Time (aPTT)",
            "test_code": "14979-9",
            "panel_ref": "PNL-004",
            "specimen_type": "plasma",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Assesses coagulation pathway.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Coagulation – Central Lab\naPTT"
            }
          },
          {
            "test_id": "LAB-031",
            "test_name": "International Normalized Ratio (INR)",
            "test_code": "34714-6",
            "panel_ref": "PNL-004",
            "specimen_type": "plasma",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Standardizes PT results.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Coagulation – Central Lab\nINR"
            }
          },
          {
            "test_id": "LAB-032",
            "test_name": "Hepatitis B surface antigen (HBsAg)",
            "test_code": "5196-1",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screening for active Hepatitis B infection (exclusion criterion).",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Viral Serologies – Central Lab\nHBsAg"
            }
          },
          {
            "test_id": "LAB-033",
            "test_name": "Hepatitis C Virus antibody (HCV ab) or RNA",
            "test_code": "13955-0",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Screening for active Hepatitis C infection (exclusion criterion).",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Viral Serologies – Central Lab\nHCV ab or RNA"
            }
          },
          {
            "test_id": "LAB-034",
            "test_name": "Amylase",
            "test_code": "1798-8",
            "panel_ref": "PNL-006",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Special chemistry test.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Special Chemistry Labs – Central Lab\nAmylase"
            }
          },
          {
            "test_id": "LAB-035",
            "test_name": "Lipase",
            "test_code": "2553-6",
            "panel_ref": "PNL-006",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Special chemistry test.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Special Chemistry Labs – Central Lab\nLipase"
            }
          },
          {
            "test_id": "LAB-036",
            "test_name": "Serum β2 Microglobulin (Sβ2M)",
            "test_code": "1969-5",
            "panel_ref": "PNL-006",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Prognostic marker in multiple myeloma.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Special Chemistry Labs – Central Lab\nSerum β2 Microglobulin (Sβ2M)"
            }
          },
          {
            "test_id": "LAB-037",
            "test_name": "C-Reactive protein (CRP)",
            "test_code": "1988-5",
            "panel_ref": "PNL-006",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Marker of inflammation.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Special Chemistry Labs – Central Lab\nC-Reactive protein (CRP)"
            }
          },
          {
            "test_id": "LAB-038",
            "test_name": "SARS-CoV-2 testing",
            "test_code": "94500-6",
            "panel_ref": "PNL-007",
            "specimen_type": "other",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Preferred molecular testing e.g., PCR.",
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "To be done at any timepoint if clinically indicated.",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "SARS-CoV-2b testing\nb. SARS-CoV-2 testing performed at local lab for all subjects on study treatment, as clinically indicated per Investigator's discretion."
            }
          },
          {
            "test_id": "LAB-039",
            "test_name": "Serum Protein Electrophoresis (SPEP)",
            "test_code": "3005-8",
            "panel_ref": "PNL-008",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "g/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures M-protein for disease assessment and response.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 84,
              "text_snippet": "Serum Protein Electrophoresis (SPEP), Serum Protein Immunofixation, Serum Quantitative Immunoglobulins (sQI)"
            }
          },
          {
            "test_id": "LAB-040",
            "test_name": "Serum Protein Immunofixation",
            "test_code": "12710-2",
            "panel_ref": "PNL-008",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Identifies M-protein type for disease assessment and response.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 84,
              "text_snippet": "Serum Protein Electrophoresis (SPEP), Serum Protein Immunofixation, Serum Quantitative Immunoglobulins (sQI)"
            }
          },
          {
            "test_id": "LAB-041",
            "test_name": "Serum Quantitative Immunoglobulins (sQI)",
            "test_code": "2465-3",
            "panel_ref": "PNL-008",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures immunoglobulin levels for disease assessment.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 84,
              "text_snippet": "Serum Protein Electrophoresis (SPEP), Serum Protein Immunofixation, Serum Quantitative Immunoglobulins (sQI)"
            }
          },
          {
            "test_id": "LAB-042",
            "test_name": "Serum Free Light Chains (sFLC)",
            "test_code": "33883-0",
            "panel_ref": "PNL-008",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "mg/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures free light chains for disease assessment and response, especially in non-secretory or oligo-secretory myeloma.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 85,
              "text_snippet": "Serum Free Light Chains (sFLC)\nBlood samples for sFLC testing will be collected for all subjects per Table 4"
            }
          },
          {
            "test_id": "LAB-043",
            "test_name": "Urine Protein Electrophoresis (UPEP)",
            "test_code": "3014-0",
            "panel_ref": "PNL-008",
            "specimen_type": "urine",
            "collection_container": "24-hour urine collection",
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "mg/24 hours",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Measures M-protein in urine for disease assessment and response.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 85,
              "text_snippet": "Urine Protein Immunofixation and Urine Protein Electrophoresis (UPEP), 24-Hour Urine"
            }
          },
          {
            "test_id": "LAB-044",
            "test_name": "Urine Protein Immunofixation",
            "test_code": "13212-5",
            "panel_ref": "PNL-008",
            "specimen_type": "urine",
            "collection_container": "24-hour urine collection",
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": null,
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Identifies M-protein type in urine for disease assessment and response.",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 85,
              "text_snippet": "Urine Protein Immunofixation and Urine Protein Electrophoresis (UPEP), 24-Hour Urine"
            }
          },
          {
            "test_id": "LAB-045",
            "test_name": "Corrected Serum Calcium",
            "test_code": null,
            "panel_ref": "PNL-008",
            "specimen_type": "serum",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Calculated value: Measured serum calcium [mg/dL] + 0.8 × (4 – serum albumin [g/dL]).",
            "unit": "mg/dL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for disease assessment, particularly for CRAB criteria (hypercalcemia).",
            "provenance": {
              "section_number": "5.3.7.1",
              "page_number": 85,
              "text_snippet": "Corrected Serum Calcium [mg/dL] = Measured serum calcium [mg/dL] + 0.8 × (4 – serum albumin [g/dL])."
            }
          },
          {
            "test_id": "LAB-046",
            "test_name": "Absolute Neutrophil Count (ANC)",
            "test_code": "751-8",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": null,
            "unit": "/µL",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for eligibility and monitoring for neutropenia.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Absolute neutrophil count (ANC) ≥ 1000/microliter (µL) within 2 weeks prior to randomization"
            }
          },
          {
            "test_id": "LAB-047",
            "test_name": "Creatinine Clearance (CrCl)",
            "test_code": "2161-8",
            "panel_ref": null,
            "specimen_type": "urine",
            "collection_container": "24-hour urine collection",
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Can also be calculated using Cockcroft-Gault formula.",
            "unit": "mL/min",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Used for eligibility to assess renal function.",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) measured by 24-hour urine collection or calculated using the Cockcroft-Gault formula."
            }
          },
          {
            "test_id": "LAB-048",
            "test_name": "PaO2 or SpO2",
            "test_code": null,
            "panel_ref": null,
            "specimen_type": "whole_blood",
            "collection_container": null,
            "collection_volume": null,
            "fasting_required": null,
            "special_handling": "Arterial blood gas analysis or percutaneous oxygen saturation.",
            "unit": "mmHg",
            "reference_ranges": [],
            "critical_values": [],
            "clinical_significance": "Eligibility criteria for France and Japan subjects only.",
            "provenance": {
              "section_number": "7",
              "page_number": 46,
              "text_snippet": "France and Japan Subjects Only: PaO2 ≥ 60 millimeter mercury (mmHg) by arterial blood gas analysis or SpO2 ≥ 93% by percutaneous oxygen saturation."
            }
          }
        ],
        "testing_schedule": [
          {
            "schedule_id": "SCH-001",
            "test_or_panel_ref": "PNL-001",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "within 21 days prior to randomization",
                "conditions": "Must include CBC, differential, and platelets. Must be done within 2 weeks prior to randomization."
              },
              {
                "timepoint_name": "Cycles 1-8",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Day 1, 4, 8, 11 of each cycle."
              },
              {
                "timepoint_name": "Cycles 9+",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Day 1, 8, 15, 22 of each cycle."
              }
            ],
            "frequency": "Per cycle schedule",
            "provenance": {
              "section_number": "Appendix E",
              "page_number": 176,
              "text_snippet": "Hematology X X X X Must include CBC, differential, platelets. May be done pre-dose within 72 h prior to scheduled visits."
            }
          },
          {
            "schedule_id": "SCH-002",
            "test_or_panel_ref": "PNL-002",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "within 21 days prior to randomization",
                "conditions": null
              },
              {
                "timepoint_name": "Cycles 1-8",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Day 1, 4, 8, 11 of each cycle."
              },
              {
                "timepoint_name": "Cycles 9+",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Day 1, 8, 15, 22 of each cycle."
              }
            ],
            "frequency": "Per cycle schedule",
            "provenance": {
              "section_number": "Appendix E",
              "page_number": 176,
              "text_snippet": "Serum Chemistry X X X X For Cycle 1, Chemistry should be collected on Days 1, 4, 8 and 11. For Cycles 2 – 8, collect on Days 1 and 11 only."
            }
          },
          {
            "schedule_id": "SCH-003",
            "test_or_panel_ref": "PNL-004",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": null,
                "conditions": "For all subjects."
              },
              {
                "timepoint_name": "Day 1 of each cycle",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Only in subjects being treated with medication for thromboembolic prophylaxis."
              }
            ],
            "frequency": "Screening, then conditional",
            "provenance": {
              "section_number": "5.3.1.1.1",
              "page_number": 69,
              "text_snippet": "Coagulation tests will be done for all subjects at screening and only in subjects being treated with medication for thromboembolic prophylaxis thereafter on Day 1 of each cycle."
            }
          },
          {
            "schedule_id": "SCH-004",
            "test_or_panel_ref": "PNL-005",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": null,
                "conditions": null
              }
            ],
            "frequency": "Screening only",
            "provenance": {
              "section_number": "Appendix D",
              "page_number": 173,
              "text_snippet": "Hepatitis serology X Will be completed per certified central laboratory."
            }
          },
          {
            "schedule_id": "SCH-005",
            "test_or_panel_ref": "PNL-008",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "within 21 days prior to randomization",
                "conditions": null
              },
              {
                "timepoint_name": "Day 1 of each cycle",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "Starting Cycle 2, until disease progression."
              },
              {
                "timepoint_name": "Confirmation of Response",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": "To confirm sCR, CR, or VGPR."
              },
              {
                "timepoint_name": "Post-Treatment Follow-up",
                "timepoint_type": "follow_up",
                "window": null,
                "conditions": "For subjects who discontinue for reasons other than PD."
              }
            ],
            "frequency": "Screening, each cycle, and for response confirmation/follow-up.",
            "provenance": {
              "section_number": "Table 4",
              "page_number": 91,
              "text_snippet": "Table 4. Assessments for IMWG Response Criteria"
            }
          },
          {
            "schedule_id": "SCH-006",
            "test_or_panel_ref": "LAB-011",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Day 1 of each cycle",
                "timepoint_type": "treatment",
                "window": null,
                "conditions": null
              },
              {
                "timepoint_name": "Treatment Completion Visit (TCV)",
                "timepoint_type": "follow_up",
                "window": null,
                "conditions": null
              }
            ],
            "frequency": "Screening, C1D1 of each cycle, TCV",
            "provenance": {
              "section_number": "Table 3",
              "page_number": 70,
              "text_snippet": "Reticulocyte Count (Screening, Day 1 of each cycle, and TCV only)"
            }
          }
        ],
        "sample_collection_requirements": {
          "fasting_requirements": "Not specified for general labs. PK sampling is timed relative to meals.",
          "timing_requirements": "On days that pre-dose PK sampling is required, venetoclax/placebo dosing will occur in the morning at the clinic to facilitate PK sampling.",
          "processing_requirements": "For Uric Acid: Blood must be collected into pre-chilled tubes containing heparin anticoagulant. Immediately immerse plasma samples in an ice water bath. Prepare plasma by centrifugation in a pre-cooled centrifuge (4°C).",
          "storage_requirements": "For Uric Acid: Plasma must be maintained in an ice water bath and analyzed within 4 hours of collection.",
          "shipping_requirements": "Refer to study specific laboratory manual.",
          "provenance": {
            "section_number": "5.3.1.2",
            "page_number": 74,
            "text_snippet": "On days that pre-dose PK sampling is required, venetoclax/placebo dosing will occur in the morning at the clinic to facilitate PK sampling.",
            "additional_provenance": [
              {
                "section_number": "Table 3",
                "page_number": 70,
                "text_snippet": "a. ...The following special sample handling procedure must be followed to avoid ex vivo uric acid degradation. 1. Uric acid must be analyzed in plasma. Blood must be collected into pre-chilled tubes containing heparin anticoagulant. Immediately immerse plasma samples for uric acid measurement in an ice water bath. Plasma samples must be prepared by centrifugation in a pre-cooled centrifuge (4°C)."
              }
            ]
          }
        },
        "lab_based_dose_modifications": [
          {
            "modification_id": "MOD-001",
            "parameter_name": "Neutropenia with infection or fever",
            "trigger_condition": "Grade 3 or Grade 4",
            "operator": "gte",
            "threshold_value": 3,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Interrupt venetoclax/placebo. First episode: resume at same dose once toxicity resolves to Grade 1 or baseline. Subsequent episodes: resume at a reduced dose per Table 7.",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Grade 3 or Grade 4 neutropenia with infection or fever... First episode: Interrupt venetoclax/placebo and once the toxicity has resolved to Grade 1 or baseline level, venetoclax/placebo may be resumed at the same dose. For subsequent episodes: Interrupt venetoclax/placebo... Follow dose reduction guidelines in Table 7 when resuming treatment..."
            }
          },
          {
            "modification_id": "MOD-002",
            "parameter_name": "Hematologic toxicities (except lymphopenia)",
            "trigger_condition": "Grade 4",
            "operator": "eq",
            "threshold_value": 4,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Interrupt venetoclax/placebo. First episode: resume at same dose once toxicity resolves to Grade 1 or baseline. Subsequent episodes: resume at a reduced dose per Table 7.",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Grade 4 hematologic toxicities (except for lymphopenia)... First episode: Interrupt venetoclax/placebo and once the toxicity has resolved to Grade 1 or baseline level, venetoclax/placebo may be resumed at the same dose. For subsequent episodes: Interrupt venetoclax/placebo... Follow dose reduction guidelines in Table 7..."
            }
          },
          {
            "modification_id": "MOD-003",
            "parameter_name": "Serious Infections",
            "trigger_condition": "Grade ≥ 3",
            "operator": "gte",
            "threshold_value": 3,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Interrupt venetoclax/placebo and upon resolution, treatment can be resumed at a reduced dose or discontinued, depending on Investigator's clinical judgment.",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Grade ≥ 3 or Serious Infections: Interrupt venetoclax/placebo and upon resolution, treatment can be resumed at a reduced dose or discontinued, depending on Investigator's clinical judgment."
            }
          },
          {
            "modification_id": "MOD-004",
            "parameter_name": "Non-hematologic events",
            "trigger_condition": "Grade 3 or 4",
            "operator": "gte",
            "threshold_value": 3,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Interrupt venetoclax/placebo. First episode: resume at same dose once toxicity resolves to Grade ≤ 1 or baseline. Subsequent episodes: resume at a reduced dose per Table 7.",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Grade 3 or 4 non-hematologic events. First episode: Interrupt venetoclax/placebo. Once toxicity has resolved to Grade ≤ 1 or baseline, venetoclax/placebo may be resumed at the same dose... For subsequent episodes: Interrupt venetoclax/placebo. Follow dose reduction guidelines in Table 7..."
            }
          },
          {
            "modification_id": "MOD-005",
            "parameter_name": "Blood chemistry changes suggestive of TLS",
            "trigger_condition": "Changes requiring more than 48 hours to resolve",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": "absolute",
            "required_action": "dose_reduce",
            "recovery_criteria": "Resume at a reduced dose (see Table 7).",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Blood chemistry changes or symptoms suggestive of TLS... For any blood chemistry changes requiring more than 48 hours to resolve, resume at a reduced dose (see Table 7)."
            }
          },
          {
            "modification_id": "MOD-006",
            "parameter_name": "Clinical TLS",
            "trigger_condition": "Any event of clinical TLS",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "reference_type": "absolute",
            "required_action": "dose_reduce",
            "recovery_criteria": "Resume at a reduced dose following resolution.",
            "provenance": {
              "section_number": "Table 8",
              "page_number": 129,
              "text_snippet": "Blood chemistry changes or symptoms suggestive of TLS... For any events of clinical TLS, resume at a reduced dose following resolution."
            }
          },
          {
            "modification_id": "MOD-007",
            "parameter_name": "Non-hematological toxicity (Bortezomib)",
            "trigger_condition": "Grade 3",
            "operator": "eq",
            "threshold_value": 3,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose.",
            "provenance": {
              "section_number": "Table 10",
              "page_number": 132,
              "text_snippet": "Grade 3 non-hematological... Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose."
            }
          },
          {
            "modification_id": "MOD-008",
            "parameter_name": "Hematological toxicity (Bortezomib)",
            "trigger_condition": "Grade 4",
            "operator": "eq",
            "threshold_value": 4,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose.",
            "provenance": {
              "section_number": "Table 10",
              "page_number": 132,
              "text_snippet": "Grade 4 hematological (other than neuropathy). Withhold bortezomib therapy until the symptoms of the toxicity resolve. When toxicity resolves, bortezomib therapy may be reinitiated at a 25% reduced dose."
            }
          },
          {
            "modification_id": "MOD-009",
            "parameter_name": "Peripheral Neuropathy (Bortezomib)",
            "trigger_condition": "Grade 2 with pain or Grade 3",
            "operator": "gte",
            "threshold_value": 2,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_hold",
            "recovery_criteria": "Withhold bortezomib therapy until toxicity resolves to baseline or ≤ Grade 1. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week.",
            "provenance": {
              "section_number": "Table 10",
              "page_number": 132,
              "text_snippet": "Grade 2 with pain or Grade 3... Withhold bortezomib therapy until toxicity resolves to baseline or ≤ Grade 1. When toxicity resolves, reinitiate with a reduced dose of bortezomib at 0.7 mg/m2 once per week."
            }
          },
          {
            "modification_id": "MOD-010",
            "parameter_name": "Peripheral Neuropathy (Bortezomib)",
            "trigger_condition": "Grade 4",
            "operator": "eq",
            "threshold_value": 4,
            "threshold_unit": "CTCAE Grade",
            "reference_type": "absolute",
            "required_action": "dose_discontinue",
            "recovery_criteria": null,
            "provenance": {
              "section_number": "Table 10",
              "page_number": 132,
              "text_snippet": "Grade 4 (life-threatening consequences; urgent intervention indicated): Discontinue bortezomib"
            }
          }
        ],
        "eligibility_lab_criteria": [
          {
            "criteria_id": "ELIG-001",
            "criteria_type": "inclusion",
            "parameter_name": "Absolute neutrophil count (ANC)",
            "condition": "Absolute neutrophil count (ANC) ≥ 1000/microliter (µL) within 2 weeks prior to randomization",
            "operator": "gte",
            "threshold_value": 1000,
            "threshold_unit": "/µL",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Absolute neutrophil count (ANC) ≥ 1000/microliter (µL) within 2 weeks prior to randomization"
            }
          },
          {
            "criteria_id": "ELIG-002",
            "criteria_type": "inclusion",
            "parameter_name": "Platelet count",
            "condition": "Platelet count ≥ 50,000/millimeter (mm)3, within 2 weeks prior to randomization. For subjects with > 50% myeloma involvement in the bone marrow, a platelet count of ≥ 30,000/mm3 is allowed.",
            "operator": "gte",
            "threshold_value": 50000,
            "threshold_unit": "/mm3",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Platelet count ≥ 50,000/millimeter (mm)3, within 2 weeks prior to randomization. For subjects with > 50% myeloma involvement in the bone marrow, a platelet count of ≥ 30,000/mm3...is allowed."
            }
          },
          {
            "criteria_id": "ELIG-003",
            "criteria_type": "inclusion",
            "parameter_name": "Hemoglobin",
            "condition": "Hemoglobin ≥ 8.0 g/dL, within 2 weeks prior to randomization.",
            "operator": "gte",
            "threshold_value": 8.0,
            "threshold_unit": "g/dL",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Hemoglobin ≥ 8.0 g/dL, within 2 weeks prior to randomization."
            }
          },
          {
            "criteria_id": "ELIG-004",
            "criteria_type": "inclusion",
            "parameter_name": "AST and ALT",
            "condition": "AST and ALT ≤ 3 × upper limit of normal (ULN).",
            "operator": "lte",
            "threshold_value": 3,
            "threshold_unit": "x ULN",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "AST and ALT ≤ 3 × upper limit of normal (ULN)."
            }
          },
          {
            "criteria_id": "ELIG-005",
            "criteria_type": "inclusion",
            "parameter_name": "Total bilirubin",
            "condition": "Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin > 1.5 × ULN with approval.",
            "operator": "lte",
            "threshold_value": 1.5,
            "threshold_unit": "x ULN",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin > 1.5 × ULN with the approval of the Primary Therapeutic Area Medical Director (TA MD)."
            }
          },
          {
            "criteria_id": "ELIG-006",
            "criteria_type": "inclusion",
            "parameter_name": "Creatinine clearance (CrCl)",
            "condition": "Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) measured by 24-hour urine collection or calculated using the Cockcroft-Gault formula.",
            "operator": "gte",
            "threshold_value": 30,
            "threshold_unit": "mL/min",
            "provenance": {
              "section_number": "6",
              "page_number": 10,
              "text_snippet": "Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) measured by 24-hour urine collection or calculated using the Cockcroft-Gault formula."
            }
          },
          {
            "criteria_id": "ELIG-007",
            "criteria_type": "inclusion",
            "parameter_name": "Serum M-protein",
            "condition": "Serum M-protein ≥ 0.5 gram (g)/deciliter (dL)",
            "operator": "gte",
            "threshold_value": 0.5,
            "threshold_unit": "g/dL",
            "provenance": {
              "section_number": "5",
              "page_number": 10,
              "text_snippet": "Subject has measurable disease at Screening, defined as at least one of the following:\n• Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR"
            }
          },
          {
            "criteria_id": "ELIG-008",
            "criteria_type": "inclusion",
            "parameter_name": "Urine M-protein",
            "condition": "Urine M-protein ≥ 200 mg in 24 hours",
            "operator": "gte",
            "threshold_value": 200,
            "threshold_unit": "mg/24 hours",
            "provenance": {
              "section_number": "5",
              "page_number": 10,
              "text_snippet": "Subject has measurable disease at Screening, defined as at least one of the following:\n• Urine M-protein ≥ 200 mg in 24 hours, OR"
            }
          },
          {
            "criteria_id": "ELIG-009",
            "criteria_type": "inclusion",
            "parameter_name": "Serum immunoglobulin free light chain (FLC)",
            "condition": "Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal.",
            "operator": "gte",
            "threshold_value": 10,
            "threshold_unit": "mg/dL",
            "provenance": {
              "section_number": "5",
              "page_number": 10,
              "text_snippet": "Subject has measurable disease at Screening, defined as at least one of the following:\n• Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal."
            }
          },
          {
            "criteria_id": "ELIG-010",
            "criteria_type": "exclusion",
            "parameter_name": "Active hepatitis B or C infection",
            "condition": "Active hepatitis B or C infection based on blood screen tests",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "provenance": {
              "section_number": "3",
              "page_number": 11,
              "text_snippet": "Active hepatitis B or C infection based on blood screen tests"
            }
          },
          {
            "criteria_id": "ELIG-011",
            "criteria_type": "inclusion",
            "parameter_name": "PaO2",
            "condition": "France and Japan Subjects Only: PaO2 ≥ 60 millimeter mercury (mmHg) by arterial blood gas analysis",
            "operator": "gte",
            "threshold_value": 60,
            "threshold_unit": "mmHg",
            "provenance": {
              "section_number": "7",
              "page_number": 46,
              "text_snippet": "France and Japan Subjects Only: PaO2 ≥ 60 millimeter mercury (mmHg) by arterial blood gas analysis"
            }
          },
          {
            "criteria_id": "ELIG-012",
            "criteria_type": "inclusion",
            "parameter_name": "SpO2",
            "condition": "France and Japan Subjects Only: SpO2 ≥ 93% by percutaneous oxygen saturation.",
            "operator": "gte",
            "threshold_value": 93,
            "threshold_unit": "%",
            "provenance": {
              "section_number": "7",
              "page_number": 46,
              "text_snippet": "France and Japan Subjects Only: ...SpO2 ≥ 93% by percutaneous oxygen saturation."
            }
          }
        ],
        "critical_value_reporting": null,
        "abnormal_result_grading": {
          "grading_system": "NCI CTCAE",
          "grading_version": "4.03",
          "clinically_significant_threshold": null,
          "ae_reporting_threshold": "Laboratory abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention, meet protocol specific criteria (see Section 6.1.7 regarding toxicity management) or if the Investigator considers them to be adverse events.",
          "provenance": {
            "section_number": "6.1.1.1",
            "page_number": 114,
            "text_snippet": "Laboratory abnormalities and changes in vital signs are considered to be adverse events only if they result in discontinuation from the study, necessitate therapeutic medical intervention...",
            "additional_provenance": [
              {
                "section_number": "6.1.2",
                "page_number": 117,
                "text_snippet": "The Investigator will rate the severity of each adverse event according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE Version 4.03)."
              }
            ]
          }
        },
        "pregnancy_testing": {
          "required": true,
          "applicable_population": "Females of childbearing potential",
          "test_type": "serum, urine",
          "timing": "At Screening on a serum sample obtained within 21 days prior to randomization. Prior to dosing on a urine sample obtained on the first day of study drug administration, if it has been > 24 hours since obtaining the serum pregnancy test results.",
          "sensitivity": "≥ 25 IU/L",
          "action_if_positive": "Subject must not be randomized. If occurs during study, administration of the study treatment must be discontinued immediately.",
          "provenance": {
            "section_number": "5.3.1.1.1",
            "page_number": 67,
            "text_snippet": "For female subjects of childbearing potential, pregnancy testing will be performed per Appendix D and Appendix E (if necessary). Pregnancy tests must have a minimal sensitivity of ≥ 25 IU/L."
          }
        },
        "pharmacokinetic_samples": {
          "pk_sampling_required": true,
          "analytes": [
            "venetoclax",
            "bortezomib",
            "dexamethasone"
          ],
          "sample_type": "plasma",
          "timepoints_description": "Venetoclax: C1D1 (6h post-dose, optional), C2/4/6/8 D1 (pre-dose). Bortezomib: C1D1 (0.5h post-dose), C2/4/6/8 D11 (pre-dose). Dexamethasone (Japan only): C1D1 (0.5, 6h post-dose); for run-in phase, also C1D11 (pre-dose, 0.5, 1, 2, 4, 8, 24h post-dose).",
          "volume_per_sample": "3 mL for venetoclax assay, 4 mL for bortezomib assay, 3 mL for dexamethasone assay.",
          "processing_requirements": "Refer to study specific laboratory manual.",
          "provenance": {
            "section_number": "5.3.2.1",
            "page_number": 79,
            "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected...\nBlood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected...",
            "additional_provenance": [
              {
                "section_number": "5.3.2.1",
                "page_number": 80,
                "text_snippet": "Blood Samples for Dexamethasone Assay (Japan Subjects Only)\nJapanese subjects enrolled in the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected..."
              }
            ]
          }
        },
        "biomarker_samples": {
          "biomarker_sampling_required": true,
          "biomarkers": [
            {
              "name": "Plasma Markers",
              "purpose": "Mandatory biomarker analysis",
              "sample_type": "plasma",
              "timing": "C1D1 (Pre-dose), C5D1 (Pre-dose), Disease Progression or TCV",
              "provenance": {
                "section_number": "5.3.1.3.1",
                "page_number": 75,
                "text_snippet": "Blood Collection for Plasma Markers\nApproximately 12 mL of blood will be collected at the following time points:\n● Cycle 1 Day 1 (Pre-dose)\n● Cycle 5 Day 1 (Pre-dose)\n● Disease Progression or TCV"
              }
            },
            {
              "name": "Serum Markers",
              "purpose": "Mandatory biomarker analysis",
              "sample_type": "serum",
              "timing": "C1D1 (Pre-dose), C5D1 (Pre-dose), Disease Progression or TCV",
              "provenance": {
                "section_number": "5.3.1.3.1",
                "page_number": 75,
                "text_snippet": "Blood Collection for Serum Markers\nApproximately 3.5 mL of blood will be collected at the following time points:\n● Cycle 1 Day 1 (Pre-dose)\n● Cycle 5 Day 1 (Pre-dose)\n● Disease Progression or TCV"
              }
            },
            {
              "name": "Immunohistochemistry (IHC) for BCL-2 expression",
              "purpose": "Predictive biomarker of response",
              "sample_type": "bone_marrow_core_biopsy",
              "timing": "Screening (fresh or archived tissue)",
              "provenance": {
                "section_number": "5.3.1.3.1",
                "page_number": 76,
                "text_snippet": "Pre-Treatment Bone Marrow Core (BMC) Biopsy Tissue Collection for Immunohistochemistry (IHC)\nOne of the following forms of pre-therapy tumor tissue (newly collected tissue or archived tissue) should be collected at Screening"
              }
            },
            {
              "name": "Quantitative polymerase chain reaction (qPCR) and MRD",
              "purpose": "Assessment of disease response and minimal residual disease",
              "sample_type": "bone_marrow_aspirate",
              "timing": "Screening or C1D1; at time of suspected CR/sCR; approx. 6 and 12 months after confirmation of CR/sCR.",
              "provenance": {
                "section_number": "5.3.1.3.1",
                "page_number": 77,
                "text_snippet": "qPCR and MRD Sample Collection\nA 6 mL aspirate sample will be collected at the following time point for qPCR and baseline assessment of disease using MRD assay:\n● Screening (preferred) or prior to first dose of study treatment (Cycle 1 Day 1)"
              }
            },
            {
              "name": "Fluorescent In Situ Hybridization (FISH)",
              "purpose": "Assessment of chromosomal abnormalities (t(11;14), t(4;14), t(14;16), del 17p, 5+, 9+, 15+)",
              "sample_type": "bone_marrow_aspirate",
              "timing": "Screening or C1D1",
              "provenance": {
                "section_number": "5.3.1.3.1",
                "page_number": 77,
                "text_snippet": "Fluorescent In Situ Hybridization (FISH)\nA 4 mL aspirate sample will be collected at the following time point for baseline assessment of chromosomal abnormalities...● Screening (preferred) or prior to first dose of study treatment (Cycle 1 Day 1)."
              }
            },
            {
              "name": "Pharmacogenetics",
              "purpose": "Optional exploratory research for genetic factors contributing to response",
              "sample_type": "whole_blood",
              "timing": "C1D1, C5D1, TCV",
              "provenance": {
                "section_number": "5.3.1.3.2",
                "page_number": 77,
                "text_snippet": "Samples for Exploratory Research\nFor all subjects in the study that consent to optional exploratory research, blood, bone marrow core and bone marrow aspirate samples will be collected per Appendix H."
              }
            }
          ],
          "optional_consent_required": true,
          "provenance": {
            "section_number": "5.3.1.3",
            "page_number": 74,
            "text_snippet": "Collection and Handling of Biomarker and Exploratory Research Samples\nSerum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected per Appendix H. Subjects will also have the option to provide samples for exploratory research."
          }
        },
        "local_lab_requirements": {
          "local_lab_allowed": true,
          "allowed_tests": [
            "Hematology Panel",
            "Serum Chemistry Panel",
            "SARS-CoV-2 testing"
          ],
          "certification_requirements": "Certified local laboratories will be utilized.",
          "provenance": {
            "section_number": "5.3.1.1.1",
            "page_number": 68,
            "text_snippet": "Certified local laboratories will be utilized to process and provide results for the hematology and chemistry labs listed in Table 3. These data will be used for all data analysis."
          }
        },
        "extraction_statistics": {
          "total_panels_discovered": 8,
          "total_tests_discovered": 48,
          "total_schedule_entries": 6,
          "dose_modification_rules": 10,
          "eligibility_criteria_count": 12,
          "critical_values_defined": 0
        },
        "provenance": {
          "section_number": "5.3.1.1.1",
          "page_number": 68,
          "text_snippet": "Clinical Laboratory Tests\nAll subjects will undergo the laboratory assessments listed in Table 3 per the schedule in Appendix D, Appendix E, and Appendix F."
        }
      },
      "_agentDocumentation": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/µL required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/µL required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds → Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "informedConsent": {
      "moduleId": "informed_consent",
      "instanceType": "InformedConsentElements",
      "data": {
        "id": "M14-031-informed-consent",
        "instanceType": "InformedConsentElements",
        "name": "M14-031 Informed Consent Elements",
        "description": "ICF content elements for M14-031",
        "study_overview": {
          "study_purpose": "To compare the progression-free survival (PFS) between treatment arms (Venetoclax + Bortezomib/Dexamethasone vs. Placebo + Bortezomib/Dexamethasone) in subjects with relapsed or refractory multiple myeloma who are sensitive or naïve to proteasome inhibitors and have received 1 to 3 prior lines of therapy.",
          "study_duration_for_participant": "Treatment continues until disease progression, unacceptable toxicity, or withdrawal. Follow-up continues until death, withdrawal of consent, or study termination.",
          "number_of_visits": null,
          "total_time_commitment": null,
          "number_of_participants": "Approximately 280 subjects at approximately 120 sites.",
          "study_locations": "This is a multicenter study with approximately 120 sites.",
          "provenance": {
            "section_number": "1.2",
            "page_number": 7,
            "text_snippet": "Protocol Title: A Phase 3, Multicenter, Randomized, Double Blind, Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors\nObjectives: The primary objective of the study is to compare the progression-free survival (PFS) between treatment arms in subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome"
          }
        },
        "study_procedures": {
          "screening_procedures": [
            {
              "procedure_id": "PROC-001",
              "procedure_name": "Informed Consent",
              "description": "Voluntarily sign and date an informed consent form.",
              "frequency": "Once, prior to any study procedures",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "9.3",
                "page_number": 153,
                "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject, the person who administered the informed consent, and any other signatories according to local requirements."
              }
            },
            {
              "procedure_id": "PROC-002",
              "procedure_name": "Eligibility Assessment",
              "description": "Review of inclusion and exclusion criteria against participant's medical history and current condition.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix D",
                "page_number": 172,
                "text_snippet": "ELIGIBILITY ASSESSMENTS\nInclusion/Exclusion Criteria"
              }
            },
            {
              "procedure_id": "PROC-003",
              "procedure_name": "Medical and Oncology History",
              "description": "Collection of complete medical history, including details of multiple myeloma diagnosis, staging, and prior treatments.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.1",
                "page_number": 60,
                "text_snippet": "Medical and Oncology History\nThe medical history includes complete medical history, including documentation of any clinically significant medical condition(s); history of tobacco and alcohol use."
              }
            },
            {
              "procedure_id": "PROC-004",
              "procedure_name": "Physical Examination",
              "description": "A full physical examination, including height and weight.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix D",
                "page_number": 172,
                "text_snippet": "Physical Examination\nFull physical examination done at screening, including height and weight."
              }
            },
            {
              "procedure_id": "PROC-005",
              "procedure_name": "Vital Signs",
              "description": "Measurement of sitting blood pressure, heart rate, respiratory rate, and body temperature.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "6.2",
                "page_number": 62,
                "text_snippet": "Vital sign determinations include sitting blood pressure, heart rate, respiratory rate, and body temperature."
              }
            },
            {
              "procedure_id": "PROC-006",
              "procedure_name": "ECOG Performance Status",
              "description": "Assessment of functional status.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix D",
                "page_number": 172,
                "text_snippet": "ECOG Performance Status"
              }
            },
            {
              "procedure_id": "PROC-007",
              "procedure_name": "12-Lead Electrocardiogram (ECG)",
              "description": "A resting 12-lead ECG to assess cardiac function.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.1",
                "page_number": 66,
                "text_snippet": "12-Lead Electrocardiogram (ECG)\nA resting 12-lead ECG will be performed per Appendix D and Appendix F."
              }
            },
            {
              "procedure_id": "PROC-008",
              "procedure_name": "Blood and Urine Laboratory Tests",
              "description": "Collection of blood and urine for hematology, serum chemistry, coagulation, viral serologies (Hepatitis B, C), and urinalysis.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.1",
                "page_number": 68,
                "text_snippet": "A certified central laboratory will be utilized to process and provide results for coagulation, viral serologies, urinalysis, and special chemistry labs listed in Table 3."
              }
            },
            {
              "procedure_id": "PROC-009",
              "procedure_name": "Pregnancy Test",
              "description": "Serum pregnancy test for females of childbearing potential.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix D",
                "page_number": 173,
                "text_snippet": "Pregnancy Test\nSerum pregnancy test within 21 days prior to randomization for women of childbearing potential. Will be completed per certified local laboratory."
              }
            },
            {
              "procedure_id": "PROC-010",
              "procedure_name": "Disease Assessment Tests",
              "description": "Includes Serum Protein Electrophoresis (SPEP), immunofixation, quantitative immunoglobulins, serum free light chains, and 24-hour urine collection for protein assessment.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix D",
                "page_number": 173,
                "text_snippet": "DISEASE ASSESSMENTS\nSerum Protein Immunofixation\nSerum Protein Electrophoresis\nSerum Quantitative Immunoglobulins\nSerum Free Light Chains"
              }
            },
            {
              "procedure_id": "PROC-011",
              "procedure_name": "Bone Marrow Aspirate and Biopsy",
              "description": "Collection of bone marrow aspirate and core biopsy for assessment of plasma cell percentage, clonality, and biomarker analysis (IHC, FISH, qPCR, MRD).",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.3",
                "page_number": 74,
                "text_snippet": "Serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue will be collected per Appendix H."
              }
            },
            {
              "procedure_id": "PROC-012",
              "procedure_name": "Skeletal Survey",
              "description": "Conventional radiography (X-Ray), low dose CT, or MRI of the skeleton to assess for bone lesions.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.7.1",
                "page_number": 86,
                "text_snippet": "Skeletal survey using conventional radiography (X-Ray) will be done at screening. Use of conventional or low dose CT scan or magnetic resonance imaging (MRI) bone survey is acceptable."
              }
            },
            {
              "procedure_id": "PROC-013",
              "procedure_name": "Plasmacytoma Evaluation",
              "description": "Assessment via physical exam or imaging (CT or MRI) for subjects with a history of or clinically indicated plasmacytomas.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.7.1",
                "page_number": 87,
                "text_snippet": "Plasmacytoma evaluation should be assessed for all subjects with a history of plasmacytomas or if clinically indicated at Screening, via physical examination or imaging..."
              }
            },
            {
              "procedure_id": "PROC-014",
              "procedure_name": "Lung Disease Risk Assessment (Japan and France only)",
              "description": "Arterial blood gas analysis or SpO2 measurement, and a chest CT scan.",
              "frequency": "Once, during screening",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.1",
                "page_number": 67,
                "text_snippet": "Lung Disease Risk Assessment – JAPAN and FRANCE ONLY\nAll subjects enrolled in Japan and France are required to complete the following assessments below:\na PaO2 by arterial blood gas analysis or SpO2 by percutaneous oxygen saturation at screening will be performed\na chest CT (high resolution) scan at screening"
              }
            }
          ],
          "treatment_procedures": [
            {
              "procedure_id": "PROC-015",
              "procedure_name": "Study Drug Administration",
              "description": "Receive oral venetoclax or placebo daily, plus subcutaneous or intravenous bortezomib and oral dexamethasone on a specified schedule depending on the treatment cycle.",
              "frequency": "Per 21-day (Cycles 1-8) and 35-day (Cycles 9+) schedules",
              "duration": "Throughout the treatment period",
              "is_optional": false,
              "provenance": {
                "section_number": "5.5.1",
                "page_number": 103,
                "text_snippet": "Subjects will take daily venetoclax/placebo 800 mg orally in combination with Bd.\nBortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) will be given following administration of venetoclax/placebo in Cycles 1 – 8 on Days 1, 4, 8 and 11, and for Cycles 9 and beyond, on Days 1, 8, 15 and 22...\nDexamethasone (20 mg) will be given orally in Cycles 1 – 8 on Days 1, 2, 4, 5, 8, 9, 11 and 12, and in Cycles 9 and beyond, Days 1, 2, 8, 9, 15, 16, 22, and 23."
              }
            },
            {
              "procedure_id": "PROC-016",
              "procedure_name": "Safety Monitoring",
              "description": "Regular monitoring of adverse events, physical exams, vital signs, ECGs, and laboratory tests (hematology, chemistry).",
              "frequency": "At specified days within each treatment cycle",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "Appendix E",
                "page_number": 175,
                "text_snippet": "SAFETY ASSESSMENTS\nMedical/Oncology History\nConcomitant Medications and Adverse Event Assessments\nECOG Performance Status\nPhysical Examination\nVital Signs\n12 Lead ECG (FRANCE ONLY)"
              }
            },
            {
              "procedure_id": "PROC-017",
              "procedure_name": "Disease Progression Assessment",
              "description": "Regular collection of blood and urine samples for myeloma protein levels (SPEP, UPEP, sFLC) to monitor response to treatment. Imaging and bone marrow assessments as needed.",
              "frequency": "Day 1 of every cycle",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.7.1",
                "page_number": 84,
                "text_snippet": "Analysis of serum protein electrophoresis (SPEP), serum protein immunofixation, serum quantitative immunoglobulins (sQI), serum free light chains (sFLC), urine protein electrophoresis (UPEP), urine protein immunofixation, corrected serum calcium, plasmacytoma evaluation (if applicable), skeletal survey, and bone marrow aspirate and biopsy, will be utilized for disease assessment."
              }
            },
            {
              "procedure_id": "PROC-018",
              "procedure_name": "Patient-Reported Outcome (PRO) Assessments",
              "description": "Completion of questionnaires (BPI-SF, EORTC QLQ-C30, EORTC QLC-MY20, PROMIS Cancer Fatigue SF, EQ-5D-5L) about pain, quality of life, and fatigue.",
              "frequency": "Throughout the trial until the final OS analysis",
              "duration": "Approximately 32 minutes per assessment set",
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.1",
                "page_number": 63,
                "text_snippet": "PRO assessments include BPI-SF, EORTC QLQ-C30, EORTC QLC-MY20, PROMIS Cancer Fatigue SF, and EQ-5D-5L. These assessments will be collected per Appendix D, Appendix E, and Appendix F throughout the trial until the final OS analysis."
              }
            },
            {
              "procedure_id": "PROC-019",
              "procedure_name": "Pharmacokinetic (PK) Blood Samples",
              "description": "Collection of blood samples at specific time points to measure the levels of venetoclax, bortezomib, and dexamethasone (Japan only) in the body.",
              "frequency": "On specified days in Cycles 1, 2, 4, 6, and 8",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.2.1",
                "page_number": 78,
                "text_snippet": "Blood samples for venetoclax, bortezomib (and dexamethasone, only in Japanese subjects), and possible metabolite(s) will be collected by venipuncture per Appendix H."
              }
            }
          ],
          "follow_up_procedures": [
            {
              "procedure_id": "PROC-020",
              "procedure_name": "Safety Follow-Up Visit",
              "description": "A visit to assess for any ongoing or new safety issues after stopping treatment.",
              "frequency": "Approximately 30 days after the last dose of study treatment",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 39,
                "text_snippet": "Follow-Up: Includes the 30 Day Safety Follow-Up Visit."
              }
            },
            {
              "procedure_id": "PROC-021",
              "procedure_name": "Disease Progression Follow-Up",
              "description": "For subjects who stop treatment for reasons other than disease progression, assessments for disease progression will be performed.",
              "frequency": "Every 4 weeks for the first year, then every 12 weeks thereafter until progression",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 43,
                "text_snippet": "Subjects who discontinue study treatment for reasons other than PD...will remain on study and continue to be followed for progressive disease per IMWG criteria every 4 weeks (± 1 week) following last dose of treatment for the first year, and then every 12 weeks (± 1 week) thereafter until PD..."
              }
            },
            {
              "procedure_id": "PROC-022",
              "procedure_name": "Survival Follow-Up",
              "description": "Contact (e.g., by phone) to collect information on survival status and any new anti-myeloma treatments received.",
              "frequency": "Approximately every 12 weeks",
              "duration": "Until death, withdrawal of consent, or study termination",
              "is_optional": false,
              "provenance": {
                "section_number": "5.3.1.1.2",
                "page_number": 72,
                "text_snippet": "Survival (i.e., alive or deceased, and if deceased, the date and cause of death) and post treatment information will be collected on the appropriate eCRF approximately every 12 weeks...continuing either until the endpoint of death, until the subject is lost to follow-up, subject withdraws consent...or until study termination by AbbVie, whichever occurs first."
              }
            }
          ],
          "optional_procedures": [
            {
              "procedure_id": "PROC-023",
              "procedure_name": "Exploratory Research Samples",
              "description": "Providing additional blood and bone marrow samples for optional exploratory research, including pharmacogenetic analysis.",
              "frequency": "At specified time points (e.g., C1D1, C5D1, TCV)",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "5.3.1.3",
                "page_number": 74,
                "text_snippet": "Subjects will also have the option to provide samples for exploratory research. Subjects may still participate in the main study even if they decide not to participate in the optional exploratory research."
              }
            }
          ],
          "provenance": {
            "section_number": "5.3.1.1",
            "page_number": 57,
            "text_snippet": "5.3.1.1 Study Procedures"
          }
        },
        "risks": {
          "known_risks": [
            {
              "risk_id": "RISK-001",
              "risk_description": "Lymphopenia (low level of lymphocytes)",
              "severity": null,
              "frequency": null,
              "management": "Monitoring of blood counts.",
              "provenance": {
                "section_number": "3.5",
                "page_number": 37,
                "text_snippet": "Based on nonclinical toxicology and clinical studies with venetoclax, toxicities may include lymphopenia, neutropenia, anemia and gastrointestinal adverse events."
              }
            },
            {
              "risk_id": "RISK-002",
              "risk_description": "Neutropenia (low level of neutrophils)",
              "severity": "severe",
              "frequency": null,
              "management": "Dose interruption/reduction, use of growth factors (G-CSF), antibiotic prophylaxis.",
              "provenance": {
                "section_number": "6.1.7.1",
                "page_number": 123,
                "text_snippet": "clinically significant neutropenia may also be observed in this study...when Grade 4 neutropenia develops (ANC < 500 cells/µL) and continued until the neutropenia improves to Grade 3 or better (ANC > 500 cells/µL)."
              }
            },
            {
              "risk_id": "RISK-003",
              "risk_description": "Anemia (low red blood cells)",
              "severity": "severe",
              "frequency": null,
              "management": "Blood transfusions may be required.",
              "provenance": {
                "section_number": "3.3",
                "page_number": 35,
                "text_snippet": "Grade 3 or 4 AEs in ≥ 10% of subjects in Study M12-901 were thrombocytopenia (22%), and anemia (16%)."
              }
            },
            {
              "risk_id": "RISK-004",
              "risk_description": "Thrombocytopenia (low platelets)",
              "severity": "severe",
              "frequency": "common",
              "management": "Dose interruption/reduction, platelet transfusions may be required.",
              "provenance": {
                "section_number": "3.3",
                "page_number": 35,
                "text_snippet": "In Study M12-901, treatment-emergent AEs occurring in ≥ 20% of the subjects were...thrombocytopenia (33%)...Grade 3 or 4 AEs in ≥ 10% of subjects in Study M12-901 were thrombocytopenia (22%), and anemia (16%)."
              }
            },
            {
              "risk_id": "RISK-005",
              "risk_description": "Gastrointestinal adverse events (e.g., constipation, diarrhea, nausea, vomiting)",
              "severity": null,
              "frequency": "common",
              "management": "Supportive care medications.",
              "provenance": {
                "section_number": "3.3",
                "page_number": 35,
                "text_snippet": "In Study M12-901, treatment-emergent AEs occurring in ≥ 20% of the subjects were constipation (40%), diarrhea (38%)...nausea (24%)."
              }
            },
            {
              "risk_id": "RISK-006",
              "risk_description": "Serious Infections (including opportunistic infections)",
              "severity": "severe",
              "frequency": null,
              "management": "Antibiotic prophylaxis is required. Dose interruption/reduction may be necessary.",
              "provenance": {
                "section_number": "6.1.7.1",
                "page_number": 123,
                "text_snippet": "Both lymphopenia and neutropenia could increase the risk for infections, including opportunistic infections. All subjects receiving treatment with venetoclax/placebo in combination with a proteasome inhibitor must receive antibiotic prophylaxis..."
              }
            },
            {
              "risk_id": "RISK-007",
              "risk_description": "Tumor Lysis Syndrome (TLS)",
              "severity": "life-threatening",
              "frequency": "rare",
              "management": "Prophylaxis with oral hydration and possibly uric acid-reducing agents. Monitoring of labs is required.",
              "provenance": {
                "section_number": "6.1.7.2",
                "page_number": 124,
                "text_snippet": "Management of Tumor Lysis Syndrome\nTLS has been reported in patients with multiple myeloma with significant disease burden...Consider TLS prophylaxis with oral hydration (at least 1 – 2 liters, as tolerable, each day) in all subjects at least 72 hours prior to the first day of dosing with venetoclax/placebo."
              }
            },
            {
              "risk_id": "RISK-008",
              "risk_description": "Peripheral Neuropathy (nerve damage causing pain, numbness, tingling)",
              "severity": "severe",
              "frequency": "common",
              "management": "Dose modification or discontinuation of bortezomib.",
              "provenance": {
                "section_number": "3.5",
                "page_number": 37,
                "text_snippet": "The rate of peripheral neuropathy in Study M12-901 is in the expected range of a bortezomib-based regimen."
              }
            },
            {
              "risk_id": "RISK-009",
              "risk_description": "Fatigue (tiredness)",
              "severity": null,
              "frequency": "common",
              "management": null,
              "provenance": {
                "section_number": "3.3",
                "page_number": 35,
                "text_snippet": "In Study M12-901, treatment-emergent AEs occurring in ≥ 20% of the subjects were...fatigue (20%)."
              }
            },
            {
              "risk_id": "RISK-010",
              "risk_description": "COVID-19 Infection",
              "severity": null,
              "frequency": null,
              "management": "Interruption of study drugs until viral clearance criteria are met.",
              "provenance": {
                "section_number": "3.5",
                "page_number": 37,
                "text_snippet": "Subjects receiving venetoclax, bortezomib, and dexamethasone may be at an increased risk for COVID-19 infection or experience serious illness if infected. Management of these adverse events will be made on a case-by-case basis with consideration of benefit/risk."
              }
            }
          ],
          "potential_risks": [],
          "reproductive_risks": "Venetoclax caused embryo-fetal toxicity in animal studies. The effects of venetoclax on an unborn fetus or embryo in humans are unknown. Females must not be pregnant or breastfeeding and must use highly effective contraception. Males must inform their partners of the potential risks.",
          "unknown_risks_statement": "There may be other risks that are not yet known.",
          "risk_mitigation_measures": "Regular safety monitoring, including laboratory tests, will be performed. Prophylactic medications for infections and Tumor Lysis Syndrome are required or recommended. Dose modifications are in place to manage toxicities.",
          "provenance": {
            "section_number": "3.5",
            "page_number": 36,
            "text_snippet": "3.5 Benefits and Risks"
          }
        },
        "benefits": {
          "potential_benefits": [
            "Subjects in the investigational arm (receiving venetoclax) may benefit from the combined treatment."
          ],
          "no_benefit_statement": "There is no guarantee of direct medical benefit from participating in this study.",
          "societal_benefits": "Information from this study may help advance the treatment of multiple myeloma for future patients.",
          "provenance": {
            "section_number": "3.5",
            "page_number": 36,
            "text_snippet": "Based on evidence of clinically meaningful activity observed in Phase 1 studies with venetoclax given as a single agent and when it is combined with the Bd regimen, it is anticipated subjects in the investigational arm may benefit from the combined treatment."
          }
        },
        "alternatives": {
          "alternative_treatments": [
            {
              "treatment_name": "Standard of Care",
              "description": "There are other available treatments for relapsed or refractory multiple myeloma. The control arm of this study uses a standard of care regimen (bortezomib and dexamethasone).",
              "provenance": {
                "section_number": "3.2",
                "page_number": 28,
                "text_snippet": "The proteasome inhibitor bortezomib combined with dexamethasone (Bd) has proven therapeutic value and is considered to be one of the standards of care in the treatment of relapsed multiple myeloma."
              }
            }
          ],
          "no_treatment_option": true,
          "standard_of_care_description": "The proteasome inhibitor bortezomib combined with dexamethasone (Bd) has proven therapeutic value and is considered to be a standard of care in the treatment of relapsed multiple myeloma.",
          "provenance": {
            "section_number": "5.6.1",
            "page_number": 111,
            "text_snippet": "The proteasome inhibitor bortezomib combined with dexamethasone has proven therapeutic value and is considered to be a standard of care listed in the National Comprehensive Cancer Network and the European Society for Medical Oncology (ESMO) guidelines as a recognized treatment for patients with previously treated"
          }
        },
        "compensation_costs": {
          "participant_compensation": "Information regarding incentives for subjects can be found in the informed consent form.",
          "payment_schedule": null,
          "travel_reimbursement": "For Japan, transportation expenses will be paid to the subjects.",
          "participant_costs": [],
          "covered_costs": [
            "For Japan, the sponsor will pay the expenses related to this study to the investigative site."
          ],
          "injury_compensation": "For Japan, if a subject suffers health impairment due to the study, the sponsor will bear the cost of treatment not covered by health insurance and provide compensation in accordance with sponsor SOPs.",
          "provenance": {
            "section_number": "Appendix L",
            "page_number": 198,
            "text_snippet": "1.0 Clinical Expense and Compensation\n1.1 Expenditure of the Clinical Expense\nThe sponsor will pay the expenses related to this study to the investigative site...To lighten the burden imposed on the subject with participation to the study, transportation expenses, etc. will be paid to the subjects...\n1.2 Compensation for Health Impairment and Insurance\n1."
          }
        },
        "confidentiality": {
          "data_protection_statement": "Confidential information shall remain the sole property of AbbVie and shall not be disclosed to others without written consent. Research information will be published or presented only in a way that does not identify any individual subject.",
          "who_has_access": [
            "Study investigators and site staff",
            "AbbVie (the sponsor) and its representatives",
            "Monitors and auditors",
            "Independent Ethics Committees (IEC) or Institutional Review Boards (IRB)",
            "Regulatory authorities (e.g., FDA)",
            "Independent Data Monitoring Committee (IDMC)"
          ],
          "hipaa_authorization": null,
          "data_retention_period": "up to 20 years",
          "international_data_transfer": null,
          "data_sharing": "Data from research may be provided to investigators, used in scientific publications, or presented at medical conventions. De-identified data may be shared.",
          "provenance": {
            "section_number": "12.0",
            "page_number": 158,
            "text_snippet": "This information may be disclosed as deemed necessary by AbbVie to other clinical Investigators, other pharmaceutical companies, and to governmental agencies."
          }
        },
        "voluntary_participation": {
          "voluntary_statement": "Participation in this study is voluntary. Subjects must voluntarily sign and date an informed consent form prior to participation.",
          "withdrawal_rights": "Each subject has the right to withdraw from the study at any time.",
          "withdrawal_consequences": "If a subject withdraws from study visits, they must also discontinue treatment.",
          "data_after_withdrawal": "In the event a subject withdraws consent to participate from the study, stored biomarker samples will continue to be used for research and analysis unless the subject specifically requests their samples be withdrawn and destroyed.",
          "provenance": {
            "section_number": "9.3",
            "page_number": 153,
            "text_snippet": "In the event a subject withdraws consent to participate from the study, stored biomarker samples will continue to be used for research and analysis. In the event that a subject would like to withdraw consent for research using these samples, the subject may request that their samples be withdrawn. Once AbbVie receives the request, remaining biomarker samples will be destroyed."
          }
        },
        "special_consents": {
          "genetic_testing": {
            "required": false,
            "description": "An optional 4 mL whole blood sample will be collected for deoxyribonucleic acid (DNA) isolation for pharmacogenetic analysis of genetic factors contributing to the response to venetoclax.",
            "opt_out_allowed": true,
            "future_use": true,
            "results_disclosure": "The results are exploratory in nature and will not be suitable for clinical decision making. The subject will not be informed of individual results.",
            "provenance": {
              "section_number": "5.3.2",
              "page_number": 78,
              "text_snippet": "Pharmacogenetic Sample (Optional JPMA Category B)\nAn optional 4 mL whole blood sample for deoxyribonucleic acid (DNA) isolation will be collected on Cycle 1 Day 1 (prior to the first dose of study treatment), Cycle 5 Day 1 and TCV from each subject who consents to provide samples for exploratory research."
            }
          },
          "biobanking": {
            "required": false,
            "storage_duration": "Up to 20 years",
            "future_research_use": true,
            "commercialization_statement": null,
            "destruction_option": true,
            "provenance": {
              "section_number": "5.3.1.3",
              "page_number": 74,
              "text_snippet": "AbbVie (or people or companies working with AbbVie) will store the biomarker and exploratory research samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on venetoclax (or drugs of this class) or this disease and related conditions continues, but for no longer than 20 years after study completion, or per local requirements."
            }
          },
          "photography_recording": {
            "required": false,
            "purpose": "To document superficial skin lesions such as a skin nodule or palpable lymph node.",
            "usage": "A photograph with a ruler must be used for documentation.",
            "provenance": {
              "section_number": "5.3.7.3",
              "page_number": 88,
              "text_snippet": "Clinical examination is only acceptable when lesions are superficial, such as a skin nodule or palpable lymph node. Skin lesions must be documented by a photograph with a ruler."
            }
          },
          "provenance": {
            "section_number": "9.3",
            "page_number": 153,
            "text_snippet": "An informed consent, approved by an IRB/IEC, must be voluntarily signed and dated before samples are collected for optional exploratory research. The nature of the testing should be explained and the subject given an opportunity to ask questions. The informed consent must be signed before the samples are collected and any testing is performed. If the subject does not consent to provide samples for the optional exploratory research, it will not impact their participation in the study."
          }
        },
        "contacts": {
          "study_questions_contact": "Contact the Investigator or his/her representative.",
          "rights_questions_contact": "Contact the Independent Ethics Committee (IEC) or Institutional Review Board (IRB).",
          "emergency_contact": "Contact information for the Primary Therapeutic Area Medical Director is provided in the protocol.",
          "twenty_four_hour_contact": "An emergency 24-hour phone number is provided for safety concerns: +1 (973) 784-6402.",
          "provenance": {
            "section_number": null,
            "page_number": 120,
            "text_snippet": "For any subject safety concerns, please contact the physician listed below:\nPrimary Therapeutic Area Medical Director:\n...In emergency situations involving study subjects when the primary Therapeutic Area Medical Director (TA MD) is not available by phone, please contact the 24-hour AbbVie Medical Escalation Hotline where your call will be re-directed to a designated backup AbbVie TA-MD:\nPhone: +1 (973) 784-6402"
          }
        },
        "reproductive_requirements": {
          "pregnancy_testing_required": true,
          "contraception_requirements": "Females of childbearing potential must practice at least one highly effective method of birth control.",
          "contraception_duration": "From Study Day 1 (or earlier) through at least 90 days after the last dose of study treatment.",
          "pregnancy_reporting": "Pregnancy must be reported to an AbbVie representative within 1 working day of the site becoming aware. Study treatment must be discontinued immediately.",
          "breastfeeding_restrictions": "Subjects who are breastfeeding are excluded from the study. Subjects must not begin breastfeeding during the study.",
          "male_requirements": "Male subjects must agree to inform their partner(s) that the effects of venetoclax on an unborn fetus or embryo in humans are unknown. Males considering fathering a child or donating sperm during the study or for approximately 90 days after the last dose are excluded.",
          "provenance": {
            "section_number": "5.2.1",
            "page_number": 47,
            "text_snippet": "10. If female, subject is either not of childbearing potential...or is of childbearing potential and is practicing at least one of the following highly effective methods of birth control on Study Day 1 (or earlier) through at least 90 days after last dose of study treatment."
          }
        },
        "extraction_statistics": {
          "has_risks": true,
          "has_benefits": true,
          "has_alternatives": true,
          "has_compensation": true,
          "has_genetic_consent": true,
          "has_biobanking": true,
          "risk_count": 10,
          "procedure_count": 23
        },
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "1.0 Title Page\nClinical Study Protocol M14-031\nA Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors"
        }
      },
      "_agentDocumentation": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "proSpecifications": {
      "moduleId": "pro_specifications",
      "instanceType": "PROSpecifications",
      "data": {
        "id": "NCT02755597-pro-specifications",
        "instanceType": "PROSpecifications",
        "name": "NCT02755597 PRO Specifications",
        "description": "PRO/COA specifications for NCT02755597",
        "pro_instruments": [
          {
            "instrument_id": "PRO-001",
            "instrument_name": "Brief Pain Inventory – Short Form",
            "instrument_abbreviation": "BPI-SF",
            "instrument_type": "symptom",
            "administration": {
              "mode": "electronic",
              "device_type": "provisioned_tablet",
              "completion_location": "clinic",
              "estimated_completion_time": "Approximately 5 minutes"
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Screening",
                  "visit_reference": "Screening",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycles 1, 3, 5, 7",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycles 9 and beyond (every other cycle)",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Treatment Completion Visit",
                  "visit_reference": "TCV",
                  "is_required": true
                }
              ],
              "recall_period": "current pain, worst, least, average"
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Worst Pain",
                  "domain_description": "Patient-reported severity of worst pain on an 11-point numeric rating scale.",
                  "provenance": {
                    "section_number": "BPI-SF",
                    "page_number": 63,
                    "text_snippet": "The BPI-SF is a pain-specific measure developed to assess patient-reported severity (or intensity) of pain (4 items) and the impact of pain on daily functioning (7 items) in patients with cancer pain. The four pain severity items assess pain at its \"worst,\" \"least,\" \"average,\" and \"now\" (current pain). For these items, patients are asked to rate their pain on an 11-point numeric rating scale with anchors of 0 (no pain) and 10 (pain as bad as you can imagine)."
                  }
                }
              ]
            }
          },
          {
            "instrument_id": "PRO-002",
            "instrument_name": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core",
            "instrument_abbreviation": "EORTC QLQ-C30",
            "instrument_type": "disease_specific",
            "instrument_version": "3",
            "administration": {
              "mode": "electronic",
              "device_type": "provisioned_tablet",
              "completion_location": "clinic",
              "estimated_completion_time": "Approximately 12 minutes"
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Screening",
                  "visit_reference": "Screening",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycles 1, 3, 5, 7",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycles 9 and beyond (every other cycle)",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Treatment Completion Visit",
                  "visit_reference": "TCV",
                  "is_required": true
                }
              ]
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Physical Functioning",
                  "higher_is_better": true,
                  "provenance": {
                    "section_number": "1.2",
                    "page_number": 7,
                    "text_snippet": "Patient Reported Outcomes (PRO) including Worst Pain (Brief Pain Inventory – Short Form [BPI-SF]), Physical Functioning and Global Health Status/Quality of Life (GHS/QoL) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core [EORTC QLQ-C30])"
                  }
                },
                {
                  "domain_name": "Global Health Status/Quality of Life",
                  "higher_is_better": true,
                  "provenance": {
                    "section_number": "1.2",
                    "page_number": 7,
                    "text_snippet": "Patient Reported Outcomes (PRO) including Worst Pain (Brief Pain Inventory – Short Form [BPI-SF]), Physical Functioning and Global Health Status/Quality of Life (GHS/QoL) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core [EORTC QLQ-C30])"
                  }
                }
              ]
            }
          },
          {
            "instrument_id": "PRO-003",
            "instrument_name": "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Multiple Myeloma Module",
            "instrument_abbreviation": "EORTC QLQ-MY20",
            "instrument_type": "disease_specific",
            "administration": {
              "mode": "electronic",
              "device_type": "provisioned_tablet",
              "completion_location": "clinic",
              "estimated_completion_time": "Approximately 5 minutes"
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Screening",
                  "visit_reference": "Screening",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycles 1, 3, 5, 7",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycles 9 and beyond (every other cycle)",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Treatment Completion Visit",
                  "visit_reference": "TCV",
                  "is_required": true
                }
              ]
            }
          },
          {
            "instrument_id": "PRO-004",
            "instrument_name": "Patient Reported Outcomes Measurement Information System Cancer Fatigue Short Form",
            "instrument_abbreviation": "PROMIS Cancer Fatigue SF",
            "instrument_type": "symptom",
            "administration": {
              "mode": "electronic",
              "device_type": "provisioned_tablet",
              "completion_location": "clinic",
              "estimated_completion_time": "Approximately 5 minutes"
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Screening",
                  "visit_reference": "Screening",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycles 1, 3, 5, 7",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycles 9 and beyond (every other cycle)",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Treatment Completion Visit",
                  "visit_reference": "TCV",
                  "is_required": true
                }
              ],
              "recall_period": "past 7 days"
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Fatigue",
                  "provenance": {
                    "section_number": "1.2",
                    "page_number": 7,
                    "text_snippet": "and Fatigue (Patient Reported Outcomes Measurement Information System [PROMIS] Cancer Fatigue Short Form [SF])"
                  }
                }
              ]
            }
          },
          {
            "instrument_id": "PRO-005",
            "instrument_name": "EuroQol EQ-5D-5L",
            "instrument_abbreviation": "EQ-5D-5L",
            "instrument_type": "utility",
            "administration": {
              "mode": "electronic",
              "device_type": "provisioned_tablet",
              "completion_location": "clinic",
              "estimated_completion_time": "Approximately 5 minutes"
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Screening",
                  "visit_reference": "Screening",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "Cycles 1, 3, 5, 7",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "Cycles 9 and beyond (every other cycle)",
                  "visit_reference": "Day 1",
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Treatment Completion Visit",
                  "visit_reference": "TCV",
                  "is_required": true
                }
              ]
            }
          }
        ],
        "epro_system": {
          "vendor_name": "Signant Health",
          "platform_name": "Trialmax",
          "integration_with_edc": false,
          "alert_triggers": [],
          "device_requirements": {
            "device_type": "provisioned_device",
            "provenance": {
              "section_number": "10.2",
              "page_number": 157,
              "text_snippet": "The ePRO data will be collected electronically via a tablet device into which the patient will directly enter the required pieces of information."
            }
          },
          "provenance": {
            "section_number": "10.2",
            "page_number": 156,
            "text_snippet": "Patient-reported data must be completed for each subject enrolled in this study. These data are being collected with an Electronic Patient Reported Outcome (ePRO) system called Trialmax, provided by the technology vendor Signant Health of Plymouth Meeting, PA, USA."
          }
        },
        "clinro_instruments": [
          {
            "instrument_id": "CLINRO-001",
            "instrument_name": "ECOG Performance Status",
            "assessor": "investigator",
            "schedule": [
              "Screening",
              "Day 1 of each cycle",
              "Treatment Completion Visit"
            ],
            "provenance": {
              "section_number": "5.3.1.1.1",
              "page_number": 62,
              "text_snippet": "The ECOG performance status will be assessed per Appendix D, Appendix E, Appendix F, and Appendix G using the following criteria:"
            }
          }
        ],
        "obsro_instruments": [],
        "perfo_instruments": [],
        "daily_diary": {
          "required": true,
          "diary_name": "Dosing Diary",
          "items_collected": [
            "Venetoclax/Placebo dosing compliance",
            "Dexamethasone dosing compliance"
          ],
          "collection_frequency": "daily",
          "collection_window": "From Cycle 1 until discontinuation",
          "provenance": {
            "section_number": "5.1",
            "page_number": 41,
            "text_snippet": "Subjects will be provided with dosing diaries to document Venetoclax/Placebo and Dexamethasone dosing compliance beginning at Cycle 1 and continuing until discontinuation."
          }
        },
        "analysis_specifications": {
          "secondary_pro_endpoints": [
            "Worst Pain (BPI-SF)",
            "Physical Functioning (EORTC QLQ-C30)",
            "Global Health Status/Quality of Life (GHS/QoL) (EORTC QLQ-C30)",
            "Fatigue (PROMIS Cancer Fatigue SF)"
          ],
          "statistical_methods": [
            "Change in score from baseline will be compared between treatment arms"
          ],
          "provenance": {
            "section_number": "8.1.5.3",
            "page_number": 145,
            "text_snippet": "For PROs, change in score from baseline will be compared between treatment arms for the following domains: Worst Pain (BPI-SF), Physical Functioning (EORTC QLQ-C30), Fatigue (PROMIS-Fatigue), and Global Health Status/QoL (EORTC QLQ-C30)."
          }
        },
        "extraction_statistics": {
          "pro_instrument_count": 5,
          "clinro_count": 1,
          "obsro_count": 0,
          "perfo_count": 0,
          "has_epro": true,
          "has_daily_diary": true,
          "total_assessment_timepoints": 20
        },
        "provenance": {
          "section_number": "5.3.1.1.1",
          "page_number": 63,
          "text_snippet": "Patient-Reported Outcome (PRO) Assessments\n\nPRO assessments include BPI-SF, EORTC QLQ-C30, EORTC QLC-MY20, PROMIS Cancer Fatigue SF, and EQ-5D-5L. These assessments will be collected per Appendix D, Appendix E, and Appendix F throughout the trial until the final OS analysis. Once the number of OS events required for the final OS analysis is reached, PRO assessments will no longer be collected."
        }
      },
      "_agentDocumentation": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA → Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "dataManagement": {
      "moduleId": "data_management",
      "instanceType": "DataManagement",
      "data": {
        "id": "M14-031-data-management",
        "instanceType": "DataManagementPlan",
        "name": "M14-031 Data Management Plan",
        "edc_specifications": {
          "instanceType": "EDCSpecifications",
          "vendor_name": "Medidata Rave",
          "system_capabilities": [
            "randomization",
            "ePRO",
            "imaging_upload",
            "central_lab_integration",
            "audit_trail",
            "electronic_signature"
          ],
          "integration_systems": [
            {
              "id": "integration-001",
              "system_type": "IWRS",
              "vendor_name": null,
              "transfer_frequency": null,
              "transfer_method": null,
              "provenance": {
                "section_number": "5.5.3",
                "page_number": 71,
                "text_snippet": "Interactive Response Technology (IRT) will be utilized to register (screen, re-screen and randomize) subjects on study. The site will contact the IRT to obtain a screening (subject) number once the subject has signed the informed consent and a study-specific procedure has been performed (e.g., labs are drawn)."
              }
            },
            {
              "id": "integration-002",
              "system_type": "central_lab",
              "vendor_name": null,
              "transfer_frequency": null,
              "transfer_method": null,
              "provenance": {
                "section_number": null,
                "page_number": 68,
                "text_snippet": "A certified central laboratory will be utilized to process and provide results for coagulation, viral serologies, urinalysis, and special chemistry labs listed in Table 3. These data will be used for all data analysis. The central laboratory will provide instructions regarding the collection, processing, handling, and shipping of samples."
              }
            },
            {
              "id": "integration-003",
              "system_type": "ePRO",
              "vendor_name": "Signant Health",
              "transfer_frequency": "real_time",
              "transfer_method": "electronic",
              "provenance": {
                "section_number": "10.2",
                "page_number": 156,
                "text_snippet": "Patient-reported data must be completed for each subject enrolled in this study. These data are being collected with an Electronic Patient Reported Outcome (ePRO) system called Trialmax, provided by the technology vendor Signant Health of Plymouth Meeting, PA, USA."
              }
            },
            {
              "id": "integration-004",
              "system_type": "imaging_vendor",
              "vendor_name": null,
              "transfer_frequency": null,
              "transfer_method": "electronic",
              "provenance": {
                "section_number": null,
                "page_number": 87,
                "text_snippet": "In addition to be reviewed by the Investigator and/or qualified medical site staff, imaging scans should be sent within 5 business days of imaging acquisition to an independent central imaging vendor. The central imaging vendor will provide instructions regarding the preparation and shipment/upload of the images."
              }
            }
          ],
          "language_requirements": null,
          "crf_modules": null,
          "provenance": {
            "section_number": "10.2",
            "page_number": 155,
            "text_snippet": "Case report forms (CRFs) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable. The CRF data for this study are being collected with an EDC system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
          }
        },
        "data_standards": {
          "instanceType": "DataStandards",
          "sdtm_version": null,
          "sdtm_ig_version": null,
          "adam_version": null,
          "controlled_terminology": {
            "cdisc_ct_version": null,
            "meddra_version": null,
            "whodrug_version": null,
            "snomed_version": null
          },
          "define_xml_required": null,
          "define_xml_version": null,
          "adrg_required": null,
          "sdrg_required": null,
          "provenance": {
            "section_number": "8.1.7.2",
            "page_number": 148,
            "text_snippet": "Treatment-emergent adverse events will be coded and summarized by system organ class and preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA) adverse event coding dictionary."
          }
        },
        "data_quality": {
          "instanceType": "DataQuality",
          "edit_checks": {
            "standard_checks": [
              "range_checks",
              "consistency_checks",
              "required_fields",
              "date_logic"
            ],
            "protocol_specific_checks": [
              "Verify IMWG response criteria are met before confirming response",
              "Check for dose modifications following specific toxicities as per protocol tables"
            ],
            "auto_query_enabled": true
          },
          "sdv_strategy": {
            "approach": "hybrid",
            "sdv_percentage": null,
            "critical_data_points": [
              "Informed Consent",
              "Eligibility Criteria",
              "Primary Endpoint (PFS)",
              "Serious Adverse Events",
              "Study Drug Administration"
            ],
            "sdv_timing": "hybrid"
          },
          "query_management": {
            "resolution_target_days": null,
            "escalation_threshold_days": null,
            "auto_query_triggers": []
          },
          "data_review": {
            "medical_review_frequency": null,
            "statistical_review_frequency": null,
            "data_review_committee": true
          },
          "provenance": {
            "section_number": "11.0",
            "page_number": 157,
            "text_snippet": "AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results. Data will be generated, documented, and reported in compliance with the protocol, ICH GCP, and applicable regulatory requirements."
          }
        },
        "database_management": {
          "instanceType": "DatabaseManagement",
          "database_design": {
            "external_data_sources": [
              "central_lab",
              "imaging_vendor",
              "ePRO"
            ],
            "calculated_fields": [
              "Creatinine Clearance",
              "Corrected Serum Calcium"
            ],
            "derived_variables": [
              "Progression Free Survival (PFS)",
              "Duration of Response (DOR)",
              "Time to Progression (TTP)",
              "Overall Survival (OS)",
              "Time to Response (TTR)",
              "Time to Next Treatment (TNT)"
            ]
          },
          "interim_locks": [
            {
              "id": "lock-001",
              "lock_name": "PFS Analysis / First OS Interim Analysis",
              "trigger": "When approximately 136 PFS events are observed",
              "scope": "partial",
              "provenance": {
                "section_number": "8.1.4",
                "page_number": 143,
                "text_snippet": "Efficacy and safety analyses will be performed when approximately 136 PFS events per IRC assessment are observed."
              }
            },
            {
              "id": "lock-002",
              "lock_name": "Second OS Interim Analysis",
              "trigger": "When approximately 87 OS events are observed",
              "scope": "partial",
              "provenance": {
                "section_number": "8.1.5.5.2",
                "page_number": 147,
                "text_snippet": "The interim analyses for OS will be considered at the time of the PFS analysis and when approximately 75% of the total 116 OS events are observed (87 OS events)."
              }
            }
          ],
          "final_database_lock": {
            "trigger_event": "When approximately 116 OS events are observed and all data is clean",
            "timeline_days_from_lplv": null,
            "prerequisites": [
              "All CRF pages completed",
              "All queries resolved",
              "Medical review completed",
              "SAE reconciliation completed",
              "External data reconciled",
              "Final IDMC review completed"
            ],
            "signoff_required": [
              "data_management",
              "biostatistics",
              "medical_monitor",
              "clinical_operations"
            ],
            "provenance": {
              "section_number": "8.1.5.5.2",
              "page_number": 147,
              "text_snippet": "The final OS analysis will be performed when approximately 116 OS events are observed."
            }
          },
          "provenance": {
            "section_number": "12.0",
            "page_number": 158,
            "text_snippet": "All data hand-entered in the database will be verified at AbbVie. Any discrepancies will be reviewed against the hard-copy case report form and corrected on-line. After completion of the entry process, computer logic and manual checks will be created to identify such items as inconsistent study dates. Any necessary corrections will be made to the database via the appropriate change form/electronic CRF."
          }
        },
        "data_transfers": {
          "instanceType": "DataTransfers",
          "central_lab": {
            "vendor_name": null,
            "transfer_frequency": null,
            "transfer_method": null,
            "data_reconciliation": true
          },
          "imaging": {
            "vendor_name": null,
            "data_collected": [
              "X-rays",
              "CT scans",
              "MRI",
              "PET scans"
            ],
            "transfer_method": "electronic"
          },
          "epro": {
            "vendor_name": "Signant Health",
            "transfer_frequency": "real_time",
            "instruments_collected": [
              "BPI-SF",
              "EORTC QLQ-C30",
              "EORTC QLQ-MY20",
              "PROMIS Cancer Fatigue SF",
              "EQ-5D-5L"
            ]
          },
          "external_adjudication": {
            "adjudication_types": [
              "endpoint"
            ],
            "export_frequency": null,
            "blinding_maintained": true
          },
          "dsmb_exports": {
            "export_frequency": "per_meeting",
            "unblinded_access": true,
            "data_included": [
              "Safety data",
              "Efficacy data"
            ],
            "provenance": {
              "section_number": "5.5.5.2",
              "page_number": 110,
              "text_snippet": "An IDMC will periodically review the safety and efficacy data for this study in an un-blinded fashion. Aggregate blinded clinical safety and efficacy data will be reviewed on a real-time basis throughout the course of the study."
            }
          },
          "provenance": {
            "section_number": "10.2",
            "page_number": 155,
            "text_snippet": "Case report forms (CRFs) must be completed for each subject screened/enrolled in this study. These forms will be used to transmit information collected during the study to AbbVie and regulatory authorities, as applicable."
          }
        },
        "data_archival": {
          "instanceType": "DataArchival",
          "retention_period_years": 20,
          "retention_basis": "Sponsor policy and local requirements",
          "archival_format": [
            "electronic"
          ],
          "archival_location": "sponsor",
          "destruction_policy": "Destruction of records will be handled according to sponsor policy and local regulations after the required retention period.",
          "provenance": {
            "section_number": "5.3.1.3",
            "page_number": 74,
            "text_snippet": "The samples will be retained while research on venetoclax (or drugs of this class) or this disease and related conditions continues, but for no longer than 20 years after study completion, or per local requirements."
          }
        },
        "extraction_statistics": {
          "has_edc_specifications": true,
          "has_data_standards": true,
          "has_sdv_strategy": true,
          "has_database_lock_plan": true,
          "integration_count": 4,
          "crf_module_count": 12
        },
        "provenance": {
          "section_number": "11.0",
          "page_number": 157,
          "text_snippet": "Data Quality Assurance"
        }
      },
      "_agentDocumentation": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "siteOperationsLogistics": {
      "moduleId": "site_operations_logistics",
      "instanceType": "SiteOperationsLogistics",
      "data": {
        "id": "NCT02755597-site-operations-logistics",
        "instanceType": "SiteOperationsLogistics",
        "name": "NCT02755597 Site Operations & Logistics",
        "site_selection": {
          "instanceType": "SiteSelectionCriteria",
          "required_criteria": [],
          "preferred_criteria": [],
          "exclusionary_criteria": [],
          "geographic_requirements": {
            "countries": [
              "JPN",
              "FRA"
            ],
            "regions": [],
            "site_count_target": 120,
            "language_requirements": [],
            "provenance": {
              "section_number": "5.1",
              "page_number": 39,
              "text_snippet": "Approximately 280 subjects at approximately 120 sites will be randomized in a 2:1 ratio to receive an oral daily dose of either venetoclax 800 mg or placebo plus Bd, respectively."
            }
          },
          "facility_requirements": {
            "equipment_required": [
              "ECG machine",
              "Conventional radiography (X-Ray)",
              "CT scanner",
              "MRI scanner"
            ],
            "laboratory_capabilities": [
              "Certified local laboratory for hematology and chemistry",
              "Ability to collect, process, and ship samples to a central laboratory"
            ],
            "pharmacy_capabilities": "Ability to store investigational product at specified temperatures and manage drug accountability.",
            "storage_capabilities": "Storage at 15° to 25°C (59° to 77°F) for Venetoclax/Placebo.",
            "provenance": {
              "section_number": "5.5.2.2",
              "page_number": 108,
              "text_snippet": "Venetoclax/placebo study drug must be stored at 15° to 25°C (59° to 77°F)."
            }
          },
          "experience_requirements": {},
          "provenance": {
            "section_number": "5.0",
            "page_number": 39,
            "text_snippet": "Investigational Plan"
          }
        },
        "regulatory_ethics": {
          "instanceType": "RegulatoryEthics",
          "regulatory_authorities": [
            {
              "id": "AUTH-001",
              "authority_name": "European Medicines Agency (EMA) jurisdiction",
              "country_region": "EU",
              "submission_type": "EudraCT",
              "submission_number": "2015-004411-20",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "EudraCT 2015-004411-20"
              }
            },
            {
              "id": "AUTH-002",
              "authority_name": "Food and Drug Administration (FDA)",
              "country_region": "USA",
              "submission_type": "NCT",
              "submission_number": "NCT02755597",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "NCT02755597"
              }
            }
          ],
          "ethics_committees": [
            {
              "id": "EC-001",
              "committee_type": "IEC/IRB",
              "centralized_or_local": null,
              "approval_requirements": "Good Clinical Practice (GCP) requires that the clinical protocol, any protocol amendments, the Investigator's Brochure, the informed consent and all other forms of subject information related to the study (e.g., advertisements used to recruit subjects) and any other necessary documents be reviewed by an IEC/IRB.",
              "approval_timeline": null,
              "continuing_review_frequency": null,
              "provenance": {
                "section_number": "9.1",
                "page_number": 151,
                "text_snippet": "Good Clinical Practice (GCP) requires that the clinical protocol, any protocol amendments, the Investigator's Brochure, the informed consent and all other forms of subject information related to the study (e.g., advertisements used to recruit subjects) and any other necessary documents be reviewed by an IEC/IRB."
              }
            }
          ],
          "informed_consent": {
            "consent_type": "written",
            "languages_required": [],
            "reconsent_triggers": [
              "protocol_amendment",
              "availability of important new information related to the subject's consent"
            ],
            "assent_required": null,
            "electronic_consent_allowed": null,
            "provenance": {
              "section_number": "9.3",
              "page_number": 153,
              "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject, the person who administered the informed consent, and any other signatories according to local requirements."
            }
          },
          "data_privacy": {
            "applicable_regulations": [],
            "data_transfer_requirements": null,
            "anonymization_requirements": "A confidential subject identification code list will be maintained at the study site. Researchers will have no access to subject identifiers.",
            "provenance": {
              "section_number": null,
              "page_number": 159,
              "text_snippet": "The Investigator will maintain a confidential subject identification code list of all subjects enrolled in the study... will not be retrieved by AbbVie.\n\nAny research that may be done using research samples from this study will be experimental in nature and the results will not be suitable for clinical decision making or subject management. Hence, the subject will not be informed of individual results, should analyses be performed, nor will anyone not directly involved in this research."
            }
          },
          "provenance": {
            "section_number": "9.0",
            "page_number": 151,
            "text_snippet": "9.0 Ethics"
          }
        },
        "site_personnel": {
          "instanceType": "SitePersonnel",
          "principal_investigator": {
            "qualifications_required": [],
            "responsibilities": [
              "Conducting the study in accordance with the protocol",
              "Personally conducting or supervising the investigation",
              "Informing subjects that drugs are for investigational purposes",
              "Complying with requirements for informed consent and ethics committee review",
              "Reporting adverse experiences",
              "Maintaining adequate and accurate records",
              "Ensuring ethics committee has reviewed and approved the investigation"
            ],
            "delegation_restrictions": [],
            "time_commitment": null,
            "provenance": {
              "section_number": "A",
              "page_number": 167,
              "text_snippet": "1. Conducting the study in accordance with the relevant, current protocol...\n2. Personally conducting or supervising the described investigation(s).\n3. Informing all subjects, or persons used as controls, that the drugs are being used for investigational purposes and complying with the requirements relating to informed consent and ethics committees...\n4. Reporting adverse experiences that occur in the course of the investigation(s) to AbbVie and the site director.\n7."
            }
          },
          "sub_investigators": {},
          "coordinators": {},
          "provenance": {
            "section_number": "A",
            "page_number": 167,
            "text_snippet": "Appendix A. Responsibilities of the Clinical Investigator"
          }
        },
        "training_requirements": {
          "instanceType": "TrainingRequirements",
          "protocol_training": {
            "required_for": [
              "Investigator(s)",
              "study coordinators/project manager(s)"
            ],
            "format": "in_person",
            "duration": null,
            "assessment_required": null,
            "completion_deadline": "Prior to enrolling any subject",
            "provenance": {
              "section_number": "11.0",
              "page_number": 157,
              "text_snippet": "Prior to enrolling any subject in the study, a study training visit will be held with AbbVie personnel, the Investigator(s), and the study coordinators/project manager(s). This meeting will include a detailed discussion and review of the protocol and essential documents, performance of study procedures, case report form completion and specimen collection methods."
            }
          },
          "gcp_training": {
            "required": true,
            "frequency": null,
            "certification_required": null,
            "accepted_providers": [],
            "provenance": {
              "section_number": "9.2",
              "page_number": 152,
              "text_snippet": "The study will be conducted in accordance with the protocol, ICH GCP guidelines, applicable regulations and guidelines governing clinical study conduct and ethical principles that have their origin in the Declaration of Helsinki."
            }
          },
          "specialized_training": [],
          "training_documentation": {},
          "provenance": {
            "section_number": "11.0",
            "page_number": 157,
            "text_snippet": "Data Quality Assurance"
          }
        },
        "monitoring_plan": {
          "instanceType": "MonitoringPlan",
          "monitoring_approach": "hybrid",
          "site_initiation_visit": {},
          "routine_monitoring": {
            "frequency": null,
            "visit_type": "hybrid",
            "sdv_percentage": null,
            "sdv_scope": [],
            "remote_monitoring_activities": [
              "Remote data review/verification of data may be employed if allowed by local regulatory authority, IRB/IEC, and the study site during the COVID-19 pandemic."
            ],
            "provenance": {
              "section_number": "10.1",
              "page_number": 155,
              "text_snippet": "During the COVID-19 pandemic, remote data review/verification of data may be employed if allowed by the local regulatory authority, IRB/IEC, and the study site."
            }
          },
          "triggered_monitoring": {},
          "close_out_visit": {
            "required": true,
            "timing": "Upon completion or termination of the study",
            "format": "on_site",
            "activities": [
              "Overall accountability of the study treatment will be performed and verified."
            ],
            "provenance": {
              "section_number": "5.5.7",
              "page_number": 111,
              "text_snippet": "An overall accountability of the study treatment will be performed and verified by AbbVie or the designated monitor(s) throughout the study and at the study site Closeout Visit. Upon completion or termination of the study, all original containers (containing partially used or unused study treatment) will be returned to AbbVie according to instructions from AbbVie or the designated monitor(s)."
            }
          },
          "provenance": {
            "section_number": "11.0",
            "page_number": 157,
            "text_snippet": "The AbbVie monitor will monitor the study site throughout the study. Source document review will be made against entries on the case report forms and a quality assurance check will be performed to ensure that the Investigator is complying with the protocol and regulations."
          }
        },
        "site_activation_timeline": {
          "instanceType": "SiteActivationTimeline",
          "site_selection_phase": null,
          "feasibility_assessment": null,
          "contract_negotiation": null,
          "regulatory_submission": null,
          "ethics_approval": null,
          "site_training": null,
          "site_initiation_visit": null,
          "first_patient_ready": null,
          "critical_path_items": [],
          "provenance": {
            "section_number": "5.0",
            "page_number": 39,
            "text_snippet": "Investigational Plan"
          }
        },
        "drug_supply_logistics": {
          "instanceType": "DrugSupplyLogistics",
          "packaging_labeling": {
            "blinding_requirements": "double_blind",
            "label_languages": [
              "Local language"
            ],
            "temperature_indicators": null,
            "tamper_evident": null,
            "kit_design": null,
            "provenance": {
              "section_number": "5.5.2.1",
              "page_number": 107,
              "text_snippet": "The venetoclax/placebo tablets will be packaged in high density polyethylene (HDPE) plastic bottles to accommodate the study dosing requirements. Each bottle will be labeled per local regulatory requirements."
            }
          },
          "storage_distribution": {
            "storage_temperature": "15° to 25°C (59° to 77°F)",
            "distribution_model": "direct_to_patient",
            "cold_chain_required": null,
            "shelf_life_months": null,
            "shipping_conditions": "Appropriately temperature controlled (qualified shipper or temperature monitoring) within the labeled storage conditions.",
            "provenance": {
              "section_number": "5.5.2.2",
              "page_number": 108,
              "text_snippet": "Venetoclax/placebo study drug must be stored at 15° to 25°C (59° to 77°F)."
            }
          },
          "inventory_management": {
            "iwrs_rtsm_system": "Interactive Response Technology (IRT)",
            "kit_design": null,
            "resupply_triggers": null,
            "resupply_threshold_days": null,
            "expiry_management": null,
            "provenance": {
              "section_number": null,
              "page_number": 71,
              "text_snippet": "Interactive Response Technology (IRT) will be utilized to register (screen, re-screen and randomize) subjects on study."
            }
          },
          "dispensing_schedule": [
            {
              "id": "DISP-001",
              "visit_name": "Cycles 1-8",
              "cycle_day": "Day 1",
              "kits_dispensed": [
                "Venetoclax/Placebo"
              ],
              "quantity_dispensed": "21-day supply",
              "titration_rules": null,
              "provenance": {
                "section_number": null,
                "page_number": 71,
                "text_snippet": "Randomized subjects will receive sufficient quantities of venetoclax/placebo for 21 days in each 21-day cycle during the Cycles 1 – 8"
              }
            },
            {
              "id": "DISP-002",
              "visit_name": "Cycles 9 and beyond",
              "cycle_day": "Day 1",
              "kits_dispensed": [
                "Venetoclax/Placebo"
              ],
              "quantity_dispensed": "35-day supply",
              "titration_rules": null,
              "provenance": {
                "section_number": null,
                "page_number": 71,
                "text_snippet": "and sufficient quantities for 35 days in each 35-day cycle for Cycles 9 and beyond."
              }
            }
          ],
          "drug_accountability": {
            "accountability_frequency": "Throughout the study and at the study site Closeout Visit.",
            "accountability_method": "site_inventory_log",
            "documentation_requirements": "Documentation of the receipt of supplies will be supported by a signed and dated Proof of Receipt or similar document. Inventory will include lot number, Proof of Receipt number(s), bottle numbers, and the date on which the study treatment is dispensed or administered.",
            "discrepancy_handling": null,
            "provenance": {
              "section_number": "5.5.7",
              "page_number": 111,
              "text_snippet": "A current (running) and accurate inventory of study treatment will be kept by the site and will include lot number, Proof of Receipt number(s), bottle numbers, and the date on which the study treatment is dispensed or administered to the subject.\n\nAn overall accountability of the study treatment will be performed and verified by AbbVie or the designated monitor(s) throughout the study and at the study site Closeout Visit."
            }
          },
          "drug_return_destruction": {
            "return_required": true,
            "return_timing": "Upon completion or termination of the study.",
            "destruction_method": "return_to_sponsor",
            "destruction_documentation": null,
            "environmental_requirements": null,
            "provenance": {
              "section_number": "5.5.7",
              "page_number": 111,
              "text_snippet": "Upon completion or termination of the study, all original containers (containing partially used or unused study treatment) will be returned to AbbVie according to instructions from AbbVie or the designated monitor(s)."
            }
          },
          "dosing_error_handling": {
            "overdose_procedures": null,
            "underdose_procedures": null,
            "missed_dose_procedures": "If a dose is missed or forgotten, the subject should take the dose as soon as possible, ensuring the dose is taken within 8 hours of the missed dose with food. Otherwise, the dose should not be taken.",
            "dose_timing_windows": null,
            "provenance": {
              "section_number": "5.5.1",
              "page_number": 103,
              "text_snippet": "In cases where a dose is missed or forgotten, the subject should take the dose as soon as possible, ensuring the dose is taken within 8 hours of the missed dose with food. Otherwise, the dose should not be taken."
            }
          },
          "comparator_medications": [
            {
              "id": "COMP-001",
              "medication_name": "Bortezomib",
              "source": "commercially_obtained",
              "procurement_requirements": "Sites are responsible for obtaining bortezomib. It should be obtained from a licensed pharmacy or wholesaler.",
              "provenance": {
                "section_number": null,
                "page_number": 107,
                "text_snippet": "Sites are responsible for obtaining bortezomib and dexamethasone. For operational or regulatory purposes, AbbVie may provide non-investigational products depending on local requirements. Bortezomib and dexamethasone should be obtained from a licensed pharmacy or wholesaler."
              }
            },
            {
              "id": "COMP-002",
              "medication_name": "Dexamethasone",
              "source": "commercially_obtained",
              "procurement_requirements": "Sites are responsible for obtaining dexamethasone. It should be obtained from a licensed pharmacy or wholesaler.",
              "provenance": {
                "section_number": null,
                "page_number": 107,
                "text_snippet": "Sites are responsible for obtaining bortezomib and dexamethasone. For operational or regulatory purposes, AbbVie may provide non-investigational products depending on local requirements. Bortezomib and dexamethasone should be obtained from a licensed pharmacy or wholesaler."
              }
            }
          ],
          "emergency_unblinding": {
            "unblinding_allowed": true,
            "unblinding_triggers": [
              "medical_emergency"
            ],
            "unblinding_procedure": "The IRT system can provide access to blinded subject treatment information.",
            "who_can_unblind": [],
            "documentation_required": "The date and reason that the blind was broken must be recorded in the source documentation and eCRF, as applicable. AbbVie must be notified within 24 hours.",
            "provenance": {
              "section_number": null,
              "page_number": 110,
              "text_snippet": "The IRT system can provide access to blinded subject treatment information during the study if identification of the study drug is required for medical emergency, i.e., situation in which the knowledge of the specific blinded treatment will affect the immediate management of the subject/subject's conditions (e.g., antidote is available). AbbVie must then be notified within 24 hours of the blind being broken."
            }
          },
          "provenance": {
            "section_number": "5.5",
            "page_number": 103,
            "text_snippet": "5.5 Treatments"
          }
        },
        "technology_systems": {
          "instanceType": "TechnologySystems",
          "edc_system": {
            "vendor_name": "Medidata Solutions Incorporated",
            "system_name": "Rave",
            "system_capabilities": [
              "electronic_signature",
              "audit_trail"
            ],
            "integration_requirements": [],
            "language_requirements": [],
            "provenance": {
              "section_number": "10.2",
              "page_number": 155,
              "text_snippet": "The CRF data for this study are being collected with an EDC system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
            }
          },
          "iwrs_rtsm": {
            "vendor_name": null,
            "system_name": "Interactive Response Technology (IRT)",
            "functions": [
              "randomization",
              "drug_dispensing",
              "unblinding"
            ],
            "integration_with_edc": null,
            "provenance": {
              "section_number": null,
              "page_number": 71,
              "text_snippet": "Interactive Response Technology (IRT) will be utilized to register (screen, re-screen and randomize) subjects on study."
            }
          },
          "epro_devices": {
            "required": true,
            "device_type": "provisioned_tablet",
            "vendor_name": "Signant Health",
            "system_name": "Trialmax",
            "instruments_collected": [
              "BPI-SF",
              "EORTC QLQ-C30",
              "EORTC QLC-MY20",
              "PROMIS Cancer Fatigue SF",
              "EQ-5D-5L"
            ],
            "training_required": null,
            "provenance": {
              "section_number": "10.2",
              "page_number": 156,
              "text_snippet": "Patient-reported data must be completed for each subject enrolled in this study. These data are being collected with an Electronic Patient Reported Outcome (ePRO) system called Trialmax, provided by the technology vendor Signant Health of Plymouth Meeting, PA, USA."
            }
          },
          "central_services": [
            {
              "id": "SVC-001",
              "service_type": "central_lab",
              "vendor_name": null,
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": null,
                "page_number": 68,
                "text_snippet": "A certified central laboratory will be utilized to process and provide results for coagulation, viral serologies, urinalysis, and special chemistry labs listed in Table 3."
              }
            },
            {
              "id": "SVC-002",
              "service_type": "central_imaging",
              "vendor_name": null,
              "data_flow": null,
              "turnaround_time": null,
              "provenance": {
                "section_number": null,
                "page_number": 87,
                "text_snippet": "In addition to be reviewed by the Investigator and/or qualified medical site staff, imaging scans should be sent within 5 business days of imaging acquisition to an independent central imaging vendor."
              }
            }
          ],
          "provenance": {
            "section_number": "10.2",
            "page_number": 155,
            "text_snippet": "Case Report Forms"
          }
        },
        "equipment_facilities": {
          "instanceType": "EquipmentFacilities",
          "specialized_equipment": [
            {
              "id": "EQUIP-001",
              "equipment": "12-lead ECG machine",
              "required_or_preferred": "required",
              "specifications": null,
              "calibration_frequency": null,
              "provenance": {
                "section_number": null,
                "page_number": 66,
                "text_snippet": "12-Lead Electrocardiogram (ECG)\n\nA resting 12-lead ECG will be performed per Appendix D and Appendix F."
              }
            },
            {
              "id": "EQUIP-002",
              "equipment": "Conventional radiography (X-Ray)",
              "required_or_preferred": "required",
              "specifications": null,
              "calibration_frequency": null,
              "provenance": {
                "section_number": null,
                "page_number": 86,
                "text_snippet": "Skeletal survey using conventional radiography (X-Ray) will be done at screening."
              }
            },
            {
              "id": "EQUIP-003",
              "equipment": "CT scanner",
              "required_or_preferred": "required",
              "specifications": "Low dose CT is acceptable. For plasmacytoma evaluation, contiguous cuts of 10 mm or less, or 5 (or 10) mm if spiral CT is used.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": null,
                "page_number": 88,
                "text_snippet": "Conventional CT, PET/CT or MRI should be performed with contiguous cuts of 10 mm or less or with cuts of 5 (or 10) mm if spiral CT scanning is used."
              }
            },
            {
              "id": "EQUIP-004",
              "equipment": "MRI scanner",
              "required_or_preferred": "required",
              "specifications": "For plasmacytoma evaluation, contiguous cuts of 10 mm or less.",
              "calibration_frequency": null,
              "provenance": {
                "section_number": null,
                "page_number": 88,
                "text_snippet": "Conventional CT, PET/CT or MRI should be performed with contiguous cuts of 10 mm or less or with cuts of 5 (or 10) mm if spiral CT scanning is used."
              }
            }
          ],
          "facility_requirements": {},
          "provenance": {
            "section_number": null,
            "page_number": 66,
            "text_snippet": "Cardiac Assessments"
          }
        },
        "vendor_coordination": [
          {
            "id": "VENDOR-001",
            "vendor_type": "EDC",
            "vendor_name": "Medidata Solutions Incorporated",
            "services_provided": [
              "Electronic Data Capture (Rave)"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": "10.2",
              "page_number": 155,
              "text_snippet": "The CRF data for this study are being collected with an EDC system called Rave® provided by the technology vendor Medidata Solutions Incorporated, NY, USA."
            }
          },
          {
            "id": "VENDOR-002",
            "vendor_type": "ePRO",
            "vendor_name": "Signant Health",
            "services_provided": [
              "Electronic Patient Reported Outcome (Trialmax)"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": null,
              "page_number": 156,
              "text_snippet": "Patient-reported data must be completed for each subject enrolled in this study. These data are being collected with an Electronic Patient Reported Outcome (ePRO) system called Trialmax, provided by the technology vendor Signant Health of Plymouth Meeting, PA, USA."
            }
          },
          {
            "id": "VENDOR-003",
            "vendor_type": "Logistics",
            "vendor_name": "Marken",
            "services_provided": [
              "Direct-to-patient (DTP) study drug shipment"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": null,
              "page_number": 105,
              "text_snippet": "Instructions will be provided by AbbVie as to how a study site can initiate a DTP shipment using Marken, a global vendor selected by AbbVie to provide this service when necessary."
            }
          }
        ],
        "extraction_statistics": {
          "has_site_selection_criteria": true,
          "has_regulatory_info": true,
          "has_personnel_requirements": true,
          "has_training_requirements": true,
          "has_monitoring_plan": true,
          "has_activation_timeline": false,
          "has_drug_supply_info": true,
          "has_technology_systems": true,
          "has_dispensing_schedule": true,
          "has_drug_accountability": true,
          "has_emergency_unblinding": true,
          "site_count_target": 120,
          "country_count": 2,
          "vendor_count": 3,
          "comparator_medication_count": 2
        },
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-031\nA Phase 3, Multicenter, Randomized, Double Blind\nStudy of Bortezomib and Dexamethasone in\nCombination with Either Venetoclax or Placebo in\nSubjects with Relapsed or Refractory Multiple\nMyeloma Who are Sensitive or Naïve to Proteasome\nInhibitors"
        }
      },
      "_agentDocumentation": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "qualityManagement": {
      "moduleId": "quality_management",
      "instanceType": "QualityManagement",
      "data": {
        "id": "M14-031-quality-management",
        "instanceType": "QualityManagement",
        "name": "M14-031 Quality Management",
        "ich_m11_section": "6.3",
        "monitoring": {
          "monitoring_approach": {
            "instanceType": "MonitoringApproach",
            "strategy": "hybrid",
            "rationale": "A hybrid approach combining on-site, remote, and centralized monitoring is employed to ensure subject safety, data integrity, and regulatory compliance, with adaptations for events like the COVID-19 pandemic.",
            "regulatory_framework": [
              "ICH_GCP",
              "ICH_E6_R2"
            ],
            "adaptive_monitoring": true,
            "centralized_monitoring_enabled": true,
            "centralized_monitoring_tools": [
              "EDC_data_review",
              "statistical_monitoring",
              "KRI_dashboard",
              "IDMC_review"
            ],
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol describes a hybrid monitoring strategy. It explicitly mentions on-site monitoring for data verification (p155), remote data review (p155), and centralized components like an IDMC (p110) and a quality management system (p157). The approach is adaptive, particularly in response to the COVID-19 pandemic, allowing for virtual visits and remote assessments (p152). This combination of on-site, remote, and centralized oversight constitutes a hybrid, risk-based approach consistent with ICH E6(R2).",
                "supporting_context": [
                  "Page 155: Clinical site monitoring is conducted to ensure that the reported trial data are accurate, complete, and verifiable...",
                  "Page 155: During the COVID-19 pandemic, remote data review/verification of data may be employed...",
                  "Page 110: An IDMC will periodically review the safety and efficacy data for this study in an un-blinded fashion.",
                  "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits..."
                ],
                "confidence": "high"
              }
            }
          },
          "sdv_strategy": {
            "instanceType": "SDVStrategy",
            "overall_approach": "risk_based",
            "default_sdv_percentage": 100,
            "critical_data_100_percent": [
              "informed_consent",
              "eligibility_criteria",
              "primary_endpoint",
              "SAEs",
              "drug_accountability",
              "dose_modifications",
              "protocol_deviations",
              "withdrawal_reason"
            ],
            "sdv_reduction_criteria": {
              "enabled": false,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not mention any criteria or process for reducing the level of Source Data Verification (SDV). The emphasis is on ensuring data accuracy and verifiability, suggesting a comprehensive approach without pre-planned reductions.",
                  "supporting_context": [
                    "Page 155: Clinical site monitoring is conducted to ensure that the reported trial data are accurate, complete, and verifiable..."
                  ],
                  "confidence": "high"
                }
              }
            },
            "sdv_escalation_criteria": {
              "error_rate_threshold_percent": 5,
              "escalated_sdv_percentage": 100,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify criteria for escalating SDV. This is a standard quality management practice inferred from the overall commitment to GCP and data integrity. An error rate threshold of 5% is a common industry standard for triggering corrective actions, including potentially expanding SDV.",
                  "supporting_context": [
                    "Page 152: The study will be conducted in accordance with the protocol, ICH GCP guidelines...",
                    "Page 155: The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported."
                  ],
                  "confidence": "low"
                }
              }
            },
            "remote_sdv_enabled": true,
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "10.1",
                "page_number": 155,
                "text_snippet": "During the COVID-19 pandemic, remote data review/verification of data may be employed if allowed by the local regulatory authority, IRB/IEC, and the study site."
              }
            }
          },
          "monitoring_visits": {
            "instanceType": "MonitoringVisits",
            "site_initiation_visit": {
              "required": true,
              "timing": "Before first subject enrolled",
              "format": "on_site",
              "key_activities": [
                "protocol_training",
                "investigator_responsibilities_review",
                "EDC_training",
                "drug_accountability_training"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "11.0",
                  "page_number": 157,
                  "text_snippet": "Prior to enrolling any subject in the study, a study training visit will be held with AbbVie personnel, the Investigator(s), and the study coordinators/project manager(s). This meeting will include a detailed discussion and review of the protocol and essential documents, performance of study procedures, case report form completion and specimen collection methods."
                }
              }
            },
            "routine_monitoring": {
              "on_site_visit_frequency": "risk_based_adaptive",
              "remote_monitoring_frequency": "risk_based_adaptive",
              "on_site_activities": [
                "ICF_review",
                "source_data_verification",
                "AE_SAE_review",
                "drug_accountability_review",
                "essential_document_collection"
              ],
              "remote_activities": [
                "data_listing_review",
                "KRI_monitoring",
                "query_management",
                "protocol_deviation_review"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "11.0",
                  "page_number": 157,
                  "text_snippet": "The AbbVie monitor will monitor the study site throughout the study. Source document review will be made against entries on the case report forms and a quality assurance check will be performed to ensure that the Investigator is complying with the protocol and regulations."
                }
              }
            },
            "triggered_visits": [
              {
                "id": "trigger-001",
                "trigger_type": "SAE_occurrence",
                "response_timeline_hours": 48,
                "actions": [
                  "remote_review_of_SAE_report",
                  "follow_up_with_site_staff"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol mandates SAE reporting within 24 hours (p119). A triggered monitoring action is a standard response to ensure timely follow-up and complete documentation for such a critical safety event, consistent with a risk-based monitoring approach.",
                    "supporting_context": [
                      "Page 119: In the event of a serious adverse event... the Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse event..."
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "trigger-002",
                "trigger_type": "major_protocol_deviation",
                "response_timeline_hours": 72,
                "actions": [
                  "root_cause_analysis",
                  "initiate_CAPA_if_needed"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol has a dedicated section for managing protocol deviations (p135). A triggered response to a major deviation is a fundamental component of quality oversight to assess impact, determine root cause, and prevent recurrence.",
                    "supporting_context": [
                      "Page 135: AbbVie does not allow intentional/prospective deviations from the protocol unless when necessary to eliminate an immediate hazard to study subjects."
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "trigger-003",
                "trigger_type": "KRI_threshold_breach",
                "response_timeline_hours": 120,
                "actions": [
                  "investigate_KRI_data",
                  "contact_site_for_clarification",
                  "determine_if_on-site_visit_is_required"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The implementation of a quality management system with quality tolerance limits (p157) implies the use of KRIs and a defined response to their breach. A triggered visit or action is the logical execution of such a system, although not explicitly detailed in the protocol.",
                    "supporting_context": [
                      "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "close_out_visit": {
              "timing": "after_LPLV",
              "timing_days_after_event": 60,
              "format": "on_site",
              "activities": [
                "final_SDV",
                "final_drug_accountability_and_reconciliation",
                "essential_document_collection",
                "archiving_preparation"
              ],
              "site_release_criteria": [
                "all_CRFs_complete",
                "all_queries_resolved",
                "all_SAEs_reconciled",
                "final_IRB_report_filed"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.5.7",
                  "page_number": 111,
                  "text_snippet": "An overall accountability of the study treatment will be performed and verified by AbbVie or the designated monitor(s) throughout the study and at the study site Closeout Visit."
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol describes different phases of site engagement, including a 'study training visit' (SIV), ongoing monitoring 'throughout the study', and a 'Closeout Visit'. This structure forms the basis of the monitoring visit plan.",
                "supporting_context": [
                  "Page 157: ...a study training visit will be held...",
                  "Page 157: The AbbVie monitor will monitor the study site throughout the study.",
                  "Page 111: ...and at the study site Closeout Visit."
                ],
                "confidence": "high"
              }
            }
          },
          "key_risk_indicators": [
            {
              "id": "KRI-001",
              "instanceType": "KeyRiskIndicator",
              "name": "Informed Consent Compliance",
              "category": "protocol_compliance",
              "metric": "Percentage of subjects with informed consent signed and dated prior to any study-specific procedures.",
              "data_source": "EDC",
              "review_frequency": "weekly",
              "threshold_green": "100%",
              "threshold_amber": "N/A",
              "threshold_red": "<100%",
              "action_amber": "N/A",
              "action_red": "Immediate site follow-up for any deviation, root cause analysis, and CAPA initiation.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "9.3",
                  "page_number": 153,
                  "text_snippet": "Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject..."
                }
              }
            },
            {
              "id": "KRI-002",
              "instanceType": "KeyRiskIndicator",
              "name": "Primary Endpoint Data Availability",
              "category": "data_integrity",
              "metric": "Percentage of expected IMWG assessments for PFS evaluation that are missing or incomplete at scheduled timepoints.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<2%",
              "threshold_amber": "2-5%",
              "threshold_red": ">5%",
              "action_amber": "Review with site to understand reasons for missing data and reinforce importance of timely entry.",
              "action_red": "Escalate to project manager, targeted retraining for site, potential triggered visit.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "8.1.3.1",
                  "page_number": 138,
                  "text_snippet": "The primary endpoint is PFS based on IMWG criteria for multiple myeloma (Appendix J)13,14 per IRC assessment."
                }
              }
            },
            {
              "id": "KRI-003",
              "instanceType": "KeyRiskIndicator",
              "name": "SAE Reporting Timeliness",
              "category": "patient_safety",
              "metric": "Percentage of SAEs reported to the sponsor within the protocol-specified 24-hour timeframe.",
              "data_source": "Safety DB",
              "review_frequency": "weekly",
              "threshold_green": "100%",
              "threshold_amber": "90-99%",
              "threshold_red": "<90%",
              "action_amber": "Follow up with site on late reports to identify process gaps.",
              "action_red": "Immediate site retraining on SAE reporting procedures, investigate for systemic issues.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "6.1.5",
                  "page_number": 119,
                  "text_snippet": "In the event of a serious adverse event, whether associated with the study treatment or not, the Investigator will notify Clinical Pharmacovigilance within 24 hours of the site being made aware of the serious adverse event..."
                }
              }
            },
            {
              "id": "KRI-004",
              "instanceType": "KeyRiskIndicator",
              "name": "Major Protocol Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Number of major protocol deviations per subject enrolled at a site.",
              "data_source": "CTMS",
              "review_frequency": "monthly",
              "threshold_green": "<0.1",
              "threshold_amber": "0.1-0.2",
              "threshold_red": ">0.2",
              "action_amber": "Review deviation details and discuss trends with site.",
              "action_red": "Investigate root cause, implement CAPA, consider enrollment hold if trends continue.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "7.0",
                  "page_number": 135,
                  "text_snippet": "Protocol Deviations. AbbVie does not allow intentional/prospective deviations from the protocol unless when necessary to eliminate an immediate hazard to study subjects."
                }
              }
            },
            {
              "id": "KRI-005",
              "instanceType": "KeyRiskIndicator",
              "name": "Visit Compliance Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of scheduled study visits completed within the protocol-defined window.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": ">95%",
              "threshold_amber": "90-95%",
              "threshold_red": "<90%",
              "action_amber": "Discuss scheduling challenges with site and review subject compliance.",
              "action_red": "Investigate reasons for out-of-window visits, provide additional support or training to site.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.1",
                  "page_number": 40,
                  "text_snippet": "Unless otherwise noted, cycle visits may be completed within a window of ± 1 day provided the 72-hour bortezomib requirement is kept."
                }
              }
            },
            {
              "id": "KRI-006",
              "instanceType": "KeyRiskIndicator",
              "name": "Screen Failure Rate",
              "category": "enrollment",
              "metric": "Percentage of screened subjects who fail to be randomized.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<30%",
              "threshold_amber": "30-50%",
              "threshold_red": ">50%",
              "action_amber": "Analyze screen failure reasons for trends.",
              "action_red": "Discuss eligibility criteria interpretation with site, provide clarification or retraining.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.1",
                  "page_number": 40,
                  "text_snippet": "Subjects who do not randomize within 21 days of screening will be screen-failed."
                }
              }
            },
            {
              "id": "KRI-007",
              "instanceType": "KeyRiskIndicator",
              "name": "Drug Accountability Discrepancy Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of monitoring visits with identified discrepancies in venetoclax/placebo accountability logs.",
              "data_source": "Monitoring Reports",
              "review_frequency": "monthly",
              "threshold_green": "0%",
              "threshold_amber": "1-5%",
              "threshold_red": ">5%",
              "action_amber": "Review findings with site and reinforce procedures.",
              "action_red": "Retraining on drug handling and accountability procedures; investigate for potential unblinding risk.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.5.7",
                  "page_number": 111,
                  "text_snippet": "A current (running) and accurate inventory of study treatment will be kept by the site and will include lot number, Proof of Receipt number(s), bottle numbers, and the date on which the study treatment is dispensed or administered to the subject."
                }
              }
            },
            {
              "id": "KRI-008",
              "instanceType": "KeyRiskIndicator",
              "name": "Rate of Grade 3/4 Cytopenias",
              "category": "patient_safety",
              "metric": "Rate of Grade 3 or higher neutropenia or thrombocytopenia per site.",
              "data_source": "EDC",
              "review_frequency": "biweekly",
              "threshold_green": "Below study average",
              "threshold_amber": "1-2 SD above study average",
              "threshold_red": ">2 SD above study average",
              "action_amber": "Review site's adherence to dose modification guidelines for toxicity.",
              "action_red": "Triggered review of site's toxicity management practices, potential for targeted training.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "6.1.7.1",
                  "page_number": 123,
                  "text_snippet": "Management of Cytopenias and Infection. Venetoclax could lead to suppression of lymphocytes (B and T sub-types). In addition, clinically significant neutropenia may also be observed in this study."
                }
              }
            }
          ],
          "quality_tolerance_limits": [
            {
              "id": "QTL-001",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Subjects without valid informed consent prior to study procedures",
              "category": "informed_consent",
              "acceptable_limit": "0%",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "N/A",
              "alert_threshold_numeric": 0,
              "action_threshold": "1 subject",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Immediate investigation and root cause analysis",
                "CAPA initiation",
                "Report to IRB/IEC and regulatory authorities as required"
              ],
              "escalation_path": [
                "Project Manager",
                "Head of Clinical Operations",
                "Sponsor QA"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "11.0",
                  "page_number": 157,
                  "text_snippet": "AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results."
                }
              }
            },
            {
              "id": "QTL-002",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects randomized who do not meet key eligibility criteria",
              "category": "eligibility",
              "acceptable_limit": "<2%",
              "acceptable_limit_numeric": 0.02,
              "alert_threshold": "1%",
              "alert_threshold_numeric": 0.01,
              "action_threshold": "2%",
              "action_threshold_numeric": 0.02,
              "predefined_actions": [
                "Halt enrollment across study",
                "Conduct root cause analysis of all eligibility deviations",
                "Retrain all sites on eligibility criteria",
                "Assess impact on study data integrity"
              ],
              "escalation_path": [
                "Medical Monitor",
                "Head of Clinical Development",
                "Steering Committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the critical nature of the study population defined in sections 5.2.1 and 5.2.2. Enrolling ineligible subjects directly threatens the integrity of the primary analysis. The concept of QTLs is established on page 157, and this parameter is a critical application of that concept.",
                  "supporting_context": [
                    "Page 157: ...define quality tolerance limits in order to ensure human subject protection and reliability of study results.",
                    "Page 7: Study Population: Adult male and female subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors..."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-003",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects in the ITT population with missing primary endpoint (PFS) assessment",
              "category": "endpoint_collection",
              "acceptable_limit": "<5%",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "3%",
              "alert_threshold_numeric": 0.03,
              "action_threshold": "5%",
              "action_threshold_numeric": 0.05,
              "predefined_actions": [
                "Investigate reasons for missing data (e.g., missed visits, data entry lag)",
                "Implement corrective actions to improve data collection",
                "Consult with statisticians on impact and potential analysis modifications"
              ],
              "escalation_path": [
                "Data Manager",
                "Biostatistician",
                "Head of Clinical Operations"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the critical importance of the primary endpoint, PFS, as stated in Section 4.0. Missing primary endpoint data directly impacts study power and the reliability of the results. The concept of QTLs is established on page 157.",
                  "supporting_context": [
                    "Page 38: The primary objective of the study is to compare PFS...",
                    "Page 157: ...define quality tolerance limits in order to ensure human subject protection and reliability of study results."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-004",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Study-wide rate of major protocol deviations impacting subject safety or primary endpoint integrity",
              "category": "protocol_compliance",
              "acceptable_limit": "<5%",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "3%",
              "alert_threshold_numeric": 0.03,
              "action_threshold": "5%",
              "action_threshold_numeric": 0.05,
              "predefined_actions": [
                "Conduct a cross-study analysis of deviation types and root causes",
                "Implement study-wide retraining or protocol clarification",
                "Assess potential need for protocol amendment"
              ],
              "escalation_path": [
                "Project Manager",
                "Medical Monitor",
                "Sponsor QA"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the general requirement to adhere to the protocol (Section 7.0) and ICH GCP (Section 9.2). A high rate of major deviations indicates a systemic failure in study conduct, threatening both safety and data integrity. The concept of QTLs is established on page 157.",
                  "supporting_context": [
                    "Page 135: Protocol Deviations",
                    "Page 152: The study will be conducted in accordance with the protocol, ICH GCP guidelines...",
                    "Page 157: ...define quality tolerance limits..."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-005",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Functional unblinding rate due to medication errors or accountability failures",
              "category": "protocol_compliance",
              "acceptable_limit": "0%",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "N/A",
              "alert_threshold_numeric": 0,
              "action_threshold": "1 event",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Investigate event immediately",
                "Quarantine affected drug supply",
                "Assess impact on subject and data integrity",
                "Implement study-wide CAPA to prevent recurrence"
              ],
              "escalation_path": [
                "Clinical Supplies Manager",
                "Head of Clinical Operations",
                "Steering Committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "This QTL is derived from the critical nature of maintaining the double-blind design (Section 5.5.5). Any unblinding event introduces bias and compromises the study's scientific validity. The acceptable limit must be zero. The concept of QTLs is established on page 157.",
                  "supporting_context": [
                    "Page 1: A Phase 3, Multicenter, Randomized, Double Blind Study...",
                    "Page 109: The Investigator, the study site personnel and the subject will remain blinded to each subject's treatment with venetoclax/placebo throughout the course of the study.",
                    "Page 157: ...define quality tolerance limits..."
                  ],
                  "confidence": "high"
                }
              }
            }
          ],
          "findings_management": {
            "instanceType": "FindingsManagement",
            "finding_categories": [
              {
                "id": "finding-cat-001",
                "category": "critical",
                "definition": "A finding that adversely affects the rights, safety, or well-being of a subject, or the integrity of the study data.",
                "response_timeline_days": 1,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard GCP principles for risk management. A 'critical' finding corresponds to issues that pose an 'immediate hazard' (p152) or significantly impact subject safety or data integrity, requiring immediate action.",
                    "supporting_context": [
                      "Page 152: ...Investigators should notify AbbVie if any urgent safety measures are taken to protect the subjects against any immediate hazard."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "finding-cat-002",
                "category": "major",
                "definition": "A finding that could potentially affect subject safety or data integrity, or represents a significant deviation from the protocol.",
                "response_timeline_days": 15,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard GCP principles. A 'major' finding corresponds to significant protocol deviations (p135) that, while not immediately critical, could impact study outcomes or subject welfare if not addressed.",
                    "supporting_context": [
                      "Page 135: Protocol Deviations"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "finding-cat-003",
                "category": "minor",
                "definition": "A finding that does not impact subject safety or data integrity but represents a departure from the protocol or GCP.",
                "response_timeline_days": 30,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is derived from standard GCP principles for issues that are departures from the protocol but do not meet the threshold of 'major' or 'critical'. These are typically administrative or procedural errors with low impact.",
                    "supporting_context": [
                      "Page 152: The study will be conducted in accordance with the protocol, ICH GCP guidelines..."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "capa_process": {
              "capa_triggers": [
                "critical_finding",
                "repeated_major_finding",
                "QTL_breach",
                "systemic_issue_identified_via_KRI_trending"
              ],
              "response_timeline_days": 30,
              "verification_required": true,
              "tracking_system": "Quality Management System",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The requirement for a CAPA process is inferred from the overall commitment to a quality management system (p157) and adherence to ICH GCP (p152), which mandates corrective and preventive actions for non-compliance. Specific triggers and timelines are based on standard industry practice.",
                  "supporting_context": [
                    "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system...",
                    "Page 152: The study will be conducted in accordance with the protocol, ICH GCP guidelines..."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "protocol_deviation_management": {
              "deviation_categories": [
                "major",
                "minor"
              ],
              "internal_reporting_timeline_days": 5,
              "irb_reporting_required": true,
              "irb_reporting_timeline_days": 10,
              "root_cause_analysis_required": true,
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "7.0",
                  "page_number": 135,
                  "text_snippet": "Protocol Deviations. AbbVie does not allow intentional/prospective deviations from the protocol unless when necessary to eliminate an immediate hazard to study subjects. The Principal Investigator is responsible for complying with all protocol requirements... If a protocol deviation occurs... the Principal Investigator is responsible for notifying IEC/IRB regulatory authorities..."
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol's requirements for managing protocol deviations (Section 7.0) and its overall adherence to a quality management system (Section 11.0) and GCP (Section 9.2) form the basis for a structured findings management process.",
                "supporting_context": [
                  "Page 135: Protocol Deviations",
                  "Page 157: Data Quality Assurance",
                  "Page 152: Ethical Conduct of the Study"
                ],
                "confidence": "high"
              }
            }
          },
          "monitoring_reports": {
            "report_types": [
              "Site Initiation Visit Report",
              "Interim Monitoring Visit Report",
              "Remote Monitoring Report",
              "Close-out Visit Report"
            ],
            "submission_timeline_days": 10,
            "review_and_approval_workflow": [
              "Monitor",
              "Clinical Research Manager",
              "Project Manager"
            ],
            "storage_location": "eTMF",
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The requirement to create monitoring reports is a fundamental aspect of GCP and is implied by the investigator's responsibility to maintain 'adequate and accurate records' and make them 'available for inspection' (p167, Appendix A). The specific report types, timelines, and workflows are standard industry practices for fulfilling this requirement, though not explicitly detailed in the protocol.",
                "supporting_context": [
                  "Page 167: Maintaining adequate and accurate records of the conduct of the study, making those records available for inspection by representatives of AbbVie...",
                  "Page 157: The AbbVie monitor will monitor the study site throughout the study."
                ],
                "confidence": "medium"
              }
            }
          },
          "provenance": {
            "kind": "explicit",
            "explicit": {
              "section_number": "11.0",
              "page_number": 157,
              "text_snippet": "Data Quality Assurance. AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results."
            }
          }
        },
        "rbqm": {
          "ract_register": {
            "critical_to_quality_factors": [
              {
                "ctq_id": "CTQ-001",
                "ctq_category": "Endpoint Integrity",
                "factor": "Accurate and timely assessment of Progression-Free Survival (PFS) per IMWG criteria.",
                "insight_type": "explicit",
                "clinical_reasoning": "PFS is the primary efficacy endpoint. Inaccurate or delayed progression assessment directly impacts the study's ability to evaluate the treatment effect and can lead to a failed study.",
                "failure_mode": "Disease progression is missed, incorrectly assessed, or reported late, leading to misclassification of PFS events and biased results.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 45,
                "affected_stakeholders": [
                  "Sponsor",
                  "Patient",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Detailed protocol definitions for disease assessment and progression",
                  "Centralized training for investigators on IMWG criteria",
                  "Use of a certified central laboratory for all myeloma lab tests"
                ],
                "detective_controls": [
                  "Independent Review Committee (IRC) for blinded assessment of disease progression",
                  "Centralized monitoring of assessment schedules and data entry"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.0",
                    "page_number": 38,
                    "text_snippet": "The primary objective of the study is to compare PFS based on the IMWG Criteria,13,14 as determined by an Independent Review Committee (IRC) between treatment arms..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-002",
                "ctq_category": "Patient Safety",
                "factor": "Effective management of known treatment-related toxicities, especially cytopenias, infections, and Tumor Lysis Syndrome (TLS).",
                "insight_type": "explicit",
                "clinical_reasoning": "Venetoclax and bortezomib have known safety profiles including neutropenia, lymphopenia, and risk of infection. Failure to manage these can lead to serious adverse events, treatment discontinuation, or death.",
                "failure_mode": "Sites fail to implement required prophylaxis, miss early signs of toxicity, or do not follow dose modification guidelines, leading to severe AEs.",
                "severity_score": 5,
                "probability_score": 4,
                "detectability_score": 2,
                "risk_priority_number": 40,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Mandatory antibiotic prophylaxis",
                  "Prophylactic measures for TLS (e.g., hydration)",
                  "Clear dose modification and management guidelines in the protocol"
                ],
                "detective_controls": [
                  "Frequent laboratory monitoring as per schedule of assessments",
                  "Centralized monitoring of lab value KRIs"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.1.7",
                    "page_number": 123,
                    "text_snippet": "Toxicity Management"
                  }
                }
              },
              {
                "ctq_id": "CTQ-003",
                "ctq_category": "GCP Compliance",
                "factor": "Maintenance of the study blind for venetoclax/placebo.",
                "insight_type": "explicit",
                "clinical_reasoning": "The study is double-blind. Any breach of the blind, whether intentional or accidental, introduces bias and can invalidate the results for the affected subject or site, potentially compromising the entire study.",
                "failure_mode": "Errors in drug dispensing, labeling, or accountability lead to the unblinding of site staff or subjects.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 4,
                "risk_priority_number": 40,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Use of a validated Interactive Response Technology (IRT) system for randomization and drug assignment",
                  "Identical packaging and labeling for active drug and placebo",
                  "Strict procedures for emergency unblinding"
                ],
                "detective_controls": [
                  "Rigorous drug accountability checks during monitoring visits",
                  "Monitoring of unblinding requests via IRT"
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.0",
                    "page_number": 1,
                    "text_snippet": "A Phase 3, Multicenter, Randomized, Double Blind Study..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-004",
                "ctq_category": "Data Quality",
                "factor": "Accurate collection and reporting of Patient-Reported Outcomes (PROs).",
                "insight_type": "explicit",
                "clinical_reasoning": "PROs are key secondary endpoints used to evaluate the treatment's impact on quality of life (e.g., pain, fatigue). Incomplete or biased PRO data undermines the ability to assess these important outcomes.",
                "failure_mode": "Subjects do not complete PROs at the specified timepoints, or site staff inappropriately influence subject responses, leading to missing or unreliable data.",
                "severity_score": 3,
                "probability_score": 4,
                "detectability_score": 3,
                "risk_priority_number": 36,
                "affected_stakeholders": [
                  "Sponsor",
                  "Patient"
                ],
                "preventive_controls": [
                  "Use of an electronic PRO (ePRO) system to ensure timely completion",
                  "Site training on proper administration of PROs and avoiding bias",
                  "Clear instructions for subjects"
                ],
                "detective_controls": [
                  "ePRO system flags for missing assessments",
                  "Centralized review of PRO completion rates"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.0",
                    "page_number": 38,
                    "text_snippet": "The secondary objectives are to compare, between treatment arms, the following: ... patient reported outcomes (PRO) including Worst Pain (Brief Pain Inventory – Short Form [BPI-SF]), Physical Functioning and Global Health Status (GHS)/Quality of Life (QoL)..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-005",
                "ctq_category": "Regulatory Compliance",
                "factor": "Adherence to eligibility criteria, particularly regarding prior proteasome inhibitor sensitivity.",
                "insight_type": "explicit",
                "clinical_reasoning": "The study population is specifically defined as subjects sensitive or naïve to proteasome inhibitors. Enrolling refractory subjects would violate the protocol, introduce heterogeneity, and confound the primary analysis.",
                "failure_mode": "Sites misinterpret or mis-document a subject's prior treatment history and response, leading to the enrollment of ineligible subjects.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 30,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulators"
                ],
                "preventive_controls": [
                  "Clear, unambiguous eligibility criteria in the protocol",
                  "Mandatory source documentation of prior therapies and responses",
                  "Investigator training on eligibility assessment"
                ],
                "detective_controls": [
                  "100% SDV of all eligibility criteria for all subjects",
                  "Medical monitoring review of complex cases"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.2.1",
                    "page_number": 45,
                    "text_snippet": "Prior treatment with bortezomib or other proteasome inhibitor is allowed, provided ALL of the following criteria are met: Disease is NOT refractory to any proteasome inhibitor..."
                  }
                }
              },
              {
                "ctq_id": "CTQ-006",
                "ctq_category": "Patient Safety",
                "factor": "Correct handling of drug-drug interactions, especially with strong/moderate CYP3A inhibitors.",
                "insight_type": "explicit",
                "clinical_reasoning": "Venetoclax is metabolized by CYP3A. Concomitant use of strong inhibitors can significantly increase venetoclax exposure, leading to increased risk of severe toxicity. Failure to manage this risk can be life-threatening.",
                "failure_mode": "A prohibited or cautionary concomitant medication is administered without the required venetoclax dose reduction, leading to overdose and toxicity.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 45,
                "affected_stakeholders": [
                  "Patient",
                  "Site"
                ],
                "preventive_controls": [
                  "Clear list of prohibited and cautionary medications in the protocol",
                  "Specific dose reduction guidelines for use with CYP3A inhibitors",
                  "Training for investigators and site pharmacists"
                ],
                "detective_controls": [
                  "Thorough review of concomitant medications at every study visit",
                  "EDC alerts for prohibited medications"
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.2.2",
                    "page_number": 130,
                    "text_snippet": "Dose Modifications for Moderate or Strong CYP3A Inhibitors Used with Venetoclax/Placebo. Use of venetoclax/placebo with moderate or strong CYP3A4 inhibitors should be avoided and the investigator should consider alternative medications."
                  }
                }
              }
            ],
            "emergent_systemic_risks": [
              {
                "risk_id": "ESR-001",
                "risk_type": "cross_domain",
                "risk_description": "The COVID-19 pandemic causes widespread disruption to study conduct, affecting patient visits, drug supply, lab sample collection, and data quality.",
                "discovery_reasoning": "Explicitly identified in the protocol with numerous 'COVID-19 Pandemic-Related Acceptable Protocol Modification' sections.",
                "affected_domains": [
                  "Data Collection",
                  "IMP Supply Chain",
                  "Operational",
                  "Endpoints"
                ],
                "trigger_conditions": "Local or national travel restrictions, healthcare system overload, subject or site staff infection/quarantine.",
                "probability": "Almost Certain",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Primary Efficacy",
                  "Timeline",
                  "Patient Safety"
                ],
                "quantitative_estimate": "Potential for >10% missing data for key assessments if not managed.",
                "preventive_redesign": "N/A (external event)",
                "monitoring_approach": "Track site status, local regulations, and rates of remote vs. on-site visits. Monitor for increases in missed visits or delayed data entry.",
                "contingency_plan": "Implement protocol-defined modifications: remote visits, direct-to-patient drug shipment, use of local labs, remote monitoring/SDV.",
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-002",
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.1",
                    "page_number": 3,
                    "text_snippet": "The purpose of this amendment is to incorporate necessary protocol modifications due to the COVID-19 pandemic..."
                  }
                }
              },
              {
                "risk_id": "ESR-002",
                "risk_type": "interaction_effect",
                "risk_description": "Complexity of the dosing regimen (two different cycle lengths, multiple drugs with different schedules) combined with unblinding procedures creates a high risk of medication errors, especially after unblinding.",
                "discovery_reasoning": "Inferred from the transition from 21-day cycles (1-8) to 35-day cycles (9+), and specific instructions for discontinuing placebo but continuing other drugs post-unblinding.",
                "affected_domains": [
                  "IMP",
                  "Operational",
                  "Blinding"
                ],
                "trigger_conditions": "Transition from Cycle 8 to Cycle 9; unblinding of the study.",
                "probability": "Likely",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Patient Safety",
                  "Data Quality"
                ],
                "quantitative_estimate": "Potential for 5-10% of subjects to have a dosing error post-unblinding if not managed.",
                "preventive_redesign": "Simplify the post-unblinding treatment schedule in the protocol design phase.",
                "monitoring_approach": "KRI on dosing errors reported in EDC. Increased scrutiny of dosing logs during monitoring visits around Cycle 9 and post-unblinding.",
                "contingency_plan": "Provide sites with clear post-unblinding dosing charts and instructions. Retrain sites on the new schedule as unblinding approaches.",
                "linked_ctq_ids": [
                  "CTQ-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.1",
                    "page_number": 41,
                    "text_snippet": "Cycles 1 – 8, 21-day cycle length... Cycles 9 and beyond, 35-day cycle length"
                  }
                }
              },
              {
                "risk_id": "ESR-003",
                "risk_type": "second_order",
                "risk_description": "The partial clinical hold mentioned in the protocol (page 5) may create a negative perception of the study drug, leading to difficulties in subject recruitment and retention, and increased scrutiny from IRBs/IECs.",
                "discovery_reasoning": "Explicitly mentioned on page 5: 'due to the partial clinical hold, they are not able to be rolled over into an extension study.'",
                "affected_domains": [
                  "Subject Population",
                  "Regulatory Compliance",
                  "Operational"
                ],
                "trigger_conditions": "Site activation and subject recruitment phases.",
                "probability": "Possible",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Timeline",
                  "Enrollment Targets"
                ],
                "quantitative_estimate": "Potential 20-30% increase in time to full enrollment.",
                "preventive_redesign": "N/A (external event)",
                "monitoring_approach": "Track enrollment rates against projections (SKRI). Monitor screen failure reasons for subject concerns about safety. Track IRB/IEC query themes.",
                "contingency_plan": "Develop clear communication materials for sites and IRBs explaining the context of the hold. Increase number of planned sites or expand recruitment efforts.",
                "linked_ctq_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.1",
                    "page_number": 5,
                    "text_snippet": "Rationale: after the unblinding, study subjects who are benefiting from study treatment will be able to continue in the study as, due to the partial clinical hold, they are not able to be rolled over into an extension study."
                  }
                }
              },
              {
                "risk_id": "ESR-004",
                "risk_type": "cross_domain",
                "risk_description": "The final OS analysis triggers study unblinding and a significant change in study procedures (e.g., discontinuation of placebo, changes in monitoring), which can lead to confusion and errors in execution during the final phase of the study.",
                "discovery_reasoning": "Inferred from multiple sections stating procedures will change 'once the final OS analysis is complete' or 'once subjects are unblinded'.",
                "affected_domains": [
                  "Endpoints",
                  "Blinding",
                  "Data Collection",
                  "Operational"
                ],
                "trigger_conditions": "Achievement of the required number of OS events (approx. 116).",
                "probability": "Almost Certain",
                "impact_severity": "Moderate",
                "affected_objectives": [
                  "Data Quality",
                  "Operational Feasibility"
                ],
                "quantitative_estimate": "Risk of procedural errors at 10-15% of sites during the transition period.",
                "preventive_redesign": "Create a detailed 'End of Blinding' operational plan as part of study startup documents.",
                "monitoring_approach": "Monitor progress towards final OS events. Proactively communicate with sites as the event trigger approaches.",
                "contingency_plan": "Issue a study-wide notification with clear instructions on procedural changes upon unblinding. Host a webinar for all site staff to review the changes.",
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "1.1",
                    "page_number": 4,
                    "text_snippet": "Rationale: the final OS analysis is planned for when approximately 116 OS events occur. All objectives specified in the protocol will be completed with the final OS analysis and therefore from a statistics/scientific perspective: 1) maintaining the study blind is not required 2) all data considered for analysis per protocol can be considered mature."
                  }
                }
              }
            ],
            "strategic_risk_indicators": [
              {
                "kri_id": "SKRI-001",
                "kri_type": "leading_indicator",
                "category": "Risk Velocity",
                "metric": "Monthly rate of change in the number of open queries older than 30 days.",
                "rationale": "A rapid increase in aging queries indicates that sites are becoming overwhelmed or disengaged, which is a leading indicator of future data quality issues and potential delays in database lock.",
                "predictive_value": "Predicts downstream delays in data cleaning and database lock, and potential for unresolved data discrepancies in the final dataset.",
                "calculation_formula": "((Current Month's Count of Queries >30 days) - (Previous Month's Count)) / (Previous Month's Count)",
                "data_sources": [
                  "EDC"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<10%",
                    "interpretation": "Normal query resolution workload."
                  },
                  "amber": {
                    "range": "10-25%",
                    "interpretation": "Potential site workload issue; monitor site-specific trends.",
                    "escalation": "Project Manager, Lead CRA"
                  },
                  "red": {
                    "range": ">25%",
                    "interpretation": "Systemic issue with data entry or site responsiveness; immediate intervention required.",
                    "escalation": "Head of Data Management, Head of Clinical Operations"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-001",
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This is a standard RBQM metric. It is derived from the protocol's requirement for accurate and timely data entry (p155) and the overall goal of ensuring data quality (p157). Monitoring query aging is a leading indicator of a site's ability to meet these requirements.",
                    "supporting_context": [
                      "Page 155: The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.",
                      "Page 157: Data Quality Assurance"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "kri_id": "SKRI-002",
                "kri_type": "leading_indicator",
                "category": "Operational Health",
                "metric": "Ratio of early terminations (non-PD) to randomized subjects, trended over time.",
                "rationale": "An increasing rate of early terminations for reasons other than progressive disease (e.g., AE, withdrawal of consent) can be a leading indicator of tolerability issues, patient burden, or poor site management.",
                "predictive_value": "Predicts potential safety signals, challenges in interpreting ITT analysis due to high dropout, and failure to meet the required number of events for analysis.",
                "calculation_formula": "(Number of subjects who discontinued for reasons other than PD in a given quarter) / (Total subjects randomized in that quarter)",
                "data_sources": [
                  "EDC",
                  "CTMS"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "<5%",
                    "interpretation": "Expected dropout rate."
                  },
                  "amber": {
                    "range": "5-10%",
                    "interpretation": "Monitor trend and analyze reasons for discontinuation.",
                    "escalation": "Medical Monitor, Project Manager"
                  },
                  "red": {
                    "range": ">10%",
                    "interpretation": "Significant issue with tolerability or study conduct; requires urgent investigation.",
                    "escalation": "IDMC, Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-002"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This metric is derived from the protocol's discontinuation criteria (Section 5.4.1). Monitoring the rate of discontinuation for reasons other than disease progression (e.g., unacceptable toxicity) provides a high-level strategic view of study-wide tolerability and patient retention, which are critical to study success.",
                    "supporting_context": [
                      "Page 99: Discontinuation of Individual Subjects from Treatment",
                      "Page 99: Unacceptable toxicity;"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-003",
                "kri_type": "leading_indicator",
                "category": "Quality Trajectory",
                "metric": "Percentage of sites requiring a CAPA plan.",
                "rationale": "This metric provides a high-level view of systemic quality issues. A rising trend indicates that initial training and routine monitoring are insufficient, predicting widespread compliance problems.",
                "predictive_value": "Predicts future audit findings, increased risk of regulatory non-compliance, and potential data integrity issues across the study.",
                "calculation_formula": "(Number of sites with an active CAPA) / (Total number of activated sites)",
                "data_sources": [
                  "CTMS",
                  "Quality Management System"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "<5%",
                    "interpretation": "Isolated site-specific issues."
                  },
                  "amber": {
                    "range": "5-15%",
                    "interpretation": "Potential for systemic issues; analyze CAPA root causes for trends.",
                    "escalation": "Head of Clinical Operations"
                  },
                  "red": {
                    "range": ">15%",
                    "interpretation": "Widespread quality or compliance failure; requires study-level intervention.",
                    "escalation": "Sponsor QA, Executive Management"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This strategic indicator is derived from the overall quality management framework implied by the protocol (p157). Tracking the proportion of sites that require intensive corrective action (CAPA) provides a macro-level view of the overall health and compliance of the study, which is a key component of strategic risk management.",
                    "supporting_context": [
                      "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system...",
                      "Page 152: The study will be conducted in accordance with the protocol, ICH GCP guidelines..."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "strategic_summary": {
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A strategic summary is a synthesis of the RACT register's findings. It is not a direct extraction but an output of the risk assessment process itself, which is based on the entire protocol. Its existence is implied by the adoption of a risk-based quality management approach.",
                  "supporting_context": [
                    "Page 157: Data Quality Assurance"
                  ],
                  "confidence": "high"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The Risk Assessment and Categorization Tool (RACT) register is not an explicit document within the protocol. It is a standard RBQM artifact created based on a thorough review of the protocol to identify critical data/processes, assess risks, and plan mitigations, as required by modern GCP standards and the protocol's stated commitment to a quality management system.",
                "supporting_context": [
                  "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results."
                ],
                "confidence": "high"
              }
            }
          },
          "risk_governance": {
            "risk_assessment_matrix": {
              "scoring_methodology": {
                "probability_scale": {
                  "1": "Rare (<5%)",
                  "2": "Unlikely (5-20%)",
                  "3": "Possible (20-50%)",
                  "4": "Likely (50-80%)",
                  "5": "Almost Certain (>80%)"
                },
                "impact_scale": {
                  "1": "Negligible",
                  "2": "Minor",
                  "3": "Moderate",
                  "4": "Major",
                  "5": "Catastrophic"
                },
                "risk_levels": {
                  "1-4": "Low",
                  "5-9": "Medium",
                  "10-14": "High",
                  "15-25": "Critical"
                }
              },
              "identified_risks": [
                {
                  "risk_id": "RISK-001",
                  "risk_category": "Endpoints",
                  "risk_description": "Inconsistent application of IMWG criteria for disease progression across sites leads to variability and bias in the primary endpoint (PFS).",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 3,
                    "score": 6,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 60,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-001",
                    "MIT-002"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.3.7.2",
                      "page_number": 92,
                      "text_snippet": "IMWG Criteria for Response and Progression. Subjects will be assessed for response using the IMWG response criteria (Appendix J)."
                    }
                  }
                },
                {
                  "risk_id": "RISK-002",
                  "risk_category": "Safety",
                  "risk_description": "Failure to adhere to dose modification rules for Grade 3/4 toxicities results in severe adverse events and potential subject harm.",
                  "risk_owner": "Investigator",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 5,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 60,
                  "linked_ctq_id": "CTQ-002",
                  "linked_mitigation_ids": [
                    "MIT-003"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "6.2",
                      "page_number": 125,
                      "text_snippet": "Guidelines for Dose Modifications and Treatment"
                    }
                  }
                },
                {
                  "risk_id": "RISK-003",
                  "risk_category": "Blinding",
                  "risk_description": "Accidental unblinding occurs due to errors in dispensing or drug accountability, compromising data integrity.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 5,
                    "score": 5,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-003",
                  "linked_mitigation_ids": [
                    "MIT-004"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.5.5",
                      "page_number": 109,
                      "text_snippet": "Blinding"
                    }
                  }
                },
                {
                  "risk_id": "RISK-005",
                  "risk_category": "Subject Population",
                  "risk_description": "Enrollment of subjects refractory to proteasome inhibitors, in violation of inclusion criteria.",
                  "risk_owner": "Investigator",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 4,
                    "score": 4,
                    "level": "Low"
                  },
                  "risk_reduction_percentage": 73,
                  "linked_ctq_id": "CTQ-005",
                  "linked_mitigation_ids": [
                    "MIT-005"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.2.2",
                      "page_number": 48,
                      "text_snippet": "Subject is refractory to any proteasome inhibitor, defined as progression on or within 60 days of the last dose of a proteasome inhibitor-containing regimen."
                    }
                  }
                },
                {
                  "risk_id": "RISK-006",
                  "risk_category": "IMP",
                  "risk_description": "Failure to implement venetoclax dose reduction when co-administered with a strong CYP3A inhibitor leads to overdose and toxicity.",
                  "risk_owner": "Investigator",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 47,
                  "linked_ctq_id": "CTQ-006",
                  "linked_mitigation_ids": [
                    "MIT-006"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.2.4.3",
                      "page_number": 56,
                      "text_snippet": "Strong and Moderate CYP3A inhibitors. Consider alternative medications. If subject requires use of these medications, use with caution and reduce the venetoclax dose..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-007",
                  "risk_category": "Operational",
                  "risk_description": "Study disruptions due to COVID-19 lead to significant amounts of missing data for primary and secondary endpoints.",
                  "risk_owner": "Sponsor",
                  "inherent_risk": {
                    "probability": 5,
                    "impact": 4,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 4,
                    "impact": 2,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 60,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-007"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "1.1",
                      "page_number": 3,
                      "text_snippet": "The purpose of this amendment is to incorporate necessary protocol modifications due to the COVID-19 pandemic..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-008",
                  "risk_category": "Data Collection",
                  "risk_description": "Poor compliance with ePRO completion results in insufficient data for key secondary endpoints.",
                  "risk_owner": "Patient",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 3,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 3,
                    "score": 6,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-004",
                  "linked_mitigation_ids": [
                    "MIT-008"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "6.3",
                      "page_number": 63,
                      "text_snippet": "Patient-Reported Outcome (PRO) Assessments. PRO assessments include BPI-SF, EORTC QLQ-C30, EORTC QLC-MY20, PROMIS Cancer Fatigue SF, and EQ-5D-5L."
                    }
                  }
                }
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The risk assessment matrix is a standard component of an RBQM system. Its structure and the identification of risks are derived from a systematic analysis of the protocol's critical factors (CTQs) and potential failure modes, guided by the principles of ICH E6(R2) and the quality management approach mentioned on page 157.",
                  "supporting_context": [
                    "Page 157: AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits..."
                  ],
                  "confidence": "high"
                }
              }
            },
            "mitigation_strategies": [
              {
                "mitigation_id": "MIT-001",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Detective",
                "control_category": "Oversight",
                "strategy_description": "Utilize a blinded Independent Review Committee (IRC) to adjudicate all potential PFS events based on central lab and imaging data.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of IRC charter and reconciliation of IRC assessments with site assessments.",
                "verification_frequency": "Per-analysis",
                "resource_requirements": "IRC vendor contract, data transfer infrastructure.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.3.7.3",
                    "page_number": 98,
                    "text_snippet": "Disease assessment for each post-baseline IMWG assessment will be performed by a team of independent multiple myeloma experts (IRC). The IRC will review subject data in a blinded fashion to provide the overall response assessment..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-002",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Preventive",
                "control_category": "Training",
                "strategy_description": "Mandatory training for all investigators and site staff on the application of IMWG response and progression criteria at SIV.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of training records and site performance on related KRIs.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Training materials, training personnel.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "11.0",
                    "page_number": 157,
                    "text_snippet": "Prior to enrolling any subject in the study, a study training visit will be held with AbbVie personnel, the Investigator(s), and the study coordinators/project manager(s). This meeting will include a detailed discussion and review of the protocol and essential documents..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-003",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Preventive",
                "control_category": "Protocol Design",
                "strategy_description": "Inclusion of specific, detailed tables and instructions in the protocol for dose modifications related to hematological and non-hematological toxicities.",
                "implementation_phase": "Protocol Design",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Monitor adherence to dose modification guidelines through data review.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Medical and statistical input during protocol development.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.2.1",
                    "page_number": 128,
                    "text_snippet": "Dose modifications and treatment guidelines for venetoclax/placebo-related toxicities are provided in Table 7 and Table 8."
                  }
                }
              },
              {
                "mitigation_id": "MIT-004",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "control_type": "Preventive",
                "control_category": "Systems and Technology",
                "strategy_description": "Employ a validated IRT system for randomization and management of investigational product supply to maintain the blind.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of IRT validation documentation and UAT results.",
                "verification_frequency": "Once at startup",
                "resource_requirements": "IRT vendor contract and configuration.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.3.1.1.1",
                    "page_number": 71,
                    "text_snippet": "Interactive Response Technology (IRT) will be utilized to register (screen, re-screen and randomize) subjects on study."
                  }
                }
              },
              {
                "mitigation_id": "MIT-005",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "control_type": "Detective",
                "control_category": "Monitoring",
                "strategy_description": "Perform 100% Source Data Verification (SDV) of all eligibility criteria, including review of source documents for prior treatment history.",
                "implementation_phase": "Conduct",
                "responsible_party": "Monitor (CRA)",
                "effectiveness_rating": "High",
                "verification_method": "Review of monitoring reports.",
                "verification_frequency": "Per monitoring visit",
                "resource_requirements": "Monitor time and resources.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This mitigation is a standard and necessary practice for a critical eligibility criterion. While the protocol doesn't state '100% SDV of eligibility', the monitor's role to ensure data is 'accurate, complete, and verifiable' (p155) and the critical nature of the eligibility criteria (p45, p48) make this a required action under a risk-based approach.",
                    "supporting_context": [
                      "Page 155: ...the reported trial data are accurate, complete, and verifiable...",
                      "Page 48: Exclusion Criteria 1. Subject is refractory to any proteasome inhibitor..."
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-006",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "control_type": "Preventive",
                "control_category": "Protocol Design",
                "strategy_description": "Provide a clear table of dose modifications for venetoclax when used with moderate or strong CYP3A inhibitors.",
                "implementation_phase": "Protocol Design",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of concomitant medication and dosing logs during monitoring.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Pharmacology expertise during protocol development.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.2.2",
                    "page_number": 130,
                    "text_snippet": "Table 9. Dose Modifications for Venetoclax/Placebo:* Moderate or Strong CYP3A Inhibitor Use"
                  }
                }
              },
              {
                "mitigation_id": "MIT-007",
                "linked_risk_ids": [
                  "RISK-007"
                ],
                "control_type": "Corrective",
                "control_category": "Process Adaptation",
                "strategy_description": "Implement pre-defined protocol modifications for COVID-19, including remote visits, direct-to-patient shipping, and use of local labs.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor/Investigator",
                "effectiveness_rating": "Medium",
                "verification_method": "Track use of alternative procedures and monitor impact on data quality and timeliness.",
                "verification_frequency": "Monthly",
                "resource_requirements": "Logistical support for DTP, contracts with local labs.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.5.1",
                    "page_number": 104,
                    "text_snippet": "COVID-19 Pandemic-Related Acceptable Protocol Modification: If a subject is unable to come to the study site to pick up their study drug due to COVID-19, a direct-to-patient (DTP) study drug shipment can be made..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-008",
                "linked_risk_ids": [
                  "RISK-008"
                ],
                "control_type": "Preventive",
                "control_category": "Systems and Technology",
                "strategy_description": "Use an ePRO system with automated reminders for subjects to complete questionnaires at the required timepoints.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Monitor ePRO compliance rates via vendor dashboard.",
                "verification_frequency": "Weekly",
                "resource_requirements": "ePRO vendor contract and device provisioning.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.2",
                    "page_number": 156,
                    "text_snippet": "Patient-reported data must be completed for each subject enrolled in this study. These data are being collected with an Electronic Patient Reported Outcome (ePRO) system called Trialmax..."
                  }
                }
              },
              {
                "mitigation_id": "MIT-009",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Preventive",
                "control_category": "Medical Intervention",
                "strategy_description": "Mandatory antibiotic prophylaxis (e.g., Bactrim, Levofloxacin) for subjects to reduce the risk of infection associated with neutropenia.",
                "implementation_phase": "Conduct",
                "responsible_party": "Investigator",
                "effectiveness_rating": "High",
                "verification_method": "Review of concomitant medication logs during monitoring.",
                "verification_frequency": "Per monitoring visit",
                "resource_requirements": "Subject access to prophylactic medications.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.1.7.1",
                    "page_number": 123,
                    "text_snippet": "All subjects receiving treatment with venetoclax/placebo in combination with a proteasome inhibitor must receive antibiotic prophylaxis with Bactrim forte® (1 tablet 3 times a week) or equivalent therapy while on treatment."
                  }
                }
              },
              {
                "mitigation_id": "MIT-010",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Preventive",
                "control_category": "Medical Intervention",
                "strategy_description": "Prophylaxis for Tumor Lysis Syndrome (TLS) with oral hydration and consideration of uric acid reducing agents for at-risk subjects.",
                "implementation_phase": "Conduct",
                "responsible_party": "Investigator",
                "effectiveness_rating": "High",
                "verification_method": "Review of subject charts and lab results for TLS monitoring.",
                "verification_frequency": "Per monitoring visit",
                "resource_requirements": "Site staff time for monitoring and patient education.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.1.7.2",
                    "page_number": 125,
                    "text_snippet": "Consider TLS prophylaxis with oral hydration (at least 1 – 2 liters, as tolerable, each day) in all subjects at least 72 hours prior to the first day of dosing with venetoclax/placebo."
                  }
                }
              }
            ],
            "safety_signal_detection": {
              "statistical_methods": [
                {
                  "method_id": "SSD-001",
                  "method_name": "Group Sequential Analysis for OS",
                  "method_description": "A stratified two-sided 3-look group sequential log-rank test with a cumulative two-sided type-I error rate of α = 0.05 is used to analyze Overall Survival (OS).",
                  "application": "Monitors OS for early evidence of efficacy or futility at pre-specified interim analyses.",
                  "data_requirements": [
                    "Time-to-event data for OS",
                    "Stratification factors"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.1.5.5.2",
                      "page_number": 146,
                      "text_snippet": "The OS will be analyzed by using a stratified two-sided 3-look group sequential log-rank test with a cumulative two-sided type-I error rate of α = 0.05 (one-sided type I error rate of α = 0.025)."
                    }
                  }
                }
              ],
              "stopping_rules": [
                {
                  "rule_id": "STOP-001",
                  "rule_type": "Efficacy",
                  "condition": "Pre-specified O'Brien-Fleming type boundaries are crossed for Overall Survival at an interim analysis.",
                  "threshold": "Group sequential plan using Lan and DeMets α-spending approach with O'Brien-Fleming type boundaries",
                  "action": "The IDMC may recommend stopping the study early for overwhelming efficacy.",
                  "decision_authority": "IDMC",
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.1.5.5.2",
                      "page_number": 151,
                      "text_snippet": "Group sequential plan using Lan and DeMets43 α-spending approach with O'Brien-Fleming type boundaries will be applied for the OS efficacy analyses."
                    }
                  }
                }
              ],
              "dsmb_interface": {
                "dsmb_required": true,
                "meeting_frequency": "Periodically",
                "review_scope": [
                  "Safety",
                  "Efficacy"
                ],
                "unblinding_criteria": "The IDMC will review safety and efficacy data in an unblinded fashion. A final review will occur once the final OS analysis is complete.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.5.5.2",
                    "page_number": 110,
                    "text_snippet": "An IDMC will periodically review the safety and efficacy data for this study in an un-blinded fashion. Aggregate blinded clinical safety and efficacy data will be reviewed on a real-time basis throughout the course of the study."
                  }
                }
              },
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The components of safety signal detection are described across multiple sections. The IDMC (p110) is responsible for safety and efficacy review, and the statistical plan (p146-151) details the group sequential analysis and stopping boundaries for OS, which are key mechanisms for formal signal detection.",
                  "supporting_context": [
                    "Page 110: Blinding of Data for Independent Data Monitoring Committee (IDMC)",
                    "Page 146: Interim Analysis",
                    "Page 151: Group sequential plan using Lan and DeMets..."
                  ],
                  "confidence": "high"
                }
              }
            },
            "issue_management_cascade": {
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "An issue management cascade is a standard component of a quality management system, but it is not explicitly detailed in the protocol. Its existence is inferred from the defined roles (Investigator, Sponsor, Monitor, IDMC) and the requirement to manage deviations, AEs, and quality issues in compliance with GCP.",
                  "supporting_context": [
                    "Page 157: Data Quality Assurance",
                    "Page 167: Responsibilities of the Clinical Investigator"
                  ],
                  "confidence": "medium"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "Risk governance is the overarching framework for managing study risks. The protocol establishes this framework by mandating a quality management system (p157), defining an IDMC for oversight (p110), and outlining processes for managing key risks like toxicities (p123) and deviations (p135).",
                "supporting_context": [
                  "Page 157: Data Quality Assurance",
                  "Page 110: Blinding of Data for Independent Data Monitoring Committee (IDMC)",
                  "Page 123: Toxicity Management"
                ],
                "confidence": "high"
              }
            }
          },
          "technology_config": {
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol specifies the use of several key technologies, including an EDC system (Rave, p155), an IRT system (p71), and an ePRO system (Trialmax, p156). The configuration of these systems to support RBQM (e.g., with alerts, dashboards) is inferred as a standard implementation practice.",
                "supporting_context": [
                  "Page 155: ...EDC system called Rave®...",
                  "Page 71: Interactive Response Technology (IRT) will be utilized...",
                  "Page 156: ...Electronic Patient Reported Outcome (ePRO) system called Trialmax..."
                ],
                "confidence": "high"
              }
            }
          },
          "provenance": {
            "kind": "explicit",
            "explicit": {
              "section_number": "11.0",
              "page_number": 157,
              "text_snippet": "AbbVie will ensure that the clinical trial is conducted with a quality management system that will define quality tolerance limits in order to ensure human subject protection and reliability of study results."
            }
          }
        },
        "extraction_statistics": {
          "has_monitoring_approach": true,
          "has_sdv_strategy": true,
          "has_monitoring_visits": true,
          "kri_count": 8,
          "qtl_count": 5,
          "ctq_count": 6,
          "emergent_risk_count": 4,
          "mitigation_strategy_count": 10,
          "identified_risks_count": 8,
          "has_ract_register": true,
          "has_risk_governance": true
        },
        "provenance": {
          "kind": "derived",
          "derived": {
            "reasoning": "The overall Quality Management object is derived from multiple sections of the protocol that describe monitoring, data quality, safety oversight, and risk mitigation (e.g., COVID-19 adaptations). While not consolidated under a single 'Quality Management' heading, these components collectively form the basis of the QM plan.",
            "supporting_context": [
              "Section 7.0 Protocol Deviations",
              "Section 10.0 Source Documents and Case Report Form Completion",
              "Section 11.0 Data Quality Assurance"
            ],
            "confidence": "high"
          }
        }
      },
      "_agentDocumentation": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents → Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "withdrawalProcedures": {
      "moduleId": "withdrawal_procedures",
      "instanceType": "WithdrawalProcedures",
      "data": {
        "id": "WP-001",
        "instanceType": "WithdrawalProcedures",
        "name": "Withdrawal and Discontinuation Procedures",
        "description": "Procedural specifications for subject withdrawal and discontinuation",
        "discontinuation_types": [
          {
            "id": "DT-001",
            "type_name": {
              "code": "TREATMENT_DISCONTINUATION",
              "decode": "Treatment Discontinuation"
            },
            "definition": "Withdrawal from study treatment due to disease progression, toxicity, noncompliance, pregnancy, or other specified reasons. Subjects remain on study for follow-up.",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "5.4.1",
              "page_number": 99,
              "text_snippet": "Discontinuation of Individual Subjects from Treatment\n\nEach subject has the right to withdraw from the study at any time. In addition, the Investigator may discontinue a subject from treatment at any time for any reason if the Investigator considers it necessary, including the occurrence of an adverse event or noncompliance with the protocol."
            }
          },
          {
            "id": "DT-002",
            "type_name": {
              "code": "STUDY_WITHDRAWAL",
              "decode": "Study Withdrawal"
            },
            "definition": "Subject decides to discontinue participation in study visits and procedures. Subject must also discontinue treatment but will be followed for Overall Survival (OS).",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "5.4.2",
              "page_number": 101,
              "text_snippet": "Withdrawal from Study Visits\n\nA subject may decide to discontinue participation in study visits and procedures. If subject withdraws from study visits, the subject must discontinue treatment, and the reason for withdrawal must be documented in the subject's medical record and signed by the Investigator. Subject will be followed for OS."
            }
          },
          {
            "id": "DT-003",
            "type_name": {
              "code": "PARTIAL_WITHDRAWAL",
              "decode": "Partial Withdrawal"
            },
            "definition": "Subject must request to be withdrawn specifically from survival follow-up. Public information sources may still be used to obtain survival status.",
            "allows_continued_followup": false,
            "provenance": {
              "section_number": "5.4.3",
              "page_number": 101,
              "text_snippet": "Withdrawal from Follow-Up\n\nSubject must request to be withdrawn specifically from survival follow-up; this request must be documented in the subject's medical record and signed by the Investigator. If the subject withdraws from survival follow-up, the site staff may use a public information source (such as county records) to obtain information about survival status only, as appropriate per local regulations."
            }
          }
        ],
        "consent_withdrawal": {
          "right_to_withdraw": "Each subject has the right to withdraw from the study at any time.",
          "withdrawal_process": "If a subject withdraws from study visits, the reason for withdrawal must be documented in the subject's medical record and signed by the Investigator.",
          "data_handling_options": [
            {
              "option": {
                "code": "RETAIN_ALL",
                "decode": "Retain All Data"
              },
              "description": "If a subject withdraws consent after their samples have already been tested, those results will still remain as part of the overall research data."
            }
          ],
          "sample_handling": "If a subject withdraws consent to participate from the study, stored biomarker samples will continue to be used for research and analysis. If a subject would like to withdraw consent for research using these samples, the subject may request that their samples be withdrawn. Once AbbVie receives the request, remaining biomarker samples will be destroyed.",
          "consequences": "No penalty or loss of benefits for withdrawing from the study.",
          "provenance": {
            "section_number": "9.3",
            "page_number": 153,
            "text_snippet": "The Investigator or his/her representative will explain the nature of the study to the subject, and answer all questions regarding this study. Prior to any study-related screening procedures being performed on the subject, the informed consent statement will be reviewed and signed and dated by the subject... In the event a subject withdraws consent to participate from the study, stored biomarker samples will continue to be used for research and analysis."
          }
        },
        "discontinuation_visit": {
          "timing": "A Treatment Completion Visit (TCV) will be completed at the end of the subject's treatment. A Safety Follow-Up Visit should be performed approximately 30 days following the last dose of treatment.",
          "timing_days_from_last_dose": 30,
          "required_assessments": [
            {
              "id": "ASS-001",
              "assessment_type": {
                "code": "AE_REVIEW",
                "decode": "Adverse Event Review"
              },
              "assessment_name": "Adverse Event Assessments",
              "mandatory": true
            },
            {
              "id": "ASS-002",
              "assessment_type": {
                "code": "CONMED_REVIEW",
                "decode": "Concomitant Medication Review"
              },
              "assessment_name": "Concomitant Medications Assessments",
              "mandatory": true
            },
            {
              "id": "ASS-003",
              "assessment_type": {
                "code": "PHYSICAL_EXAM",
                "decode": "Physical Examination"
              },
              "assessment_name": "Physical Examination",
              "mandatory": true
            },
            {
              "id": "ASS-004",
              "assessment_type": {
                "code": "VITAL_SIGNS",
                "decode": "Vital Signs"
              },
              "assessment_name": "Vital Signs",
              "mandatory": true
            },
            {
              "id": "ASS-005",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory Tests"
              },
              "assessment_name": "IMWG disease assessments",
              "mandatory": false
            },
            {
              "id": "ASS-006",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "Return of study drug",
              "mandatory": true
            },
            {
              "id": "ASS-007",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory Tests"
              },
              "assessment_name": "Pregnancy Test (if applicable)",
              "mandatory": true
            }
          ],
          "documentation_requirements": [],
          "provenance": {
            "section_number": "5.4.1",
            "page_number": 99,
            "text_snippet": "At the end of the subject's treatment, a TCV will be completed.\n\nA Safety Follow-Up Visit should be performed for all subjects approximately 30 days following last dose of treatment."
          }
        },
        "post_discontinuation_followup": {
          "safety_followup": {
            "duration_days": 30,
            "duration_description": "A Safety Follow-Up Visit should be performed for all subjects approximately 30 days following last dose of treatment.",
            "assessments": [
              "Concomitant Medications and Adverse Event Assessments",
              "Physical Examination",
              "Vital Signs",
              "Pregnancy Test",
              "Subsequent myeloma therapy, and Response"
            ],
            "contact_method": {
              "code": "IN_PERSON",
              "decode": "In-person visit"
            }
          },
          "survival_followup": {
            "required": true,
            "frequency": "Approximately every 12 weeks",
            "duration": "Until death, the subject is lost to follow-up, the subject withdraws consent, the number of OS events required for the final OS analysis is reached, or the study is terminated by AbbVie, whichever occurs first.",
            "information_collected": [
              "Survival status (alive or deceased)",
              "Date and cause of death (if deceased)",
              "Post-therapy regimens (name, initiation and completion dates)"
            ]
          },
          "ae_followup": {
            "ongoing_ae_followup": true,
            "followup_until": "satisfactory clinical resolution"
          },
          "provenance": {
            "section_number": "5.3.1.1.2",
            "page_number": 72,
            "text_snippet": "Follow-Up\n\nAfter treatment has ended, subjects will be followed for post-therapy information, overall survival, non-treatment emergent death information, and progressive disease (if applicable)."
          }
        },
        "lost_to_followup": null,
        "replacement_strategy": {
          "allows_replacement": false,
          "provenance": {
            "section_number": "5.1",
            "page_number": 39,
            "text_snippet": "Approximately 280 subjects at approximately 120 sites will be randomized in a 2:1 ratio to receive an oral daily dose of either venetoclax 800 mg or placebo plus Bd, respectively. The study is designed to meet scientific and regulatory objectives without enrolling an undue number of subjects in alignment with ethical considerations. Therefore, if the target number of subjects has been enrolled, there is a possibility that additional subjects in screening will not be enrolled."
          }
        },
        "administrative_withdrawal": {
          "reasons": [
            {
              "id": "AWR-001",
              "reason_type": {
                "code": "STUDY_TERMINATION",
                "decode": "Study Termination"
              },
              "description": "The study may be terminated prematurely by the sponsor (AbbVie) or an Investigator for reasonable cause. If termination is due to safety concerns, advance notice is not required."
            }
          ],
          "notification_requirements": "If the sponsor has decided to prematurely discontinue the study, the sponsor will promptly notify the Investigators in writing as well as regulatory authorities. The Investigators must promptly notify the enrolled subjects of the premature discontinuation.",
          "irb_notification": true,
          "provenance": {
            "section_number": "5.4.4",
            "page_number": 102,
            "text_snippet": "AbbVie may terminate this study prematurely, either in its entirety or at any study site, for reasonable cause provided that written notice is submitted in advance of the intended termination. An Investigator may also terminate the study at his/her site for reasonable cause, after providing written notice to AbbVie in advance of the intended termination. Advance notice is not required by either party if the study is stopped due to safety concerns."
          }
        },
        "data_retention": {
          "retention_period_years": 20,
          "retention_policy": "Biomarker and exploratory research samples will be retained while research on venetoclax or this disease continues, but for no longer than 20 years after study completion, or per local requirements.",
          "analysis_populations": [
            {
              "population": {
                "code": "ITT",
                "decode": "Intent-to-Treat"
              },
              "inclusion_criteria": "All randomized subjects. The data from the ITT population will be analyzed by the treatment group assignment given at the time of randomization, even if the subject does not receive the correct treatment or is not compliant to the protocol procedures."
            },
            {
              "population": {
                "code": "SAFETY",
                "decode": "Safety"
              },
              "inclusion_criteria": "All randomized subjects who take at least one dose of study drug."
            }
          ],
          "provenance": {
            "section_number": "5.3.1.3",
            "page_number": 74,
            "text_snippet": "AbbVie (or people or companies working with AbbVie) will store the biomarker and exploratory research samples in a secure storage space with adequate measures to protect confidentiality. The samples will be retained while research on venetoclax (or drugs of this class) or this disease and related conditions continues, but for no longer than 20 years after study completion, or per local requirements."
          }
        },
        "retention_strategies": {
          "prevention_measures": [],
          "incentives": [],
          "re_consent_procedures": "In Japan, when important new information related to the subject's consent becomes available, the principal investigator will revise the consent form and explanatory material, provide the information to each subject already participating, and confirm their intention to continue or not.",
          "provenance": {
            "section_number": "9.3.2",
            "page_number": 154,
            "text_snippet": "Revision of the Consent Form and Explanatory Material\n\nIn Japan, when important new information related to the subject's consent becomes available, the principal investigator will revise the consent form and explanatory material based on the information without delay and will obtain the approval of the IRB prior to use in the study."
          }
        },
        "provenance": {
          "section_number": "5.4",
          "page_number": 99,
          "text_snippet": "5.4 Removal of Subjects from Therapy or Assessment"
        }
      },
      "_agentDocumentation": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "imagingCentralReading": {
      "moduleId": "imaging_central_reading",
      "instanceType": "ImagingCentralReading",
      "data": {
        "id": "NCT02755597-imaging-central-reading",
        "instanceType": "ImagingCentralReading",
        "name": "NCT02755597 Imaging & Central Reading",
        "description": "Tumor assessment and imaging specifications for Clinical Study Protocol M14-031",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-031\nA Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors"
        },
        "response_criteria": {
          "primary_criteria": "IMWG criteria",
          "criteria_version": null,
          "secondary_criteria": [],
          "modifications": "All response categories (i.e., sCR, CR, VGPR, PR, MR and PD) require two consecutive assessments completed by the central lab to be considered confirmed. All response categories sCR, CR, VGPR, PR, MR and SD also require no known evidence of progressive or new bone lesions if radiographic studies were performed. Radiographic studies are not required to satisfy these response requirements. Subjects with measurable disease in both serum (SPEP) and urine (UPEP) at study entry are required to meet response criteria in both UPEP and SPEP to qualify for a MR or better. On the other hand, criteria for PD only need to be met and confirmed in one parameter.",
          "provenance": {
            "section_number": "5.3.7.2",
            "page_number": 92,
            "text_snippet": "Subjects will be assessed for response using the IMWG response criteria (Appendix J). All response categories (i.e., sCR, CR, VGPR, PR, MR and PD) require two consecutive assessments completed by the central lab to be considered confirmed. All response categories sCR, CR, VGPR, PR, MR and SD also require no known evidence of progressive or new bone lesions if radiographic studies were performed..."
          }
        },
        "imaging_modalities": [
          {
            "modality_id": "IMG-001",
            "modality_type": "X-Ray",
            "body_regions": [
              "skull",
              "spine",
              "pelvis",
              "ribs",
              "femora",
              "tibiae",
              "fibulae",
              "humeri",
              "ulnae",
              "radii"
            ],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "Skeletal survey using conventional radiography. Comprised of lateral radiograph of skull; antero-posterior and lateral views of the spine; antero-posterior views of pelvis, ribs, femora, tibiae, fibulae, humeri, ulnae and radii.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "Skeletal Survey",
              "page_number": 86,
              "text_snippet": "Skeletal survey using conventional radiography (X-Ray) will be done at screening. ... A skeletal survey will be comprised of the following:\n● Lateral radiograph of skull\n● Antero-posterior and lateral views of the spine\n● Antero-posterior views of pelvis, ribs, femora, tibiae, fibulae, humeri, ulnae and radii"
            }
          },
          {
            "modality_id": "IMG-002",
            "modality_type": "CT",
            "body_regions": [
              "whole body"
            ],
            "contrast_required": null,
            "contrast_type": null,
            "slice_thickness": "≤10mm for conventional, 5mm or 10mm for spiral",
            "technical_requirements": "Conventional or low dose CT scan for bone survey is acceptable. For plasmacytoma evaluation, conventional CT or spiral CT is used. The same method should be used throughout the study.",
            "preferred_modality": true,
            "provenance": {
              "section_number": null,
              "page_number": 88,
              "text_snippet": "CT, PET/CT or MRI scanning are the preferable methods of assessment. Conventional CT, PET/CT or MRI should be performed with contiguous cuts of 10 mm or less or with cuts of 5 (or 10) mm if spiral CT scanning is used."
            }
          },
          {
            "modality_id": "IMG-003",
            "modality_type": "MRI",
            "body_regions": [
              "whole body"
            ],
            "contrast_required": null,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "MRI bone survey is acceptable. For plasmacytoma evaluation, MRI is used. The same method should be used throughout the study.",
            "preferred_modality": true,
            "provenance": {
              "section_number": "Plasmacytoma Evaluation",
              "page_number": 87,
              "text_snippet": "CT, PETCT (CT component) or MRI (same method should be used throughout study if possible) should be performed in all subjects if clinically indicated at baseline to assess for the presence of extramedullary plasmacytoma."
            }
          },
          {
            "modality_id": "IMG-004",
            "modality_type": "PET-CT",
            "body_regions": [
              "whole body"
            ],
            "contrast_required": null,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "For plasmacytoma evaluation, PETCT (CT component) is used. The same method should be used throughout the study. PET scan alone is not acceptable.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "Plasmacytoma Evaluation",
              "page_number": 87,
              "text_snippet": "Plasmacytoma evaluation should be assessed for all subjects with a history of plasmacytomas or if clinically indicated at Screening, via physical examination or imaging... Positron emission tomography (PET) scan or ultrasound tests are not acceptable to document the size of extramedullary plasmacytomas.\nCT, PETCT (CT component) or MRI (same method should be used throughout study if possible) should be performed in all subjects if clinically indicated at baseline..."
            }
          },
          {
            "modality_id": "IMG-005",
            "modality_type": "Ultrasound",
            "body_regions": [],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "Ultrasound tests are not acceptable to document the size of extramedullary plasmacytomas.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "Plasmacytoma Evaluation",
              "page_number": 87,
              "text_snippet": "Positron emission tomography (PET) scan or ultrasound tests are not acceptable to document the size of extramedullary plasmacytomas."
            }
          }
        ],
        "assessment_schedule": {
          "baseline_window": "Skeletal survey at screening. Historical results obtained within 30 days prior to randomization may be used. Plasmacytoma evaluation at screening if clinically indicated or for subjects with a history of plasmacytomas.",
          "on_treatment_frequency": "Skeletal survey and plasmacytoma evaluation should be done while on study only if clinically indicated (e.g., pain, concern for disease progression).",
          "first_assessment_timing": null,
          "post_treatment_schedule": null,
          "confirmatory_scan_required": false,
          "confirmatory_scan_window": null,
          "assessment_timepoints": [],
          "provenance": {
            "section_number": "Skeletal Survey",
            "page_number": 86,
            "text_snippet": "Skeletal survey using conventional radiography (X-Ray) will be done at screening. ... Historical skeletal survey results obtained within 30 days prior to randomization may be used for Screening... After the screening procedure, skeletal survey should be done while on study only if clinically indicated."
          }
        },
        "lesion_requirements": {
          "measurable_disease_definition": "For plasmacytoma: lesions that can be accurately measured in 2 dimensions and both diameters must be ≥ 20 mm when evaluated by standard CT scanning or ≥ 10 mm when evaluated by spiral CT scanning.",
          "target_lesion_minimum_size": null,
          "lymph_node_criteria": null,
          "max_target_lesions": null,
          "max_target_lesions_per_organ": null,
          "non_target_lesion_definition": "For plasmacytoma: all other lesions (or sites of disease), including those that are too small, occur within a previously irradiated area (unless new), bone lesions, leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses not pathologically/cytologically confirmed, and cystic lesions.",
          "non_measurable_disease": [
            "bone lesions",
            "leptomeningeal disease",
            "ascites",
            "pleural or pericardial effusion",
            "lymphangitis cutis/pulmonis",
            "cystic lesions"
          ],
          "provenance": {
            "section_number": null,
            "page_number": 88,
            "text_snippet": "Measurable disease are lesions that can be accurately measured in 2 dimensions and both diameters must be ≥ 20 mm when evaluated by standard CT scanning or ≥ 10 mm when evaluated by spiral CT scanning. Non-measurable disease are all other lesions (or sites of disease), including those that are too small (i.e., do not meet above criteria), occur within a previously irradiated area..., bone lesions, leptomeningeal disease, ascites, pleural or pericardial effusion..., lymphangitis cutis/pulmonis,"
          }
        },
        "response_categories": [
          {
            "category_code": "sCR",
            "category_name": "Stringent complete response",
            "definition": "Negative immunofixation on serum and urine AND Disappearance of any soft tissue plasmacytomas AND < 5% plasma cells in bone marrow AND Normal FLC ratio AND Absence of clonal cells in bone marrow.",
            "target_lesion_criteria": "Disappearance of any soft tissue plasmacytomas",
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Stringent complete response (sCR)*\n- Negative immunofixation on the serum and urine (regardless of whether disease at baseline was measurable on serum, urine, both, or neither) and\n- Disappearance of any soft tissue plasmacytomas and\n- < 5% plasma cells in bone marrowb and\n- Normal FLC (free light chain) ratio and\n- Absence of clonal cells in bone marrowb by immunohistochemistry or immunofluorescencec or 2 to 4 color flow cytometry"
            }
          },
          {
            "category_code": "CR",
            "category_name": "Complete response",
            "definition": "Negative immunofixation on serum and urine AND Disappearance of any soft tissue plasmacytomas AND < 5% plasma cells in bone marrow. For subjects with only FLC measurable disease, a normal FLC ratio is also required.",
            "target_lesion_criteria": "Disappearance of any soft tissue plasmacytomas",
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Complete response (CR)*\n- Negative immunofixation on the serum and urine (regardless of whether disease at baseline was measurable on serum, urine, both, or neither) and\n- Disappearance of any soft tissue plasmacytomas and\n- < 5% plasma cells in bone marrowb and\n- For subjects in whom the only measurable disease is by serum FLC levels, a normal FLC ratio** is also required."
            }
          },
          {
            "category_code": "VGPR",
            "category_name": "Very good partial response",
            "definition": "Serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M component < 100 mg per 24-hr. For FLC-only subjects: ≥ 90% decrease in the difference between involved and uninvolved FLC levels.",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Very good partial response (VGPR)*\n- Serum and urine M-component detectable by immunofixation but not on electrophoresis or\n- ≥ 90% reduction in serum M-component plus urine M component < 100 mg per 24-hr\nFor subjects in whom the only measurable disease is by serum FLC levels, VGPR is defined as:\n- ≥ 90% decrease in the difference between involved and uninvolved FLC levels"
            }
          },
          {
            "category_code": "PR",
            "category_name": "Partial response",
            "definition": "≥ 50% reduction of serum M-protein AND Reduction in 24-hr urinary M-protein by ≥ 90% or to < 200 mg per 24-hr AND ≥ 50% reduction in the size of soft tissue plasmacytomas, if present at baseline. For FLC-only subjects, a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required.",
            "target_lesion_criteria": "≥ 50% reduction in the size of soft tissue plasmacytomas, if present at baseline",
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Partial response (PR)\n- ≥ 50% reduction of serum M-protein and\n- Reduction in 24-hr urinary M-protein by ≥ 90% or to < 200 mg per 24-hr\n  o If the serum and urine M-protein are unmeasurable,d a ≥ 50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.\n- ≥ 50% reduction in the size of soft tissue plasmacytomas is also required, if present at baseline."
            }
          },
          {
            "category_code": "MR",
            "category_name": "Minimal response",
            "definition": "25% – 49% reduction of serum M-protein AND 50% – 89% reduction in 24-hour urinary M-protein AND 25% – 49% reduction in size of soft tissue plasmacytomas, if present at baseline, AND No increase in size or number of lytic bone lesions.",
            "target_lesion_criteria": "25% – 49% reduction in size of soft tissue plasmacytomas, if present at baseline",
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "No new lesions",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Minimal response (MR)\n- 25% – 49% reduction of serum M-protein and\n- 50% – 89% reduction in 24-hour urinary M-protein and\n- 25% – 49% reduction in size of soft tissue plasmacytomas, if present at baseline, and\n- No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response)."
            }
          },
          {
            "category_code": "SD",
            "category_name": "Stable disease",
            "definition": "Not meeting criteria for sCR, CR, VGPR, PR, MR or progressive disease (PD).",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 194,
              "text_snippet": "Stable disease (SD)e\nNot meeting criteria for sCR, CR, VGPR, PR, MR or progressive disease (PD)."
            }
          },
          {
            "category_code": "PD",
            "category_name": "Progressive disease",
            "definition": "Requires any one or more of: Increase of ≥ 25% from lowest response level in M-protein or FLC levels (with absolute increase criteria); Definite development of new bone lesions or soft tissue plasmacytomas; Definite increase in the size of existing bone lesions or soft tissue plasmacytomas (≥ 50% increase from nadir); Development of hypercalcemia.",
            "target_lesion_criteria": "Definite increase in the size of existing soft tissue plasmacytomas (≥ 50% increase from nadir in the sum of the product of the cross-diameters of > 1 lesion, or ≥ 50% increase in the longest diameter of a previous lesion > 1 cm in short axis)",
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": "Definite development of new bone lesions or soft tissue plasmacytomas",
            "provenance": {
              "section_number": "Appendix J",
              "page_number": 196,
              "text_snippet": "Progressive disease (PD)*\nRequires any one or more of the following:\n- Increase of ≥ 25% from lowest response level in any of the following:\n- Definite development of new bone lesions or soft tissue plasmacytomas, and/or\n- Definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n- Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder."
            }
          }
        ],
        "central_reading": {
          "bicr_required": true,
          "bicr_purpose": "The primary analysis of PFS will be based on data from the IRC's assessment of disease progression. The IRC will review subject data in a blinded fashion to provide the overall response assessment. With the completion of the PFS analysis, post-baseline IMWG assessments are no longer required to be sent to the IRC.",
          "reading_methodology": null,
          "reader_qualifications": "team of independent multiple myeloma experts (IRC)",
          "blinding_requirements": "The IRC will review subject data in a blinded fashion.",
          "adjudication_process": null,
          "vendor_name": "An independent central imaging vendor will be used for plasmacytoma evaluation.",
          "turnaround_time": null,
          "provenance": {
            "section_number": "5.3.7.3",
            "page_number": 98,
            "text_snippet": "Disease assessment for each post-baseline IMWG assessment will be performed by a team of independent multiple myeloma experts (IRC). The IRC will review subject data in a blinded fashion to provide the overall response assessment and associated response assessment date. The IRC will only review clinical data and imaging relevant for the disease assessment. Interpretations from the IRC will not be sent to the site."
          }
        },
        "image_submission": {
          "submission_method": "Electronic upload/shipment",
          "format_requirements": null,
          "anonymization_requirements": null,
          "submission_timeline": "For plasmacytoma evaluation, imaging scans should be sent within 5 business days of imaging acquisition to an independent central imaging vendor.",
          "quality_requirements": null,
          "provenance": {
            "section_number": "Plasmacytoma Evaluation",
            "page_number": 87,
            "text_snippet": "In addition to be reviewed by the Investigator and/or qualified medical site staff, imaging scans should be sent within 5 business days of imaging acquisition to an independent central imaging vendor. The central imaging vendor will provide instructions regarding the preparation and shipment/upload of the images."
          }
        },
        "special_assessments": [
          {
            "assessment_id": "SA-001",
            "assessment_name": "Skeletal Survey",
            "purpose": "To assess for bone lesions.",
            "methodology": "Conventional radiography (X-Ray), low dose CT scan, or MRI bone survey.",
            "schedule": "Done at screening. On-study only if clinically indicated.",
            "provenance": {
              "section_number": "Skeletal Survey",
              "page_number": 86,
              "text_snippet": "Skeletal survey using conventional radiography (X-Ray) will be done at screening. Use of conventional or low dose CT scan or magnetic resonance imaging (MRI) bone survey is acceptable. ... After the screening procedure, skeletal survey should be done while on study only if clinically indicated."
            }
          },
          {
            "assessment_id": "SA-002",
            "assessment_name": "Plasmacytoma Evaluation",
            "purpose": "To assess for the presence and size of extramedullary plasmacytoma.",
            "methodology": "CT, PETCT (CT component), or MRI. The same method should be used throughout the study.",
            "schedule": "At screening for subjects with a history or if clinically indicated. On-study only if clinically indicated.",
            "provenance": {
              "section_number": "Plasmacytoma Evaluation",
              "page_number": 87,
              "text_snippet": "Plasmacytoma evaluation should be assessed for all subjects with a history of plasmacytomas or if clinically indicated at Screening, via physical examination or imaging... CT, PETCT (CT component) or MRI (same method should be used throughout study if possible) should be performed in all subjects if clinically indicated at baseline to assess for the presence of extramedullary plasmacytoma. ... on-study assessments should only be performed if clinically indicated..."
            }
          }
        ],
        "immune_related_criteria": {
          "irecist_used": false,
          "pseudoprogression_handling": null,
          "confirmation_requirements": null,
          "treatment_beyond_progression": null,
          "provenance": {
            "section_number": "5.3.7.2",
            "page_number": 92,
            "text_snippet": "Subjects will be assessed for response using the IMWG response criteria (Appendix J).13,14 Disease status categories include sCR, CR, VGPR, PR, MR, defined per EBMT criteria, stable disease (SD) and PD."
          }
        },
        "extraction_statistics": {
          "has_response_criteria": true,
          "has_bicr": true,
          "has_immune_criteria": false,
          "modality_count": 5,
          "response_category_count": 7
        }
      },
      "_agentDocumentation": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints → Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      }
    },
    "pkpdSampling": {
      "moduleId": "pkpd_sampling",
      "instanceType": "PKPDSampling",
      "data": {
        "id": "NCT02755597-pkpd-sampling",
        "instanceType": "PKPDSampling",
        "name": "NCT02755597 PK/PD Sampling",
        "description": "Pharmacokinetic and pharmacodynamic sampling requirements for the M14-031 study of Venetoclax.",
        "provenance": {
          "section_number": "1.0",
          "page_number": 1,
          "text_snippet": "Clinical Study Protocol M14-031\nA Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma Who are Sensitive or Naïve to Proteasome Inhibitors"
        },
        "pk_sampling": {
          "pk_sampling_required": true,
          "pk_sampling_purpose": "To characterize the pharmacokinetics of venetoclax, bortezomib, and dexamethasone (in Japanese subjects). Venetoclax results may be incorporated into a population PK analysis to estimate parameters such as clearance and support exposure-response analyses.",
          "provenance": {
            "section_number": "1.2",
            "page_number": 12,
            "text_snippet": "Pharmacokinetic (PK) samples will be collected and analyzed for venetoclax and bortezomib (and dexamethasone, in subjects enrolled in Japan only). Venetoclax results may be incorporated into a population PK analysis to estimate parameters such as clearance."
          },
          "analytes": [
            {
              "analyte_id": "ANALYTE-001",
              "analyte_name": "venetoclax",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "bioanalytical_method": "Validated method at AbbVie",
              "lloq": null,
              "provenance": {
                "section_number": "5.3.2.1",
                "page_number": 78,
                "text_snippet": "Blood samples for venetoclax, bortezomib (and dexamethasone, only in Japanese subjects), and possible metabolite(s) will be collected by venipuncture per Appendix H."
              }
            },
            {
              "analyte_id": "ANALYTE-002",
              "analyte_name": "bortezomib",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "bioanalytical_method": "Validated method at AbbVie",
              "lloq": null,
              "provenance": {
                "section_number": "5.3.2.1",
                "page_number": 78,
                "text_snippet": "Blood samples for venetoclax, bortezomib (and dexamethasone, only in Japanese subjects), and possible metabolite(s) will be collected by venipuncture per Appendix H."
              }
            },
            {
              "analyte_id": "ANALYTE-003",
              "analyte_name": "dexamethasone",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "bioanalytical_method": "Validated method at AbbVie",
              "lloq": null,
              "provenance": {
                "section_number": "5.3.2.1",
                "page_number": 78,
                "text_snippet": "Blood samples for venetoclax, bortezomib (and dexamethasone, only in Japanese subjects), and possible metabolite(s) will be collected by venipuncture per Appendix H."
              }
            },
            {
              "analyte_id": "ANALYTE-004",
              "analyte_name": "venetoclax metabolite(s)",
              "analyte_type": "metabolite",
              "matrix": "plasma",
              "bioanalytical_method": "Validated or non-validated methods at AbbVie",
              "lloq": null,
              "provenance": {
                "section_number": "5.3.2.2",
                "page_number": 80,
                "text_snippet": "Plasma concentrations of venetoclax will be determined by the Drug Analysis Department at AbbVie using validated method. Plasma concentrations of other possible metabolites from venetoclax may be determined with validated or non-validated methods."
              }
            }
          ],
          "sampling_schedule": [
            {
              "schedule_id": "SCHED-VEN-001",
              "analyte_name": "venetoclax",
              "visit_name": "Cycle 1 Day 1",
              "timepoints": [
                {
                  "timepoint_name": "6 hours post-dose",
                  "nominal_time": "6h",
                  "window": null,
                  "timepoint_comment": "Optional"
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": null,
                "page_number": 79,
                "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected at the following times:\n● Cycle 1 Day 1: 6 hour post dose (optional)"
              }
            },
            {
              "schedule_id": "SCHED-VEN-002",
              "analyte_name": "venetoclax",
              "visit_name": "Cycles 2, 4, 6, 8 Day 1",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h",
                  "window": null,
                  "timepoint_comment": null
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": null,
                "page_number": 79,
                "text_snippet": "Blood Samples for Venetoclax Assay\nBlood samples (3 mL) for venetoclax assay will be collected at the following times:\n● Cycles 2, 4, 6 and 8 (Day 1): 0 hour (pre-dose)"
              }
            },
            {
              "schedule_id": "SCHED-BOR-001",
              "analyte_name": "bortezomib",
              "visit_name": "Cycle 1 Day 1",
              "timepoints": [
                {
                  "timepoint_name": "0.5 hour post-dose",
                  "nominal_time": "0.5h",
                  "window": null,
                  "timepoint_comment": null
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": null,
                "page_number": 79,
                "text_snippet": "Blood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected at the following times:\n● Cycle 1 Day 1: 0.5 hour post dose"
              }
            },
            {
              "schedule_id": "SCHED-BOR-002",
              "analyte_name": "bortezomib",
              "visit_name": "Cycles 2, 4, 6, 8 Day 11",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h",
                  "window": null,
                  "timepoint_comment": null
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": null,
                "page_number": 79,
                "text_snippet": "Blood Samples for Bortezomib Assay\nBlood samples (4 mL) for bortezomib assay will be collected at the following times:\n● Cycles 2, 4, 6 and 8 (Day 11): 0 hour (pre-dose)"
              }
            },
            {
              "schedule_id": "SCHED-DEX-JP-RUNIN-001",
              "analyte_name": "dexamethasone",
              "visit_name": "Cycle 1 Day 1 (Japan Run-in Phase)",
              "timepoints": [
                {
                  "timepoint_name": "0.5 hour post-dose",
                  "nominal_time": "0.5h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "6 hours post-dose",
                  "nominal_time": "6h",
                  "window": null,
                  "timepoint_comment": null
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": null,
                "page_number": 80,
                "text_snippet": "Japanese subjects enrolled in the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected at the following times:\n● Cycle 1 Day 1: 0.5 and 6 hour post dose"
              }
            },
            {
              "schedule_id": "SCHED-DEX-JP-RUNIN-002",
              "analyte_name": "dexamethasone",
              "visit_name": "Cycle 1 Day 11 (Japan Run-in Phase)",
              "timepoints": [
                {
                  "timepoint_name": "Pre-dose",
                  "nominal_time": "0h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "0.5 hour post-dose",
                  "nominal_time": "0.5h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "1 hour post-dose",
                  "nominal_time": "1h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "2 hours post-dose",
                  "nominal_time": "2h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "4 hours post-dose",
                  "nominal_time": "4h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "8 hours post-dose",
                  "nominal_time": "8h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "24 hours post-dose",
                  "nominal_time": "24h",
                  "window": null,
                  "timepoint_comment": "Day 12 pre-dose"
                }
              ],
              "sample_type": "intensive",
              "provenance": {
                "section_number": null,
                "page_number": 80,
                "text_snippet": "● Cycle 1 Day 11: 0 (pre-dose), 0.5, 1, 2, 4, 8 and 24 (Day 12 pre-dose) hours post dose"
              }
            },
            {
              "schedule_id": "SCHED-DEX-JP-POSTRUNIN-001",
              "analyte_name": "dexamethasone",
              "visit_name": "Cycle 1 Day 1 (Japan Post Run-in Phase)",
              "timepoints": [
                {
                  "timepoint_name": "0.5 hour post-dose",
                  "nominal_time": "0.5h",
                  "window": null,
                  "timepoint_comment": null
                },
                {
                  "timepoint_name": "6 hours post-dose",
                  "nominal_time": "6h",
                  "window": null,
                  "timepoint_comment": null
                }
              ],
              "sample_type": "sparse",
              "provenance": {
                "section_number": null,
                "page_number": 80,
                "text_snippet": "For the remaining Japanese subjects enrolled after the run-in phase, blood samples (3 mL) for dexamethasone assay will be collected at the following times:\n● Cycle 1 Day 1: 0.5 and 6 hour post dose"
              }
            }
          ],
          "intensive_pk_visits": [
            "Cycle 1 Day 11 (Dexamethasone, Japan Run-in Phase)"
          ],
          "sparse_pk_visits": [
            "Cycle 1 Day 1 (Venetoclax, Bortezomib, Dexamethasone)",
            "Cycles 2, 4, 6, 8 Day 1 (Venetoclax)",
            "Cycles 2, 4, 6, 8 Day 11 (Bortezomib)"
          ],
          "sample_volume": "3 mL for venetoclax, 4 mL for bortezomib, 3 mL for dexamethasone",
          "total_pk_samples": "Venetoclax: 4-5 samples. Bortezomib: 5 samples. Dexamethasone (Japan run-in): 9 samples. Dexamethasone (Japan post run-in): 2 samples."
        },
        "pk_parameters": {
          "primary_parameters": [],
          "secondary_parameters": [
            "CL/F"
          ],
          "calculation_method": "Population PK approach",
          "software": null,
          "provenance": {
            "section_number": "5.3.5",
            "page_number": 81,
            "text_snippet": "Values for the PK parameters of venetoclax, including the apparent clearance (CL/F), may be determined using a population PK approach. Additional parameters may be calculated if useful in the interpretation of the data."
          }
        },
        "population_pk": {
          "pop_pk_planned": true,
          "modeling_approach": "Nonlinear mixed effect population PK modeling",
          "covariates": [],
          "objectives": "To estimate PK parameters such as clearance and to support exposure-response analyses.",
          "provenance": {
            "section_number": "8.1.7.8",
            "page_number": 149,
            "text_snippet": "An analysis of venetoclax plasma concentrations may be performed using a nonlinear mixed effect population PK modeling approach. The results from the population PK analysis may not be reported in the clinical study report. Additional analyses may be performed if useful in the interpretation of the data."
          }
        },
        "pd_assessments": {
          "pd_assessments_required": true,
          "provenance": {
            "section_number": "5.3.6",
            "page_number": 81,
            "text_snippet": "Biomarker and Exploratory Research Variables\nBiospecimens (blood, serum, plasma, bone marrow aspirate and bone marrow core biopsy tissue) will be collected to conduct biomarker and exploratory analyses. The types of biomarkers to be analyzed may include, but are not limited to, nucleic acids, proteins, lipids or metabolites."
          },
          "pd_biomarkers": [
            {
              "biomarker_id": "BIOMARKER-001",
              "biomarker_name": "BCL-2 protein expression",
              "biomarker_type": "predictive",
              "matrix": "Bone marrow core biopsy",
              "assay_method": "IHC",
              "sampling_schedule": [
                "Screening",
                "Treatment Completion Visit (Optional)"
              ],
              "purpose": "Predictive biomarker of response to venetoclax combination.",
              "provenance": {
                "section_number": "5.3.6",
                "page_number": 82,
                "text_snippet": "These include assessment of BCL-2 expression at baseline as a predictive biomarker of response to the combination of venetoclax with bortezomib and dexamethasone. BCL-2 protein expression will be determined by IHC analysis in bone marrow core biopsy samples."
              }
            },
            {
              "biomarker_id": "BIOMARKER-002",
              "biomarker_name": "BCL-XL protein expression",
              "biomarker_type": "exploratory",
              "matrix": "Bone marrow core biopsy",
              "assay_method": "IHC",
              "sampling_schedule": [
                "Screening"
              ],
              "purpose": "Exploratory marker of resistance.",
              "provenance": {
                "section_number": "5.3.6",
                "page_number": 82,
                "text_snippet": "Furthermore, BCL-XL and MCL-1 protein expression will be assessed as exploratory markers."
              }
            },
            {
              "biomarker_id": "BIOMARKER-003",
              "biomarker_name": "MCL-1 protein expression",
              "biomarker_type": "exploratory",
              "matrix": "Bone marrow core biopsy",
              "assay_method": "IHC",
              "sampling_schedule": [
                "Screening"
              ],
              "purpose": "Exploratory marker of resistance.",
              "provenance": {
                "section_number": "5.3.6",
                "page_number": 82,
                "text_snippet": "Furthermore, BCL-XL and MCL-1 protein expression will be assessed as exploratory markers."
              }
            },
            {
              "biomarker_id": "BIOMARKER-004",
              "biomarker_name": "BCL-2, BCL-XL, MCL-1 gene expression",
              "biomarker_type": "exploratory",
              "matrix": "CD138-enriched bone marrow aspirate",
              "assay_method": "Sequencing-based methodologies, including qPCR",
              "sampling_schedule": [
                "Screening"
              ],
              "purpose": "To evaluate the ratio of target expression to resistance factors.",
              "provenance": {
                "section_number": "5.3.6",
                "page_number": 82,
                "text_snippet": "Additionally, BCL-2, BCL-XL and MCL-1 gene expression may be evaluated in CD138-enriched bone marrow aspirate samples by sequencing-based methodologies, including qPCR."
              }
            },
            {
              "biomarker_id": "BIOMARKER-005",
              "biomarker_name": "Chromosomal abnormalities (t(11;14), t(4;14), t(14;16), del17p, 5+, 9+, 15+)",
              "biomarker_type": "prognostic",
              "matrix": "CD138-enriched bone marrow aspirate",
              "assay_method": "FISH",
              "sampling_schedule": [
                "Screening",
                "Treatment Completion Visit (Optional)"
              ],
              "purpose": "Assessment of prognostic markers in MM.",
              "provenance": {
                "section_number": "5.3.6",
                "page_number": 82,
                "text_snippet": "Additional biomarker objectives include the assessment of FISH markers that are known to be prognostic in MM. These include, but not limited to, t(11;14), t(4;14), t(14;16), del17p, and 5+, 9+, or 15+."
              }
            },
            {
              "biomarker_id": "BIOMARKER-006",
              "biomarker_name": "Minimal Residual Disease (MRD)",
              "biomarker_type": "efficacy",
              "matrix": "Bone marrow aspirate",
              "assay_method": "NGS, qPCR",
              "sampling_schedule": [
                "Screening",
                "At time of suspected CR/sCR",
                "Approximately 6 and 12 months after confirmation of CR/sCR"
              ],
              "purpose": "To assess depth of response.",
              "provenance": {
                "section_number": null,
                "page_number": 77,
                "text_snippet": "qPCR and MRD Sample Collection\nA 6 mL aspirate sample will be collected at the following time point for qPCR and baseline assessment of disease using MRD assay:\n● Screening (preferred) or prior to first dose of study treatment (Cycle 1 Day 1)\nMRD Assessment\nA 3 mL aspirate sample will be collected at the following time points for MRD assessment:\n● At the time of suspected CR/stringent complete response (sCR) for confirmation of clinical response\n● At approximately 6 months and 12 months after"
              }
            },
            {
              "biomarker_id": "BIOMARKER-007",
              "biomarker_name": "Pharmacogenetics",
              "biomarker_type": "exploratory",
              "matrix": "Whole blood",
              "assay_method": "DNA isolation and analysis",
              "sampling_schedule": [
                "Cycle 1 Day 1",
                "Cycle 5 Day 1",
                "Treatment Completion Visit"
              ],
              "purpose": "To analyze for genetic factors contributing to the response to venetoclax.",
              "provenance": {
                "section_number": null,
                "page_number": 78,
                "text_snippet": "Pharmacogenetic Sample (Optional JPMA Category B)\nAn optional 4 mL whole blood sample for deoxyribonucleic acid (DNA) isolation will be collected on Cycle 1 Day 1 (prior to the first dose of study treatment), Cycle 5 Day 1 and TCV from each subject who consents to provide samples for exploratory research."
              }
            }
          ],
          "pk_pd_relationship": "Potential biomarkers for association with PK, safety and efficacy will be assessed."
        },
        "immunogenicity": {
          "ada_testing_required": false,
          "ada_assay_type": null,
          "sampling_schedule": [],
          "tiered_approach": null,
          "impact_on_pk": null,
          "provenance": {
            "section_number": null,
            "page_number": 1,
            "text_snippet": "Immunogenicity and anti-drug antibody (ADA) testing are not mentioned in this protocol for the small molecule drug venetoclax."
          }
        },
        "sample_handling": {
          "collection_tubes": null,
          "processing_requirements": "Refer to the study specific laboratory manual for detailed instructions on sample collection, processing, and shipment.",
          "storage_conditions": null,
          "shipping_requirements": null,
          "central_lab": "AbbVie Drug Analysis Department",
          "provenance": {
            "section_number": null,
            "page_number": 79,
            "text_snippet": "Refer to the study specific laboratory manual for detailed instructions on sample collection, processing, and shipment."
          }
        },
        "special_populations": {
          "hepatic_impairment": "No specific clinical trials have been conducted. No dose adjustment is recommended in patients with mild or moderate hepatic impairment based on population PK analysis.",
          "renal_impairment": "No specific clinical trials have been conducted. No dose adjustment is recommended in patients with mild or moderate renal impairment (CrCl ≥ 30 mL/min) based on population PK analysis.",
          "pediatric": null,
          "elderly": null,
          "provenance": {
            "section_number": "3.3",
            "page_number": 32,
            "text_snippet": "No specific clinical trials have been conducted in the subjects with hepatic or renal impairment. No dose adjustment is recommended in patients with mild or moderate hepatic or renal (creatinine clearance [CrCl] ≥ 30 mL/min) impairment based on results of the population pharmacokinetic analysis. The analysis indicated no relationship between apparent clearance or apparent volume of distribution and hepatic function."
          },
          "other": [
            {
              "population_name": "Japanese Subjects",
              "considerations": "Specific PK sampling for dexamethasone is required for Japanese subjects, with a more intensive schedule for the first 12 subjects in a run-in phase. Pharmacogenetic research on samples from Japan will be restricted to the subject's response to treatment."
            }
          ]
        },
        "extraction_statistics": {
          "has_pk_sampling": true,
          "has_pd_assessments": true,
          "has_immunogenicity": false,
          "has_population_pk": true,
          "analyte_count": 4,
          "biomarker_count": 7,
          "total_pk_timepoints": 23
        }
      },
      "_agentDocumentation": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      }
    }
  },
  "provenanceSummary": {
    "totalPagesReferenced": 123,
    "pageRange": [
      1,
      198
    ],
    "sectionPageCounts": {
      "studyMetadata": 7,
      "studyDesign": 10,
      "endpointsEstimandsSAP": 17,
      "adverseEvents": 9,
      "safetyDecisionPoints": 10,
      "concomitantMedications": 13,
      "biospecimenHandling": 10,
      "laboratorySpecifications": 22,
      "informedConsent": 34,
      "proSpecifications": 7,
      "dataManagement": 12,
      "siteOperationsLogistics": 22,
      "qualityManagement": 31,
      "withdrawalProcedures": 8,
      "imagingCentralReading": 8,
      "pkpdSampling": 10
    },
    "pageToSections": {
      "1": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement",
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "3": [
        "studyMetadata",
        "qualityManagement"
      ],
      "4": [
        "qualityManagement"
      ],
      "5": [
        "qualityManagement"
      ],
      "7": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "biospecimenHandling",
        "informedConsent",
        "proSpecifications"
      ],
      "8": [
        "studyDesign",
        "endpointsEstimandsSAP"
      ],
      "9": [
        "studyDesign"
      ],
      "10": [
        "studyMetadata",
        "laboratorySpecifications"
      ],
      "11": [
        "studyMetadata",
        "laboratorySpecifications"
      ],
      "12": [
        "studyDesign",
        "pkpdSampling"
      ],
      "13": [
        "endpointsEstimandsSAP"
      ],
      "28": [
        "informedConsent"
      ],
      "32": [
        "safetyDecisionPoints",
        "pkpdSampling"
      ],
      "35": [
        "informedConsent"
      ],
      "36": [
        "informedConsent"
      ],
      "37": [
        "informedConsent"
      ],
      "38": [
        "endpointsEstimandsSAP",
        "qualityManagement"
      ],
      "39": [
        "studyMetadata",
        "informedConsent",
        "siteOperationsLogistics",
        "withdrawalProcedures"
      ],
      "40": [
        "qualityManagement"
      ],
      "41": [
        "proSpecifications",
        "qualityManagement"
      ],
      "43": [
        "informedConsent"
      ],
      "45": [
        "qualityManagement"
      ],
      "46": [
        "laboratorySpecifications"
      ],
      "47": [
        "informedConsent"
      ],
      "48": [
        "qualityManagement"
      ],
      "49": [
        "concomitantMedications"
      ],
      "50": [
        "concomitantMedications"
      ],
      "51": [
        "concomitantMedications"
      ],
      "52": [
        "concomitantMedications"
      ],
      "53": [
        "concomitantMedications"
      ],
      "54": [
        "concomitantMedications"
      ],
      "55": [
        "concomitantMedications"
      ],
      "56": [
        "concomitantMedications",
        "qualityManagement"
      ],
      "57": [
        "informedConsent"
      ],
      "60": [
        "informedConsent"
      ],
      "62": [
        "informedConsent",
        "proSpecifications"
      ],
      "63": [
        "informedConsent",
        "proSpecifications",
        "qualityManagement"
      ],
      "66": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "67": [
        "studyMetadata",
        "laboratorySpecifications",
        "informedConsent"
      ],
      "68": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "69": [
        "laboratorySpecifications"
      ],
      "70": [
        "biospecimenHandling",
        "laboratorySpecifications"
      ],
      "71": [
        "studyDesign",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "72": [
        "informedConsent",
        "withdrawalProcedures"
      ],
      "74": [
        "concomitantMedications",
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement",
        "withdrawalProcedures"
      ],
      "75": [
        "biospecimenHandling",
        "laboratorySpecifications"
      ],
      "76": [
        "biospecimenHandling",
        "laboratorySpecifications"
      ],
      "77": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "78": [
        "biospecimenHandling",
        "informedConsent",
        "pkpdSampling"
      ],
      "79": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "80": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "81": [
        "pkpdSampling"
      ],
      "82": [
        "pkpdSampling"
      ],
      "84": [
        "laboratorySpecifications",
        "informedConsent"
      ],
      "85": [
        "laboratorySpecifications"
      ],
      "86": [
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "87": [
        "informedConsent",
        "dataManagement",
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "88": [
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading"
      ],
      "91": [
        "laboratorySpecifications"
      ],
      "92": [
        "qualityManagement",
        "imagingCentralReading"
      ],
      "98": [
        "qualityManagement",
        "imagingCentralReading"
      ],
      "99": [
        "safetyDecisionPoints",
        "withdrawalProcedures"
      ],
      "101": [
        "withdrawalProcedures"
      ],
      "102": [
        "safetyDecisionPoints",
        "withdrawalProcedures"
      ],
      "103": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "104": [
        "qualityManagement"
      ],
      "105": [
        "siteOperationsLogistics"
      ],
      "107": [
        "siteOperationsLogistics"
      ],
      "108": [
        "siteOperationsLogistics"
      ],
      "109": [
        "qualityManagement"
      ],
      "110": [
        "adverseEvents",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "111": [
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "114": [
        "adverseEvents",
        "laboratorySpecifications"
      ],
      "115": [
        "adverseEvents"
      ],
      "116": [
        "adverseEvents"
      ],
      "117": [
        "adverseEvents",
        "laboratorySpecifications"
      ],
      "118": [
        "adverseEvents"
      ],
      "119": [
        "adverseEvents",
        "qualityManagement"
      ],
      "120": [
        "informedConsent"
      ],
      "122": [
        "adverseEvents"
      ],
      "123": [
        "concomitantMedications",
        "informedConsent",
        "qualityManagement"
      ],
      "124": [
        "informedConsent"
      ],
      "125": [
        "safetyDecisionPoints",
        "concomitantMedications",
        "qualityManagement"
      ],
      "126": [
        "safetyDecisionPoints"
      ],
      "128": [
        "studyDesign",
        "safetyDecisionPoints",
        "qualityManagement"
      ],
      "129": [
        "studyDesign",
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "130": [
        "safetyDecisionPoints",
        "qualityManagement"
      ],
      "132": [
        "studyDesign",
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "133": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "135": [
        "qualityManagement"
      ],
      "136": [
        "endpointsEstimandsSAP"
      ],
      "137": [
        "endpointsEstimandsSAP"
      ],
      "138": [
        "endpointsEstimandsSAP",
        "qualityManagement"
      ],
      "139": [
        "endpointsEstimandsSAP"
      ],
      "140": [
        "endpointsEstimandsSAP"
      ],
      "141": [
        "endpointsEstimandsSAP"
      ],
      "142": [
        "endpointsEstimandsSAP"
      ],
      "143": [
        "endpointsEstimandsSAP",
        "dataManagement"
      ],
      "144": [
        "endpointsEstimandsSAP"
      ],
      "145": [
        "endpointsEstimandsSAP",
        "proSpecifications"
      ],
      "146": [
        "endpointsEstimandsSAP",
        "qualityManagement"
      ],
      "147": [
        "endpointsEstimandsSAP",
        "dataManagement"
      ],
      "148": [
        "adverseEvents",
        "dataManagement"
      ],
      "149": [
        "pkpdSampling"
      ],
      "151": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "152": [
        "siteOperationsLogistics"
      ],
      "153": [
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "154": [
        "withdrawalProcedures"
      ],
      "155": [
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "156": [
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "157": [
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "158": [
        "informedConsent",
        "dataManagement"
      ],
      "159": [
        "siteOperationsLogistics"
      ],
      "167": [
        "siteOperationsLogistics"
      ],
      "172": [
        "informedConsent"
      ],
      "173": [
        "laboratorySpecifications",
        "informedConsent"
      ],
      "175": [
        "informedConsent"
      ],
      "176": [
        "laboratorySpecifications"
      ],
      "192": [
        "concomitantMedications"
      ],
      "193": [
        "concomitantMedications"
      ],
      "194": [
        "imagingCentralReading"
      ],
      "196": [
        "imagingCentralReading"
      ],
      "198": [
        "informedConsent"
      ]
    }
  },
  "agentDocumentation": {
    "description": "Agent documentation for downstream system automation. Each agent's documentation describes its purpose, key insights, downstream system integrations, and automation use cases.",
    "agents": {
      "withdrawal_procedures": {
        "agentId": "withdrawal_procedures",
        "displayName": "Withdrawal Procedures",
        "instanceType": "WithdrawalProcedures",
        "wave": 2,
        "priority": 2,
        "purpose": "Extracts study discontinuation procedures for EDC disposition forms and protocol deviation tracking.",
        "scope": "Discontinuation types, consent withdrawal, early termination visits, survival follow-up, lost to follow-up.",
        "keySectionsAnalyzed": [
          "Section 5: Subject Withdrawal",
          "Section 6: Early Termination",
          "Section 9: Follow-up Procedures"
        ],
        "keyInsights": [
          {
            "name": "Discontinuation Types",
            "description": "Treatment vs study discontinuation with criteria",
            "dataPath": "discontinuation_types[]",
            "downstreamUses": [
              "EDC disposition forms",
              "Analysis programming",
              "DSMB reporting"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Create EDC disposition forms",
          "Configure survival follow-up tracking"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "withdrawal_procedures_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "site_operations_logistics": {
        "agentId": "site_operations_logistics",
        "displayName": "Site Operations & Logistics",
        "instanceType": "SiteOperationsLogistics",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts site operational requirements for site initiation planning and CTMS configuration.",
        "scope": "Site equipment, training requirements, drug storage, IP accountability, vendor coordination.",
        "keySectionsAnalyzed": [
          "Section 9: Study Procedures",
          "Section 10: Drug Supply",
          "Appendix: Site Requirements"
        ],
        "keyInsights": [
          {
            "name": "Equipment Requirements",
            "description": "Site equipment needs for assessments",
            "dataPath": "equipment_requirements[]",
            "downstreamUses": [
              "Site feasibility",
              "Site initiation checklist",
              "Budget planning"
            ],
            "automationCategory": "Site Training Materials",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Trial Master File"
        ],
        "automationUseCases": [
          "Generate site initiation checklists",
          "Configure LMS training assignments"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "arms_design",
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2)",
        "schemaFile": "site_operations_logistics_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "biospecimen_handling": {
        "agentId": "biospecimen_handling",
        "displayName": "Biospecimen Handling",
        "instanceType": "BiospecimenHandling",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts specimen collection, processing, storage, and shipping requirements for central lab and biobank setup.",
        "scope": "Specimen types, tube types/volumes, processing instructions, storage conditions, shipping requirements, biobanking.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 8: Specimen Collection",
          "Appendix: Laboratory Manual"
        ],
        "keyInsights": [
          {
            "name": "Specimen Collection Requirements",
            "description": "Tubes, volumes, special handling for each sample type",
            "dataPath": "specimens[]",
            "downstreamUses": [
              "Central lab kit configuration",
              "Site lab manual",
              "Supply ordering"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate lab kit contents from specimen requirements",
                "sourceDataPath": "specimens[]",
                "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Biospecimen Repository",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Generate central lab sample collection kits",
          "Configure biobank sample tracking",
          "Create site laboratory manuals"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "laboratory_specifications"
          ],
          "crossReferences": [
            "pkpd_sampling"
          ]
        },
        "cdiscDomains": [
          "LB",
          "IS",
          "MB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.3",
        "schemaFile": "biospecimen_handling_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate lab kit contents from specimen requirements",
            "sourceDataPath": "specimens[]",
            "ruleLogic": "FOR EACH specimen: ADD tube(specimen.tube_type, specimen.volume) TO visit_kit",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_BIO_SOA_001",
            "name": "Specimens + SOA → Visit-Based Lab Kits",
            "agentsInvolved": [
              "biospecimen_handling",
              "soa_schedule"
            ],
            "description": "Specimen requirements + visit schedule = visit-specific lab kit configurations",
            "combinedInsight": "What samples at which visits = Complete lab kit manifest per visit",
            "automationEnabled": "Central lab auto-generates visit-specific kit labels",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "imaging_central_reading": {
        "agentId": "imaging_central_reading",
        "displayName": "Imaging & Central Reading",
        "instanceType": "ImagingCentralReading",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts imaging specifications for oncology and imaging-endpoint studies.",
        "scope": "Response criteria (RECIST, RANO), imaging modalities, central vs local reading, adjudication procedures.",
        "keySectionsAnalyzed": [
          "Section 7: Tumor Assessments",
          "Section 8: Response Criteria",
          "Appendix: Imaging Charter"
        ],
        "keyInsights": [
          {
            "name": "Response Criteria",
            "description": "RECIST/iRECIST/RANO version and modifications",
            "dataPath": "response_criteria",
            "downstreamUses": [
              "Central imaging vendor setup",
              "Endpoint adjudication",
              "Analysis programming"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IMAGING_RESP_001",
                "ruleType": "derivation",
                "targetSystem": "Central Imaging",
                "description": "Configure central imaging for response assessment",
                "sourceDataPath": "response_criteria",
                "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Imaging",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central imaging vendor systems",
          "Set up response assessment workflows"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "TU",
          "TR",
          "RS"
        ],
        "regulatoryRelevance": "FDA Oncology Guidance, ICH M11 Section 7",
        "schemaFile": "imaging_central_reading_schema.json",
        "automationRules": [
          {
            "ruleId": "IMAGING_RESP_001",
            "ruleType": "derivation",
            "targetSystem": "Central Imaging",
            "description": "Configure central imaging for response assessment",
            "sourceDataPath": "response_criteria",
            "ruleLogic": "SET imaging_vendor.response_criteria = response_criteria.version; SET timepoints = response_criteria.assessment_schedule",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_IMG_EP_001",
            "name": "Imaging + Endpoints → Response-Based Efficacy",
            "agentsInvolved": [
              "imaging_central_reading",
              "endpoints_estimands_sap"
            ],
            "description": "Response criteria + primary endpoint = complete efficacy assessment workflow",
            "combinedInsight": "RECIST definitions + ORR/PFS endpoints = Imaging-derived efficacy programming",
            "automationEnabled": "Central imaging outputs directly feed efficacy analysis datasets",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "laboratory_specifications": {
        "agentId": "laboratory_specifications",
        "displayName": "Laboratory Specifications",
        "instanceType": "LaboratorySpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts laboratory panel definitions, eligibility criteria, and lab-triggered dose modifications for central lab and EDC setup.",
        "scope": "Lab panels, individual tests, eligibility lab criteria, lab-triggered dose modifications, hepatotoxicity monitoring.",
        "keySectionsAnalyzed": [
          "Section 7: Laboratory Assessments",
          "Section 5: Eligibility Criteria",
          "Section 6: Dose Modifications"
        ],
        "keyInsights": [
          {
            "name": "Laboratory Panels",
            "description": "Panel definitions with constituent tests",
            "dataPath": "panels[]",
            "downstreamUses": [
              "Central lab requisition forms",
              "EDC lab CRF design",
              "Cost estimation"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "LAB_PANEL_001",
                "ruleType": "derivation",
                "targetSystem": "Central Laboratory",
                "description": "Generate central lab requisition from panel definitions",
                "sourceDataPath": "panels[]",
                "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Eligibility Lab Criteria",
            "description": "Lab values required for study entry",
            "dataPath": "eligibility_lab_criteria[]",
            "downstreamUses": [
              "EDC eligibility edit checks",
              "Site screening tools",
              "Subject ID verification"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_LABELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate screening labs against eligibility criteria",
                "sourceDataPath": "eligibility_lab_criteria[]",
                "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
                "example": "ANC >= 1500/µL required for eligibility"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure central lab panel requisitions",
          "Set up EDC lab data entry",
          "Create eligibility screening lab checklists"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria",
            "safety_decision_points"
          ],
          "crossReferences": [
            "biospecimen_handling"
          ]
        },
        "cdiscDomains": [
          "LB"
        ],
        "regulatoryRelevance": "ICH M11 Section 7.2",
        "schemaFile": "laboratory_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "LAB_PANEL_001",
            "ruleType": "derivation",
            "targetSystem": "Central Laboratory",
            "description": "Generate central lab requisition from panel definitions",
            "sourceDataPath": "panels[]",
            "ruleLogic": "FOR EACH panel: CREATE requisition_form WITH tests = panel.tests[]",
            "example": null
          },
          {
            "ruleId": "EDC_LABELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate screening labs against eligibility criteria",
            "sourceDataPath": "eligibility_lab_criteria[]",
            "ruleLogic": "FOR EACH criterion:\n                        IF lab.value NOT IN criterion.range THEN\n                            RAISE 'Lab value outside eligibility range'",
            "example": "ANC >= 1500/µL required for eligibility"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_LAB_SAFETY_001",
            "name": "Lab Panels + Safety Thresholds → Lab Alert System",
            "agentsInvolved": [
              "laboratory_specifications",
              "safety_decision_points"
            ],
            "description": "Lab test definitions + safety thresholds = complete lab alerting system",
            "combinedInsight": "Normal ranges + dose modification thresholds = Tiered lab alerts (normal, caution, action required)",
            "automationEnabled": "EDC displays color-coded lab values with action recommendations",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "adverse_events": {
        "agentId": "adverse_events",
        "displayName": "Adverse Events",
        "instanceType": "AdverseEvents",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts comprehensive adverse event management specifications including AE/SAE definitions,\n    grading systems, causality assessment, reporting timelines, and AESI lists. Critical for\n    safety database configuration and pharmacovigilance workflows.",
        "scope": "- AE and TEAE definitions\n    - SAE criteria per ICH E2A\n    - CTCAE grading system version and definitions\n    - Causality assessment methodology\n    - MedDRA coding specifications\n    - Reporting timelines (routine AE, SAE, SUSAR, pregnancy)\n    - AESI list with special monitoring requirements\n    - DLT criteria (oncology protocols)\n    - Safety committees (DSMB, SMC)",
        "keySectionsAnalyzed": [
          "Section 7: Safety Reporting",
          "Section 8: Adverse Events",
          "Section 9: Safety Assessments",
          "Appendix: CTCAE Grading Tables",
          "Appendix: AESI Definitions"
        ],
        "keyInsights": [
          {
            "name": "AE Collection Period",
            "description": "When AE collection starts and ends relative to study drug",
            "dataPath": "ae_definitions.collection_start, ae_definitions.collection_end",
            "downstreamUses": [
              "EDC AE form display logic",
              "Safety database query rules",
              "Site training"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_AE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate AE dates within collection period",
                "sourceDataPath": "ae_definitions",
                "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
                "example": "AE start date must be >= first dose date for TEAE flag"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "SAE Criteria",
            "description": "ICH E2A serious criteria with protocol-specific exceptions",
            "dataPath": "sae_criteria.criteria[]",
            "downstreamUses": [
              "Safety database serious flag logic",
              "EDC serious field validation",
              "Expedited reporting triggers"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_SAE_001",
                "ruleType": "alert",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure SAE detection and expedited reporting workflow",
                "sourceDataPath": "sae_criteria.criteria[]",
                "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
                "example": "Death → 24hr initial report, 7-day follow-up"
              },
              {
                "ruleId": "EDC_SAE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Enforce SAE documentation requirements",
                "sourceDataPath": "sae_criteria",
                "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Reporting Timelines",
            "description": "Hours/days for initial SAE report, follow-up, SUSAR",
            "dataPath": "reporting_procedures",
            "downstreamUses": [
              "Safety database workflow rules",
              "Site alert configuration",
              "PV team SLAs"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAFETY_TIMELINE_001",
                "ruleType": "workflow",
                "targetSystem": "Safety Database (Pharmacovigilance)",
                "description": "Configure safety reporting timeline workflows",
                "sourceDataPath": "reporting_procedures",
                "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "AESI List",
            "description": "Adverse events of special interest with monitoring requirements",
            "dataPath": "aesi_list[]",
            "downstreamUses": [
              "Safety database AESI flags",
              "EDC AESI prompts",
              "Medical monitor alerts"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_AESI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Prompt for AESI-specific data collection",
                "sourceDataPath": "aesi_list[]",
                "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
                "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "DLT Criteria",
            "description": "Dose-limiting toxicity definitions, observation period, MTD rules",
            "dataPath": "dlt_criteria",
            "downstreamUses": [
              "Dose escalation committee dashboards",
              "IRT dose assignment rules",
              "Safety stopping rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_DLT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure DLT-based dose escalation rules",
                "sourceDataPath": "dlt_criteria",
                "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
                "example": "3+3 design with 28-day DLT window"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Safety Database (Pharmacovigilance)",
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure safety database with protocol-specific SAE criteria",
          "Set up expedited reporting workflows and timelines",
          "Create EDC AE/SAE CRFs with proper grading dropdowns",
          "Configure AESI flag logic in safety database",
          "Generate site training materials on AE reporting",
          "Set up DLT tracking dashboards for dose escalation"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management",
            "withdrawal_procedures"
          ],
          "crossReferences": [
            "safety_decision_points",
            "concomitant_medications"
          ]
        },
        "cdiscDomains": [
          "AE",
          "MH",
          "FA"
        ],
        "regulatoryRelevance": "ICH E2A, ICH E6(R2), ICH M11 Section 8",
        "schemaFile": "adverse_events_extraction_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_AE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate AE dates within collection period",
            "sourceDataPath": "ae_definitions",
            "ruleLogic": "IF ae.start_date < first_dose_date THEN SET ae.treatment_emergent = 'N'\n                    IF ae.start_date > last_dose_date + followup_days THEN RAISE 'AE outside collection window'",
            "example": "AE start date must be >= first dose date for TEAE flag"
          },
          {
            "ruleId": "SAFETY_SAE_001",
            "ruleType": "alert",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure SAE detection and expedited reporting workflow",
            "sourceDataPath": "sae_criteria.criteria[]",
            "ruleLogic": "IF any(sae_criteria) THEN:\n                        SET serious_flag = 'Y'\n                        SET report_due_hours = sae_criteria.initial_report_hours\n                        TRIGGER expedited_workflow\n                        NOTIFY medical_monitor, sponsor_safety",
            "example": "Death → 24hr initial report, 7-day follow-up"
          },
          {
            "ruleId": "EDC_SAE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Enforce SAE documentation requirements",
            "sourceDataPath": "sae_criteria",
            "ruleLogic": "IF serious = 'Y' THEN REQUIRE (\n                        seriousness_criteria IS NOT NULL,\n                        onset_date IS NOT NULL,\n                        outcome IS NOT NULL,\n                        causality IS NOT NULL\n                    )",
            "example": null
          },
          {
            "ruleId": "SAFETY_TIMELINE_001",
            "ruleType": "workflow",
            "targetSystem": "Safety Database (Pharmacovigilance)",
            "description": "Configure safety reporting timeline workflows",
            "sourceDataPath": "reporting_procedures",
            "ruleLogic": "CREATE workflow_rules:\n                        - SAE initial: due_hours = reporting_procedures.sae_initial_hours\n                        - SAE followup: due_days = reporting_procedures.sae_followup_days\n                        - SUSAR: due_days = 15 (unexpected), 7 (fatal/life-threatening)\n                    SET escalation_path = [site, medical_monitor, sponsor_safety, regulatory]",
            "example": null
          },
          {
            "ruleId": "EDC_AESI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Prompt for AESI-specific data collection",
            "sourceDataPath": "aesi_list[]",
            "ruleLogic": "FOR EACH aesi:\n                        IF ae.meddra_pt IN aesi.matching_terms THEN:\n                            DISPLAY aesi.additional_questions\n                            SET aesi_flag = 'Y'\n                            IF aesi.immediate_notification THEN NOTIFY medical_monitor",
            "example": "Hepatotoxicity → Prompt for Hy's Law labs, trigger medical monitor alert"
          },
          {
            "ruleId": "IRT_DLT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure DLT-based dose escalation rules",
            "sourceDataPath": "dlt_criteria",
            "ruleLogic": "SET dlt_window_days = dlt_criteria.observation_period_days\n                    SET escalation_rules = {\n                        '0 DLTs in 3': 'ESCALATE',\n                        '1 DLT in 3': 'EXPAND to 6',\n                        '1 DLT in 6': 'ESCALATE',\n                        '>=2 DLTs in 6': 'MTD exceeded, DE-ESCALATE'\n                    }",
            "example": "3+3 design with 28-day DLT window"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_AE_SAFETY_001",
            "name": "AE Grading + Safety Thresholds → Automated Dose Decisions",
            "agentsInvolved": [
              "adverse_events",
              "safety_decision_points"
            ],
            "description": "CTCAE grades combined with safety thresholds enable automated dose recommendations",
            "combinedInsight": "Grade 3 neutropenia + safety rules = Hold dose, check ANC in 1 week",
            "automationEnabled": "EDC displays recommended action when AE grade is entered",
            "exampleOutput": "{\"ae\": \"Neutropenia Grade 3\", \"action\": \"Hold dose\", \"recheck\": \"7 days\", \"resume_criteria\": \"ANC >= 1500\"}"
          },
          {
            "synergyId": "SYN_AE_CM_001",
            "name": "AE + Concomitant Meds → Drug Interaction Alerts",
            "agentsInvolved": [
              "adverse_events",
              "concomitant_medications"
            ],
            "description": "AE patterns combined with prohibited medications enables interaction detection",
            "combinedInsight": "QT prolongation AE + QT-prolonging concomitant med = Potential drug interaction",
            "automationEnabled": "Real-time drug interaction alert when entering concomitant medications",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_AE_001",
            "name": "CTCAE Version Consistency",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "consistency",
            "description": "Verify CTCAE version is specified and consistent throughout",
            "checkLogic": "ctcae_version IS NOT NULL AND ctcae_version == data_standards.ctcae_version",
            "severity": "error"
          },
          {
            "ruleId": "VAL_AE_002",
            "name": "AESI-SAE Overlap",
            "agentsInvolved": [
              "adverse_events"
            ],
            "validationType": "completeness",
            "description": "Check if AESIs have SAE reporting guidance",
            "checkLogic": "FOR EACH aesi: EXISTS sae_guidance OR aesi.always_serious == true",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Safety Database (Pharmacovigilance)",
            "configType": "protocol_profile",
            "description": "Safety database protocol-specific configuration",
            "dataSources": [
              "sae_criteria.criteria[]",
              "reporting_procedures",
              "aesi_list[]",
              "dlt_criteria"
            ],
            "outputFormat": "Safety database import (Argus, ARISg, Oracle Empirica)",
            "exampleConfig": {
              "sae_criteria": [
                {
                  "criterion": "Death",
                  "code": "C48275",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Life-threatening",
                  "code": "C84266",
                  "timeline_hours": 24
                },
                {
                  "criterion": "Hospitalization",
                  "code": "C84268",
                  "timeline_hours": 72
                }
              ],
              "aesi_list": [
                {
                  "term": "Hepatotoxicity",
                  "meddra_codes": [
                    "10019670"
                  ],
                  "enhanced_collection": true
                }
              ],
              "meddra_version": "26.0",
              "ctcae_version": "5.0"
            }
          }
        ]
      },
      "arms_design": {
        "agentId": "arms_design",
        "displayName": "Treatment Arms & Study Design",
        "instanceType": "StudyDesign",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts the complete treatment design including study arms, epochs, dosing regimens,\n    randomization configuration, and drug supply requirements. This is the primary source\n    for IRT/IWRS and drug supply management system configuration.",
        "scope": "- Study arms (experimental, comparator, placebo)\n    - Treatment epochs (screening, treatment, follow-up)\n    - Study cells (arm × epoch matrix)\n    - Dosing regimens (dose, frequency, route, cycle length)\n    - Dose modification rules and triggers\n    - Randomization details (ratio, stratification, block size, algorithm)\n    - Drug supply kit configurations",
        "keySectionsAnalyzed": [
          "Section 4: Study Design",
          "Section 5: Study Population",
          "Section 6: Study Drug/Treatment",
          "Section 7: Dose Modifications",
          "Section 9: Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "Study Arms",
            "description": "Complete arm definitions with interventions, types, and allocation ratios",
            "dataPath": "studyArms[]",
            "downstreamUses": [
              "IRT arm configuration",
              "EDC treatment assignment forms",
              "Drug supply forecasting"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Generate IRT arm configuration from study arms",
                "sourceDataPath": "studyArms[]",
                "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
                "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
              },
              {
                "ruleId": "EDC_ARM_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate treatment assignment dropdown options",
                "sourceDataPath": "studyArms[].name",
                "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dosing Regimens",
            "description": "Dose, unit, frequency, route, cycle length, dose calculation basis",
            "dataPath": "studyArms[].interventions[].dosingRegimen",
            "downstreamUses": [
              "Drug accountability forms",
              "IRT dispensing rules",
              "Pharmacy manual generation"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DISP_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT dispensing rules from dosing regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
                "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
                "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
              },
              {
                "ruleId": "EDC_DOSE_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dispensed dose against protocol regimen",
                "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
                "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stratification Factors",
            "description": "Randomization stratification with levels and definitions",
            "dataPath": "designMetadata.stratificationFactors[]",
            "downstreamUses": [
              "IRT stratification setup",
              "EDC stratification CRF",
              "Analysis programming"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT stratification from protocol factors",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
                "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
              },
              {
                "ruleId": "EDC_STRAT_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate stratification CRF fields",
                "sourceDataPath": "designMetadata.stratificationFactors[]",
                "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Dose Modification Rules",
            "description": "Reduction levels, triggers, hold/resume criteria",
            "dataPath": "studyArms[].interventions[].doseModifications",
            "downstreamUses": [
              "EDC dose modification forms",
              "Safety alert rules",
              "Medical monitor dashboards"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DOSEMOD_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate dose modification follows protocol levels",
                "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
                "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Supply Configuration",
            "description": "Kit types, dispensing schedule, supply model",
            "dataPath": "designMetadata.drugSupply",
            "downstreamUses": [
              "IRT kit management",
              "Depot configuration",
              "Supply chain forecasting"
            ],
            "automationCategory": "Drug Supply & Kit Management",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "IRT_KIT_001",
                "ruleType": "derivation",
                "targetSystem": "Randomization & Trial Supply Management",
                "description": "Generate kit configuration and depot requirements",
                "sourceDataPath": "designMetadata.drugSupply",
                "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Interactive Response Technology",
          "Interactive Web Response System",
          "Randomization & Trial Supply Management",
          "Electronic Data Capture",
          "Drug Supply Management"
        ],
        "automationUseCases": [
          "Auto-generate IRT randomization and drug dispensing configuration",
          "Create EDC treatment assignment and dose modification CRFs",
          "Configure drug supply forecasting models",
          "Generate pharmacy manuals and dispensing instructions",
          "Set up stratification factor data entry forms",
          "Configure enrollment caps by stratum/region"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "safety_decision_points",
            "pkpd_sampling",
            "biospecimen_handling"
          ],
          "crossReferences": [
            "concomitant_medications",
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "TA",
          "TE",
          "TI",
          "TV",
          "EX",
          "EC"
        ],
        "regulatoryRelevance": "ICH M11 Section 6 (Treatment), CTD Module 2.7.1",
        "schemaFile": "arms_design_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Generate IRT arm configuration from study arms",
            "sourceDataPath": "studyArms[]",
            "ruleLogic": "FOR EACH arm IN studyArms:\n                        CREATE irt_arm {\n                            arm_code: arm.id,\n                            arm_name: arm.name,\n                            arm_type: arm.type.decode,\n                            allocation: arm.allocationPercentage,\n                            interventions: arm.interventions[].name\n                        }",
            "example": "{\"arm_code\": \"A\", \"arm_name\": \"Drug + Chemo\", \"allocation\": 66.7}"
          },
          {
            "ruleId": "EDC_ARM_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate treatment assignment dropdown options",
            "sourceDataPath": "studyArms[].name",
            "ruleLogic": "CREATE codelist 'TREATMENT_ARM' WITH values FROM studyArms[].name",
            "example": null
          },
          {
            "ruleId": "IRT_DISP_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT dispensing rules from dosing regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen",
            "ruleLogic": "FOR EACH regimen:\n                        SET dispense_quantity = regimen.dose * regimen.frequency * cycle_length\n                        SET kit_type = DERIVE_KIT(regimen.route, regimen.formulation)\n                        SET dispense_visits = MATCH(soa_schedule.visits, regimen.schedule)",
            "example": "400mg BID x 28 days = 56 tablets per cycle, dispense at Day 1 of each cycle"
          },
          {
            "ruleId": "EDC_DOSE_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dispensed dose against protocol regimen",
            "sourceDataPath": "studyArms[].interventions[].dosingRegimen.dose",
            "ruleLogic": "IF dispensed_dose != protocol_dose AND NOT dose_modification THEN RAISE query",
            "example": null
          },
          {
            "ruleId": "IRT_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT stratification from protocol factors",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor:\n                        CREATE strat_factor {\n                            name: factor.name,\n                            levels: factor.levels[],\n                            edc_field: DERIVE_FIELD(factor.name)\n                        }\n                    GENERATE strat_combinations = CARTESIAN_PRODUCT(all_factors.levels)",
            "example": "ECOG (0-1, 2) × Prior Therapy (Yes, No) = 4 strata"
          },
          {
            "ruleId": "EDC_STRAT_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate stratification CRF fields",
            "sourceDataPath": "designMetadata.stratificationFactors[]",
            "ruleLogic": "FOR EACH factor: CREATE dropdown_field WITH options = factor.levels",
            "example": null
          },
          {
            "ruleId": "EDC_DOSEMOD_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate dose modification follows protocol levels",
            "sourceDataPath": "studyArms[].interventions[].doseModifications.levels[]",
            "ruleLogic": "IF new_dose NOT IN allowed_dose_levels THEN RAISE 'Invalid dose level'\n                    IF dose_reduction_reason IS NULL THEN RAISE 'Reason required for dose modification'",
            "example": null
          },
          {
            "ruleId": "IRT_KIT_001",
            "ruleType": "derivation",
            "targetSystem": "Randomization & Trial Supply Management",
            "description": "Generate kit configuration and depot requirements",
            "sourceDataPath": "designMetadata.drugSupply",
            "ruleLogic": "FOR EACH kit_type:\n                        SET initial_depot_stock = enrollment_target * cycles * safety_stock_factor\n                        SET reorder_point = site_average_enrollment * lead_time_days",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_ARMS_SAFETY_001",
            "name": "Dosing + Safety Rules → Complete Dose Management",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining dosing regimens with safety thresholds and lab triggers enables intelligent dose management",
            "combinedInsight": "Protocol doses + reduction levels + lab thresholds = Automated dose recommendation engine",
            "automationEnabled": "EDC can suggest appropriate dose level based on current labs and AEs",
            "exampleOutput": "{\"current_dose\": \"400mg\", \"recommended_action\": \"REDUCE to 300mg\", \"trigger\": \"ANC < 1000\", \"confidence\": 0.95}"
          },
          {
            "synergyId": "SYN_ARMS_SOA_001",
            "name": "Arms + SOA → Visit-Based Dispensing",
            "agentsInvolved": [
              "arms_design",
              "soa_schedule"
            ],
            "description": "Arm-specific dosing matched to visit schedule enables precise dispensing rules",
            "combinedInsight": "Which drug, what dose, at which visits = Complete dispensing matrix",
            "automationEnabled": "IRT auto-dispense based on visit and arm assignment",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_ARMS_001",
            "name": "Arm Allocation Total",
            "agentsInvolved": [
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify arm allocations sum to 100%",
            "checkLogic": "SUM(studyArms[].allocationPercentage) == 100",
            "severity": "error"
          },
          {
            "ruleId": "VAL_ARMS_002",
            "name": "Dose Levels Consistency",
            "agentsInvolved": [
              "arms_design",
              "safety_decision_points"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels in arms match safety decision points",
            "checkLogic": "arms.doseModifications.levels SUBSET_OF safety.dose_modification_levels.levels",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Interactive Response Technology",
            "configType": "randomization_module",
            "description": "Complete IRT randomization configuration",
            "dataSources": [
              "studyArms[].id",
              "studyArms[].name",
              "studyArms[].allocationPercentage",
              "designMetadata.stratificationFactors[]",
              "designMetadata.randomizationRatio"
            ],
            "outputFormat": "IRT vendor import (Medidata RTSM, Oracle Siebel CTMS, Parexel ClinPhone)",
            "exampleConfig": {
              "study_arms": [
                {
                  "code": "A",
                  "name": "Drug A + Chemo",
                  "ratio": 2
                },
                {
                  "code": "B",
                  "name": "Placebo + Chemo",
                  "ratio": 1
                }
              ],
              "stratification_factors": [
                {
                  "name": "ECOG Status",
                  "levels": [
                    "0-1",
                    "2"
                  ]
                },
                {
                  "name": "Prior Therapy",
                  "levels": [
                    "Yes",
                    "No"
                  ]
                }
              ],
              "block_size": [
                3,
                6
              ],
              "randomization_method": "permuted_block"
            }
          }
        ]
      },
      "pro_specifications": {
        "agentId": "pro_specifications",
        "displayName": "PRO/eCOA Specifications",
        "instanceType": "PROSpecifications",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts patient-reported outcome specifications for ePRO/eCOA vendor configuration.",
        "scope": "PRO instruments, ePRO system config, ClinRO/ObsRO/PerfO instruments, daily diaries, compliance thresholds.",
        "keySectionsAnalyzed": [
          "Section 7: Efficacy Assessments",
          "Section 8: Patient-Reported Outcomes",
          "Schedule of Assessments"
        ],
        "keyInsights": [
          {
            "name": "PRO Instruments",
            "description": "Questionnaires with administration mode, timing, scoring",
            "dataPath": "pro_instruments[]",
            "downstreamUses": [
              "ePRO vendor setup",
              "Site training",
              "Compliance monitoring"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EPRO_CONFIG_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Patient-Reported Outcomes",
                "description": "Generate ePRO vendor configuration from PRO specifications",
                "sourceDataPath": "pro_instruments[]",
                "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Patient-Reported Outcomes",
          "Electronic Clinical Outcome Assessment",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure ePRO/eCOA vendor systems",
          "Set up compliance monitoring and alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "endpoints_estimands_sap"
          ],
          "enriches": [],
          "crossReferences": [
            "endpoints_estimands_sap",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "QS",
          "RS"
        ],
        "regulatoryRelevance": "FDA PRO Guidance, ICH M11 Section 7.4",
        "schemaFile": "pro_specifications_schema.json",
        "automationRules": [
          {
            "ruleId": "EPRO_CONFIG_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Patient-Reported Outcomes",
            "description": "Generate ePRO vendor configuration from PRO specifications",
            "sourceDataPath": "pro_instruments[]",
            "ruleLogic": "FOR EACH instrument:\n                        CREATE epro_config {\n                            instrument_id: instrument.instrument_id,\n                            schedule: MATCH(instrument.schedule, soa_schedule.visits),\n                            recall_period: instrument.schedule.recall_period,\n                            compliance_window: instrument.schedule.completion_window_hours\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_PRO_SOA_001",
            "name": "PRO + SOA → Complete ePRO Schedule",
            "agentsInvolved": [
              "pro_specifications",
              "soa_schedule"
            ],
            "description": "PRO instruments + visit timing = exact ePRO administration schedule",
            "combinedInsight": "Which PRO at which visit with what window = Complete ePRO schedule",
            "automationEnabled": "ePRO system auto-schedules assessments based on subject visit dates",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "data_management": {
        "agentId": "data_management",
        "displayName": "Data Management",
        "instanceType": "DataManagement",
        "wave": 1,
        "priority": 2,
        "purpose": "Extracts data management specifications for EDC setup and data management planning.",
        "scope": "EDC requirements, CDISC standards versions, data entry timelines, query management, database lock procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Data Management",
          "Section 11: Quality Assurance",
          "Appendix: Data Management Plan"
        ],
        "keyInsights": [
          {
            "name": "CDISC Standards",
            "description": "Required CDASH, SDTM, ADaM versions",
            "dataPath": "cdisc_standards",
            "downstreamUses": [
              "CRF standards library selection",
              "SDTM mapping",
              "ADaM specifications"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System"
        ],
        "automationUseCases": [
          "Configure EDC data entry timelines",
          "Set up CDISC standards compliance checks"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "All"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR Part 11",
        "schemaFile": "data_management_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "quality_management": {
        "agentId": "quality_management",
        "displayName": "Quality Management",
        "instanceType": "QualityManagement",
        "wave": 2,
        "priority": 1,
        "purpose": "Extracts quality management specifications including RBQM, KRIs, and QTLs for CTMS monitoring configuration.",
        "scope": "Monitoring approach, RBQM, Key Risk Indicators, Quality Tolerance Limits, SDV extent, audit procedures.",
        "keySectionsAnalyzed": [
          "Section 10: Quality Management",
          "Section 11: Monitoring",
          "Appendix: Monitoring Plan"
        ],
        "keyInsights": [
          {
            "name": "Key Risk Indicators",
            "description": "KRIs with thresholds and escalation procedures",
            "dataPath": "kris[]",
            "downstreamUses": [
              "Central monitoring dashboards",
              "Site risk scores",
              "Escalation rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "CTMS_KRI_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Configure KRI monitoring thresholds",
                "sourceDataPath": "kris[]",
                "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Clinical Trial Management System",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure CTMS monitoring schedules",
          "Set up KRI dashboards"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata",
            "adverse_events",
            "safety_decision_points"
          ],
          "enriches": [],
          "crossReferences": [
            "data_management"
          ]
        },
        "cdiscDomains": [
          "Not applicable"
        ],
        "regulatoryRelevance": "ICH E6(R2) 5.0, ICH E8(R1)",
        "schemaFile": "quality_management_schema.json",
        "automationRules": [
          {
            "ruleId": "CTMS_KRI_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Configure KRI monitoring thresholds",
            "sourceDataPath": "kris[]",
            "ruleLogic": "FOR EACH kri:\n                        CREATE dashboard_metric {\n                            name: kri.name,\n                            calculation: kri.formula,\n                            thresholds: {yellow: kri.warning_threshold, red: kri.action_threshold},\n                            escalation: kri.escalation_path\n                        }",
            "example": null
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_QM_ALL_001",
            "name": "All Agents → Complete RBQM Dashboard",
            "agentsInvolved": [
              "quality_management",
              "adverse_events",
              "safety_decision_points",
              "data_management"
            ],
            "description": "KRI definitions + safety events + data quality = comprehensive central monitoring",
            "combinedInsight": "Site-level risk scores based on all protocol-defined indicators",
            "automationEnabled": "Automated site risk scoring and monitoring prioritization",
            "exampleOutput": null
          }
        ],
        "validationRules": [],
        "systemConfigurations": []
      },
      "concomitant_medications": {
        "agentId": "concomitant_medications",
        "displayName": "Concomitant Medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts medication restrictions, drug interactions, washout requirements, and required\n    premedications. Essential for site guidance, eligibility verification, and drug\n    interaction checking in EDC.",
        "scope": "- Prohibited medications (with reasons and periods)\n    - Restricted medications (with conditions for use)\n    - Required premedications and prophylaxis\n    - Rescue medications\n    - Washout requirements\n    - Drug-drug interactions (CYP450, QT, etc.)\n    - Vaccine policy\n    - Herbal/supplement restrictions",
        "keySectionsAnalyzed": [
          "Section 5: Prohibited/Restricted Medications",
          "Section 6: Concomitant Medications",
          "Section 7: Prior Medications",
          "Appendix: Drug Interaction Tables"
        ],
        "keyInsights": [
          {
            "name": "Prohibited Medications",
            "description": "Completely banned drug classes with prohibition reasons and periods",
            "dataPath": "prohibited_medications[]",
            "downstreamUses": [
              "EDC CM edit checks",
              "Site reference cards",
              "Eligibility screening"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_PROHIB_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Alert when prohibited medication is entered",
                "sourceDataPath": "prohibited_medications[]",
                "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
                "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Washout Requirements",
            "description": "Required washout periods before study entry",
            "dataPath": "washout_requirements[]",
            "downstreamUses": [
              "Eligibility calculator",
              "Screening visit scheduling",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_WASHOUT_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Validate washout period for prior medications",
                "sourceDataPath": "washout_requirements[]",
                "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
                "example": "Prior chemotherapy end date + 28 days must be before first dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Drug Interactions",
            "description": "CYP450 inhibitors/inducers, QT prolonging agents with management",
            "dataPath": "drug_interactions[]",
            "downstreamUses": [
              "EDC drug interaction alerts",
              "Medical monitor reviews",
              "Pharmacy guidance"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_DDI_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Real-time drug interaction checking",
                "sourceDataPath": "drug_interactions[]",
                "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Required Premedications",
            "description": "Mandatory premedications with dosing and timing",
            "dataPath": "required_medications[]",
            "downstreamUses": [
              "Treatment day CRFs",
              "Site procedures",
              "Drug supply planning"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_PREMED_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Verify required premedications were administered",
                "sourceDataPath": "required_medications[]",
                "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
                "example": "Diphenhydramine 50mg IV required 30 min before infusion"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Configure EDC concomitant medication edit checks",
          "Generate site reference cards for prohibited/restricted meds",
          "Create eligibility screening tools with washout calculators",
          "Set up drug interaction alerts in safety database",
          "Auto-populate premedication requirements in visit forms"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "eligibility_criteria"
          ],
          "crossReferences": [
            "adverse_events",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "CM"
        ],
        "regulatoryRelevance": "ICH M11 Section 6.6",
        "schemaFile": "concomitant_medications_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_PROHIB_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Alert when prohibited medication is entered",
            "sourceDataPath": "prohibited_medications[]",
            "ruleLogic": "FOR EACH cm_entry:\n                        IF cm_entry.drug_class IN prohibited_medications[].medication_class THEN:\n                            IF cm_entry.dates OVERLAP study_period THEN\n                                RAISE 'Prohibited medication during study period'\n                            SET protocol_deviation = TRUE",
            "example": "Strong CYP3A4 inhibitor during treatment → Protocol deviation query"
          },
          {
            "ruleId": "EDC_WASHOUT_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Validate washout period for prior medications",
            "sourceDataPath": "washout_requirements[]",
            "ruleLogic": "FOR EACH prior_med:\n                        washout = LOOKUP(prior_med.drug_class, washout_requirements)\n                        IF prior_med.end_date + washout.duration_days > first_dose_date THEN\n                            RAISE 'Insufficient washout period for ' + prior_med.drug_class",
            "example": "Prior chemotherapy end date + 28 days must be before first dose"
          },
          {
            "ruleId": "EDC_DDI_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Real-time drug interaction checking",
            "sourceDataPath": "drug_interactions[]",
            "ruleLogic": "FOR EACH new_cm:\n                        interactions = MATCH(new_cm, drug_interactions[].affected_drugs)\n                        IF interactions.length > 0 THEN:\n                            DISPLAY interaction_warning(interactions)\n                            IF interaction.severity == 'strong' THEN NOTIFY medical_monitor",
            "example": null
          },
          {
            "ruleId": "EDC_PREMED_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Verify required premedications were administered",
            "sourceDataPath": "required_medications[]",
            "ruleLogic": "FOR EACH treatment_visit:\n                        required_premeds = FILTER(required_medications, type='premedication')\n                        FOR EACH premed IN required_premeds:\n                            IF NOT premed_administered(premed) THEN\n                                RAISE 'Required premedication not documented: ' + premed.name",
            "example": "Diphenhydramine 50mg IV required 30 min before infusion"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_CM_ELIG_001",
            "name": "Washouts + Eligibility → Complete Screening Tool",
            "agentsInvolved": [
              "concomitant_medications",
              "eligibility_criteria"
            ],
            "description": "Washout requirements combined with eligibility criteria enables smart screening",
            "combinedInsight": "Prior therapy exclusions + washout periods = Earliest eligible date calculator",
            "automationEnabled": "Site tool that calculates when patient becomes eligible based on prior meds",
            "exampleOutput": "{\"prior_med\": \"Irinotecan\", \"last_dose\": \"2024-01-15\", \"washout\": \"28 days\", \"earliest_eligible\": \"2024-02-12\"}"
          }
        ],
        "validationRules": [],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "drug_dictionary_config",
            "description": "Configure drug dictionary with protocol-specific flags",
            "dataSources": [
              "prohibited_medications[]",
              "restricted_medications[]",
              "drug_interactions[]"
            ],
            "outputFormat": "WHODrug/MedDRA mapping with protocol flags",
            "exampleConfig": {
              "drug_flags": [
                {
                  "atc_class": "L01",
                  "flag": "PRIOR_CHEMO",
                  "washout_days": 28
                },
                {
                  "drug_name": "Ketoconazole",
                  "flag": "CYP3A4_INHIBITOR",
                  "status": "PROHIBITED"
                }
              ]
            }
          }
        ]
      },
      "informed_consent": {
        "agentId": "informed_consent",
        "displayName": "Informed Consent Elements",
        "instanceType": "InformedConsentElements",
        "wave": 1,
        "priority": 1,
        "purpose": "Extracts key informed consent content elements for ICF template generation and IRB submission.",
        "scope": "Key risks, potential benefits, treatment alternatives, compensation, genetic/biobanking consents, witness requirements.",
        "keySectionsAnalyzed": [
          "Section 10: Informed Consent",
          "Section 11: Subject Information",
          "Appendix: Informed Consent Form"
        ],
        "keyInsights": [
          {
            "name": "Key Risks",
            "description": "Common, serious, and unknown risks to communicate",
            "dataPath": "risks[]",
            "downstreamUses": [
              "ICF template generation",
              "IRB submission",
              "Site training"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Optional Consents",
            "description": "Biobanking, genetic testing, future research options",
            "dataPath": "optional_consents[]",
            "downstreamUses": [
              "ICF optional sections",
              "EDC consent tracking",
              "Biobank enrollment"
            ],
            "automationCategory": "EDC Form Design & Edit Checks",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Trial Master File",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate ICF templates with protocol-specific risks",
          "Create consent tracking CRFs"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "adverse_events"
          ]
        },
        "cdiscDomains": [
          "DS"
        ],
        "regulatoryRelevance": "ICH E6(R2), 21 CFR 50",
        "schemaFile": "informed_consent_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "pkpd_sampling": {
        "agentId": "pkpd_sampling",
        "displayName": "PK/PD Sampling",
        "instanceType": "PKPDSampling",
        "wave": 2,
        "priority": 3,
        "purpose": "Extracts pharmacokinetic and pharmacodynamic sampling specifications for clinical pharmacology studies.",
        "scope": "PK sampling timepoints, PD biomarker sampling, bioanalytical methods, population PK specifications.",
        "keySectionsAnalyzed": [
          "Section 7: Pharmacokinetic Assessments",
          "Section 8: Pharmacodynamic Assessments",
          "Appendix: PK Sampling Schedule"
        ],
        "keyInsights": [
          {
            "name": "PK Sampling Schedule",
            "description": "Intensive and sparse PK timepoints",
            "dataPath": "pk_sampling.timepoints[]",
            "downstreamUses": [
              "Site PK procedure guides",
              "Central lab setup",
              "Visit schedule"
            ],
            "automationCategory": "Laboratory Panel Configuration",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Central Laboratory",
          "Electronic Data Capture"
        ],
        "automationUseCases": [
          "Configure bioanalytical lab sample requirements",
          "Create PK sampling procedure guides"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [],
          "crossReferences": [
            "biospecimen_handling",
            "arms_design",
            "soa_schedule"
          ]
        },
        "cdiscDomains": [
          "PC",
          "PP"
        ],
        "regulatoryRelevance": "FDA Clinical Pharmacology Guidance",
        "schemaFile": "pkpd_sampling_schema.json",
        "automationRules": [],
        "crossAgentSynergies": [],
        "validationRules": [],
        "systemConfigurations": []
      },
      "endpoints_estimands_sap": {
        "agentId": "endpoints_estimands_sap",
        "displayName": "Endpoints, Estimands & SAP",
        "instanceType": "EndpointsEstimandsSAP",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts study objectives, endpoints, estimands (per ICH E9 R1), analysis populations,\n    and statistical analysis specifications. This is the definitive source for programming\n    analysis datasets and statistical outputs.",
        "scope": "- Primary, secondary, and exploratory objectives\n    - Endpoint definitions with outcome types and assessment methods\n    - ICH E9(R1) compliant estimands with intercurrent event strategies\n    - Analysis populations (ITT, mITT, PP, Safety)\n    - Sensitivity and subgroup analyses\n    - Multiplicity adjustment strategy\n    - Missing data handling",
        "keySectionsAnalyzed": [
          "Section 2: Study Objectives and Endpoints",
          "Section 3: Study Objectives",
          "Section 8: Statistical Considerations",
          "Section 9: Statistical Analysis Plan",
          "Appendix: Statistical Analysis Plan (if separate)"
        ],
        "keyInsights": [
          {
            "name": "Primary Endpoints",
            "description": "Primary efficacy endpoints with outcome type, timepoints, and assessment method",
            "dataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "downstreamUses": [
              "Primary analysis programming",
              "Sample size validation",
              "DSMB reporting"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_EP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADaM ADEFF specification from primary endpoint",
                "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
                "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Estimands",
            "description": "ICH E9(R1) estimands with treatment comparison, population, variable, ICE strategies",
            "dataPath": "protocol_endpoints.estimands[]",
            "downstreamUses": [
              "Analysis programming specifications",
              "SAP finalization",
              "Regulatory submission narrative"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "SAP_EST_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate SAP estimand section from extracted estimands",
                "sourceDataPath": "protocol_endpoints.estimands[]",
                "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Analysis Populations",
            "description": "ITT, mITT, PP, Safety population definitions with inclusion/exclusion criteria",
            "dataPath": "protocol_endpoints.analysis_populations[]",
            "downstreamUses": [
              "ADSL derivation",
              "Population flag programming",
              "CSR population tables"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "ADAM_POP_001",
                "ruleType": "derivation",
                "targetSystem": "Regulatory Submission Systems",
                "description": "Generate ADSL population flags from definitions",
                "sourceDataPath": "protocol_endpoints.analysis_populations[]",
                "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
                "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Statistical Methods",
            "description": "Model specifications, covariates, multiplicity adjustment",
            "dataPath": "sap_analyses.statistical_methods[]",
            "downstreamUses": [
              "Analysis program templates",
              "Validation programming",
              "TLF shells"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Subgroup Analyses",
            "description": "Pre-specified subgroup definitions and analysis methods",
            "dataPath": "sap_analyses.subgroup_analyses[]",
            "downstreamUses": [
              "Forest plot programming",
              "Subgroup TLF generation",
              "Regulatory response preparation"
            ],
            "automationCategory": "CDISC Data Standards Mapping",
            "priority": "medium",
            "automationRules": [],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Generate CDISC ADaM dataset specifications from estimands",
          "Auto-create TLF shells from endpoint definitions",
          "Pre-configure statistical analysis programs",
          "Generate SAP templates with population definitions",
          "Create endpoint assessment CRFs in EDC",
          "Configure DSMB reporting data cuts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "pro_specifications",
            "imaging_central_reading"
          ],
          "crossReferences": [
            "adverse_events",
            "quality_management"
          ]
        },
        "cdiscDomains": [
          "ADSL",
          "ADEFF",
          "ADTTE"
        ],
        "regulatoryRelevance": "ICH E9(R1), ICH M11 Sections 2-3, CTD Module 2.7.3/2.7.6",
        "schemaFile": "endpoints_estimands_sap_schema.json",
        "automationRules": [
          {
            "ruleId": "ADAM_EP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADaM ADEFF specification from primary endpoint",
            "sourceDataPath": "protocol_endpoints.endpoints[?(@.level.decode=='Primary')]",
            "ruleLogic": "FOR EACH primary_endpoint:\n                        CREATE adam_spec {\n                            dataset: 'ADEFF' or 'ADTTE',\n                            paramcd: DERIVE_PARAMCD(endpoint.name),\n                            param: endpoint.text,\n                            dtype: endpoint.outcome_type.decode,\n                            avisit: endpoint.primary_timepoint_text\n                        }",
            "example": null
          },
          {
            "ruleId": "SAP_EST_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate SAP estimand section from extracted estimands",
            "sourceDataPath": "protocol_endpoints.estimands[]",
            "ruleLogic": "FOR EACH estimand:\n                        GENERATE estimand_table {\n                            population: estimand.population.description,\n                            treatment: estimand.treatment,\n                            variable: estimand.variable.description,\n                            intercurrent_events: estimand.intercurrent_events[],\n                            summary_measure: estimand.summary_measure.decode\n                        }",
            "example": null
          },
          {
            "ruleId": "ADAM_POP_001",
            "ruleType": "derivation",
            "targetSystem": "Regulatory Submission Systems",
            "description": "Generate ADSL population flags from definitions",
            "sourceDataPath": "protocol_endpoints.analysis_populations[]",
            "ruleLogic": "FOR EACH population:\n                        CREATE adsl_flag {\n                            flag_name: population.label + 'FL',\n                            definition: population.text,\n                            inclusion_criteria: population.inclusion_criteria,\n                            exclusion_criteria: population.exclusion_criteria\n                        }",
            "example": "ITTFL = 'Y' if randomized and received ≥1 dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_EP_SOA_001",
            "name": "Endpoints + SOA → Assessment Schedule Validation",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "soa_schedule"
            ],
            "description": "Endpoint timepoints matched to SOA visits ensures all assessments are scheduled",
            "combinedInsight": "Primary endpoint at Week 12 + SOA Week 12 visit with efficacy assessment = Validated schedule",
            "automationEnabled": "Auto-verify SOA includes all required endpoint assessments",
            "exampleOutput": null
          },
          {
            "synergyId": "SYN_EP_AE_001",
            "name": "Endpoints + AEs + Withdrawal → Complete Estimand Definition",
            "agentsInvolved": [
              "endpoints_estimands_sap",
              "adverse_events",
              "withdrawal_procedures"
            ],
            "description": "Combining endpoint definitions with AE handling and withdrawal reasons enables complete ICE specification",
            "combinedInsight": "What happens to endpoint when subject discontinues due to AE = Complete intercurrent event strategy",
            "automationEnabled": "Generate regulatory-ready estimand framework documentation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_EP_001",
            "name": "Endpoint-Objective Linkage",
            "agentsInvolved": [
              "endpoints_estimands_sap"
            ],
            "validationType": "completeness",
            "description": "Every endpoint must link to at least one objective",
            "checkLogic": "FOR EACH endpoint: EXISTS objective WHERE endpoint.id IN objective.endpoint_ids",
            "severity": "error"
          }
        ],
        "systemConfigurations": []
      },
      "safety_decision_points": {
        "agentId": "safety_decision_points",
        "displayName": "Safety Decision Points",
        "instanceType": "SafetyDecisionPoints",
        "wave": 1,
        "priority": 0,
        "purpose": "Extracts actionable safety decision rules including dose modification triggers,\n    study stopping rules, and organ-specific adjustments. These translate directly\n    into EDC edit checks and medical monitor alert configurations.",
        "scope": "- Safety parameter categories discovered in protocol\n    - Decision points with conditions and actions\n    - Dose modification levels (reduction percentages, absolute doses)\n    - Re-escalation criteria\n    - Study stopping rules (individual and aggregate)\n    - Organ-specific dose adjustments (hepatic, renal, cardiac)\n    - Recovery/rechallenge criteria",
        "keySectionsAnalyzed": [
          "Section 6: Dose Modifications",
          "Section 7: Dose Reductions",
          "Section 8: Study Drug Discontinuation",
          "Section 9: Stopping Rules",
          "Appendix: Dose Modification Tables"
        ],
        "keyInsights": [
          {
            "name": "Dose Reduction Levels",
            "description": "Defined dose levels (-1, -2, etc.) with absolute or percentage reductions",
            "dataPath": "dose_modification_levels.levels[]",
            "downstreamUses": [
              "IRT dose assignment options",
              "EDC dose level dropdown",
              "Drug accountability forms"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_DOSELEVEL_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure allowed dose levels in IRT",
                "sourceDataPath": "dose_modification_levels.levels[]",
                "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
                "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Decision Rules",
            "description": "If-then rules mapping safety findings to required actions",
            "dataPath": "decision_points[].decision_rules[]",
            "downstreamUses": [
              "EDC edit checks",
              "Medical monitor alerts",
              "Safety dashboard rules"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_DECISION_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate edit checks from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
                "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
              },
              {
                "ruleId": "ALERT_DECISION_001",
                "ruleType": "alert",
                "targetSystem": "Electronic Data Capture",
                "description": "Configure real-time safety alerts from decision rules",
                "sourceDataPath": "decision_points[].decision_rules[]",
                "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Stopping Rules",
            "description": "Individual and study-level stopping conditions",
            "dataPath": "stopping_rules_summary.stopping_conditions[]",
            "downstreamUses": [
              "DSMB monitoring triggers",
              "Sponsor alert rules",
              "IRT enrollment stops"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_STOP_001",
                "ruleType": "workflow",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure enrollment stops based on stopping rules",
                "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
                "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
                "example": null
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Organ-Specific Adjustments",
            "description": "Hepatic, renal, cardiac, hematologic dose adjustments",
            "dataPath": "organ_specific_adjustments[]",
            "downstreamUses": [
              "Lab-triggered alerts",
              "Dose recommendation logic",
              "Site guidance documents"
            ],
            "automationCategory": "Safety Monitoring Rules",
            "priority": "high",
            "automationRules": [
              {
                "ruleId": "EDC_ORGAN_001",
                "ruleType": "derivation",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate lab-triggered dose recommendations",
                "sourceDataPath": "organ_specific_adjustments[]",
                "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
                "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Interactive Response Technology",
          "Safety Database (Pharmacovigilance)"
        ],
        "automationUseCases": [
          "Generate EDC edit checks for dose modification triggers",
          "Configure IRT dose assignment validation rules",
          "Set up medical monitor safety alert thresholds",
          "Create dose modification decision trees for site training",
          "Configure DSMB stopping rule monitoring",
          "Generate lab-triggered safety alerts"
        ],
        "integration": {
          "dependsOn": [
            "study_metadata"
          ],
          "enriches": [
            "quality_management"
          ],
          "crossReferences": [
            "adverse_events",
            "laboratory_specifications",
            "arms_design"
          ]
        },
        "cdiscDomains": [
          "DS",
          "EX",
          "LB"
        ],
        "regulatoryRelevance": "ICH E6(R2), ICH M11 Section 6-7",
        "schemaFile": "safety_decision_points_schema.json",
        "automationRules": [
          {
            "ruleId": "IRT_DOSELEVEL_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure allowed dose levels in IRT",
            "sourceDataPath": "dose_modification_levels.levels[]",
            "ruleLogic": "FOR EACH level IN dose_modification_levels.levels:\n                        CREATE irt_dose_option {\n                            level_id: level.level_name,\n                            dose_value: level.absolute_dose OR (starting_dose * level.percentage/100),\n                            kit_assignment: DERIVE_KIT(dose_value)\n                        }\n                    SET allowed_transitions = DEFINE_REDUCTION_PATH(levels)",
            "example": "Level -1 = 300mg, Level -2 = 200mg, discontinue if further reduction needed"
          },
          {
            "ruleId": "EDC_DECISION_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate edit checks from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule IN decision_rules:\n                        CREATE edit_check {\n                            trigger: PARSE_CONDITION(rule.condition),\n                            action: rule.action,\n                            message: 'Protocol requires: ' + rule.action + ' when ' + rule.condition,\n                            severity: IF rule.action CONTAINS 'discontinue' THEN 'hard' ELSE 'soft'\n                        }",
            "example": "IF ALT > 5x ULN THEN 'Hold study drug, notify medical monitor'"
          },
          {
            "ruleId": "ALERT_DECISION_001",
            "ruleType": "alert",
            "targetSystem": "Electronic Data Capture",
            "description": "Configure real-time safety alerts from decision rules",
            "sourceDataPath": "decision_points[].decision_rules[]",
            "ruleLogic": "FOR EACH rule WHERE rule.notify IS NOT NULL:\n                        CREATE alert {\n                            condition: rule.condition,\n                            recipients: rule.notify,\n                            urgency: DERIVE_URGENCY(rule.action),\n                            include_data: [rule.parameter, subject_id, site_id]\n                        }",
            "example": null
          },
          {
            "ruleId": "IRT_STOP_001",
            "ruleType": "workflow",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure enrollment stops based on stopping rules",
            "sourceDataPath": "stopping_rules_summary.stopping_conditions[]",
            "ruleLogic": "FOR EACH stop_rule WHERE stop_rule.scope == 'study':\n                        CREATE enrollment_hold_trigger {\n                            condition: stop_rule.condition,\n                            action: 'PAUSE_ENROLLMENT',\n                            notify: ['sponsor', 'dsmb', 'irb'],\n                            resume_requires: 'sponsor_authorization'\n                        }",
            "example": null
          },
          {
            "ruleId": "EDC_ORGAN_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate lab-triggered dose recommendations",
            "sourceDataPath": "organ_specific_adjustments[]",
            "ruleLogic": "FOR EACH adjustment:\n                        CREATE lab_alert {\n                            lab_test: adjustment.lab_parameter,\n                            thresholds: adjustment.thresholds,\n                            actions: adjustment.actions,\n                            display_message: FORMAT_RECOMMENDATION(adjustment)\n                        }",
            "example": "CrCl 30-50 mL/min → Reduce to 75% of dose"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_SAFETY_LAB_001",
            "name": "Safety Thresholds + Lab Specs → Smart Lab Alerts",
            "agentsInvolved": [
              "safety_decision_points",
              "laboratory_specifications"
            ],
            "description": "Combining safety thresholds with lab panel definitions enables intelligent lab alerting",
            "combinedInsight": "Which labs to monitor + what thresholds trigger action = Complete lab safety system",
            "automationEnabled": "EDC auto-calculates if labs trigger dose modification upon data entry",
            "exampleOutput": "{\"lab\": \"ANC\", \"value\": 800, \"threshold\": \"<1000\", \"action\": \"Hold dose\", \"triggered\": true}"
          },
          {
            "synergyId": "SYN_SAFETY_ARMS_001",
            "name": "Safety Rules + Arms → Arm-Specific Modifications",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "description": "Safety rules applied to specific arm dosing enables precise modification tracking",
            "combinedInsight": "Which dose level applies to which arm = Accurate dose tracking per subject",
            "automationEnabled": "IRT knows exact dose options for each arm based on safety rules",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_SAFETY_001",
            "name": "Dose Level Consistency",
            "agentsInvolved": [
              "safety_decision_points",
              "arms_design"
            ],
            "validationType": "cross_reference",
            "description": "Verify dose modification levels align with arm dosing regimens",
            "checkLogic": "FOR EACH level: level.absolute_dose IN arms.interventions.possible_doses",
            "severity": "error"
          },
          {
            "ruleId": "VAL_SAFETY_002",
            "name": "Stopping Rule Completeness",
            "agentsInvolved": [
              "safety_decision_points"
            ],
            "validationType": "completeness",
            "description": "Verify all stopping rules have clear conditions and actions",
            "checkLogic": "FOR EACH stop_rule: condition IS NOT NULL AND action IS NOT NULL",
            "severity": "error"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "edit_check_library",
            "description": "Complete set of safety-related edit checks",
            "dataSources": [
              "decision_points[].decision_rules[]",
              "dose_modification_levels.levels[]",
              "organ_specific_adjustments[]"
            ],
            "outputFormat": "EDC edit check specification (Medidata, Oracle, Veeva)",
            "exampleConfig": {
              "edit_checks": [
                {
                  "id": "EC_ALT_001",
                  "condition": "ALT > 5 * ULN",
                  "action": "FIRE",
                  "message": "ALT elevation requires dose hold per protocol section 6.2",
                  "severity": "HARD_STOP"
                },
                {
                  "id": "EC_ANC_001",
                  "condition": "ANC < 1000",
                  "action": "FIRE",
                  "message": "Neutropenia requires dose modification per Table 6-1",
                  "severity": "SOFT_STOP"
                }
              ]
            }
          }
        ]
      },
      "study_metadata": {
        "agentId": "study_metadata",
        "displayName": "Study Metadata",
        "instanceType": "Study",
        "wave": 0,
        "priority": 0,
        "purpose": "Extracts foundational study-level metadata that all other agents depend on.\n    This agent runs first and provides the context (protocol ID, phase, therapeutic area,\n    population characteristics) that enables accurate extraction by downstream agents.",
        "scope": "- Protocol identification (NCT, EudraCT, IND numbers)\n    - Study phase, type, and design overview\n    - Sponsor information\n    - Target population characteristics (disease, age, sex, biomarkers)\n    - Key milestones and timelines\n    - Design metadata (randomization, blinding, enrollment targets)",
        "keySectionsAnalyzed": [
          "Title Page / Cover",
          "Synopsis",
          "Section 1: Introduction and Background",
          "Section 3: Study Objectives",
          "Section 4: Study Design",
          "Section 5: Study Population"
        ],
        "keyInsights": [
          {
            "name": "Protocol Identifiers",
            "description": "NCT number, EudraCT, IND numbers for regulatory cross-referencing",
            "dataPath": "studyIdentifiers[]",
            "downstreamUses": [
              "CTMS study registration",
              "Regulatory submission linking",
              "ClinicalTrials.gov sync"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "CTMS_REG_001",
                "ruleType": "derivation",
                "targetSystem": "Clinical Trial Management System",
                "description": "Auto-populate CTMS study record from protocol identifiers",
                "sourceDataPath": "studyIdentifiers[].identifier",
                "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
                "example": "NCT number → CTMS.NCT_ID field"
              }
            ],
            "validationChecks": [
              "All identifiers must match ClinicalTrials.gov registry"
            ]
          },
          {
            "name": "Study Phase",
            "description": "Clinical trial phase with NCI Thesaurus code",
            "dataPath": "studyPhase",
            "downstreamUses": [
              "Regulatory pathway determination",
              "Site qualification criteria",
              "Budget estimation"
            ],
            "automationCategory": "Regulatory Document Generation",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_PHASE_001",
                "ruleType": "validation",
                "targetSystem": "Interactive Response Technology",
                "description": "Validate IRT complexity requirements based on phase",
                "sourceDataPath": "studyPhase.decode",
                "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
                "example": "Phase 1 → Enable dose escalation cohort management"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Target Population",
            "description": "Disease, age range, sex, biomarker requirements, performance status",
            "dataPath": "studyPopulation",
            "downstreamUses": [
              "Site feasibility scoring",
              "Patient recruitment targeting",
              "EDC eligibility forms"
            ],
            "automationCategory": "Eligibility Verification",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "EDC_ELIG_001",
                "ruleType": "edit_check",
                "targetSystem": "Electronic Data Capture",
                "description": "Generate age range edit check for eligibility form",
                "sourceDataPath": "studyPopulation.ageRange",
                "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
                "example": "Age 18-75 → Edit check: BRTHDT must result in age between 18 and 75 at screening"
              }
            ],
            "validationChecks": []
          },
          {
            "name": "Study Milestones",
            "description": "Screening period, enrollment duration, treatment duration, follow-up",
            "dataPath": "studyMilestones",
            "downstreamUses": [
              "CTMS timeline configuration",
              "Site contract milestones",
              "Resource planning"
            ],
            "automationCategory": "Visit Schedule Programming",
            "priority": "high",
            "automationRules": [],
            "validationChecks": []
          },
          {
            "name": "Design Metadata",
            "description": "Randomization ratio, blinding type, target enrollment, countries",
            "dataPath": "studyDesignInfo",
            "downstreamUses": [
              "IRT configuration",
              "Drug supply planning",
              "Regulatory strategy"
            ],
            "automationCategory": "Randomization Configuration",
            "priority": "critical",
            "automationRules": [
              {
                "ruleId": "IRT_RAND_001",
                "ruleType": "derivation",
                "targetSystem": "Interactive Response Technology",
                "description": "Configure IRT randomization ratio",
                "sourceDataPath": "studyDesignInfo.randomizationRatio",
                "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
                "example": "2:1 ratio → IRT blocks of 3 or 6"
              }
            ],
            "validationChecks": []
          }
        ],
        "downstreamSystems": [
          "Electronic Data Capture",
          "Clinical Trial Management System",
          "Interactive Response Technology",
          "Regulatory Submission Systems"
        ],
        "automationUseCases": [
          "Pre-populate EDC study header and demographics forms",
          "Configure CTMS study record with identifiers and milestones",
          "Set IRT enrollment caps by country/region",
          "Generate ClinicalTrials.gov registration data",
          "Auto-configure site feasibility questionnaires"
        ],
        "integration": {
          "dependsOn": [],
          "enriches": [
            "arms_design",
            "endpoints_estimands_sap",
            "eligibility_criteria"
          ],
          "crossReferences": [
            "quality_management",
            "data_management"
          ]
        },
        "cdiscDomains": [
          "DM",
          "DS"
        ],
        "regulatoryRelevance": "Foundation for ICH M11 sections 1-5, CTD Module 5",
        "schemaFile": "study_metadata_schema.json",
        "automationRules": [
          {
            "ruleId": "EDC_STUDY_001",
            "ruleType": "derivation",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate study-level EDC configuration",
            "sourceDataPath": "*",
            "ruleLogic": "CREATE study_config FROM (protocolId, studyTitle, studyPhase, therapeuticArea)",
            "example": null
          },
          {
            "ruleId": "CTMS_REG_001",
            "ruleType": "derivation",
            "targetSystem": "Clinical Trial Management System",
            "description": "Auto-populate CTMS study record from protocol identifiers",
            "sourceDataPath": "studyIdentifiers[].identifier",
            "ruleLogic": "FOR EACH id IN studyIdentifiers: SET ctms.registry[id.type] = id.identifier",
            "example": "NCT number → CTMS.NCT_ID field"
          },
          {
            "ruleId": "IRT_PHASE_001",
            "ruleType": "validation",
            "targetSystem": "Interactive Response Technology",
            "description": "Validate IRT complexity requirements based on phase",
            "sourceDataPath": "studyPhase.decode",
            "ruleLogic": "IF phase IN ['Phase 1', 'Phase 1/2'] THEN require dose_escalation_module",
            "example": "Phase 1 → Enable dose escalation cohort management"
          },
          {
            "ruleId": "EDC_ELIG_001",
            "ruleType": "edit_check",
            "targetSystem": "Electronic Data Capture",
            "description": "Generate age range edit check for eligibility form",
            "sourceDataPath": "studyPopulation.ageRange",
            "ruleLogic": "IF subject_age < min_age OR subject_age > max_age THEN RAISE eligibility_failure",
            "example": "Age 18-75 → Edit check: BRTHDT must result in age between 18 and 75 at screening"
          },
          {
            "ruleId": "IRT_RAND_001",
            "ruleType": "derivation",
            "targetSystem": "Interactive Response Technology",
            "description": "Configure IRT randomization ratio",
            "sourceDataPath": "studyDesignInfo.randomizationRatio",
            "ruleLogic": "SET irt.allocation_ratio = randomizationRatio; SET irt.block_size = CALCULATE(ratio)",
            "example": "2:1 ratio → IRT blocks of 3 or 6"
          }
        ],
        "crossAgentSynergies": [
          {
            "synergyId": "SYN_META_ARMS_001",
            "name": "Study Context + Arms → IRT Complete Configuration",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "description": "Combining study design info with arm definitions enables complete IRT setup",
            "combinedInsight": "Randomization ratio + arm definitions + stratification = Complete IRT randomization module",
            "automationEnabled": "One-click IRT vendor specification generation",
            "exampleOutput": "{\"randomization\": {\"ratio\": \"2:1\", \"arms\": [\"Drug A\", \"Placebo\"], \"stratification\": [\"ECOG\", \"Prior Therapy\"]}}"
          },
          {
            "synergyId": "SYN_META_ELIG_001",
            "name": "Population + Eligibility → Smart Screening",
            "agentsInvolved": [
              "study_metadata",
              "eligibility_criteria",
              "laboratory_specifications"
            ],
            "description": "Population characteristics + criteria + lab values = intelligent screening tool",
            "combinedInsight": "Age/sex + inclusion/exclusion + lab ranges = Complete eligibility calculator",
            "automationEnabled": "Site-facing eligibility screening app with real-time validation",
            "exampleOutput": null
          }
        ],
        "validationRules": [
          {
            "ruleId": "VAL_META_001",
            "name": "Phase-Design Consistency",
            "agentsInvolved": [
              "study_metadata",
              "arms_design"
            ],
            "validationType": "consistency",
            "description": "Verify study phase is consistent with arm complexity",
            "checkLogic": "IF phase='Phase 1' THEN arms.count SHOULD BE <= 3",
            "severity": "warning"
          }
        ],
        "systemConfigurations": [
          {
            "system": "Electronic Data Capture",
            "configType": "study_header",
            "description": "EDC study-level configuration derived from metadata",
            "dataSources": [
              "protocolId",
              "studyTitle",
              "studyPhase",
              "sponsorName"
            ],
            "outputFormat": "EDC vendor import format (Medidata Rave, Oracle InForm, Veeva Vault)",
            "exampleConfig": {
              "study_id": "{protocolId}",
              "study_name": "{studyTitle}",
              "phase": "{studyPhase.decode}",
              "sponsor": "{sponsorName}",
              "therapeutic_area": "{therapeuticArea}"
            }
          }
        ]
      }
    },
    "downstreamSystemCoverage": {
      "Electronic Data Capture": [
        "withdrawal_procedures",
        "biospecimen_handling",
        "imaging_central_reading",
        "laboratory_specifications",
        "adverse_events",
        "arms_design",
        "pro_specifications",
        "data_management",
        "quality_management",
        "concomitant_medications",
        "informed_consent",
        "pkpd_sampling",
        "endpoints_estimands_sap",
        "safety_decision_points",
        "study_metadata"
      ],
      "Clinical Trial Management System": [
        "withdrawal_procedures",
        "site_operations_logistics",
        "adverse_events",
        "data_management",
        "quality_management",
        "study_metadata"
      ],
      "Trial Master File": [
        "site_operations_logistics",
        "informed_consent"
      ],
      "Central Laboratory": [
        "biospecimen_handling",
        "laboratory_specifications",
        "pkpd_sampling"
      ],
      "Biospecimen Repository": [
        "biospecimen_handling"
      ],
      "Central Imaging": [
        "imaging_central_reading"
      ],
      "Safety Database (Pharmacovigilance)": [
        "adverse_events",
        "concomitant_medications",
        "safety_decision_points"
      ],
      "Interactive Response Technology": [
        "arms_design",
        "safety_decision_points",
        "study_metadata"
      ],
      "Interactive Web Response System": [
        "arms_design"
      ],
      "Randomization & Trial Supply Management": [
        "arms_design"
      ],
      "Drug Supply Management": [
        "arms_design"
      ],
      "Electronic Patient-Reported Outcomes": [
        "pro_specifications"
      ],
      "Electronic Clinical Outcome Assessment": [
        "pro_specifications"
      ],
      "Regulatory Submission Systems": [
        "informed_consent",
        "endpoints_estimands_sap",
        "study_metadata"
      ]
    },
    "automationCategories": {
      "EDC Form Design & Edit Checks": [
        {
          "agent": "withdrawal_procedures",
          "insight": "Discontinuation Types",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "AE Collection Period",
          "priority": "critical"
        },
        {
          "agent": "pro_specifications",
          "insight": "PRO Instruments",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Required Premedications",
          "priority": "high"
        },
        {
          "agent": "informed_consent",
          "insight": "Optional Consents",
          "priority": "high"
        }
      ],
      "Site Training Materials": [
        {
          "agent": "site_operations_logistics",
          "insight": "Equipment Requirements",
          "priority": "medium"
        }
      ],
      "Laboratory Panel Configuration": [
        {
          "agent": "biospecimen_handling",
          "insight": "Specimen Collection Requirements",
          "priority": "critical"
        },
        {
          "agent": "laboratory_specifications",
          "insight": "Laboratory Panels",
          "priority": "critical"
        },
        {
          "agent": "pkpd_sampling",
          "insight": "PK Sampling Schedule",
          "priority": "high"
        }
      ],
      "CDISC Data Standards Mapping": [
        {
          "agent": "imaging_central_reading",
          "insight": "Response Criteria",
          "priority": "critical"
        },
        {
          "agent": "data_management",
          "insight": "CDISC Standards",
          "priority": "high"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Primary Endpoints",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Estimands",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Analysis Populations",
          "priority": "critical"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Statistical Methods",
          "priority": "high"
        },
        {
          "agent": "endpoints_estimands_sap",
          "insight": "Subgroup Analyses",
          "priority": "medium"
        }
      ],
      "Eligibility Verification": [
        {
          "agent": "laboratory_specifications",
          "insight": "Eligibility Lab Criteria",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Prohibited Medications",
          "priority": "critical"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Washout Requirements",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Target Population",
          "priority": "critical"
        }
      ],
      "Safety Monitoring Rules": [
        {
          "agent": "adverse_events",
          "insight": "SAE Criteria",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "Reporting Timelines",
          "priority": "critical"
        },
        {
          "agent": "adverse_events",
          "insight": "AESI List",
          "priority": "high"
        },
        {
          "agent": "adverse_events",
          "insight": "DLT Criteria",
          "priority": "high"
        },
        {
          "agent": "arms_design",
          "insight": "Dose Modification Rules",
          "priority": "high"
        },
        {
          "agent": "quality_management",
          "insight": "Key Risk Indicators",
          "priority": "high"
        },
        {
          "agent": "concomitant_medications",
          "insight": "Drug Interactions",
          "priority": "high"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Dose Reduction Levels",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Decision Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Stopping Rules",
          "priority": "critical"
        },
        {
          "agent": "safety_decision_points",
          "insight": "Organ-Specific Adjustments",
          "priority": "high"
        }
      ],
      "Randomization Configuration": [
        {
          "agent": "arms_design",
          "insight": "Study Arms",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Stratification Factors",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Design Metadata",
          "priority": "critical"
        }
      ],
      "Drug Supply & Kit Management": [
        {
          "agent": "arms_design",
          "insight": "Dosing Regimens",
          "priority": "critical"
        },
        {
          "agent": "arms_design",
          "insight": "Drug Supply Configuration",
          "priority": "high"
        }
      ],
      "Regulatory Document Generation": [
        {
          "agent": "informed_consent",
          "insight": "Key Risks",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Protocol Identifiers",
          "priority": "critical"
        },
        {
          "agent": "study_metadata",
          "insight": "Study Phase",
          "priority": "critical"
        }
      ],
      "Visit Schedule Programming": [
        {
          "agent": "study_metadata",
          "insight": "Study Milestones",
          "priority": "high"
        }
      ]
    },
    "integrationGraph": {
      "nodes": [
        {
          "id": "withdrawal_procedures",
          "displayName": "Withdrawal Procedures",
          "wave": 2,
          "priority": 2
        },
        {
          "id": "site_operations_logistics",
          "displayName": "Site Operations & Logistics",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "biospecimen_handling",
          "displayName": "Biospecimen Handling",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "imaging_central_reading",
          "displayName": "Imaging & Central Reading",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "laboratory_specifications",
          "displayName": "Laboratory Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "adverse_events",
          "displayName": "Adverse Events",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "arms_design",
          "displayName": "Treatment Arms & Study Design",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "pro_specifications",
          "displayName": "PRO/eCOA Specifications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "data_management",
          "displayName": "Data Management",
          "wave": 1,
          "priority": 2
        },
        {
          "id": "quality_management",
          "displayName": "Quality Management",
          "wave": 2,
          "priority": 1
        },
        {
          "id": "concomitant_medications",
          "displayName": "Concomitant Medications",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "informed_consent",
          "displayName": "Informed Consent Elements",
          "wave": 1,
          "priority": 1
        },
        {
          "id": "pkpd_sampling",
          "displayName": "PK/PD Sampling",
          "wave": 2,
          "priority": 3
        },
        {
          "id": "endpoints_estimands_sap",
          "displayName": "Endpoints, Estimands & SAP",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "safety_decision_points",
          "displayName": "Safety Decision Points",
          "wave": 1,
          "priority": 0
        },
        {
          "id": "study_metadata",
          "displayName": "Study Metadata",
          "wave": 0,
          "priority": 0
        }
      ],
      "edges": [
        {
          "source": "study_metadata",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "depends_on"
        },
        {
          "source": "withdrawal_procedures",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "site_operations_logistics",
          "type": "depends_on"
        },
        {
          "source": "site_operations_logistics",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "site_operations_logistics",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "biospecimen_handling",
          "type": "depends_on"
        },
        {
          "source": "biospecimen_handling",
          "target": "laboratory_specifications",
          "type": "enriches"
        },
        {
          "source": "biospecimen_handling",
          "target": "pkpd_sampling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "imaging_central_reading",
          "type": "depends_on"
        },
        {
          "source": "imaging_central_reading",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "imaging_central_reading",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "laboratory_specifications",
          "type": "depends_on"
        },
        {
          "source": "laboratory_specifications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "laboratory_specifications",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "adverse_events",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "withdrawal_procedures",
          "type": "enriches"
        },
        {
          "source": "adverse_events",
          "target": "safety_decision_points",
          "type": "cross_references"
        },
        {
          "source": "adverse_events",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "depends_on"
        },
        {
          "source": "arms_design",
          "target": "safety_decision_points",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "pkpd_sampling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "biospecimen_handling",
          "type": "enriches"
        },
        {
          "source": "arms_design",
          "target": "concomitant_medications",
          "type": "cross_references"
        },
        {
          "source": "arms_design",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "depends_on"
        },
        {
          "source": "pro_specifications",
          "target": "endpoints_estimands_sap",
          "type": "cross_references"
        },
        {
          "source": "pro_specifications",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "depends_on"
        },
        {
          "source": "data_management",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "adverse_events",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "depends_on"
        },
        {
          "source": "quality_management",
          "target": "data_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "concomitant_medications",
          "type": "depends_on"
        },
        {
          "source": "concomitant_medications",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "concomitant_medications",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "concomitant_medications",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "informed_consent",
          "type": "depends_on"
        },
        {
          "source": "informed_consent",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "pkpd_sampling",
          "type": "depends_on"
        },
        {
          "source": "pkpd_sampling",
          "target": "biospecimen_handling",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "pkpd_sampling",
          "target": "soa_schedule",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "depends_on"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "pro_specifications",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "imaging_central_reading",
          "type": "enriches"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "endpoints_estimands_sap",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "safety_decision_points",
          "type": "depends_on"
        },
        {
          "source": "safety_decision_points",
          "target": "quality_management",
          "type": "enriches"
        },
        {
          "source": "safety_decision_points",
          "target": "adverse_events",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "laboratory_specifications",
          "type": "cross_references"
        },
        {
          "source": "safety_decision_points",
          "target": "arms_design",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "arms_design",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "endpoints_estimands_sap",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "eligibility_criteria",
          "type": "enriches"
        },
        {
          "source": "study_metadata",
          "target": "quality_management",
          "type": "cross_references"
        },
        {
          "source": "study_metadata",
          "target": "data_management",
          "type": "cross_references"
        }
      ]
    }
  }
}